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Abstract
During malaria infection there is significant depression of the host’s immune response to 
concurrent infections and heterologous vaccine antigens as well as the response to the 
parasite itself. Using the murine Plasmodium chabaudi chabaudi AS model, I examined 
whether the malaria parasite can suppress immune responses via effects on dendritic cells 
(DC), which are important for initiating primary immune responses. As the morbidity and 
mortality associated with malaria are derived exclusively from the asexual erythrocytic 
stages, I investigated the effects that this stage has on DC function.
I found that malaria infected erythrocytes (pRBC) do not directly activate bone marrow- 
derived DCs in vitro; rather, they inhibit the LPS induced upregulation of Class II MHC 
and costimulatory molecules (CD40 and CD8 6 ) on DCs and significantly reduce the 
ability of these cells to induce proliferation and effector function of naïve T cells. 
Nevertheless, pRBC-treated DCs induce equivalent levels of the very early activation 
marker CD69 on antigen-specific naïve T cells compared with RBC-treated DCs, 
indicating that T cells in both conditions are antigen experienced. Furthermore, the 
proliferation of T cells cultured with pRBC-treated DCs could be recovered by the 
addition of exogenous IL-2, suggesting that they are functionally anergic.
In search of a mechanistic explanation for this parasite-mediated inhibition of DC 
function, I investigated the possible role of selected parasite components. Haemozoin, the 
end-product of the haemoglobin catabolism by intraerythrocytic malaria parasite, was 
found to contribute significantly to the immunosuppressive effects induced in DCs. A 
soluble factor(s) secreted by pRBCs was also found to affect the ability of DCs to mature 
in response to LPS treatment in vitro. Furthermore, following gene array analysis, I have 
identified a number of candidate molecules in pRBC-treated DC that may be involved in 
the observed alterations in functional activity.
The present study provides a better insight of how the malaria parasite affects DC 
function and identifies a number of parasite-induced changes in these cells related to their
XXI
decreased ability to induce effective primary immune responses. These observations may 
therefore facilitate the development of more effective vaccines and immunisation 
protocols.
XXil
1. Introduction
1.1 Plasmodium and malaria
1.1.1 Life cycle
Malaria is an arthropod-borne disease caused by protozoan parasites of the genus 
Plasmodium (Wakelin, 1996). Four species infect humans: F. falciparum, P. vivax, P. 
malariae and P.ovale. The life cycle of all species of human malaria parasites is 
essentially the same (Phillips, 2001)(Figure 1). It comprises an exogenous sexual phase 
(sporogony) with multiplication in certain female Anopheles mosquitoes and an 
endogenous asexual phase (schizogony) with multiplication in the vertebrate host.
Infection is initiated by inoculation of sporozoites through mosquito bites. The 
sporozoites circulate in the blood for 30-45 minutes before invading liver cells 
(hepatocytes) (Fairley, 1947; Sihden and Smith, 1982). Here they undergo a process of 
development and multiplication known as ‘pre-erythrocytic schizogony’ leading to the 
development of merozoites (Gamham, 1966).
In P. vivax and P. ovale infections, the sporozoites differentiate into ‘hypnozoites’ as well 
as merozoites (Krotoski et al., 1982). The hypnozoites remain dormant in hepatocytes for 
considerable periods of time. The mechanism of activating the growth of these parasites 
is not known. When "reactivated" they grow and undergo ‘exo-erythrocytic schizogony’ 
forming a wave of merozoites that invade the blood and produce a clinical relapse.
In P. falciparum and P. malariae, hypnozoites are not formed and the parasite develops 
directly into pre-erythrocytic schizonts. Upon reaching maturity, the schizonts rupture 
releasing merozoites into the blood stream, where they invade erythrocytes and initiate a 
schizogonie cycle in the blood. Within the circulating erythrocytes, the merozoite begins 
to feed on haemoglobin leaving, as the product of digestion, a pigment called haemozoin, 
a combination of haematin with protein (Arese and Schwarzer, 1997). This iron- 
containing pigment is seen in the body of the parasite in the form of dark granules, which
are more obvious in the later stages of development.
During their development within the red blood cells, the parasites transform into a 
uninucleated feeding stage called a‘trophozoite’, shortly after which the nucleus begins to 
divide into a variable number of small nuclei. This is soon followed by the division of the 
cytoplasm, leading to schizont formation. In P. falciparum infections, mature trophozoite 
stages disappear from the peripheral circulation and cytoadhere to endothelial cells lining 
post-capillary venules within different organs, a process known as ‘sequestration’ (David 
et ah, 1983). When sequestration of infected erythrocytes occurs in the vessels of the 
brain, it is believed to cause the severe disease syndrome known as cerebral malaria, 
which is associated with high mortality (Gamham, 1966).
Mature schizonts are fully developed forms in which, as a result of segmentation of the 
nucleus and the cytoplasm, a number of small rounded merozoites are produced. When 
the process of schizogony is completed, the red cell lyses and the merozoites are released 
into the blood stream (Dvorak et ah, 1975). The merozoites then invade fresh red cells in 
which another generation of parasites is produced by the same process. This erythrocytic 
cycle of schizogony can be repeated many times in the course of infection, leading to a 
progressive increase of parasitaemia until the process is slowed down by the immune 
response of the host (Phillips, 1983).
After several rounds of blood schizogony, a proportion of the merozoites develop into the 
sexual stages of the parasites - the gametocytes. Microgamétocytes (male) and 
macrogamétocytes (female) circulate in the peripheral blood where they remain infective 
for a limited period of time (Gamham, 1966). When these infective stages are taken up 
by a mosquito, they develop into gametes and fertilization occurs. The resulting zygote 
matures within 24h to the motile ookinete, which burrows through the stomach wall 
leading to the formation of an oocyst (Sinden and Strong, 1978). Within the developing 
oocyst many mitotic divisions occur, resulting in oocysts full of sporozoites. Rupture of 
oocysts releases the sporozoites, which migrate to the mosquito’s salivary glands 
(Vanderberg, 1975) to complete the cycle approximately 7 to 18 days after gametocyte
ingestion.
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Figure 1.1 Plasmodium life cycle
1.1.2 Human malaria parasites
1.1.2.1 Plasmodium vivax
P. vivax is found mostly in Asia, Latin America, and in some parts of Africa (Sina, 2002). 
Because of the population densities, especially in Asia, it is probably the most prevalent 
human malaria parasite (Sina, 2002). P. vivax (as well as P. ovale) has dormant liver 
stages ("hypnozoites") that can activate and invade the blood ("relapse") several months 
or years after the infecting mosquito bite (Krotoski et al., 1982). It is a selective parasite 
as it only invades young, immature erythrocytes (Kitchen, 1939). After an incubation 
period of usually 10-17 days, the patient experiences influenza-like symptoms with 
headache, muscle pain, nausea and vomiting (Garnham, 1966). As the infection 
progresses, increased numbers of rupturing erythrocytes liberate merozoites as well as 
toxic debris into the circulation. Together, these produce the typical pattern of chills and 
fever. These symptoms usually re-appear periodically, every 48 hours, which is why P. 
vivax is said to cause tertian malaria or benign malaria as most patients can tolerate the 
attacks and can survive for years without treatment (Gamham, 1966). However, there are 
occasional reports of severe and fatal P. vivax infections. These are associated with lung 
injury and respiratory distress (Carlini et al., 1999; Torres et al., 1997), splenic rupture 
and associated pathology (Leclerc et al., 1989), and even instances of cerebral malaria 
associated with apparently pure P. vivax infections (Sachdev and Mohan, 1985). Thus, 
under rare and yet poorly understood circumstances, P. vivax infections can present in 
dangerous forms.
1.1.2.2 Plasmodium ovale
P. ovale is found mostly in Africa (especially West Africa) and the islands of the western 
Pacific (Collins and Jeffery, 2005). It is biologically and morphological very similar to P. 
vivax including its selectivity for young erythrocytes (Garnham, 1966). However, 
differently from P. vivax, it can infect individuals who are negative for the Duffy blood
group, which is the case for many residents of sub-Saharan Africa (Collins and Jeffery, 
2005). This explains the greater prevalence of P. ovale (rather than P. vivax) in most of 
Africa. Following parasite invasion of erythrocytes, the host cell becomes enlarged and 
distorted, usually assuming an oval form (Garnham, 1966). It causes benign tertian 
malaria and infection is similar to P. vivax. Untreated infections however last only about 
one year (Collins and Jeffery, 2005).
1.1.2.3 Plasmodium malariae
P. malariae, in contrast to P.ovale and P. vivax, only infects mature erythrocytes 
(Chwatt, 1948). The incubation period is the longest of the Plasmodia, usually 18 to 40 
days, but possibly several months or years. The early symptoms are influenza-like, with 
fever occurring every 72 hours and hence said to cause quartan malaria (Phillips, 1983). 
Attacks are moderate to severe and last several hours. It causes a long-lasting chronic 
infection that in some cases can last a lifetime (Gamham, 1966).
1.1.2.4 Plasmodium falciparum
P. falciparum is found in tropical and subtropical areas (Phillips, 1983). It demonstrates 
no selectivity in host erythrocytes and invades any red blood cell at any stage in its 
existence (Chwatt, 1948). The incubation period is the shortest of all the plasmodia  
ranging from 7 to 10 days. After the early influenza-like symptoms, P. falciparum rapidly 
produces daily chills and fever as well as severe nausea and vomiting. The periodicity of 
the attacks then becomes tertian (Garnham, 1966). Although any malaria infection may 
be fatal, P. falciparum is the most likely to result in death if left untreated. It is estimated 
that every year 700,000 to 2.7 million people are killed by P. falciparum, especially in 
Africa where this species predominates (Snow et a l, 2005). P. falciparum can cause 
severe malaria because it multiples rapidly in the blood, and can thus cause severe loss of 
red blood cells (anaemia). In addition, the infected red cells can sequester in capillaries of 
internal organs, attaching through ‘knobs’ on the red cell (Crabb et a l, 1997). Thus,
parasitized erythrocytes can obstruct small blood vessels and when this occurs in the 
brain, cerebral malaria results, a complication that can be fatal.
1.1.3 Geographic distribution of malaria
Despite advances in understanding malaria ecology and development of interventions, 
more than 50% of the world’s population is exposed to malaria. In many parts of the 
world, changes in the environment, population migration and financial problems have led 
to serious increases in malaria. For example, deforestation can increase human-vector 
contact and create improved breeding conditions for several vector species (Collins and 
Paskewitz, 1995). Water management projects such as irrigation, impoundments and 
dams can also create additional breeding grounds (Keiser et al., 2005). Furthermore, 
economic and political stress often results in population migration, which increases 
movement of non-immune individuals into malarious areas and of carriers into non­
endemic areas.
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Figure 1.2. Malaria world distribution (Source: World Health Organization, 2004)
Intensive malaria is confined to the tropical and subtropical areas (Figure 1.2). The 
African continent is the most affected, accounting for more than 90% of the burden 
(Breman et aU, 2004). Recently, malaria outbreaks have been reported in some locations 
of Africa that had been previously thought to be at elevations too high for malaria 
transmission, such as the highlands of Kenya. This might be due to climatic change or to 
human migration. Also, malaria has resurged in certain locations of Africa that previously 
had effective control programmes, such as Madagascar, South Africa, and Zanzibar 
(Kiszewski and Teklehaimanot, 2004).
Malaria epidemics generally afflict immunologically vulnerable populations. The very 
instability of malaria epidemics exacerbates their clinical threat (Kiszewski and 
Teklehaimanot, 2004). Long inter-epidemic periods of low transmission allow immunity 
to wane in populations. Thus in areas where malaria is transmitted less stably, the risk of 
severe disease in children is greater (Snow et al., 1998), and older children and adults are 
more likely to have cerebral manifestations that are often fatal (Imbert et a l, 1997).
In Africa, malaria is most prevalent in the highlands of the eastern and southern parts of 
the continent. In the tropics, the upper limits of transmission are often set by an altitude 
of approximately 2 , 0 0 0  metres, but anomalous weather conditions may occasionally 
render higher altitudes permissive for vector and parasite development (Fisher, 1985). In 
east Africa, unstable highland malaria affects Ethiopia, Eritrea, western Kenya, 
southwestern Uganda, the highlands of Tanzania and much of Rwanda and Burundi 
(Kiszewski and Teklehaimanot, 2004). Ethiopia has historically had the most intensive 
experience with recurrent malaria epidemics (Kiszewski and Teklehaimanot, 2004). 
Localised malaria epidemics occur every year somewhere in Ethiopia with occasional 
massive outbreaks affecting most of the country (Kiszewski and Teklehaimanot, 2004). 
The highlands of Kenya are sometimes affected concurrently with the Ethiopian malaria 
outbreaks, perhaps triggered by the same climatic determinants. Some reports have 
suggested that Kenyan epidemics simply represent unusually high peaks in seasonal 
transmission (Hay et a l, 2002a; Hay et a l, 2002b). Others report a growing risk of
widespread malaria epidemics in Kenya due to environmental changes associated with 
agricultural development that favour the breeding of the vector mosquitoes (Malakooti et 
al., 1998). Malaria eradication efforts apparently succeeded in temporarily interrupting 
transmission in the highlands, which remained almost malaria free from the late 1950s to 
the early 1970s (Roberts, 1964a, b, c). A trend of increasing transmission has developed 
since then with an upsurge of epidemic outbreaks since 1990 (Brown et al., 1998).
In Tanzania, epidemic malaria is concentrated in the highlands along the Rift Valley, an 
area that includes approximately 8.4 million people, or approximately 25% of the 
country’s population (Kiszewski and Teklehaimanot, 2004). Epidemic-prone districts in 
Uganda are clustered in the southwestern comers of the country near the Tanzanian and 
Rwandan borders. Generally malaria in Uganda is transmitted stably below 1,500 meters 
in elevation, with less stable transmission occurring between 1,500 and 2,300 meters 
(Kiszewski and Teklehaimanot, 2004).
In Southern Africa, unstable transmission affects parts of Mozambique, Malawi, 
Zimbabwe, Swaziland and the northern provinces of South Africa. (Kiszewski and 
Teklehaimanot, 2004). In Swaziland, epidemics may have strong links with human 
factors, particular nutritional status (Packard, 1984, 1986).
Malaria epidemics have been regularly reported in the arid and semi-arid regions of Mali, 
Senegal, Chad, Niger and Sudan (Kiszewski and Teklehaimanot, 2004). Many other parts 
of Africa have localised malaria epidemics including Angola, Botswana, Cape Verde, 
Namibia, Somalia and Zambia (Kiszewski and Teklehaimanot, 2004).
In Asia, a diverse array of mosquito vectors imposes different dynamics on malaria 
transmission. P. vivax occurs more frequently in Asia than in Africa where P. falciparum 
dominates (Sina, 2002; Snow et al., 2005). Malaria epidemics have long afflicted parts of 
India, Sri Lanka and Pakistan (Kiszewski and Teklehaimanot, 2004). Along the borders 
of Thailand and Cambodia, increased malaria transmission has been associated with gem 
mining and other human activities (Luxemburger et al., 1997). Population movements
from these sites to less endemic regions have also triggered localised outbreaks through 
the return of infected people into vulnerable communities (Singhanetra-Renard, 1993). 
Epidemic malaria transmission in Irian Jay a and Papua New Guinea is due to the 
Anopheles punctulatus mosquitoes, occurring in extensive areas of populated highlands 
(Bangs et al., 1996). Thus, epidemic malaria is usually diverse across Asia due to the 
wide variety of mosquito vectors.
In South America, malaria transmission is less frequent than in Africa, but can break out 
in occasional localised epidemics. P. vivax is the predominant cause of disease. In Brazil, 
gold mining has regularly brought immunologically vulnerable people into seasonally 
intense malaria transmission areas (Camargo et al., 1994). Other nations that are 
repeatedly afflicted with outbreaks of P. vivax and/or P. falciparum malaria include 
Colombia, Venezuela, Peru and Ecuador (Kiszewski and Teklehaimanot, 2004). 
Outbreaks in Colombia and Venezuela often severely affect isolated Native American 
communities. Malaria in Venezuela has been concentrated in Roraima State where it 
occasionally flares into epidemics mainly affecting the indigenous populations. Rain-fall 
associated outbreaks of P. falciparum malaria occasionally occur along the Pacific coasts 
of Peru and Ecuador, where malaria is generally much less stable than in the interior 
Amazonian lowlands (Kiszewski and Teklehaimanot, 2004).
Malaria occurs in low-altitude areas of the countries of Central America including 
Honduras, Nicaragua, and Guatemala. Limited numbers of cases occur in -Panama, Costa 
Rica, and southern Mexico, Active control programmes are in place in several of these 
countries. P. vivax is the dominant species, and fortunately remains susceptible to 
chloroquine (Kiszewski and Teklehaimanot, 2004).
Malaria has been eliminated from several countries of the Caribbean. However, P. 
falciparum  occurs in Haiti and there are a limited numbers of cases in the Dominican 
Republic (Kiszewski and Teklehaimanot, 2004).
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Malaria eradication programmes during the 1940s and 1950s, along with widespread use 
of screening, eliminated malaria from North America, and there is no year-to-year local 
transmission. However, isolated, rare cases of local transmission have occurred. North 
America, the Caribbean region, Europe, Australia, Mexico and Central America are the 
major success stories of malaria vector control efforts (Collins and Paskewitz, 1995).
1.1.4 Animal models of malaria
Various animal model systems have been developed to examine the interaction of the 
malaria parasite and its host. The most common host-pathogen combinations are simian 
models, either with their natural parasites or adapted human parasites, and rodent models 
with parasites isolated from African wild rodents (Langhorne, 1994). Rodent models, 
particularly those using mouse and rat, offer an advantage over simian malaria models in 
that they are easy and cheap to maintain and above all a great deal is known about their 
immune system. Therefore dissective studies of mechanisms can be carried out 
(Langhorne, 1994). However, all laboratory rodents are artificial hosts of malaria 
parasites to which they have been adapted and care must be taken in extrapolating results 
from these models to human malaria.
1.1.4.1 Murine models
Studies using murine models of malaria have greatly contributed to our understanding of 
the immunobiology of host responses to the malaria parasite and elucidation of the 
mechanism of anti-malaria immunity. Analogous to four human Plasmodium species, 
there are four rodent species, P. chabaudi, P. vinkei, P. yoelii and P. berghei, which 
cause malaria infection in mice with varying degrees of morbidity and mortality 
(Stevenson, 1989). The outcome of infections with various strains of P. berghei, P. yoelii 
and P. chabaudi has been described to depend on the genetic background of the host 
(Stevenson, 1989). Moreover the sex of the host also influences the outcome of malaria 
infection in mice as well as in humans, and testosterone has been found to be 
immunosuppressive (Benten et ah, 1993).
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Murine malaria parasites can be divided into two groups based on the immune response 
required for control of acute infection and elimination of the parasite (Sherman, 1998). 
Infection with P. yoelii and P. berghei cannot be controlled or eliminated in the absence 
of B cells. Immunity to these parasites is therefore antibody-dependent. Acute infections 
with P. chabaudi adami or P. chabaudi AS and secondary infections with P. vinckei can 
be controlled in the absence of B cells, implicating antibody-independent mechanisms. In 
the absence of B cells however, parasitaemia in the peripheral blood of P. chabaudi AS 
infected animals is reduced to low levels but the parasites are not completely eliminated. 
Collectively these observations stress the importance of both antibody-independent and 
antibody-dependent mechanisms of acquired immunity against blood-stage malaria 
parasite as it has been extensively discussed in section 1 .1 .6 .2 .
The most characterised murine model is P. chabaudi AS, which can result in non-lethal 
infections in mouse strains such as BALB/c, C57/BL6, C57/BL10 and NIH mice and 
lethal infections in A/Laiid DBA/2 mice (Langhorne et al., 2002). P. chabaudi AS has 
been used in many studies as a model for examining acquired immunity to the asexual 
erythrocytic stages of malaria parasites as it is considered to be the most similar to P. 
falciparum infection in humans. Like P. falciparum, P. chabaudi AS has been shown to 
sequester in the post-capillary venules (Cox et al., 1987) although with a different site of 
sequestration. In the case of P. falciparum, the asexual stage-infected erythrocytes tend to 
sequester in the heart, brain, lungs, kidneys, small intestine and liver (Aikawa et al., 
1990; Pongponratn et al., 1991) while P. chabaudi AS-infected erythrocytes 
preferentially sequester in the liver. Both P. falciparum and P. chabaudi AS exhibit 
antigenic variation during the asexual erythrocytic stage (McLean et al., 1982) and in 
resistant strains of laboratory mice recovery from the acute primary parasitaemia of a P. 
chabaudi AS infection is followed by one or more patent recrudescences (Cox et al., 
1987; Gilks et al., 1990). Furthermore, P. chabaudUmfQoXQé erythrocytes have been 
shown to be able to adhere to specific cell types and sequester by interacting with 
molecules such as CD36 (Mota et ah, 2000), which has been described to mediate 
suppression of DC function by P. falciparum-miQciQà erythrocytes (Urban et ah, 1999).
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1.1.5 Protective immunity to malaria
The complex life cycle of malaria poses a number of challenges to the immune response. 
Since stages in the cycle express varying antigen profiles and have different locations, 
they require different effector mechanisms. Even with repeated infection, protective 
immunity is non-sterile and it is species-, stage-, strain- and variant-specific (Andrysiak 
et a l, 1986; Fandeur and Chalvet, 1998; Rotman et al., 1999). Acquired protective 
immunity induced by malaria parasites involves both antibody-mediated and cell- 
mediated immunity.
1 . 1 . 5 . 1  I m m u n i t y  t o  p r e - e r y t h r o c y t i c  s t a g e s
1.1.5.1.1 Antibody-mediated immunity
It has been known for many years that immunisation with irradiated sporozoites induces 
protective immunity against malaria in both humans and animals (Clyde et al., 1973; 
Nussenzweig et a l, 1967). Early studies provided clear evidence that this protective 
immunity is mediated by antibodies (Abs) that recognise sporozoite surface proteins, 
thereby inhibiting the ability of the parasite to invade hepatocytes (Weiss, 1990). The 
strongest evidence of an important role of anti-sporozoite antibodies in protective 
immunity has been obtained in experiments showing that protection against sporozoites 
occurred after passive transfer of monoclonal antibodies (mAbs) against the repeat 
domain of the circumsporozoite protein (CSP) of P. yoelii (Charoenvit et a l, 1987) and 
by immunisation of mice with synthetic subunit vaccines designed to induce high levels 
of anti-CSP antibodies (Zavala et a l, 1987). In humans, more than 90% of the adult 
population in West Africa was shown to have Abs to P. falciparum sporozoites in the 
blood (Nardin et a l, 1979). Less than half the children had this Ab indicating that 
repeated exposure to sporozoites over many years is necessary to induce its formation 
(Nardin et a l, 1979). Nevertheless, the observation that B cell-deficient mice could also
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mount a protective immune response after sporozoite immunisation strongly suggested 
that T cells also played a protective role (Chen et aL, 1977).
1.1.5.1.2 Cell-mediated immunity
1.1.5.1.2.1 Role of CDS'^T cells
A number of studies using the rodent parasites P. yoelii and P. berghei have 
demonstrated that CD8^ T cells are critical for protective immunity against Plasmodium 
liver stages. Early studies established that the in vivo depletion of CD8  ^T cells reduces 
the immunity induced by immunisation with irradiated sporozoites (Schofield et aL, 
1987; Weiss et al., 1988). Furthermore, it was demonstrated that immunisation with 
irradiated sporozoites induced CD8  ^T cells specific for defined epitopes located in the 
CSP of P. berghei and P. yoelii. The identification of these epitopes allowed the 
generation of epitope-specific CD8  ^T cell-clones that were used to study the in vivo anti­
parasite activity of these T cells (Rodrigues et al., 1991; Romero et al,, 1989; Weiss et 
al., 1992). Transfer of these CD8  ^T cell clones into mice subsequently challenged with 
viable sporozoites, inhibited the development of liver stages and thus prevented infection 
of red blood cells (Rodrigues et al., 1991). This protective activity was shown to be 
stage-specific as transfer of the T cells did not protect mice from a challenge with 
infected erythrocytes.
The molecular mechanisms by which CD8  ^ T cells inhibit the development of 
Plasmodium liver stages of malaria remain to be elucidated. It is known that mice lacking 
perforin or Fas molecules can still develop protective immunity against liver stages 
(Doolan and Hoffman, 2000; Renggli et al., 1997). Furthermore, it has been 
demonstrated that memory CDS’*" T cells lacking perforin and Fas, can still efficiently 
inhibit the development of P. yoelii liver stages (Morrot and Zavala, 2004). These 
findings raised the possibility that CD 8  ^T cell-derived cytokines such as IFN-y may act 
as effector molecules thus destroying intracellular parasites. In fact, early studies have 
shown that injection of IFN-y in mice and rats infected with P. berghei sporozoites a few
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hours before sporozoite challenge, inhibited the development of the exoerythi'ocytic 
forms in the liver cells of the hosts (Ferreira et al., 1986). Instead, administration of 
neutralising mAbs against IFN-y to immune hosts reversed sterile immunity to sporozoite 
challenge, by allowing the growth of exoerythrocytic forms and thus the development of 
parasitaemia (Schofield et al., 1987). Furthermore, a potential role for nitric oxide (NO) 
as part of the downstream effector mechanisms associated with protection conferred by 
attenuated sporozoites has also been proposed. Irradiated P. berghei sporozoite 
immunised mice subsequently challenged with viable sporozoites developed parasitaemia 
when treated orally with substrate inhibitors of nitric oxide synthase (NOS), suggesting 
that the production of NO prevents the development of exoerythrocytic stages of malaria 
in liver (Seguin et al., 1994).
Studies in humans living in malaria-endemic areas indicate that CD 8  ^T cell responses to 
liver stages are rather restricted because they are generally found at very low levels, even 
in individuals living in regions with intense malaria transmission (Lalvani et al., 1996; 
Plebanski et al., 1997). Limiting dilution analysis of CTL precursor frequencies was 
performed on peripheral blood of previously identified West African responders to a wide 
range of epitopes derived from different liver stage antigens (LSA-1, CSP, TRAP and 
STRAP) (Plebanski et al., 1997). The results indicated that in this population there was 
normally a low precursor frequency of specific memory CTL against any single malarial 
epitope. By comparison, a secondary response to an influenza epitope in the same 
population was 3-fold higher (Plebanski et al., 1997). Interestingly, low CTL responses 
were found even in areas where malaria transmission is approximately 300-fold higher 
(Lalvani et al., 1996).
The situation found in human populations is not entirely different from that observed in 
experimental rodent models. Immunisation of mice with irradiated P. yoelii sporozoites 
induces rather low CD8  ^T cell responses, barely detectable by highly sensitive ex vivo 
assays (Carvalho et al., 2001). The generation of transgenic (Tg) mice expressing a T cell 
receptor (TCR) specific for the CD8  ^ T-cell epitope located in the P. yoelii CSP has 
proven to be a valuable tool to study basic features of this T-cell response such as the
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kinetics of differentiation and proliferation as it occurs in vivo.
It was shown that in contrast to memory cells, which can eliminate infected cells 
immediately after antigen recognition naïve CDS’* T cells need to differentiate before 
achieving effector status (Sano et al., 2001). Nevertheless the time required for this 
process was shown to be very short. In fact sporozoites induced a rapid activation of 
naïve CD8  ^ T cells, which in only 24h displayed clear signs of differentiation and 
produced IFN-y and perforin (Sano et al., 2 0 0 1 ). The maximum proliferation and 
cytotoxic activity of specific CD8  ^T cells was instead observed 48h after immunisation 
(Sano et al., 2001). Furthermore, the CD8  ^T cell anti-parasitic activity was shown to 
depend on the number of naïve cell precursors transferred into mice before immunisation 
(Sano et ah, 2001). Therefore the limited efficacy of primary CD8  ^ T cell responses 
observed in humans and normal mice did not appear to be due to the time it takes for 
naïve cells to achieve an effector status as this was attained after just 24h post 
immunisation. Instead it was the low frequency of antigen-specific precursors present 
before immunisation that seemed to limit the protective activity of primary CD8  ^T cell 
responses. Interestingly it was demonstrated that the proper development of this CD8  ^T 
cell response was strictly dependent on CD4^ T cells (Carvalho et al., 2002). BALB/c 
mice were depleted of CD4^ T cells by using a mAb specific for CD4 and were 
immunised two days later with irradiated P. yoelii sporozoites. Epitope-specific CD8  ^T 
cell responses were measured at different time points using an ELISPOT assay (Carvalho 
et al., 2001) to detect antigen-specific IFN-y secretion in the spleen. Parasite-induced 
CD8  ^T cell responses were detectable in CD4-depleted and control mice with no major 
differences in the responses in both groups. As this T cell response evolved, however, it 
became evident that the absence of CD4"^  T cells greatly reduced the magnitude of the 
CD8  ^ T cell response (Carvalho et al., 2002). The CD8  ^ T cell response was in fact 
reduced by 96% in CD4-depleted mice as compared to that in normal mice. Thus, CD4^ 
T cells are important in maintaining or enhancing arising CD8  ^T cell responses. It was 
found that IL-4 secreted by CD4’^ T cells was essential for the full development of the 
CD8  ^T cell response although it is still not clear whether this cytokine acts directly on 
CD8 ’* T cells or through other cell types (Carvalho et al., 2002).
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The findings described above are similar to those obtained by Bourgeois et a l who re­
assessed the role of CD4’*' T cells on CD 8  ^T cell responses and demonstrated that CD4'*' 
T cells are absolutely essential for the generation of CD8  memory cells (Bourgeois and 
Tanchot, 2003). Bourgeois and colleagues investigated the role of CD4^ T cells in the 
response of CDS’*" Tg T cells to the male antigen HY (Bourgeois and Tanchot, 2003). It 
was shown that the absence of CD4^ T cell help had no impact on the early events of the 
primary immune response. Naïve CD8  ^Tg T cells stimulated in vivo by HY were able to 
proliferate and eliminate the antigen in the absence of CD4^ T cells. CD4^ T cells, 
however, played a role in the expansion of CD 8  ^T cells, since the recovery of CD 8  ^Tg 
T cells at the end of the primary response was 3-4-fold less in the absence of CD4^ T 
cells. Moreover, CD8  ^T cells primed in the absence of CD4^ cells did not acquire the 
properties of memory cells. They proliferated poorly both in vitro and in vivo in 
secondary immune responses, and their cytokine secretion upon in vitro re-stimulation 
with the male antigen was very low and similar to that of naïve cells (Bourgeois and 
Tanchot, 2003).
Although it is clear that the magnitude of the primary CD8  ^ T cell response closely 
correlates with the number of parasites used for immunisation (Sano et a l,  2001), 
increasing the time of antigen presentation by daily immunisations did not enhance the 
magnitude of this response (Hafalla et a l, 2002). These results suggest that naïve CD8  ^T 
cells become refractory to further antigenic stimulation. Thus while recently activated T 
cells continue their differentiation and proliferation process, naïve T cells are somehow 
prevented from being activated despite additional antigen supply.
The inability of CD8  ^ T cells to expand further despite an increased antigen exposure 
during the development of the primary response is reminiscent of what is observed in 
endemic areas where very low frequencies of T cells against liver-stage antigens are 
observed despite continued sporozoite inoculations through the bites of malaria-infected 
mosquitoes (Lalvani et a l, 1996; Plebanski et a l, 1997). Indeed it was also demonstrated 
in mice that repeated bites of infected mosquitoes failed to expand the number of 
activated cells once a primary CD8  ^ T cell response was established (Hafalla et a l,
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2002). Transfer of primed spleen cells from infected mice into normal mice that 
subsequently received naïve specific-CDS'*' T cells and were then immunised with 
parasites strongly inhibited the activation of the naïve T cells (Hafalla et aL, 2003). These 
results indicate that primed/activated antigen specific T cells themselves contributed to or 
were directly responsible for preventing activation of naïve CD8  ^T cells in immunised 
hosts (Hafalla et al., 2003).
To identify the inhibitory T cell population, spleen cells from parasite-immunised 
animals were systematically depleted of different T cell populations before transfer into 
normal mice. Depletion of NK cells, yà T cells and CD4'*' T cells did not affect the 
inhibitory capacity of the primed spleen cells (Hafalla et al., 2003). However, depletion 
of CDS’*" T cells allowed the naïve CD8  ^ specific T cells to proliferate normally. To 
confirm this observation CD8  ^T cells purified from spleens of parasite-immunised mice 
were shown to inhibit the activation of naïve CDS’*' T cells as efficiently as the whole 
primed spleen (Hafalla et al., 2003). Furthermore the expansion of naïve CD8  ^T cells 
was shown to decrease drastically as the number of transferred activated CD8  ^ T cells 
increased (Hafalla et al., 2003).
I"Interestingly, the transfer of large numbers of CDS ’*' T cell-specific peptide-loaded DCs 
into the animals overcame the inhibitory effect exerted by activated cells on naïve CDS’*"
T cells (Hafalla et al., 2003). These studies indicated that DCs play a key role in 
mediating the self-regulatory mechanism among activated and naïve CD8 ’*’ T cells. They 
also strongly suggested that the limited activation and proliferation of naïve cells within 
an immunogenic environment were not due to a functional disability that was induced 
upon these T cells, i.e. anergy; rather, they appeared to be caused by limited access of 
naïve CD8  ^T cells to antigen presenting DCs (Hafalla et al., 2003).
Collectively these results suggest that immediately after the initial clonal burst, and 
together with the rapid development of CDS’*" T cell populations expressing effector 
functions, inducible regulatory mechanisms are switched on to prevent the activation of 
naïve CDS’* T cells after exposure to antigen. While these regulatory mechanisms may
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lirait the magnitude of the anti-malaria primary response, they may also play a key 
physiological role by preventing an overwhelming T cell activation that may be 
deleterious to the tissues and organs infected by the parasite. However, while these 
studies establish that competition between naïve and activated CDS’*" T cells at the level 
of APCs is an early regulatory mechanism, it is likely that additional regulatory 
mechanisms are subsequently developed as the immune response evolves. In fact as
mentioned earlier, CD4^ T cells have been shown to be important in sustaining the 
development of CDS'*' T cell responses after clonal expansion (Carvalho et a l, 2002).
1.1.5.1.2.2 Role ofCD4+ T cells
CD4^ T cells are known to play an important role in the induction of protective anti- 
sporozoite antibodies. In fact, early studies using P. yoelii infection in mice have 
demonstrated the importance of CD4^ T cells in the induction of humoral responses 
(Weiss et a l, 1993). Mice treated with anti-CD4 mAbs prior to sporozoite immunisation 
produced very little anti-sporozoite Abs (Weiss e ta l,  1993). This observation suggested 
that CD4'*' T cells played a crucial role in protection against sporozoites by helping B sj
cells to induce anti-malaria humoral responses. However passive transfer of 
hyperimmune serum containing high titres of anti-Abs revealed that CD4-depleted mice 
were still not protected against small numbers of sporozoites (Weiss et a l, 1993). These 
observations indicated that the defect in immunity observed in anti-CD4 treated animals 
was not solely due to the lack of anti-sporozoite Abs and suggested that CD4^ T cells can 
exert an inhibitory effect upon the development of intrahepatocytlc parasites. One of the 
first studies demonstrating a direct inhibitory effect of CD4'*' T cells against liver stages 
of malaria parasites described a CD4^ T cell clone obtained from a mouse immunised 
with irradiated P. berghei sporozoite that recognised an unidentified antigen shared by 
sporozoites and blood-stages and differed from the CSP (Tsuji et a l, 1990). Passive 
transfer of these T cell clones into naïve mice protected most of these animals against 
sporozoite challenge. Furthermore, these clones were shown to display cytotoxic activity 
upon stimulation with antigen, as they lysed antigen-pulsed B cells (A20.2J cell line) in 
vitro. In addition, they produced IFN-y and IL- 2  in vitro, and recognised the plasmodia!
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antigen in the context of class II MHC (Tsuji et al., 1990). Other studies using CD4’*’ T 
cell clones specific for defined epitopes of the P. yoelii CSP also confirmed the ability of 
CD4^ T cells to inhibit the development of malaria liver stages directly both in vitro and 
in vivo (Renia et a l, 1993; Takita-Sonoda et a l, 1996). It was shown that some of these 
clones eliminated liver stage parasites from cultured hepatocytes in an MHC restricted 
manner (Renia et a l,  1993). Although MHC class II molecules are not normally 
expressed at the surface of hepatocytes, the expression of these molecules was shown to 
be induced by IFN-y during viral infections (Franco e/ al, 1988). Therefore, it has been 
proposed that activated, parasite antigen-specific T cells could produce cytokines that 
induce class II expression in neighbouring infected cells (Renia et a l, 1993). Therefore, 
CD4^ T cells, as well as assisting and sustaining the proper development of CD8  ^T cell 
responses, they help B cells to induce a high level of anti-malaria humoral response and 
directly inhibit the development of liver stage parasites.
1.1.5.1.2.3Role of yô T cells
The role of yô T cells in protective immunity against the liver stages was studied in mice 
deficient of ap  T cells (Tsuji et a l, 1994). ap  T cell-deficient mice were subjected daily 
to the bites of irradiated malaria-infected mosquitoes for a period of two weeks. Mice 
exposed to the bites of irradiated non-infected mosquitoes were used as controls. Five 
days after the last exposure to mosquitoes, ap  T cell-deficient mice and their respective 
heterozygous counterparts, which develop normal a p  T cells, were challenged 
intravenously with viable sporozoites. As expected, parasite development in the liver of 
sporozoite-immunised heterozygous mice was strongly inhibited. Most importantly, ap  T 
cell-deficient mice also mounted an immune response that significantly inhibited the 
development of intrahepatocytlc parasites (assessed by measuring plasmodial rRNA), 
suggesting that yô T cells might be responsible for the observed decrease in liver-stage 
parasites (Tsuji et a l, 1994). To define further the possible involvement of yô T cells in 
protective immunity against liver stages, sporozoite-immunised ap  T cell-deficient mice 
were transiently depleted of yÔ T cells by injection of a mAb specific for all TCR y chains 
(Tsuji et a l, 1994). The injection of this anti-TCR y antibody into sporozoite-immunised
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aP  T cell-deficient mice abrogated the inhibition of liver stages induced by their 
immunisation (Tsuji et al., 1994). These findings suggest that yb T cells play an 
important role in the anti-parasitic activity observed in sporozoite-immunised «P T cell- 
deficient animals. Furthermore, when ybT cell clones, derived from spleen cells of 
sporozoite-immunised a p  T cell-deficient mice, were transferred into normal mice, that 
were later inoculated with viable sporozoites, parasite development was shown to be 
significantly inhibited, confirming the protective role of yb T cells against the liver stages 
of malaria parasites (Tsuji et al., 1994). Further studies in yb T cell-deficient mice 
immunised with irradiated sporozoites, revealed that these animals had increased liver 
parasite burden when challenged with P. yoelii sporozoites compared to similarly 
challenged immunocompetent mice, suggesting that yb T cells are a component of early 
immunity directed against malaria pre-erythrocytic parasites (McKenna et a l, 2000).
1.1.6.2 Immunity to erythrocytic stages
1.1.6.2.1 Antibody-mediated Immunity
Early studies showed that passive immunisation with purified immunoglobulin obtained 
from adults living in malaria endemic areas transferred clinical protection against P. 
falciparum (Cohen et al., 1961; Sabchareon et al., 1991). Similarly, passive transfer of 
mAbs against parasite antigens was shown to confer protection in naive mice (Narum et 
al., 2000; Spencer Valero et al., 1998). Various studies using animal models further 
confirmed the involvement of B cells in parasite clearance. Mice rendered deficient of B 
cells due to a targeted mutation of the transmembrane exon of the IgM m-chain (m-MT 
(Kitamura et al., 1991)), were unable to resolve a primary infection with the erythrocytic 
stages of P. chabaudi AS (von der Weid et a l, 1996). m-MT mice could reduce the initial 
acute infection to relatively low levels of parasitaemia with kinetics similar to wild type 
mice. Mutated animals however developed chronic unresolved infections characterised 
by relapsing peaks of parasitaemia (von der Weid et a l, 1996). This indicated that B cell- 
independent mechanisms of immunity were sufficient to reduce the acute parasitaemia of 
a primary P. chabaudi AS infection, but were not able to resolve the infection (von der
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Weid et al., 1996). B cell transfers into these chronically infected mice demonstrated that 
B cells were potent effectors of parasite clearance (von der Weid et al., 1996). Studies in 
B cell deficient mice also indicated that B cells played an essential role in switching from 
Thl to Th2 responses, which is critical for the complete resolution of P. chabaudi 
infection (Langhorne et al., 1998; Taylor-Robinson and Phillips, 1994).
It has been demonstrated that naturally acquired immunity to malaria in individuals living 
in endemic areas depends on the acquisition of a repertoire of specific, protective Abs 
directed against the polymorphic target antigen, P. falciparum erythrocyte membrane 
protein-1 (PfEMP-l)(Bull et al., 1998). In 1986, Marsh and Howard (Marsh and Howard, 
1986) showed that sera taken from children after an infection were able to agglutinate in 
vitro RBCs infected with the same strain of parasite that the child was exposed to but not 
strains to which other children were exposed. Sera taken from immune adults, by 
contrast, were able to agglutinate most strains circulating in the community. It was 
subsequently shown that each agglutinate formed with sera from immune adults 
contained parasite of the same strain, suggesting that the immune sera does not recognise 
a common epitope found on all infected RBCs, but epitopes that are strain specific 
(Newbold et al., 1992). These strain-specific antigens were principally the ‘variant’ 
antigens that are termed PfEMP-1, which are expressed on the surface of trophozoite- 
infected RBCs (Leech et al., 1984) and encoded by approximately 60 genes of the ‘var’ 
multigene family (Smith et al., 1995; Su et al., 1995). PfEMP-1 has been shown to 
mediate cytoadherence of infected RBCs to endothelial receptors such as CD36, and 
ICAM-1 (Baruch et al., 1996), a process that is believed to be involved in the 
pathogenesis of cerebral malaria and placental malaria. Abs to PfEMP-lwere reported to 
prevent the cytoadherence property of infected cells (Smith et al., 2000). This may 
therefore avoid the development of cerebral malaria (Smith et al., 2000) and presumably 
allow infected cells to be removed by the spleen (David et al., 1983). Similarly, it was 
reported that Abs disrupt spontaneous binding of uninfected RBCs to Plasmodium- 
infected RBCs (rosetting) (Carlson et al., 1990). This in vitro phenomenon is thought to 
be associated with cerebral malaria although its occurrence in vivo has not been 
demonstrated yet.
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Typically, only a single PfEMP-1 antigen is expressed at any one time and the ability of 
the parasite to switch expression from one variant to another is believed to be primarily 
responsible for the ability of the parasite to evade immune responses, a strategy now 
known as antigenic variation (Biggs et a l, 1991). Thus immunity to the parasite develops 
once an individual acquires Abs against multiple PfEMP-1 variants, which might explain 
why natural immunity takes several years to develop. This idea is substantiated by the 
fact that the levels of variant-specific Abs increase in an age dependent manner and 
correlate with a decline in both the prevalence and density of parasitaemia (Piper et al,,
1999).
Therefore the degree of protective immunity in humans correlates with the level of Abs 
against asexual blood-stage antigens, and has been shown to depend on Ab isotypes 
(Astagneau et a l, 1995; Chizzolini et a l, 1988; Piper et a l, 1999). Various studies have 
reported that Abs, which were protective in vivo by passive transfer of immune 
immunoglobulin in humans had no effect in vitro on the growth of P. falciparum asexual 
blood-stages, unless they were allowed to cooperate with blood monocytes by binding to 
Fc receptors (Bouharoun-Tayoun et a l, 1990; Khusmith and Druilhe, 1983). It was also 
shown that Abs, which were not protective in vivo were unable to exert an anti-malaria 
effect in vitro by cooperation with monocytes (Bouharoun-Tayoun et a l, 1990; Khusmith 
and Druilhe, 1983). For these reasons, the subclasses of Abs produced in response to 
infection are of particular importance, since certain isotypes, being non cytophilic (i.e. 
they do not have an affinity to cells), are unable to cooperate with cells in parasite-killing 
effector responses such as opsonization and antibody-dependent cellular inhibition 
(Bouharoun-Tayoun a/., 1990).
Resistance to P. falciparum infection in humans was reported to be mainly associated 
with the ability to produce IgGl and IgG3, two cytophilic Abs, and to reduce the 
proportion of the non-cytophilic isotypes IgG2, IgM and IgG4 of the same specificity 
(Bouharoun-Tayoun and Druilhe, 1992). The non-cytophilic Abs were suggested to block 
the effector mechanism induced by cytophilic isotypes because of their higher
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concentration in serum and their greater affinity to the target antigen, thus providing a 
means of escape induced by the parasite (Bouharoun-Tayoun and Druilhe, 1992). 
Furthermore, the IgG2 isotype appeared to be the main blocking Ab in some adult 
patients, whereas, in young children, who are unable to produce high levels of IgG2, the 
parasite has been shown to induce the synthesis of IgM preferentially (Bouharoun- 
Tayoun and Druilhe, 1992). Interestingly, IgG2 has also been reported to be associated 
with low risk of infection and protection against P. falciparum (Aucan et al., 2000). A 
polymorphism of the gene encoding FcyRJIa has been found that explains such 
conflicting results.
FcyRIIa (CD32) is expressed on the surface of lymphocytes and monocyte/macrophages, 
and provides an important link between humoral and cellular immune systems 
(Nimmerjahn and Ravetch, 2006). It is a low affinity IgG receptor capable of binding 
immunoglobulin subtypes IgGw- However the recognition of IgG by CD32 is influenced 
by a polymorphism within the gene (Cooke et al., 2003). A single nucleotide change 
within the CD32 molecule alters a histidine (H) to an arginine (R) residue at position 131 
and changes its function in vitro. The presence of the H I31 allele is essential for the 
efficient binding of IgG2 subtypes (Warmerdam et al., 1991). In its absence, those with 
the R131 genotype have preferential affinity for IgG3 and IgGl subtypes. Therefore the 
functional activity of IgG subtypes is likely to depend, at least in part, on the CD32 
genotype of the host.
In mice, the isotype IgG2a is associated with protection against Plasmodium infection 
(Matsumoto et ah, 2000; Smith et al., 1997; Su and Stevenson, 2000). IgG2a is 
predominant during the primary ascending parasitaemia in mice infected with P. 
chabaudi AS followed by an IgGl response during the chronic stage of infection, as a 
consequence of Thl to Th2 switching (Taylor-Robinson and Phillips, 1994). It has been 
shown that IgGl and IgG2b can confer protection against lethal challenge infection with 
P. yoelii in mice immunised with MSP-1 (Hirunpetcharat et al., 1997). IgG3 may also be 
important as passive transfer of anti-MSP-1 IgG3 into naïve recipient resolves P. yoelii 
infection (Majarian et al., 1984).
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Ab responses directed against surface proteins of the merozoite may function either by 
blocking RBC invasion or by making the merozoite susceptible to phagocytosis. MSP-1 
is the best studied of the merozoite antigens (Holder et a l, 1999). Following release from 
infected RBCs, the membrane-bound component of MSP-1 is subjected to a single 
proteolytic cleavage known as ‘secondary processing’ (Blackman et a l, 1991a). The 
cleavage product is shed prior to merozoite invasion (Blackman et a l, 1991b) and only 
the small carboxyl-terminal 19 KDa domain MSP-119, is carried into the newly infected 
RBC (Blackman et a l, 1990). It was shown that Abs inhibited merozoite invasion by 
both binding to MSP-119 and blocking secondary processing of the MSP-1  protein 
(Blackman et a l, 1990; Blackman et a l, 1994). Similarly, Abs to the Duffy binding 
protein, which is necessary for P. vivax merozoite invasion of RBC (Michon et a l, 2000), 
may inhibit the establishment of P. vivax infections. Furthermore, it has been reported 
that Abs use other mechanism to block merozoite invasion of RBCs, such as causing 
complement-mediated damage and preventing merozoites release by causing 
agglutination of merozoites in rupturing schizonts (Ramasamy et a l, 2001).
Despite the importance of Ab responses in malaria infection, it seems that not all Abs are 
protective. Polyclonal Abs specific for MSP-2 but not mAbs specific to the same antigen 
have been shown to enhance invasion of multiple merozoites into RBC (Ramasamy et a l, 
2001; Ramasamy et a l, 1999). Furthermore, high-titre Abs against MSP-2 fails to induce 
complement-mediated damage (Ramasamy e ta l ,  1999). In this regard, it has been 
suggested that merozoites might have evolved a mechanism to limit complement- 
mediated damage by adopting strategies such as rapid shedding of the surface proteins 
(Ramasamy 6  ^a/., 2001). To explain the increase in multiple invasion instead, it has been 
proposed that merozoites crosslinked by anti-MSA-2 Abs can recognize RBC ligands, re­
orientate one or more of their apical surfaces to contact the RBC membrane and 
successfully complete invasion together (Ramasamy et a l, 1999). Alternatively, Ab- 
cross-linked merozoites attracted to the same RBC, might dissociate and invade the RBC 
independently (Ramasamy et a l, 1999). The formation of ring-stages lying within 
discrete parasitophorus vacuoles favours the latter model (Ramasamy et a l,  2001).
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Moreover it has been reported that Abs, which inhibit MSP-1 processing and erythi’ocyte 
invasion can be blocked by naturally acquired antibodies (Guevara Patino et al,, 1997). 
All of the above in vitro observations illustrate the importance of identifying epitopes that 
induce protective Abs when designing a vaccine against malaria.
1.1.6.2,2 Cell-mediated Immunity
The role of cell-mediated immune responses directed against the erythrocytic stages of 
malaria has been extensively studied in many experimental animal models (Taylor- 
Robinson, 1995).
1 ,1 .6.2.2.1 Role of CD4^ T cells
Both Thl and Th2 cells have been shown to be involved in protective immunity against 
blood-stage malaria. P berghei and P yoelii were reported to induce a rapid and strong 
Th2 immune response whereas P. chahaudi adami a strong Thl response (Taylor- 
Robinson, 1995). These findings were substantiated by the fact that severe combined 
immunodeficient (SCID) mice reconstituted with enriched immune T cells suppressed 
acute P. chahaudi adami parasitaemia, suggesting that T, but not B, cells are required to 
clear this strain of malaria (van der Heyde et ah, 1994). In addition, B cell deficient mice 
were also shown to resolve P, chahaudi adami, P. vinckei petteri and P, chahaudi 
chahaudi malaria at the same rate as normal mice (van der Heyde et al., 1994). 
Collectively, these observations establish that T cells alone can mediate the clearance of 
acute malaria caused by these subspecies of Plasmodium. Moreover, the protective 
immune response was shown to depend upon CD4^ T cells, as B cell deficient mice 
treated with anti-CD4 mAh did not resolve their infections (van der Heyde et al., 1994).
Nevertheless, several studies in P. chahaudi AS have shown that protective immunity to 
blood-stage malaria requires both CD4^ T cells and Abs, and sequential activation of Thl 
and Th2 cells is critical for protection (Langhorne et a l, 1998; Taylor-Robinson and 
Phillips, 1994). The importance of Thl and Th2 cells in protection against R  chahaudi
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AS infection has been investigated in resistant and susceptible mice (Stevenson and Tam,
1993). It is now well established that in resistant mice, the acute phase of P. chahaudi AS 
infection is predominantly characterised by the production of IFN-y during the first week 
of infection, which declines as the parasitaemia decreases, and is replaced by IL-4 and 
IL-10 production during the later stages of infection (Taylor-Robinson and Phillips,
1994). In contrast, mouse strains for which P. chahaudi infection is fatal, produced high 
levels of IL-5 within the first week of infection (Stevenson and Tam, 1993). These 
observations indicate that resolution of primary blood-stage P. chahaudi infection occurs 
by sequential activation of Thl CD4^ T cells followed by activation of the Th2 subset, 
and that induction of a strong Th2 response early in infection may lead to a severe and 
lethal course of malaria. Furthermore, the size of the infective dose, thus the level of 
antigen presented to the immune system, was reported to affect significantly the nature of 
the prevailing immune response to P. chahaudi infection (Taylor-Robinson and Phillips, 
1998). In resistant mice, production of IFN-y was directly proportional to the size of the 
innoculum whereas IL-4 production correlated indirectly with the size of the infective 
dose (Taylor-Robinson and Phillips, 1998). In contrast, increasing the infective dose in a 
susceptible mouse strain led to a prominent and accelerated up-regulation of IL-4 
production (Taylor-Robinson and Phillips, 1998).
It has been speculated that the initial Thl type response observed during P. chahaudi 
infection could be due to the high concentration of antigens that the host is exposed to 
following schizont rupture due to the synchronous nature of the asexual erythrocytic 
cycle (Taylor-Robinson and Phillips, 1998). Conversely, Th2 type responses were 
suggested to be due to the continuous and increasing stimulation with antigen which 
would occur in asynchronous infections such as in P. herghei and P. yoelii infections. 
Indeed there is strong evidence indicating that antigen dose affects Thl/Th2 responses 
(Constant and Bottomly, 1997). However, there are no clear-cut conclusions regarding 
whether ‘high’ or ‘low’ doses of antigen are best suited to induce each type of immune 
response. Interestingly, most of the studies in which low doses of antigen induced Thl- 
like responses used parasites as immunogens, whereas low doses of soluble proteins 
tended to skew toward Th2-type cells (Constant and Bottomly, 1997). Therefore, it may
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be that the antigen itself can influence the type of response initiated. However, whether 
the type of the immune response elicited during malaria and the synchronicity of 
bloodstream infection are linked requires further studies. Nevertheless, collectively these 
results show that CD4^ T cells are crucial for resistance to malaria. Both Thl and Th2 
cells contribute to protective immunity at different times of infection and the balance 
between these two subsets determines the outcome of the disease.
1:
The role of CD4^ T cells in immunity to malaria in humans is less well understood.
Individuals lacking previous exposure to P. falciparum, as well as malaria-exposed 
individuals, have T cells that proliferate and secrete IFN-y in response to parasite antigen 
and inhibit parasite growth in vitro (Fell et al., 1994). The degree of proliferation of 
peripheral blood mononuclear cells (PBMCs) isolated from malaria-exposed individuals 
and stimulated in vitro with parasite antigens, correlated with the number of previous 
malaria episodes (Carvalho et a l, 1999). In children living in highly endemic areas, 
protection against P. falciparum correlates with the level of antigen-specific proliferative 
responses (Migot-Nabias et al., 1999). However, acute P. falciparum  malaria is 
associated with loss of in vitro T cell responsiveness to antigenic stimulation as well as 
reduction in the number of T cells in the peripheral circulation (Elhassan et al., 1994;
Hviid et al., 1991). This cellular hyporesponsiveness has been associated with the 
sequestration of T cells expressing the adhesion molecule leukocyte function-associated 
molecule-1 (LFA-1) on their surface (Elhassan et al., 1994; Hviid et al., 1991). 
Particularly, depressed frequencies of CD4^ T cells were observed in patients with 
cerebral malaria (Hviid et a l, 1997). After the clearance of parasitaemia, previously 
sequestered cells re-emerge into the periphery, with subsequent restoration of immune 
responsiveness, thus explaining why acute P. falciparum malaria is associated with a 
transient inability of peripheral blood cells to respond to antigenic stimulation in vitro 
(Elhassan et a l, 1994). A shift from a Th2 response to a more pronounced Thl response 
has been suggested to resolve P. falciparum  infection (Winkler et a l,  1998). 
Nevertheless, the precise role of effector CD4^ T cells in protection of humans against 
malaria needs further investigation.
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1.1.6.2.2.2 Role ofyô T cells
yô T cells are found in increased numbers in the spleens of humans and mice infected 
with malaria (Nakazawa et ah, 1994), but their role in immunity to blood-stage infection 
remains unclear. It has been shown that depletion of yô T cells does not alter 
parasitaemia, anaemia or survival rates of mice infected with the avirulent P.c. adami or 
virulent P. c. chahaudi CB, whereas mice depleted of ap  T cells had higher levels of 
parasitaemia, lower RBC counts, and decreased survival rates (Sayles and Rakhmilevich, 
1996). These results indicate that a p  but not yô T cells play an essential role in host 
defence against P. chahaudi infection in mice (Sayles and Rakhmilevich, 1996).
In contrast, other studies emphasise the importance of this population of T cells in the 
resolution of malaria. Mice lacking yô T cells were shown to develop chronic 
parasitaemia following P. c. chahaud AS infection (Langhorne et ah, 1995; Seixas and 
Langhorne, 1999). Proliferation of yô T cells was also associated with parasite clearance 
from the blood in P. c. adami infected mice (Nakazawa et ah, 1994). As the parasitaemia 
decreased, the number of yô T cells was shown to decline towards basal levels as 
observed in immunohistochemical preparations of spleen sections (Nakazawa et al., 
1994). The expansion of yô T cells was suggested to require the presence of ap  T cells 
and was supported by the observation that the expansion of yô T cells did not occur in 
anti-CD4 treated mice and by the finding of large numbers of yô T cells in the spleens of 
infected SCID mice which received CD4-enriched fractions containing few yÔ T cells 
(van der Heyde et ah, 1993b). Furthermore, the fact that the ap  T cell population was 
found to be maximally activated to become blast cells during the period of ascending 
parasitaemia, whereas the maximal yô T cell blast response was found during the period 
of descending parasitaemia, suggests that these cells may function in the resolution of 
blood-stage malaria (van der Heyde et ah, 1993b). The detection of high levels of yô T 
cells only in models that resolve their infection further reinforces this possibility (van der 
Heyde et ah, 1993b).
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Human yà T cells isolated from peripheral blood of malaria non-immune individuals can 
inhibit growth of the late or extracellular stages of P. falciparum in vitro (Troye- 
Blomberg et al., 1999). The inhibitory activity correlates with the number of yô T cells 
present in the culture, suggesting that yô T cells contribute to the control of infection 
(Troye-Blomberg et al., 1999). Thus a role of yÔ T cells in providing protective immunity 
against malaria cannot be excluded and requires further investigation.
1.1.6.2.2.3 Role ofCD8+ T cells
Regarding CD8'*' T cells, as described earlier, there is clear evidence for their contribution 
to immune effector mechanisms aimed at pre-erythrocytic stages of the malaria life cycle. 
However, in contrast to CD4^ T cells, CD 8  ^T cells have been shown not to be essential 
for control of asexual erythrocytic malaria parasites. p2-microglobulin (P2m) deficient 
mice effectively lack major histocompatibility complex (MHC) class I molecules, thus 
they virtually lack CD8 ap  T cells. When infected with P. c. adami, P. c. chahaudi or P. 
yoelii 17xNL, p2m-deficient mice were as resistant to blood-stage infection as control 
animals (van der Heyde et al., 1993a). Together with selective lymphocyte depletion 
experiments performed with P. c. chahaudi (Suss et ah, 1988), these data demonstrate 
that CD8^ T cells are not required to suppress blood-stage malaria and that the 
suppression mechanism is not MHC class I-restricted.
1.1.6.2.2.4 Cytokines involved in protection against blood-stage malaria
T cells play a central role in the elimination of blood-stage malaria parasites through the 
release of cytokines that activate other effector cells. Cytokines involved in immunity to 
blood-stage malaria include IL-12, IFN-y and TNF-a,
(a) IL-12
The major immunological role of IL-12, that is of relevance to protective immunity to
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blood-stage malaria, is its ability to induce IFN-y production by both natural killer (NK) 
and CD4^ T cells (Trinchieri, 2003). Systemic administration of IL-12 was shown to 
protect susceptible A/J mice against lethal P. chahaudi AS infection (Stevenson et a l, 
2001). Moreover, this IL-12-induced protection occurred through IFN-y, TNF-a, and 
NO-dependent mechanisms, associated with Thl cell-mediated immune responses (Sam 
and Stevenson, 1999). Administration of anti-IL-12 to mice infected with P. herghei led 
to increased parasitaemia and fatal outcome (Yoshimoto et a l, 1998b). Anti-IL-12 
treatment significantly reduced the secretion and mRNA expression of IFN-y, showing 
that IL-12 is a potent inducer of IFN-y during malaria infection (Yoshimoto et a l, 
1998b). In humans, the levels of IL-12 were found to be significantly elevated in patients 
who suffered less severe disease whereas they were found to be lower in patients who 
suffered more severely from the disease (Luty et a l, 2000; Malaguamera et al, 2002).
While many studies provide evidence for a protective role of IL-12 in immunity to blood- 
stage malaria, others have shown that IL-12 is also implicated in mediating pathology 
during malaria. Yoshimoto et a l demonstrated that IL-12p40 mRNA expression is 
upregulated in the spleen and liver during early infection in mice inoculated with lethal 
blood-stage P. herghei parasites (Yoshimoto et al, 1998a). Infection with this parasite 
was also found to upregulate mRNA expression of IFN-y, IL-4, IL-10, TNF-a and iNOS 
in these organs. Infected mice were found to experience severe liver damage, reduced 
body weight and severe anaemia. Treatment of infected mice with mAh against IL-12 
significantly decreased liver injury and prolonged survival, although all the animals 
eventually succumbed. Anti-IL-12 treatment also significantly reduced mRNA 
expression and secretion of IFN-y in the liver as well as the spleen (Yoshimoto et al., 
1998a). These results provide evidence that IL-12 is involved in the pathogenesis of liver 
injury via production of IFN-y during lethal P. herghei infection. Therefore, while IL-12 
has protective effects against blood-stage malaria, this molecule could also be involved in 
malaria pathology due to its ability to induce excessive production of inflammatory 
mediators.
(b) IFN-y
31
IFN-y plays an important role in resistance to blood-stage malaria infection. P. 
falciparum  erythrocytic stages were lethally susceptible to oxygen-dependent and 
oxygen-independent mediators released by IFN-y-activated, monocyte-derived human 
macrophages (Ockenhouse et a l, 1984). PBMCs from children with mild P. falciparum 
infection produce high levels of IFN-y when stimulated in vitro with merozoite antigens, 
and these children have a lower risk of re-infection (Luty et al., 1999). In contrast, 
children with severe malaria show lower levels of IFN-y production by PBMCs and are 
more susceptible to re-infection (Luty et a l, 1999). In the mouse model, infection oflFN- 
y deficient mice with P. chahaudi AS results in increased morbidity and mortality 
indicating a role for this cytokine in protection (Su and Stevenson, 2000). Furthermore, 
mice defective in IFN-y and its receptor show a predominantly Th2 response, which is 
associated with susceptibility to P. chahaudi infection (Balmer et a l,  2000; Su and 
Stevenson, 2000). These results therefore provide evidence for a protective role for IFN-y 
in blood-stage malaria.
(c) TNF-a
TNF-a production is greatly augmented during malaria infection, as shown by elevated 
levels of TNF-a in plasma of patients with malaria (Luty et a l, 2000; Perkins et a l,
2000) and infected mice (Choudhury et a l ,  2000; Stevenson et a l,  1995). Malaria 
parasites and their products, such as malaria pigment (haemozoin) (Pichyangkul et a l,
1994) and glycosylphosphatidyl-inositols (Schofield and Hackett, T993) can directly 
induce the release of TNF-a by macrophages. Early studies reported that parasites 
incubated overnight with recombinant TNF-a (rTNF-a) showed no loss of viability, but 
repeated injection of rTNF-a into infected mice reduced parasitaemia and significantly 
prolonged survival of mice infected with a lethal variant of P. yoelii parasite (Taverne et 
a l, 1987). These observations suggested that TNF-a acted on blood-stage malaria in vivo 
via host cells. This hypothesis was confirmed in later studies where rTNF-a was shown 
to cause an increase in the phagocytosis of P.falciparum-mÎQQXQà erythrocytes by human
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monocytes (Muniz-Junqueira et a l, 2001). The phagocytosis-enhancing effect of TNF-a 
was observed exclusively when mti-P.falciparum antibody was present in the culture 
(Muniz-Junqueira et al., 2001). Other studies using neutrophils as phagocytic cells, also 
observed an increase in phagocytosis induced by this cytokine (Kumaratilake et a l, 1991; 
Kumaratilake et a l, 1990), suggesting that TNF-a is an important component of the 
phagocytic effector mechanisms, which are involved in the destruction of the malarial 
parasite.
In addition to its protective role, TNF-a is also associated with pathology of malaria. The 
balance between the protective and pathologic roles of TNF-a is dependent on the 
amount, timing and location of TNF-a expression. In fact, resistant C57BL/6 mice had 
higher levels of TNF-a mRNA in the spleen and liver early during infection than did 
susceptible A/J mice, which succumb to the disease 10 days after initiation of infection. 
Administration of anti-TNF-a Ab to these resistant mice abrogated the immunity, 
indicating a protective role for TNF-a. (Jacobs et a l, 1996). Furthermore, resistant 
C57BL/6 mice also expressed high levels of IFN-y mRNA and low levels of IL-4 mRNA 
in the spleen, whereas susceptible A/J mice had low levels of IFN-y mRNA but high 
levels of TNF-a mRNA in the liver as well as having high levels of TNF-a protein in 
serum, later during infection just before death occurred (Jacobs et a l, 1996). These 
results demonstrate that a Thl-associated increase in TNF-a mRNA expression in the 
spleen early during infection correlates with resistance to P. chahaudi AS, whereas 
increased TNF-a mRNA levels in the liver and excessive levels of the TNF-a protein in 
serum later during infection correlate with susceptibility.
Injections of neutralizing mAb against recombinant murine IFN-y in P. herghei infected 
mice, markedly reduced serum levels of TNF-a, which led to reduced incidence of 
experimental cerebral malaria, suggesting that these cytokines contribute to pathology in 
P. herghei infection (Grau et a l, 1989a). Furthermore, experiments with blocking Abs 
revealed that production of TNF-a during P. herghei blood-stage malaria infection was 
responsible for weight loss and anaemia (Hirunpetcharat et a l, 1999). These findings
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concurred with P.falciparum infection in humans where analysis of post-mortem human 
tissues showed expression of TNF-a in brains of patients with cerebral malaria (Brown et 
ah, 1999). In addition, high levels of TNF-a in children with P, falciparum malaria 
correlated with hypoglycaemia and high mortality rates (Grau et al., 1989b).
Collectively, the data suggest that infection control is cell mediated but that immime 
pathology from cell mediated mechanisms contributes to disease. To achieve desirable 
outcomes, the balance of mediators that are involved in the immune response to malaria 
must be tightly controlled. An understanding of the mechanisms by which cytokines 
induce protection and/or pathology in malaria will prove to be fundamental for designing 
vaccines and developing new therapies for malaria.
1.1.7 Malaria-induced immunosuppression
Asymptomatic and symptomatic malaria patients often show reduced immune responses 
not only to malaria parasites but also to unrelated antigens, including vaccines 
(Williamson and Greenwood, 1978), suggesting that an active immune suppression 
mechanism may operate during the course of malaria. In humans, the depressed 
responsiveness to heterologous antigens was originally reported in 1962 by measuring the 
antibody responses of infected and uninfected children to vaccination -with tetanus toxoid 
(McGregor, 1962). Standard doses of the same batch of tetanus toxoid failed to induce an 
anti-toxin response in significantly more Gambian children with malarial parasitaemia 
than in counterparts who had been kept free from malaria by continuous 
chemoprophylaxis (McGregor, 1962). Later studies confirmed this diminished antibody 
response to tetanus toxoid and also reported that children with acute malaria showed a 
significantly reduced antibody response to the O antigen of Salmonella typhimurium 
(Greenwood et al., 1972), However, their antibody response to the H antigen of S. 
typhimurium and their cellular immune responses were normal (Greenwood et al., 1972).
In an attempt to establish the duration of this immune defect, the immune response of 
children with acute malaria to vaccination with S. typhimurium and meningococcal
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vaccines were studied at vaiying times after the onset of their illness (Williamson and 
Greenwood, 1978). Children with acute malaria were randomly allocated to one of tliree 
groups. Children in group I were immimised at the time of their presentation at hospital. 
Group II received the immunisations 7 days after presentation with acute malaria and 
group III were vaccinated 28 days after presentation. All children were treated 
immediately with chloroquine and weekly pyrimethamine was given to patients and 
controls to prevent any further attacks of malaria during the study period. A significant 
correlation was found between the level of parasitaemia and the degree of 
immunosuppression, children with the highest parasitaemia making almost no antibody 
response to vaccination. After treatment immune responsiveness to S. typhimurium 
vaccine rapidly returned. However, recovery of immune responsiveness to 
meningococcal vaccine was delayed. These results suggested that an attack of acute 
malaria, even when treated promptly, could have a prolonged suppressive effect on the 
humoral immune system (Williamson and Greenwood, 1978).
In addition to studies documenting impaired responses to heterologous antigens in 
children with acute falciparum  malaria (Greenwood et al., 1972; McGregor, 1962; 
Williamson and Greenwood, 1978), there is also evidence of suppression of immune 
responses to malaria-specific antigens (Brasseur et al., 1983; Ho et al., 1986; Troye- 
Blomberg et al., 1984). Malarial antigens (MA) were prepared from a natural isolate of P. 
falciparum collected in eastern Thailand. PBMCs were collected from patients with acute 
malaria or from healthy controls and stimulated either with a mitogen or with MA or a 
control antigen prepared from cultured uninfected erythrocytes obtained from the same 
donor who was used for parasite cultures. Patients with acute P. falciparum malaria were 
found to have an antigen-specific T cell proliferative defect that persisted for more than 
four weeks following treatment (Ho et al., 1986). The duration of this specific 
immunosuppression correlated with the initial parasite count and the severity of clinical 
illness and was more prolonged in patients with more serious disease (Ho et a l, 1986). 
The antigen-specific immunosuppression may explain the difficulty associated with the 
development of protective immunity to P. falciparum malaria. These results indicate that 
blood-stage malaria infections may suppress responses important for immunity to malaria
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thereby allowing the parasite to survive. Furthermore, they suggest that patients infected 
with P. falciparum may not respond as well to a malaria vaccine as would uninfected 
individuals.
While malaria-induced immunosuppression may have evolved as a mechanism by which 
the parasite can avoid immune-mediated clearance, it leaves malaria-infected individuals 
more susceptible to secondary infections. Salmonella septicaemia was found to be more 
common and more severe during outbreaks of malaria (Mabey et aL, 1987) and it has 
been suggested that malaria-induced immunosuppression was one of the reasons for the 
persistence of tuberculosis in malaria-endemic regions (Enwere et al., 1999). In addition, 
malaria infections have been implicated in the development of Burkitt’s lymphoma, a 
tumour in which B lymphocytes, infected with Epstein-Barr virus (EBV), proliferate 
abnormally in immunosuppressed patients (Lam et a l, 1991; Moormann et al., 2005; 
Whittle et al., 1984). An early study reported that during an attack of P. falciparum  
malaria, T cell subpopulations are altered so that, in vitro, B lymphocytes infected with 
EBV proliferate abnormally to secrete large amounts of Abs (Whittle et ah, 1984). 
PBMCs were obtained from patients during and three weeks after an acute attack of P. 
falciparum malaria and were used in in vitro regression assays, which provide a measure 
of the strength of T cell control of EBV-infected B cells. All patients had antibodies to 
the viral capsid antigen (VCA) of EBV. It was found that regression indices were high 
during the attack, denoting loss of T cell control, but they fell on recovery, signifying a 
return to normal control (Wliittle et al., 1984). These observations concurred with a later 
study by Lam et al. that demonstrated that the numbers of EBV-infected B cells were 
higher in acute malaria patients than in convalescent malaria patients and in healthy 
control adults (Lam et a l, 1991). More recently, it was reported that elevated EBV loads 
were found in children 1-4 years of age living in a region in Kenya where malaria is 
endemic (Moormann et al., 2005).
The incidence of herpes zoster was also shown to be markedly increased in malaria- 
infected individuals (Cook, 1985). Papua New Guinean children under 9 years of age 
were reported to have developed herpes zoster following an episode of malaria, due to P.
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falciparum  or vivax (Cook, 1985). The reactivation of the varicella-zoster virus in 
these patients may reflect transient depression of cell-mediated immunity by these 
malaria parasites. Furthermore, a high rate of parvovirus B19 and P. falciparum co­
infection has been reported in children from Nigeria (Jones et al., 1990) and patients with 
malaria showed severe anaemia as a result of concomitant parvovirus B19 infection 
(Scarlata et al., 2002). These results confirm the possibility that the depression of cell- 
mediated immunity during P. falciparum  malaria may favour the appearance of 
opportunistic viral infections.
Hepatitis B virus carriage was found to be significantly increased among cases of severe 
malaria (Thursz et al., 1995). It was suggested that in individuals with persistent hepatitis 
B virus infection the protective role of cytotoxic T cells in lysing parasite-infected 
hepatocytes could be impaired due to the reduced levels of HLA class I on hepatocytes 
infected by hepatitis B virus, leading to increased susceptibility to severe malaria (Thursz 
et al., 1995).
The pattern of immunosuppression observed in children with acute malaria is similar to 
that observed in experimental animal models. At the time of maximal parasitaemia, P. 
berghei infection in mice caused profound suppression of antibody response to some 
antigens including human-y-globulin, but not to others, such as to keyhole limpet 
haemocyanin (KLH)(Greenwood et al., 1971). However, no suppressive effect of cell- 
mediated immunity was demonstrated, as skin graft rejection and contact hypersensitivity 
were not impaired (Greenwood et al., 1971).
Back in 1965, Kaye et a l demonstrated lowered resistance to S. typhimurium in mice 
infected with P. berghei (Kaye et a l, 1965). Depression of antibody responses to tetanus 
toxoid was demonstrated in malaria-infected mice infected (Voiler et a l,  1972). 
Similarly, a reduced immune response to sheep erythrocytes was reported during malaria 
infection in mice (Salaman et a l, 1969). Acute P. yoelii and chronic P. berghei infections 
in mice were accompanied by a reduced capacity to mount an antibody response to type 
III pneumococcal polysaccharide (McBride et a l, 1977). P. yoelii infection in mice was
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shown to suppress the response to killed Bordetella pertussis (whooping cough) vaccine 
(Viens et a l, 1974), depress the primary antibody response to alum-absorbed bovine 
serum albumin (McBride and Micklem, 1977) and to have depressed immune responses 
to Moloney leukemia virus (MLV), the latter resulting in the induction of lymphomas, 
accompanied by reduced levels of circulating neutralising Ab to MLV and in particular 
by the absence of IgG antibody (Bomford and Wedderbum, 1973).
The observations described above suggest that repeated episodes of malaria-induced 
immunosuppression may contribute to a high incidence of bacterial infections and 
recrudescence of viral infections, may interfere with vaccination programmes and may 
have other long-term effects such as predisposing to the development of Burkitt’s 
lymphoma. Furthermore, the demonstration that P. falciparum infection in humans is 
associated with a similar type of immunosuppression observed in experimental animal 
models support the view that animal experiments have relevance to human disease and 
they may aid in determining and overcoming the mechanisms of malaria 
immunosuppression as well as the development of a much needed effective vaccine 
against malaria.
Dendritic cells (DCs) play a pivotal role in the activation of T cells and consequently the 
induction of adaptive immune responses and immunity (Adams et al., 2005). Therefore, it 
is reasonable to assume that DCs also play a critical role in initiating immune responses 
to malaria. There is evidence that memy pathogens have evolved mechanisms to subvert 
the function of these important cells thereby modulating the host’s immune response to 
their advantage (Rescigno, 2002; Rescigno and Borrow, 2001). Thus, it is likely that 
malaria parasites may modulate key functions of DCs that could potentially lead to or 
contribute to more generalised immunosuppression observed in infected individuals.
38
1.2 Dendritic Cell biology
Dendritic cells (DCs) are bone marrow-derived mononuclear cells that are found in 
tissues throughout the body and are specialised for the uptake, transport, processing and 
presentation of antigens to T cells (Adams et a l, 2005). It is now clear that DCs are a 
heterogenous group of cells that vary in cell-surface marker expression and function. 
Originally, they have been divided into two subpopulations, myeloid and lymphoid, as 
they can efficiently derive from myeloid and lymphoid precursors respectively (Ardavin, 
1997; Inaba et a l, 1993). The concept that DC subtypes are the product of entirely 
separate developmental lineages however, has been challenged by studies showing that 
both subsets can arise from common myeloid progenitors (Traver et a l, 2000). Therefore, 
a second model for the generation of functionally distinct DC subtypes has been proposed 
whereby all DCs are thought to belong to a single haematopoietic lineage, the different 
subtypes of DCs being generated by local environmental signals (Shortman and Liu,
2002). The reality is probably a mixture of these two models, and a large degree of 
functional plasticity seems to be a general feature of both DCs and their precursors 
(Shortman and Liu, 2002).
Despite the tremendous interest in DCs, there are great difficulties in studying the 
development and lineage of a cell, which is present in such low numbers within multiple 
tissues. The in vitro culture of DC using cocktails of cytokines and growth factors has 
provided a reliable source of these rare cells for functional studies. The majority of 
studies to date have identified subsets of cells on the basis of cell surface phenotype or 
function (Shortman and Liu, 2002).
1 . 2 . 1  M u r i n e  D C s
Murine DCs are defined by their expression of a range of cell surface markers including 
C D llc  (Metlay et a l, 1990), C D llb  (Crowley et a l, 1990), CD205 (Inaba et a l, 1995) 
and MHC class II (Pierre et a l, 1997). Furthermore, the T cell markers CD4 and CDS are
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also expressed on mouse DCs and are useful for segregating subtypes (Vremec et a l,
2000). Using these surface markers, five DC subtypes are consistently found in the 
lymphoid tissues of uninfected laboratory mice. Tliree common subtypes of CD llc^ 
MHCII^ DCs can be found in spleens and lymph nodes: CD4'*‘CD8a'CD205"CDl Ib^ DC, 
CD4"CD8aCD205-CDl lb'" DC and CD4'CD8a'"CD205''CDl lb' DC (Shortman and Liu,
2002). These are all thought to be blood-derived although it is unclear whether they 
undergo maturation within the spleen or arrive in a mature state (Wilson and O'Neill,
2003). Both CD4'CD8aCD205'CDllb^ DC and CD4^CD8aCD205-CDllb'" DC 
resemble myeloid lineage cells since they express myeloid markers such as CDl lb  and 
F4/80 and because they lack CD8 a  expression (Vremec et a l, 2000). Therefore, CD8 a ‘ 
DCs are generally referred to as ‘myeloid DCs’. The CD4'*’CD8a'CD205'CDllb^ subset 
differs from the CD4'CD8a‘CD205'CDllb^ DCs by their greater adhesion capacity, 
higher levels of F4/80 expression (Vremec et a l,  2000) and lower cytokine production 
following stimulation (Hochrein et a l, 2001). However both CD8 a" subsets are efficient 
stimulators of CD4^ and CDS'*" T cells and show efficient MHC Class II presentation to 
antigen-specific CD4^ T cells (Kronin et a l,  1996; Pooley et a l, 2001). Other reports 
have shown that CD8 a" DCs can induce Th2 type immune responses since they stimulate 
cells that produce IL-4 but little IFN-y (Maldonado-Lopez et a l, 1999). Both subsets of 
CD 8 a" DCs are located in the marginal zone of the spleen between the white and red pulp 
(Vremec and Shortman, 1997) but they migrate into the T cell zone on stimulation with 
microbial products (Reis e Sousa et a l, 1997).
CD4"CD8a^CD205^CDl lb" DCs are generally referred to as ‘lymphoid’ DCs and are 
concentrated in the T cell areas of the spleen (Vremec and Shortman, 1997). They exhibit 
different functional capacities compared with CD8 a" DCs. Freshly isolated CD8 a^ DCs 
can have regulatory effects on T cells. They activate both CD4^ and CD8  ^T cells, but 
can induce apoptosis in CD4^ T cells (Suss and Shortman, 1996) and limit CD8  ^T cell 
proliferation by reducing IL-2 production (Kronin et a l, 1996). They have also been 
identified as the DCs responsible for maintaining T cell tolerance in lymphoid organs in 
the absence of infection (Belz et a l, 2002). In contrast, under conditions consistent with 
activation, such as the presence of IL-2 (Pooley et a l, 2001), CD8 a^ DCs can efficiently
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present antigen to CD8  ^ T cells in the context of MHC class I (den Haan et al., 2000; 
Pooley et a l, 2001). They can cross-present exogenous soluble antigens for stimulation 
of cytotoxic T cells (den Haan et a l, 2000) and It has been reported that they can induce 
Thl type immune responses in vivo, consistent with activated CD8 a^ DCs being the 
major producers of IL-12 (Hochrein e ta l,  2001; Maldonado-Lopez et a l,  1999).
In addition to the three subsets described in the spleen, lymph nodes contain two extra 
DC subtypes: CD4'CD8a'CDl lb"*" DCs, which express moderate levels of CD205 and are 
believed to be the mature form of tissue interstitial DCs and CD4"CD8a^“CD205^CDl Ib^ 
DCs, only found in skin-draining lymph nodes and express high levels of langerin, a 
characteristic marker of epidermal Langerhans cells. This latter subset is believed to be 
the mature form of Langerhans cells (Henri et a l, 2001). Langerhans DCs in lymph 
nodes are also distinguished by their high surface expression of MHC class II, CD40, 
CD80 and CD8 6 , typical characteristic of activated DCs (Henri et al, 2001).
Murine plasmacytoid DC represent a distinct class of DC recently identified in bone 
marrow, thymus, spleen and lymph nodes. This population had been missed in mouse cell 
suspensions because it expresses B220 (CD45) (so might be eliminated along with B 
cells during selection procedures), Gr-1 (so might be eliminated along with granulocytes) 
together with only low levels of C D llc and MHC class II (Martin et a l, 2002; Nakano et 
a l, 2001; Nikolic e ta l, 2002). They have atypical morphology of large, round cells with 
a diffuse nucleus and rare dendrites, with some cells expressing CD62L (Nakano et a l, 
2001; Nikolic et a l, 2002). Murine plasmacytoid DCs, like their human counterparts, 
have been shown to produce IFN-a following virus infection and thus may play 
important roles in antiviral responses once activated (Nakano et a l, 2001). A summary of 
mouse DC subsets is shown in Table 1.1.
1 . 2 . 2  H u m a n  D C s
A direct comparison of human DCs with mouse DCs has been challenging at a number of 
levels. First of all, there are relatively few studies on human DCs freshly isolated from
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In a few cases, human DCs have been isolated from lymphoid tissues and directly 
analysed without any incubation steps that may promote their differentiation ex vivo. 
Only in these cases it is possible to compare these DCs with murine DC subtypes directly 
and there are now studies on human thymic DCs supporting the idea of subset 
segregation, similar to that observed in the mouse (Bendriss-Vermare et al., 2001; 
Vandenabeele et al., 2001). Most human thymic DCs are CDl Ic^CDl lb'CD45RO*°, lack 
myeloid markers and therefore resemble mouse thymic CD8 a^ DCs. A minority of 
human DCs are CDl lc‘'*CDllb^CD45RO*^‘ and express many myeloid markers, so 
resemble mouse CD8 a ' DCs (Shortman and Liu, 2002). However, most of the insights 
into human DC subsets have not come from direct isolation of mature DCs from tissues 
but from studies on their development in culture from immature DCs or precursors DCs.
Three different precursor-cells have been used to generate human DC in culture: CD34^ 
blood monocytes and CDllcTL-3R^' precursors (Shortman and Liu, 2002). CD34^ 
precursors yield different DC subsets depending on the combination of cytokines used. 
Culture with GM-CSF and TNF-a leads to the production of DCs resembling Langerhans 
cells and interstitial DCs, the former strongly depending on TGF-P for development 
(Shortman and Liu, 2002). Blood monocytes are the most common precursors used for 
the generation of DCs in culture. They yield immature DCs following culture with GM- 
CSF and IL-4 and final maturation is achieved by stimulation with pro-inflammatory 
cytokines such as TNF-a or microbial products such as LPS (Shortman and Liu, 2002).
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tissues. Moreover, ex vivo DCs are likely to differ from their in vivo counterparts since 
they are easily activated upon handling, leading to altered phenotypes. This problem 
further emphasises the difficulties associated with subset analysis for both human and 
murine DCs. Blood is the only readily available source of human DCs although it is more 
a source of precursor DCs and even when some blood DCs are sufficiently mature, their 
surface expression of different markers may represent differences in activation states
%rather than separate DC subsets (Shortman and Liu, 2002). Another barrier to comparing 
human DCs directly with mouse DCs is the lack of expression of CD8  on human DCs, so 
the human DC equivalent of mouse CDSct^ DC remains elusive.
The final pathway for human DC development involves culture of CDllc'IL~3Ra^" 
precursors with IL-3, which leads to the formation of IFN-a producing plasmacytoid DCs 
(Shortman and Liu, 2002). Human DC subsets are summarised below in Table 1.1.
Mouse DC subsets
CD4 CD8a CD205 CDllb
Found in spleen and 
lymph nodes
Found In lymph nodes
+
+
+
Plasmacytoid DCs
moderate H ► Interstitial DCs
low +  +   ► Langerhans Cells
B220+ (CD45) 
Gr-1+
C D llc  low 
MHC low
Human DC subsets in vitro
Precursors
CD34^
GM-CSF
TN F-a
GM-CSF
TN F-a
TGF-p
■> Interstitial DC-like
Langerhans cell-like
Blood monocyte
CDllc'»
IL-SRa»^
G M -CSF ► Immature DC >  mature DC
IL-4
-► IL-3 -> Plasmacytoid DC
Table 1.1 Murine and human Dendritic cell subtypes
Although a number of different DC subtypes has now been identified, myeloid DCs are 
the focus of the present study. Thus from this point onwards any reference to DCs should 
be taken to mean myeloid DCs, unless otherwise stated.
43
1 . 2 . 3  A n t i g e n  u p t a k e ,  p r o c e s s i n g  a n d  p r e s e n t a t i o n
DC precursors from the bone marrow pass through the blood to peripheral tissues where 
they reside as immature DCs, continuously sampling the antigenic environment. 
Immature DCs have been shown to recognise invading pathogens via conserved pattem- 
recognition receptors (PRRs) that recognise pathogen-associated molecular patterns 
(PAMPs) within microbial carbohydrates, lipids and nucleic acids (Janeway and 
Medzhitov, 2002). Toll-like receptors (TLRs) have emerged as a major family of PRRs, 
recognising a wide range of molecules including prokaryote-derived lipoproteins, 
glycolipids, flagellin, CpG DNA, and lipopolysaccharides (LPS)(Akira et a l, 2001). 
There is now evidence that TLR expression is not uniform among DCs, raising the 
possibility that different DC subtypes may be preferentially involved in recognition of 
distinct classes of pathogens (Edwards et a l, 2003; Kadowaki et a l, 2001). For instance, 
plasmacytoid DCs uniquely express TLR9 and TLR7, which allow them to respond to 
viral CpG DNA and viral single-stranded RNA respectively (Coccia et a l, 2004; Ito et 
a l, 2005). However, plasmacytoid DCs do not express TLR4 and therefore respond to 
LPS relatively weakly. In fact, myeloid DCs, which express TLR4, primarily mediate the 
responses to bacterial infections (Pitha, 2004). A summary of the many TLR ligands and 
the distribution of these receptors among the different DC subsets are shown in Tables
1.2 and 1.3 respectively.
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TLR Ligands
TLR-1 Tri-acyl lipopeptides (bacteria, mycobacteria) 
Soluble factors {Neisseria meningitides)
TLR-2 Lipoprotein/lipopeptides (a variety o f pathogens) 
Peptidoglycan (Gram-positive bacteria) 
Lipoteichoic acid (Gram-positive bacteria) 
Lipoarabinomannan (mycobacteria)
A phenol-soluble modulin {Staphylococcus epidermidis) 
Glycoinositolphospholipids {Trypanosoma cruzi) 
Glycolipids {Treponema maltophilum)
Porins (Neisseria)
Zymosan (fungi)
Atypical LPS {Leptospira interrogans)
Atypical LPS {Porphyromonas gingivalis)
HSP70 (host)
TLR-3 Double-stranded RNA (virus)
TLR-4 LPS (Gram-negative bacteria)
Taxol (plant)
Fusion protein (RSV)
Envelope proteins 
HSP60 {Chlamydia pneumoniae)
HSP60 (host)
HSP70 (host)
Type in repeat extra domain A o f flbronectin (host) 
Oligosaccharides o f hyaluronic acid (host) 
Polysaccharide fragments o f heparan sulfate (host) 
Fibrinogen (host)
TLR-5 Flagellin (bacteria)
TLR-6 Di-acyl lipopeptides (mycoplasma)
TLR-7 Imidazoquinoline (synthetic compounds) 
Loxoribine (synthetic compounds) 
Bropirimine (synthetic compounds)
TLR-8 ?
TLR-9 CpG DNA (bacteria)
TLR-10 ?
Table 1.2 TLRs and their ligands as reported in reference (Takeda et al., 2003).
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H um an blood
CDllc"- PDC CD4+
Mouse spleen
CD8 a+ CD4-CD8a- PDC
TLR-1 high low moderate
TLR-2 high moderate
TLR-3 high low high moderate low
TLR-4 moderate low low low low
TLR-5 low high low moderate
TLR- 6 low low high moderate
TLR-7 high low low high
TLR-8 low high low low high
TLR-9 high moderate high
TLR-10 low low N/A N/A N/A N/A
Table 1.3 TLR expression on DC subsets isolated from human blood and murine spleen 
as reported in references (Edwards et al., 2003; Kadowaki et a l,  2001). PDC, 
plasmacytoid DCs; N/A, not applicable.
TLRs are members of the TLR-IL-1 receptor superfamily, all of which share an 
intracytoplasmic Toll-IL-1 receptor (TIR) domain that mediates the recruitment of TIR- 
containing adaptor molecules such as MyD8 8 , TIRAP, TRIP and TRAM (Akira et a l, 
2001). These adaptor molecules function to recruit other signalling molecules, notably 
the IL-1 receptor-associated kinase complex (IRAK), which activates the TRAF6  protein 
that is required for DC maturation in response to a number of different stimuli 
(Kobayashi et a l, 2003). In mice, all TLRs can initiate signalling through the MyD8 8 - 
IRAK-TRAF6  pathway, which results in the activation of the transcription factor NF-kB 
and mitogen-activated protein (MAP) kinases, inducing the transcription of genes such as 
TNF-a, IL-1 and IL- 6  (Akira et a l, 2001). MyD8 8 -independent signalling pathways have 
also been described. For example TRIF controls a MyD8 8 -independent pathway that is
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unique to TLR3 and TLR4 signalling and is important for the secretion of IFN-j3 (Hoebe 
et al., 2003; Yamamoto et al., 2003) (Figure 1.3).
MyD88-independent TLR  MyD88-dependent 
TRIF ^ R A nT ^ T IR  ^ y P ^  TIRAP
] Membrane
CytosolTRIF IRAK
TRAF6 TRAF6
MAP kinases
NF-kB JNK/p38 NF-kBIRF3
Nucleus
Figure 1.3 Toll-like receptor-signalling pathways. Interaction of microbial products with 
TLRs initiates two major signalling pathways. The MyD8 8 -dependent pathway leads to 
the phosphorylation of IRAK, recruitment of TRAF6 , activation of NF-kB and JNK/p38 
and release of pro-inflammatory cytokines. Activation of NF-kB can also occur via MyD- 
8 8 -independend pathway, which also leads to the activation of IRF3 and the induction of 
IFN-P and RANTES.
Besides TLRs, immature DCs also express several C-type lectin receptors, which 
recognise carbohydrate structures on pathogens (Figdor et al., 2002). Examples include 
mannose receptor, DC-SIGN, DEC-205 and langerin (Geijtenbeek et al., 2000; Sallusto 
et al., 1995; Valladeau et al., 2000). Once in contact with antigen, immature DCs use 
several pathways to facilitate uptake. These include receptor-mediated endocytosis 
through C-type lectins, Fc receptors (FcyRI, FcyRII, FcyRIII) and complement receptors 
(CR3) (Banchereau et al., 2000; Peiser et al., 2002; Sallusto et al., 1995). They also have
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high capacity to non-specifically endocytose particulates and solutes through 
phagocytosis and macropinocytosis (Sallusto et al., 1995). Although many of these 
pathways are used for uptake of pathogen-related molecules, they may also be utilised for 
uptake of self-antigens (Steinman et al., 2000). Indeed, immature DCs express avpS- and 
avp5-integrins and CD36, which help to facilitate continuous uptake of apoptotic 
material in the immune steady state (Albert et al., 1998). These may be important in DC- 
mediated maintenance of peripheral self-tolerance (Steinman et al., 2000).
Following antigen recognition and uptake, DCs process protein antigens into peptides, 
which are loaded onto MHC class I and II molecules and transported to the cell surface 
for recognition by antigen-specific T cells (Quah and O'Neill, 2005). Endogenous protein 
antigens, which are processed onto MHC class I, are degraded into peptides by the 
proteasome in the cytosol. These are then transported via transporters for antigen 
presentation (TAP) molecules into the endoplasmic reticulum (ER), where they are 
loaded on MHC class I. The peptide-MHC I complexes are then transported from the ER 
via the trans-Golgi network to the cell surface for presentation to CD8  ^T cells (Quah and 
O'Neill, 2005).
Exogenously acquired protein antigens are instead engulfed and processed in endosomes, 
which then fuse with lysosomes, where proteases degrade the proteins into peptides that 
are loaded onto MHC II molecules (Quah and O'Neill, 2005). This requires proteolytic 
degradation of the MHC 11-associated invariant chain that normally blocks access to the 
peptide-binding pocket of MHC II (Guermonprez et a l, 2002). Peptide-MHC II 
complexes are then transported to the cell surface for presentation to CD4^ T cells (Chow 
et al., 2002). Exogenous antigens may also be processed by DCs onto MHC 1 (Albert et 
al., 1998). This phenomenon called ‘cross-presentation’ or ‘cross-priming’ allows DCs to 
elicit CD8  ^ as well as CD4^ T cell responses to exogenously acquired antigens 
(Ackerman et a l, 2003; Fonteneau et a l, 2002; Guermonprez et al, 2003). Furthermore, 
lipid antigens expressed on pathogens (such as mycobacterial mycolates) or self-tissues 
(such as sphingolipids) are presented on DCs by CDl molecules, which heterodimerise
48
' with (32-microgiobulin and are structurally similar to MHC I (Joyce and Van Kaer, 2003;
Moody and Porcelli, 2003).
1 . 2 . 4  D C  m a t u r a t i o n
The antigen generally induces immature DCs to undergo phenotypic and functional 
changes that culminate in the activation of immature DCs. This maturation process is 
accompanied by cytoskeletal reorganization, reduced phagocytic activity, acquisition of 
cellular motility, migration to lymphoid tissues, enhanced T cell activation potential and 
the development of characteristic cytoplasmic extensions usually referred to as 
‘dendrites’ (Quah and O'Neill, 2005), Mature DCs secrete cytokines that determine the 
type of ensuing immune response and upregulate the expression of adhesion and 
costimulatory molecules, which are involved in bidirectional signalling between DCs and 
T cells, modulating both T cell activation and DC function (Quah and O'Neill, 2005). 
Furthermore, maturation imparts on the peripheral DCs the ability to migrate from the 
tissues to T cell zones of lymph nodes. This is accomplished through downregulation of 
CCRl and CCR5 and upregulation of CCR7, which helps localise DCs to lymphatic 
vessels and lymph nodes via chemokines CCL19 and CCL21. Maturation also induces 
DCs to secrete chemokines such as IP-10, which recruits various T cell subsets and 
RANTES, M IP-la and M IP-lp, which recruit monocytes and DCs into the local 
environment (Adams et a l, 2005).
1 . 2 . 5  O u t c o m e s  o f  D C - T  c e l l  i n t e r a c t i o n
1.2.5.1 Induction of Thl/Th2 responses
Effective priming of naïve T cells results in their clonal expansion and differentiation into 
cytokine secreting effector cells and memory cells. The ensuing T cell response is 
dependent on many factors, including the concentration of antigen on the DC, the affinity 
of the T cell receptor (TCR) for the peptide-MHC complex, the duration of the DC-T cell
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interaction, the state of DC maturation and the type of DC maturation stimulus (Gett et 
al., 2003). Following priming, CD4^ T cells may differentiate towards T helper 1 (Thl) 
cells, which produce IFN-y and support CDS'*" cytotoxic T-lymphocyte (CTL) responses, 
or toward T helper 2 (Th2) cells, which produce IL-4, IL-5 and IL-13, support humoral 
immunity and downregulate Thl responses (Adams et al, 2005). The secreted cytokine 
profile of the stimulating DCs determines the direction of this Th polarization. IL-12, IL- 
18 and IL-27 polarize toward Thl, whereas CCL17, CCL-2, and the absence of IL-12 
skew the response toward Th2 (Adams et a l, 2005).
T cell stimulation and Thl/Th2 polarization requires three DC-derived signals: the 
stimulatory signal 1, which results from the ligation of TCRs by pathogen-derived 
peptides, presented by MHC class II molecules on the cell surface of DCs and determines 
the antigen-specificity of the response (Kapsenberg, 2003); the co-stimulatory signal 2, 
provided by molecules such as CD80/CD86 on the DCs interacting with CD28 on the T 
cells (Harding et a l, 1992); and signal 3, which as mentioned above, is the polarising 
signal that is mediated by various soluble or membrane-bound factors such as IL-12 or 
CCL2 that promote the development of Thl or Th2 cells respectively (Kalinski et a l, 
1999). Most T cell polarising factors are either weakly or transiently expressed after 
pathogen recognition. High expression of such factors require a further signal as it has 
been reported in the case of IL-12 (Snijders et a l, 1998). For optimal expression of Th- 
cell polarising molecules during DC-T cell interaction, the primed DC requires intimate 
cross-talk with the T cells involving ligation of CD40 by CD40L, which is rapidly 
expressed by the T cells after their activation by the DC-derived signals 1 and 2 (Grewal 
and Flavell, 1998). Stimulation through CD40 results in a complex series of events within 
the DC. Engagement of CD40 by its ligand, CD 154 (CD40L), leads to trimeric clustering 
of CD40 and the recruitment of adaptor proteins known as TNF-receptor-associated 
factors (TRAFs) to the cytoplasmic tail (Pullen e ta l,  1998). Binding of TRAFs results in 
the formation of a signalling complex that includes multiple kinases such as NF-kB 
inducing kinase (NIK), receptor interacting protein (RIP), members of the mitogen- 
activated protein kinase (MAPK) family and possibly others (Quezada et a l, 2004). 
Clustering of these kinases then initiates a downstream cascade of signalling events,
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resulting in activation of the MAPK and NF-kB pathways and finally transcription of 
target genes, leading to physiological effects, such as production of inflammatory 
mediators, DC survival and prolonged MHC/antigen complex presentation (Quezada et 
al., 2004) (Figure 1.4).
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TRAF2
TRAF3
CytosolNIK
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Others?
NF-kB
Survival and 
continued antigen 
presentation
IL-12, IL-18 
Inflammation Nucleus
Figure 1.4 CD40 activation of NF-kB in DCs.
A variety of surface molecules other than CD40-CD40L and CD80/CD86-CD28 on DCs 
and T cells have been demonstrated to promote T cell and/or DC activation; these 
molecules include several members of the TNF receptor family such as TRANCE 
(Bachmann et al., 1999), 0X40 (Chen et a l, 1999), 4-IBB (Cannons et al., 2001) and 
CD27 (Hendriks et a l, 2000) and their corresponding ligands. A diagram of the events 
involved in the induction of effector T cell responses is shown in Figure 1.5.
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Figure 1.5 Dendritic cell-derived signals involved in T cell stimulation 
and Thl/Th2-cell polarisation modified from (Kapsenberg, 2003).
It has to be noted that Figure 1.5 represents a very simplistic and basic diagram of the 
events involved in the induction of Thl/Th2 polarisation. In fact, it is now known that the 
type of costimulation may also control T cell polarisation. For instance, ICOS may play 
an important role in the development of Th2 cells (MeAdam et al., 2000), although a 
recent report showed that ICOS was upregulated on antigen-specific T and B cells 
following Thl induction (Smith et a l,  2005). CD40-CD40L interaction may instead 
sustain Thl responses (Grewal and Flavell, 1998).
1.2.5.2 Induction of regulatory T cells
During the last few years it has become clear that DCs not only play a role in the 
promotion of effector Thl and Th2 cell responses but under some circumstances, the T 
cell may be inactivated leading to immunological tolerance. Tolerance is a state in which
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the immune system fails to make an active response to antigen and it is therefore critical 
for preventing immune responses to tissue antigens by self-reactive T cells as well as 
preventing inappropriate responses to harmless foreign antigens, particularly when such 
responses could lead to tissue damage (Fazekas de St Groth, 2001). The induction of 
regulatory T cells plays an important role in the maintenance of tolerance (Sakaguchi, 
2005; Schwartz, 2005). Two subsets of regulatory T cells can be distinguished: naturally 
occurring and adaptive regulatory T cells (Bluestone and Abbas, 2003). Naturally 
occurring T regulatory cells are CD4^CD25^ cells that obtain their regulatory function in 
the thymus and are primarily involved in tolerance to autoantigens (Bach, 2003). 
Adaptive regulatory T cells include Trl cells, which secrete high levels of IL-10, and Th3 
cells, which secrete TGF-p (Jonuleit and Schmitt, 2003). In contrast to natural regulatory 
T cells, adaptive regulatory cells originate, like Thl and Th2 cells, from uncommitted 
peripheral naïve or memory Th cells upon activation by antigen-presenting DCs in a 
certain immunological context (Jonuleit and Schmitt, 2003). Adaptive regulatory T cells 
may normally respond to innocuous foreign antigens and are therefore primarily 
associated with tolerance to environmental antigens (Jonuleit and Schmitt, 2003).
The current belief is that mainly immature or semi-mature DCs play a role in T 
regulatory cell development. Several studies have suggested that immature DCs might 
acquire chemokine receptors (e.g. CCR7) under homeostatic conditions, enabling their 
migration towards lymph nodes (Dhodapkar and Steinman, 2002; Dhodapkar et al., 2001; 
Geissmann et al., 2002). It has been hypothesised that because of their total lack of 
expression of co-stimulatory and Thl/Th2 polarising molecules, immature DCs can drive 
the development of adaptive T regulatory cells from naïve T cells (Jonuleit et a l, 2000). 
Semi-mature DCs were also reported to induce T regulatory cell development. Immature 
DCs exposed to tissue-derived TNF-a in the absence of pathogen acquire part of the 
characteristics of fully mature DCs, including the expression of co-stimulatory molecules 
and the ability to migrate to draining lymph nodes (Lutz and Schuler, 2002). However, 
they lack the ability to produce polarising signals and, as a consequence, predominantly 
drive the development of adaptive T regulatory cells.
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1.2.5.3 T cell anergy
Besides inducing functional Thl/Th2 cell responses and T regulatory cells, interaction of 
DCs with T cells may result in failure of T cell activation leading to T cell anergy, 
providing another important mechanism by which peripheral tolerance can be 
maintained. T cell anergy is defined as a state in which the cell is viable but fails to 
display certain functional responses (proliferation and lL-2 production) upon exposure to 
its specific antigen and results from partial T cell activation due to a lack of adequate co­
stimulation (lack of signal 2) (Alegre et aL, 2001; Lechler et aL, 2001). This type of 
anergy may be reversed by the stimulation of T cells with IL-2 (DeSilva et al., 1991). 
Another form of anergy has also been described and is associated with the failure to 
proliferate after activation, despite the presence of co-stimulatory signals (Wells et a l,
2001). This division-arrest-associated form of anergy cannot be reversed by lL-2 and is 
dependent on CTLA-4 (Wells et ah, 2001).
1.2.5.4 Deletion/apoptosis of antigen-specific T cells
Activation through the TCR can result in apoptosis of T cells and in this regard it is 
becoming clear that two pathways control the fate of antigen-specifrc T cells; activation- 
induced cell death (AJCD) and activated T cell-autonomous death (ACAD) (Hildeman et 
ah, 2003; Hildeman et ah, 2002). AICD is driven by death receptors such as Fas (CD95), 
which, once engaged, activate downstream pathways that lead to caspase activation and 
cell apoptosis (Hildeman et ah, 2002). Furthermore, AICD requires repetitive or high 
dose stimulation via the TCR (Hildeman et ah, 2002). Conversely, ACAD does not 
require death receptors. It is instead controlled by members of the Bcl-2 family of 
proteins, which induce apoptosis by releasing cytoclirome c and other apoptogenic factors 
from mitochondria (Li et ah, 2004a). Moreover, contrary to AICD, a single antigen 
exposure is enough to cause cell death (Hildeman et ah, 2002). Finally, in functional 
terms, ACAD plays a major role in the removal of T cells at the end of immune 
responses, whereas both AICD and ACAD seem to have a role in auto-reactive T cell 
removal (Hildeman et ah, 2002).
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1 . 2 . 6  P a t h o g e n - d r i v e n  T  c e l l  r e s p o n s e s
There is accumulating evidence that microbes drive the development of protective Thl or 
Th2 responses by directly affecting DCs at the time of pathogen encounter. Both Cholera 
toxin (Gagliardi et a l, 2000) and a phosphorylcholine-containing glycoprotein (ES-62) 
secreted by the filarial nematode Ancanthocheilonema viteae (Whelan et a l,  2000) have 
been shown to induce the maturation of DCs with the capacity to drive Th2 responses. 
Conversely, influenza virus was shown to activate DCs to drive polarised Thl responses 
(Celia et ah, 1999). Furthermore DCs have been reported to interact with the fungus 
Candida albicans in its different forms and to elicit different effector T cell responses 
(d'Ostiani et ah, 2000). C. albicans can reversibly switch between unicellular yeast to 
filamentous (hyphal) forms. Yeasts activated DCs for lL-12 production and priming of 
Thl cells, whereas ingestion of hyphae inhibited lL-12 and Thl responses and induced 
IL-4 production (d'Ostiani et a l, 2000).
More recently it has been demonstrated that microbial compounds induce Th cell 
polarisation via the polarisation of DCs into committed Thl cell-promoting or Th2 cell- 
promoting effector DCs (de Jong et al., 2002). Soluble egg antigens (SEA) of the 
helminth Schistosoma mansoni and Cholera toxin, both associated with Th2 cell 
responses, promoted immature DCs to develop into functional effector cells with 
polarised type 2 phenotypes (de Jong et al., 2 0 0 2 ). SEA induced the development of type 
2 DCs, which promoted Th2 cells via the enhanced expression of OX40L, whereas 
Cholera toxin induced Th2 responses via an OX40L-independent mechanism (de Jong et 
al., 2002). Instead, double-stranded RNA (poly (1:C), a mimic of viral RNA) and the 
toxin of the intracellular bacterium Bordetella pertussis, both associated with Thl cell 
responses, promoted immature DCs to develop into functional effector cells with 
polarised type 1 phenotypes (de Jong et al., 2002). The toxin from Bortdetella pertussis 
induced the development of type 1 DCs with enhanced IL-12 production, which promotes 
Thl cell development, whereas poly (1:C) induced the development of extremely potent 
Thl-inducing DCs without an enhanced IL-12 production (de Jong et ah, 2002).
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These observations suggest that analogous to the development of polarised Th cell 
subsets from a single precursor population, DCs are guided by environmental stimuli to 
acquire stable polarised functional effector phenotypes, supporting the concept that the 
type of the immune response is optimally adapted to the type of the pathogen.
1.2.7 ‘Alternatively activated’ DCs induced by pathogens
Extending the concept that pathogens cause priming of immature DCs to become mature 
effector DCs that drive Thl or Th2 responses, accumulating information suggest that 
particular pathogens and /or tissue factors could prime for an alternative subset of DCs 
that may not be able to induce appropriate effector T cell responses. Some of these 
‘alternatively activated DCs’ may drive the generation of regulatory T cells, in which 
case they are generally referred to as ‘regulatory DCs’. Pathogens were originally thought 
to evade immunity by inducing T regulatory cells through inhibition of DC maturation. 
However more recent studies suggest that certain pathogens and tissue factors can prime 
for T regulatory cell development through inducing DC maturation into an ‘alternatively 
activated’ state.
1.2.7.1 Pathogen-driven immature regulatory DCs
Immature regulatory DCs express low levels of MHC and co-stimulatory molecules and 
therefore do not support substantial development of effector T cells from naïve T cells 
(Smits et al., 2005). However, they are different from steady-state immature DCs because 
they are unresponsive to inducers of DC maturation, such as LPS (Smits et al., 2005). 
Furthermore, on CD40 stimulation they show decreased IL-12 production but increased 
levels of lL-10 (Smits et al., 2005). These immature regulatory DCs can develop in 
response to a variety of pathogens or pathogen-derived compounds. Examples include 
hepatitis C virus, Plasmodium falciparum  and mannosylated lipoarabinomannans 
(ManLAM) derived from Mycobacterium tuberculosis (Auffermann-Gretzinger et al., 
2001; Dolganiuc et a l, 2003; Geijtenbeek et a l, 2003; Kanto et a l, 1999; Nigou et a l, 
2001; Ocana-Morgner et a l, 2003; Urban et a l, 1999).
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Patients chronically infected with hepatitis C virus harbour IL-10 secreting CD4^ T cells 
(MacDonald et al, 2002). In vitro studies with human monocyte-derived DCs show that 
DC functions, such as maturation, expression of co-stimulatory molecules, cytokine 
production and T cell stimulatory capacity, are all severely hampered on exposure to 
hepatitis C virus core protein and non-structural protein 3 (Dolganiuc et al,, 2003). 
Similar defects are observed in monocyte-derived DCs generated from hepatitis C virus- 
infected patients and these defects cannot be overcome by stimulation with LPS, 
suggesting a role of regulatory DCs in the induction of regulatory T cells in hepatitis C 
virus infection (Auffermann-Gretzinger et al., 2001; Kanto et al., 1999).
ManLAM derived from M. tuberculosis and also from M  leprae or M. bovis BSG 
(Geijtenbeek et al., 2003; Nigou et al., 2001), has been shown to bind to DC-SIGN 
expressed on DC membrane. In the case of human monocyte-derived DCs, this 
interaction inhibits the LPS-induced DC maturation and IL-12 production and enhances 
DC expression of IL-10. In contrast to ManLAM, whole mycobacteria do not inhibit DC 
maturation, but do have the same DC-SIGN-dependent effect on cytokine production 
(Geijtenbeek et al., 2003; Giacomini et al., 2001; Nigou et al., 2001).
Plasmodium falcîparum-mÎQQXQà. erythrocytes have been shown to bind to CD36 on DCs 
and inhibit the LPS-induced DC maturation and, thus, the capacity of DCs to stimulate 
naïve T cells (Urban et ah, 1999). Instead, infected erythrocytes induce high levels of IL- 
10 production by DCs (Urban et al., 1999). CD36 normally binds apoptotic cells, 
preventing detrimental inflammation by regulation of DC function (Voll et al., 1997). 
Apparently this system has been hijacked by Plasmodium parasites in order to evade 
immune responses directed against infected erythrocytes (Urban et al., 2001b). A detailed 
analysis of Plasmodium-DC interaction is described further.
1.2.7.2 Pathogen-driven mature regulatory DCs
In contrast to pathogen-driven immature regulatory DCs, pathogen-driven mature 
regulatory DCs normally express high levels of MHC and co-stimulatory molecules.
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although compared to fully mature immunogenic DCs, CD40 expression is somewhat 
reduced in some studies (McGuirk et a l, 2000). Studies with human monocyte-derived 
DCs revealed that Schistosoma-àQïivQà. lysophosphatidylserine primes, in a TLR2- 
dependent fashion, for mature DCs that drive the generation of IL-lO-producing 
regulatory T cells (van der Kleij et a l, 2002). These DCs are characterised by decreased 
IL-12 and increased IL-10 production.
In a recent study using Bordetella pertussis, the causative agent of whooping cough, 
pathogen-specific Trl clones have been isolated from the lungs of infected mice 
(McGuirk et a l, 2002), These Trl cells were found to be specific for filamentous 
haemagglutinin (FHA), a virulence factor. FHA enhances the maturation of mouse DCs, 
inhibits IL-12 and induces some IL-10 production. These FHA-mature DCs drive the 
development of regulatory T cells, which are capable of blocking Thl responses to 
secondary, unrelated infections, such as influenza virus (McGuirk et a l, 2002). Similar 
effects have been described for adenylate cyclase toxin from B. pertussis (Ross et a l,
2004) and for cholera toxin from Vibrio cholerae (Lavelle et a l, 2003).
Measles virus is another example of pathogen that induces mature regulatory DCs. 
Ligation of CD46, a complement regulatory transmembrane protein, by envelope 
haemagglutinin of Measles virus strongly decreases IL-12 production in human 
monocyte-derived DCs and murine DCs (Karp et a l, 1996) and profoundly inhibits their 
T cell-stimulatory capacity, despite normal maturation (Marie et a l, 2001; Schnorr et a l, 
1997; Servet-Delprat et a l, 2000).
1 . 2 . 8  P a t h o g e n - i n d u c e d  h o s t  f a c t o r s  p r o m o t i n g  t h e  f o r m a t i o n  o f  r e g u l a t o r y  
D C s
Besides directly affecting the activation state of DCs, pathogens may indirectly modulate 
DC maturation and function by inducing host cells to secrete cytokines or express 
molecules, which may, in turn, be responsible for the failure of DCs to mount an
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appropriate T cell response directed against the pathogen itself. Some examples of 
possible ‘immunosuppressive factors’ secreted /induced by DCs are explained beloAv.
1.2.8.1 Role of eicosanoids on DC function
Eicosanoids, which include prostaglandins (PGs) and leukotrienes (LTs), are potent 
modulators of immune responses in addition to playing a role in numerous basic host 
physiological processes (Funk, 2001). The biological functions of the E series 
prostaglandins (PGE) have been the most intensively studied, PGEa being one of the best- 
known eicosanoids to date. PGE% formation is initiated by the action of phospholipase Az, 
which releases arachidonic acid from the membrane phospholipid bilayer in response to 
inflammatory stimuli (Murakami et al,, 1997). Free arachidonic acid is rapidly 
metabolised to prostaglandin Hz (PGHz) via the enzymatic activity of the cyclooxygenase 
(COX) enzymes, of which there are 2 distinct isoforms encoded by separate genes: COX- 
1 and COX-2 (Appleton et al., 1996; Vane et al., 1998). COX-1 is constitutively 
expressed in most tissues and generates PGs for physiological homeostasis, whereas 
COX-2 is an inducible gene that generates high levels of PGs during inflammation 
(Seibert and Masferrer, 1994). Following formation of PGHz by COX, PGEz synthase 
converts PGHz to PGEz (Smith et al., 1991).
In the immune system, eicosanoids are predominantly produced by APCs and act as 
autocrine and paracrine lipid mediators. For many years macrophages have been the 
focus of studies on the generation of arachidonic acid-derived mediators and these cells 
were considered to be the major source of eicosanoids, which also drastically affect 
macrophage functions (Humes et al., 1977; Nathan, 1987). In fact exogenous PGEz has 
been shown to inhibit macrophage proliferation (Pelus et ah, 1979), oxygen radical 
generation (Smith and Weidemann, 1980), the production of lL-1 (Kunkel et al., 1986a) 
and the accumulation of LPS-induced TNF-a mRNA (Kunkel et ah, 1988; Kunkel et al., 
1986b).
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There is now evidence demonstrating the ability of DCs to produce arachidonic acid 
metabolites. In vitro generated DCs have been reported to possess the whole enzymatic 
equipment necessary for the biosynthesis of eicosanoids starting with endogenous 
arachidonic acid and produce a full range of arachidonic acid products, especially PGEz 
(Harizi et a l, 2001). Furthermore, in vitro generated BM-DCs have been shown to 
express all the PGE receptors (EPi, EPz, EP3 and EP4) with EPz and EP4 playing a central 
role in the modulation of DC functions by PGEz (Harizi et a l, 2003; Meja et al., 1997). 
Depending on the site of encounter and the maturation stage, PGEz has opposite effects 
on DC activation. In peripheral tissues, PGEz appears to have stimulatory effects on DCs. 
In fact PGEz cooperates with inflammatory cytokines, such as TNF-a, 1L-1(3 and lL-6 , to 
promote DC maturation (Gualde and Harizi, 2004). Furthermore, PGEz upregulates the 
DC expression of CCR7 chemokine receptor and promotes their migration to lymphoid 
organs (Luff et a l, 2 0 0 2 ; Scandella et al., 2002), Conversely, in lymphoid organs PGEz 
plays an inhibitory role, reducing the activation of DCs and their ability to present 
antigen to T cells (Harizi et al., 2001). Another established action of PGEz on DC 
function is the regulation of cytokine production, depending on the context and the 
microenvironment. For instance, the presence of PGEz during the priming of DC with 
antigen completely inhibits their ability to produce the Thl-driving cytokine IL-12. 
Instead PGEz-primed DCs have been shown to produce high levels of IL-10 (Kalinski et 
al., 1997). In addition to its potential to modulate the maturation, IL-12-producing 
capacity and Th-cell-polarising ability of DCs, there is also evidence that PGEz inhibits 
the production of inflammatory chemokines CCL3 and CCL4 in mouse bone marrow- 
derived DCs (Jing et al., 2003).
Although PGEz is known as the major COX metabolite generated by APC, DCs can also 
produce other prostanoids including thromboxanes Az (TXAz) and PGDz. It has been 
demonstrated that DC-derived TXAz affects, in a paracrine manner, the activity of T cells 
and modulates acquired immunity by negatively regulating DC/T cell interactions 
(Kabashima et a l, 2003a). Other studies have explored the effects of PGDz as a potential 
regulator of the adaptive immune response through its action on DCs. PGDz has been 
shown to affect the migratory properties of Langerhans cells (Angeli et a l, 2001) and the
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maturation of human DCs (Cosset et a l, 2003). Moreover, it has been reported that PGDz 
suppresses the CD40- and LPS-induced IL-12 secretion by murine splenic DCs (Faveeuw 
et ah, 2003).
The effects of PGEz on lymphocytes have also been extensively studied. PGEz has been 
shown to induce B cell unresponsiveness (Schad and Phipps, 1989) and inhibition of B 
cell proliferation and antibody production (Kurland et a l, 1977; Simkin et al., 1987; 
Thompson et a l, 1984). Furthermore, PGEz inhibits not only T cell lL-2 production 
(Minakuchi et a l, 1990; Rappaport and Dodge, 1982), but also accumulation of lL-2 
mRNA (Minakuchi et a l, 1990), IL-2 receptor expression (Rincon et a l, 1988) and 
antigen- and mitogen-induced T cell proliferation (Ellner and Spagnuolo, 1979; 
Minakuchi et a l, 1990).
Host cells are therefore one source of eicosanoids during infection. Pathogens may 
induce the production of these lipid mediators, which could in turn act in an autocrine 
manner and suppress some key functions of the secreting cell itself or in a paracrine 
manner and modulate the biology of immune cells present in the local environment. 
Another potential source of eicosanoids is the pathogen itself. Many reports have 
suggested that pathogenic helminths, protozoa and fungi have the ability to produce 
prostaglandins and prostaglandin-like molecules (Noverr et a l, 2003), which may play a 
role in suppression of the host immune response, inhibiting macrophages, DCs and T and 
B cell functions or induce inappropriate T cell responses that could affect the severity of 
the infection (Belley and Chadee, 1995). It is also possible that parasite-derived 
eicosanoids are directly involved in the pathogenesis of parasitic diseases, regulating 
physiological processes in host tissues that enable the parasites to disseminate, migrate, 
reproduce and persist in the body (Belley and Chadee, 1995). Among the parasites known 
to produce eicosanoids are T. brucei (Kubata et a l, 2000), S. mansoni (Fusco et a l, 
1985), B. malayi (Liu et a l, 1992) and P. falciparum (Kilunga Kubata et a l, 1998).
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1.2.8.2 Role of peroxisome proliferation-activated receptors on DC ftinction
Some eicosanoids, such as PGJz and 15-deoxy PGJz, are potent ligands of the 
intracellular receptors peroxisome proliferation-activated receptors (PPARs) (Daynes and 
Jones, 2002). PPARs are ligand-activated transcription factors belonging to the nuclear 
receptor superfamily (Oberfield et ah, 1999). They function as regulators of lipid and 
lipoprotein metabolism, glucose homeostasis, cellular differentiation and inflammatory 
responses (Lemberger et ah, 1996; Pineda Torra et ah, 1999). So far three PPAR 
isoforms have been identified and are encoded by separate genes on different 
chromosomes: PPARa, PPAR^/Ô and PPARy (Daynes and Jones, 2002). There is 
evidence indicating a role of PPARs in the control of various types of inflammatory 
responses. These functions are mediated largely through the abilities of PPARa and 
PPARy isoforms to repress the activities of many activated transcription factors such as 
nuclear factor-kB (NF-kB), signal transducers and activators of transcriptions (STATs), 
activator protein 1 (AP-1) and nuclear factor of activated T cells (NFAT) (Daynes and 
Jones, 2002).
Recent reports have shown that DCs predominantly expressed the PPARy isoform and 
that agonist-induced activation of PPARy can influence DC maturation (Gosset et ah, 
2001). Shorter PPARy activation periods was found to have milder immunological effects 
on DCs mainly leading to the development of Th2 immune responses due to a down- 
regulation of IL-12 secretion and to a selective inhibition of Thl lymphocyte-recruiting 
chemokines in DCs (Gosset et ah, 2001). Sustained PPAR-y activation, achieved by 
generating human DCs in the presence of 15-deoxy PGJz or synthetic PPARy agonists, 
resulted in more profound effects on DC function causing impairment of the expression 
of costimulatory molecules and cytokine production (including Th2 cytokines) and 
affecting the ability of DCs to induce lymphocyte proliferation and antigen-specific T cell 
responses (Nencioni et a l, 2002). Therefore, it was suggested that sustained PPARy 
activation in DCs might result in induction of anergy/tolerance in T lymphocytes instead 
of committing them toward type 2 cytokine- secreting cells. Furthermore, the activation 
of PPARy was shown to reduce the ability of murine splenic DCs to produce IL-12 in
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response to CD40 or LPS stimulation (Faveeuw et al., 2000) and to affect the maturation 
of human monocyte-derived DCs by reducing the secretion of chemokines, such as CCL3 
(Gosset et al., 2001). More recently Appel et al. (Appel et a l, 2005) reported that TLR 
ligand-induced activation and migration of human monocyte-derived DCs, as well as 
their ability to initiate lymphocyte proliferation, was impaired upon PPARy activation. 
Activation of PPARy resulted in down-regulation of costimulatory and adhesion 
molecules by DCs and reduced secretion of cytokines and chemokines involved in T 
lymphocyte activation and recruitment. These inhibitory effects on TLR induced DC 
activation were shovm to be mediated via inhibition of the NF-kB and MAP kinase 
pathways (Appel et a l, 2005). Therefore, it is reasonable to assume that pathogens may 
modulate DC function by inducing activation of PPARy.This could potentially be 
achieved either by inducing DCs to produce prostaglandins, which in turn can activate 
PPARy or in certain cases by prostaglandins produced by the pathogen itself as explained 
in section 1 .2 .8 .1 .
1.2.8.3 Indoleamine 2,3 dioxygenase-regulation of DC function
Recently there has been a growing interest in investigating an immunosuppressive 
mechanism, involving tryptophan catabolism by DCs through expression of the enzyme 
indoleamine 2,3-dioxygenase (IDO). It has been reported that PGEz induces mRNA 
expression of IDO in DCs via interaction with the EPz receptor. However, the enzyme 
remained inactive (Braun et a l, 2005). A second signal through TNF receptor or a TLR 
was shown to be necessary to activate the enzyme (Braun et a l, 2005). Interestingly, the 
use of TNF-a or LPS alone did not upregulate IDO expression (Braun et a l, 2005). Early 
studies documented the ability of IDO to inhibit the proliferation of intracellular 
pathogens and tumour cells in vitro through consumption of the essential amino acid 
tryptophan (Taylor and Feng, 1991). Although many microorganisms can synthesize their 
own tryptophan, some depend on exogenous sources. Such organisms are sensitive to the 
tryptophan-depleting activity of IDO. Examples include Chlamydia pneumoniae, 
Toxoplasma gondii and certain bacteria such as group B streptococci and mycobacteria 
(Carlin et a l, 1989; Gupta et a l, 1994; Hayashi et al, 2001; MacKenzie et a l, 1998;
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Pfefferkorn et al., 1986). Furthermore, it has been reported that during viral infection, 
IDO inhibits the replication of cytomegalovirus and herpes simplex virus in vitro (Adams 
et al., 2004; Bodaghi et al., 1999). Although tryptophan depletion was the first 
mechanism recognized for IDO, other models suggested that toxic metabolites of 
tryptophan played an important role in mediating its effects. Mouse thymocytes and 
mouse CD4’*' T cell clones were shown to be sensitive to apoptosis induced by tryptophan 
metabolites such as quinolinic acid (Fallarino et al., 2002). In the latter study, Thl cell 
clones but not Th2 cell clones were sensitive to metabolite-induced apoptosis, raising the 
possibility that IDO might alter the Thl/Th2 balance. Human T cells were also found to 
be sensitive to the anti-proliferative and cytotoxic effects of exogenously added 
tryptophan metabolites (Frumento et al., 2002; Temess et a l, 2002). A third mechanism 
by which IDO might exert its effects is by altering the biology of the ID 0-expressing 
APCs (Hwu et a l, 2000; Munn et a l, 1999) It has been reported that pre-activation of 
CD8 a^ DCs in vitro with IFN-y, which has been shown to be a potent inducer of IDO 
expression (Taylor and Feng, 1991), rendered them tolerogenic when subsequently 
injected in vivo (Grohmann et a l, 2000). This effect required IDO expression during the 
in vitro pre-activation, as addition of a pharmacological inhibitor of IDO, 1-methyl 
tryptophan (1-MT), (Cady and Sono, 1991) during that time blocked the development of 
tolerogenic activity (Grohmann et a l,  2000). The effect of IDO, however, seemed to be 
exerted on the DCs themselves rather than on the responding T cells as 1-MT was not 
present when DCs were subsequently transferred into the recipient host (Grohmann et a l, 
2000). The nature of this effect is unknown but it has been speculated to be mediated 
either by intracellular tryptophan depletion, or by some effect of intracellular tryptophan 
metabolites. IDO might, therefore, functionally alter the DC either by decreasing its APC 
function or by upregulating the expression of suppressive ligands (such as CD95) or by 
triggering the secretion of immunoregulatory cytokines (such as IL-10 or TGF-P). 
Although these notions are speculative in the case of DCs, IDO has been shown to 
regulate gene expression and cell biology in other cell types (Li et a l, 2004b; Marshall et 
a l, 2 0 0 1 ).
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IDO-dependent suppression of T cell responses has also been reported and might function 
as a natural immunoregulatory mechanism (Mellor and Munn, 1999). Studies from a 
range of mouse models demonstrated that IDO regulates adaptive T cell immunity 
(Mellor and Munn, 2004). In many of these studies 1-MT was used to inhibit IDO 
activity in vivo. Administration of I-MT to pregnant mice resulted in rejection of 
allogeneic fetuses (Mellor et al., 2001; Munn et al., 1998). In autoimmune models, 1-MT 
treatment exacerbated symptoms of experimental autoimmune encephalomyelitis 
(Sakurai et al., 2002) and markedly increased disease severity and lethality in a model of 
T cell mediated colitis (Gurtner et al., 2003). By contrast, overexpression of IDO results 
in immunosuppression and tolerance. IDO-transfected cell lines suppressed antigen- 
specific T cell responses in vitro (Mellor et a l, 2002) and IDO overexpression in mouse 
tumour cell lines rendered them resistant to immune rejection (Uyttenhove et a l, 2003).
1.2.8.4 Nitric oxide-regulation of DC function
Nitric oxide (NO) is a pleiotropic second messenger, that can exert its effects in an 
autocrine or paracrine fashion on neighbouring cells (Korhonen et a l, 2005). It is 
generated intracellularly by NO synthases (NOS), which can be constitutive (cNOS) or 
inducible (iNOS). cNOS can produce only low levels of NO, whereas iNOS is expressed 
primarily in response to pro-inflammatory cytokines or bacterial products and catalyses 
the production of much higher amounts of NO (Korhonen et a l, 2005). It is known that 
NO can exert beneficial or detrimental effects on immune responses depending on the 
timing and amounts of its production and the biological milieu in which it is released 
(Korhonen et a l, 2005). In activated macrophages, NO and its metabolites have been 
shown to mediate a number of host defence functions that include anti-microbial and 
tumoricidal activity (Bogdan, 2001). Due to its anti-microbial effects, NO is an important 
molecule of the innate immune system. Nevertheless, suppression of host immune 
responses by NO and other reactive nitrogen intermediates (RNI) has also been reported 
during many infections. They were shown to be involved in the immunosuppression of T 
cell proliferative response in mice infected with T. brucei (Sternberg and McGuigan, 
1992) and L. monocytogenes (Gregory et a l, 1993). RNI were also reported to be
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responsible for the decreased proliferative responses of splenocytes observed in a murine 
model of filariasis (O'Connor et a t, 2000) and toxoplasmosis (Candolfi et al., 1994).
Evidence obtained from murine models, indicates that NO may also modulate DC 
function. Bone marrow-derived DCs were shown to produce NO following IFN-y and 
LPS stimulation in vitro and inhibited T cell proliferation (Bonham et al., 1996). In 
addition to its ability to inhibit T cell proliferation, NO was also shown to induce 
programmed cell death in DCs (Bonham et al., 1996; Lu et al., 1996). The percentage of 
DC apoptosis correlated with the level of NO in the cultures and was blocked by using 
inhibitors of NOS (Bonham et al., 1996). Other studies showed that NO, either 
exogenous or produced by iNOS in DCs themselves, inhibited the antigen presenting 
function of DCs (Holt et al., 1993; Lu et al., 1996). More recent studies have confirmed 
the inhibitory role that NO may play on DC function. NO has been reported to selectively 
downregulate the expression of the costimulatory molecule CD8 6  on monocyte-derived 
DCs in respone to LPS or soluble CD40 ligand and led to a decreased capacity of DCs to 
stimulate T cells in vitro (Corinti et al., 2003). Furthermore, NO inhibited the release of 
IL-10 and IL-12p40 by mature DCs as well as the secretion of chemokines crucially 
involved in T cell recruitment (IP-IO/CXCLIO and RANTES/CCL5) (Corinti et al.,
2003). A subsequent study confirmed the involvement of NO in the suppression of IL- 
12p40 production by murine macrophages and dendritic cells (Xiong et al., 2004). 
Splenocytes derived from iNOS-deficient mice were shown to produce increased IL- 
12p40 protein and mRNA compared to wild type mice of the same strain. The inhibitory 
effects of NO on IL-12 production were reported to be independent , of IL-10 (Xiong et 
al., 2004). Furthermore, NO was shown to inhibit TLR signal transduction through 
inhibition of IRAK activity and consequent attenuation of the molecular interaction 
between TRAF6  and IRAK (see Figure 1.3 for TLR signaling pathway) (Xiong et al.,
2004). These experiments suggest a role for NO in the regulation of Thl-type immunity 
through inhibition of IRAK activity, NF-kB and consequently IL-12. The effects that NO 
exert on plasmacytoid DCs has also been recently examined (Morita et a l, 2005). NO 
was reported to inhibit IFN-a, IL- 6  and TNF-a production by human plasmacytoid DCs 
and polarized them toward a Th2-promoting phenotype partly via a Guanosine 3’, 5’-
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Cyclic Monophosphate (cGMP)~dependent pathway (Morita et a l, 2005). All the above 
studies clearly indicate that NO can affect the outcome of the host immune response by 
interfering with DC function and may therefore represent a potential mechanism used by 
pathogens to subvert protective immune responses directed against them.
1.2.8.5 TGF-p regulation of DC function
TGF-p is a potent regulatory cytokine with a pivotal role in maintaining tolerance via the 
regulation of lymphocyte proliferation, differentiation and survival (Li et a l, 2005). In 
addition, TGF-p controls the initiation and resolution of inflammatory responses through 
the regulation of chemotaxis, activation and survival of lymphocytes, NK cells, DCs, 
macrophages, mast cells and granulocytes (Li et a l, 2005). It is produced by a wide range 
of cells including macrophages, DCs, NK cells and T and B cells and is secreted in a 
biologically inactive or latent form that must be cleaved and activated before interaction 
with its receptor (Letterio and Roberts, 1998).
Many studies have reported the role of TGF-p in affecting DC function. It regulates the 
maturation of differentiated DCs and DC-mediated T cell responses (Li et a l, 2005). DCs 
differentiated from human haematopoietic progenitor cells or monocytes in the presence 
of TGF-P have been shown to express predominantly intracellular MHC class II, low 
levels of CDld and costimulatory molecules CD80, CD83 and CD8 6  (Geissmann et a l, 
1999; Ronger-Savle et a l, 2005). These observations are consistent with murine studies 
in which TGF-P inhibits maturation of DCs differentiated from bone marrow cells with 
GM-CSF (Yamaguchi et a l, 1997), demonstrating that TGF-p promotes the generation of 
DCs with an immature phenotype. TGF-p also regulates the antigen presenting function 
of differentiated DCs in vitro. The presence of TGF-P in LPS-stimulated DC cultures 
inhibits the expression of MHC class II and costimulatory molecules, which attenuates 
the antigen presenting function of DCs (Geissmann et a l, 1999). In addition, DC 
maturation and IL-12 production induced by inflammatory cytokines such as IL-1 and 
TNF-a are inhibited by TGF-p (Geissmann et a l, 1999). In contrast, CD40L-induced DC 
maturation or cytokine production is not affected by TGF-p (Geissmann et a l, 1999).
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CD40L represents a key T helper signal for DC maturation as explained earlier in section 
1.2.5.1. Lack of TGF-P inhibition of CD40L-induced DC maturation implies that TGF-p 
primarily suppresses non-cognate DC activation.
There is evidence that pathogens have evolved mechanisms to induce infected host cells 
to secrete active TGF-p, which in turn suppresses APC function, enhancing pathogen 
survival. For example, infection of macrophages with the intracellular bacteria M. avium 
increases macrophage production of active TGF-p and suppresses their antibacterial 
activity (Champsi et al,, 1995). Parasites have also developed similar mechanisms for 
their survival and proliferation in the mammalian host. For instance, T. cruzi directly uses 
the host TGF-p signaling pathway to invade host cells (Ming et a l, 1995). T. cruzi is in 
fact unable to invade cells lacking TGF-P receptors or cells in which the downstream 
signaling of these receptors is interrupted (Ming et a l, 1995). Furthermore, T. cruzi has 
been shown to activate the TGF-p signaling pathway directly to facilitate its entry into 
mammalian cells (Ming et a l, 1995). Leishmania species have also been reported to be 
potent inducers of TGF-p (Barral-Netto et a l, 1992) and are able to activate latent TGF-p 
directly to its bioactive form. Activation of TGF-P was linked to enhanced parasite 
survival within macrophages (Gantt et a l, 2003).
1 . 2 . 9  P a t h o g e n - i n d u c e d  T  c e l l  a n e r g y
The ability of pathogens to induce T cell anergy has been extensively reported. In a 
recent study human rhinovirus was shown to significantly down-regulate the T cell 
stimulatory capacity of DCs through the induction of a novel DC activation program 
(Kirchberger et a l, 2005). It was demonstrated that co-cultivation of DC with the virus 
induces the expression of inhibitory receptors B7-H1 (PDL-1) and sialoadhesin (Sn, 
Siglec-1, CD 169) without affecting stimulatory receptors such as CD80 or CD8 6 . The 
consequence of this altered accessory repertoire on rhinovirus-treated DCs is that co­
cultured T cells acquire a deep anergic state, which is antigen-nonspecific and not 
reversible by exogenous IL-2 (Kirchberger et a l,  2005). Hepatitis C virus provides 
another example of a virus, which induces T cell anergy characterized by a decreased IL-
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2  response and impaired activation of the JNK signaling pathway (Sundstrom et a l,
2005). Similarly Helminth parasites have been shown to secrete substances, such as ES- 
62, that render lymphocytes anergic (Harnett et a l, 1998) and Leishmania antigens were 
found to induce T cell anergy due defective antigen presentation (Pinheiro et a l, 2004).
Although induction of regulatory T cells, anergy and apoptosis play important roles in the 
maintenance of central and peripheral tolerance by providing mechanisms to avoid 
inappropriate immune responses to ‘self or to harmless foreign antigens, it has become 
clear that many pathogens have evolved the ability to use these mechanisms to their 
advantage. Altering DC function is particularly advantageous to pathogens as these cells 
have the unique ability to induce primary immune responses by efficient activation of 
naïve T cells. By interfering with DC functions, microbes can therefore avoid the 
induction of immune responses directed against them, thus prolonging their survival and 
increasing the possibility of transmission to other hosts.
1 . 2 . 1 0  P a t h o g e n - i n d u c e d  a p o p t o s i s
Interaction of some pathogens with DCs has been reported to result in T cell apoptosis, A 
recent report demonstrated that both inactivated and infectious HIV-1 stimulated 
plasmacytoid DCs to secrete IFN-a, which in turn regulated the expression of TRAIL 
(TNF-related apoptosis-inducing ligand) by primary CD4^Tcells, leading to T cell 
apoptosis (Herbeuval et a l, 2005). This observation provided a unique role for 
plasmacytoid DCs in TRAIL-mediated apoptosis of CD4^T cell in HIV-1 infection and 
progression to AIDS.
DCs have also been shown to acquire killer functions via expression of TRAIL during 
Measles infection, hence becoming cytotoxic effector cells with the ability to kill facing 
activated T cells (Vidalain et a l, 2001). Furthermore, Measles virus-infected DCs have 
been reported to undergo Fas ligand (FasL)-dependent apoptosis by up-regulation of Fas 
following interaction with the virus. As activation up-regulates FasL expressed by T 
cells, early apoptosis of Fas-sensitive infected DCs would prevent subsequent T cell
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activation and could account for the in vivo suppression of cell-mediated immunity 
(Vidalain et aï., 2001). Therefore, besides inducing the development of DCs with 
‘regulatory’ phenotype and inhibiting naïve or activated T cell proliferation, Measles 
virus induces the synthesis of TRAIL death factor in DCs, leading to activated T cell 
apoptosis and finally induces FasL-dependent apoptosis of the DCs themselves (Vidalain 
et al., 2 0 0 1 ).
The ability to induce DC apoptosis is not unique to Measles virus. Vaccinia virus and 
canarypox virus have both been associated with inhibition of DC maturation and DC 
apoptosis (Engelmayer et ah, 1999; Ignatius et al., 2000). Likewise, Streptococcus 
pneumoniae has been reported to induce DC apoptosis through two distinct mechanism: a 
rapid caspase-independent mechanism, critically dependent on bacterial expression of 
pneumolysin, and a delayed-onset caspase-dependent mechanism associated with 
terminal DC maturation (Colino and Snapper, 2003). The latter mechanism was found to 
be independent of Fas/FasL interactions and TNF-a and did not require bacterial 
internalisation. Instead it was dependent upon interaction between bacterial subcapsular 
components with a cell-surface receptor on DCs (likely a TLR) acting in a MyD8 8 - 
dependent manner (Colino and Snapper, 2003).
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1,3 Plasmodium and Dendritic cells
As previously described in section 1.2, DCs are professional antigen presenting cells with 
the ability to induce primary immune responses by efficient activation of naïve T cells 
(Adams et al., 2005). They are generally the first cells of the immune system to encounter 
foreign organisms and their subsequent interaction with other cells of the immune system 
is a major component of the immune response (Adams et a l, 2005). Therefore, it is 
reasonable to assume that DCs also play a critical role in initiating immune responses to 
malaria.
Urban et a l first showed that P. falciparum  infected erythrocytes could prevent up- 
regulation of MHC class II and co-stimulatory molecules CD83 and CD 8 6  on human 
DCs in response to LPS treatment in vitro (Urban et a l, 1999). In addition to affecting 
maturation, they impeded the ability of DCs to induce antigen-specific primary and 
secondary T cell responses (Urban et a l, 1999). CD36 and CD51 were identified as the 
receptors on DCs responsible for this inhibitory effect (Urban et a l, 2001b). These same 
receptors were found to mediate the inhibitory effect of macrophages by decreasing TNF- 
a  and IL-1 secretion during malaria infection (Schwarzer et a l, 1992). It is interesting 
that these molecules are responsible for the recognition of apoptotic cells by phagocytic 
cells, which can also have suppressive effects on DC function and maturation (Voll et a l, 
1997). Interaction of infected erythrocytes with human DCs also resulted in decreased IL- 
12 secretion by DCs, which would otherwise promote adequate effector T cell 
proliferation and differentiation towards a Thl phenotype as described in section 1.2.5.1. 
Instead, an increase in IL-10 was observed, which could potentially directly suppress the 
stimulatory function of DCs (Haase et a l, 2002; McBride et a l, 2002) as well as promote 
the generation of T regulatory cells as previously explained in section 1.2.5.2. Moreover, 
a study in malaria-exposed children showed that DCs in peripheral blood may have 
down-regulated MHC class II expression (Urban et a l, 2001a), suggesting that DC 
function can be impaired in vivo during the acute stages of malaria infection.
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These human studies provoked the generation of a number of animal models 
investigating the function of DCs during malaria infection in vivo. Although there are less 
than a handful published studies, there are already inconsistencies in the literature on the 
effect of DC function after interaction with malaria parasites. Seixas and colleagues 
reported that bone marrow-derived DCs up-regulated the expression of MHC class II, 
CD40 and CD8 6  after exposure to P. chabaudi infected erythrocytes (Seixas et ah, 2001). 
Their ability to stimulate T cell responses was maintained and increased production of 
TNF-a, IL-12 and IFN-y was observed (Seixas et al., 2001). Similarly Pichyangkul et al. 
reported activation of murine bone marrow-derived and human plasmacytoid DCs 
following interaction with P. falciparum  schizonts in vitro as observed by the up- 
regulation of CD8 6  expression and IFN-a production (Pichyangkul et al., 2004). In this 
particular study the schizont immune stimulatory effects were shown to require the 
TLR9-MyD88 signalling pathway (Pichyangkul et a l, 2004).
Luyendyk and colleagues focused on analysing splenic CD llb^ and C D llc^ DC 
subtypes after acute infection with P. yoelii infected mice. They found that MHC class II 
and CD80 molecules on DCs were up-regulated and supported IFN-y production 
(Luyendyk et al., 2002). A similar study carried out by Perry and colleagues confirmed 
these results as they showed that DCs taken from P. yoelii infected animals expressed 
high levels of co-stimulatory molecules, activated naïve T cells to produce IL-2 and 
supported high levels of IFN-y and TNF-a production in an IL-12-dependend manner 
(Perry et al., 2004). Furthermore, in a subsequent study. Perry et al. showed that as the 
infection progressed, DCs became refractory to TLR-mediated IL-12 and TNF-a 
production, while increasing their ability to produce IL-10 and retaining their capacity for 
activation of naïve T cells (Perry et al., 2005).
The above observations contrast human studies vdth P. falciparum (Urban et al., 1999) as 
well as a study in mice carried out by Ocana-Morgner and colleagues who showed that P. 
yoelii infected erythrocytes inhibited the LPS-induced maturation of bone marrow- 
derived DCs in vitro (Ocana-Morgner et a l, 2003), Thus, there is disagreement in the 
literature on the role of DCs in protective immunity to blood-stage malaria. Since the
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Plasmodia parasites have been shown to impair human (Urban et a l, 1999) and murine 
(Ocana-Morgner et a l, 2003) DC maturation in vitro, it has been suggested that DCs 
cannot prime protective immunity during infection. However, Bruna-Romero and 
colleagues have shown that DCs presenting P. yoelii sporozoite antigens can induce 
protective immunity against liver-stage malaria in mice and can stimulate both CD4  ^and 
CD8  ^T cell responses (Bruna-Romero and Rodriguez, 2001). Furthermore Pouniotis et 
a l  have directly addressed the hypothesis that DCs can prime blood-stage malaria 
immunity (Pouniotis et a l,  2004). Maturation-arrested DCs in vitro were used to 
immunise animals, which were then challenged 1 0  days later with freshly isolated 
infected erythrocytes. DCs pulsed with P. yoelii or P. chabaudi infected erythrocytes 
were shown to be able to induce antigen-specific T cell responses, antibody responses 
and potent protection against lethal blood-stage malaria challenge in vivo despite an in 
vitro parasite-induced maturation defect (Pouniotis et a l, 2004). It was suggested that 
one possibility to explain the efficacy of the parasite-treated DCs immunisation was that, 
although a maturation defect was evident in vitro, once returned to the in vivo 
environment, these DCs can eventually develop into mature DCs (Pouniotis et a l, 2004). 
Thus, there may be a delay in maturation rather than a maturation arrest. These results 
suggest that DCs may be involved in the induction of immunity against blood-stage 
malaria parasites and further indicate that targeting of parasite antigens to DCs may 
provide an attractive approach for the development of blood-stage malaria vaccines.
1 . 3 . 1  E f f e c t  o f  h a e m o z o i n  o n  p h a g o c y t i c  c e l l s
Besides reports describing contrasting effects of Plasmodium-infQoXQà erythrocytes on 
DC function, different outcomes have also been reported regarding the effects of 
haemozoin on phagocytic cells.
The malaria parasite resides inside the erythrocytes of the infected host during the 
asexual blood-stage of its life cycle and uses haemoglobin as a nutrient (Goldberg, 1993). 
The parasite digests about 75% of the host haemoglobin but is unable to catabolize the 
toxic free haeme, which is formed as a byproduct of haemoglobin degradation (Francis et
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al., 1997). To protect the parasite membranes against the toxic effect of haeme 
molecules, the parasite converts the free haeme into haemozoin (malaria pigment) using a 
unique pathway referred to as the haeme polymerisation or biocrystallisation (Slater et 
a l, 1991).
Haemozoin enters phagocytes either within parasitized erythrocytes or, after schizont 
rupture, as a residual body and it has been reported to influence the immune responses of 
the host. Arese and colleagues have extensively studied the effects of haemozoin on 
human monocyte/macrophage function. In vitro studies have shown that haemozoin-fed 
monocytes are viable but functionally impaired (Arese and Schwarzer, 1997). They are 
unable to digest haemozoin or to repeat phagocytosis (Schwarzer et a l, 1992), to 
generate oxidative burst upon appropriate stimulation (Schwarzer and Aiese, 1996) or to 
kill ingested bacteria, fungi or tumor cells (Fiori et a l, 1993). Haemozoin-fed human and 
murine monocytes/macrophages were found to release large amounts of TNF-a 
(Pichyangkul et a l, 1994; Prada et a l, 1995; Sherry et a l, 1995), nitric oxide (Prada et 
a l,  1996), macrophage-inhibitory protein l a  and macrophage-inhibitory protein 1(3 
(Sherry et a l, 1995) and reduced amounts of IL- 6  (Prada et a l, 1995). In addition, 
monocyte protein kinase C, an effector of phagolysosome formation, lysosomal 
acidification and lysosomal enzyme production (Gewert et al, 1995; Tapper and Sundler, 
1995), was found to be inhibited after haemozoin phagocytosis (Schwarzer et a l, 1993). 
Inhibition of protein kinase C activity was suggested to be responsible for the increased 
levels of 4-hydroxy-nonenal in haemozoin-loaded monocytes, which was found to 
depress expression of MHC class II proteins in monocytes (Schwarzer et a l, 1998; 
Schwarzer et a l, 1996).
More recent studies have confirmed the potent pro-inflammatory effects of haemozoin in 
vivo (Jaramillo et a l, 2004) as well as demonstrating its involvement in the generation of 
large amounts of bioactive peroxidation derivatives of polyunsaturated fatty acids that 
inhibit monocyte function (Schwarzer et a l, 2003). Furthermore haemozoin has been 
reported to inhibit the proliferative response of mitogen-stimulated human peripheral 
blood mononuclear cells via an IL-10-dependent mechanism (Deshpande et a l, 2004) as
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well as affecting the ability of monocytes to differentiate and mature to functioning DCs 
(Skorokhod et a l, 2004).
The effects that haemozoin exert on DC function have not been extensively investigated 
and there are only two published studies to date on this subject. Coban and colleagues 
first reported that purified haemozoin from P. falciparum enhanced the maturation of 
myeloid DCs in vitro as observed by the up-regulation of DC surface markers CD83, 
CD8 6  and CD la  (Coban et al., 2002). Subsequently, the ability of haemozoin to activate 
innate immune responses, resulting in the production of cytokines, chemokines and up- 
regulation of costimulatory molecules, was confirmed in vivo and demonstrated that 
haemozoin exerted its effects through TLR9 (Coban et al., 2005).
All of the above studies clearly indicate that when ingested by phagocytic cells, 
haemozoin is not inert but can either impair a number of functional parameters in the case 
of monocytes and macrophages or activate immune responses by inducing DC maturation 
and cytokine production. A better understanding of the mechanisms by which haemozoin 
exerts its effects on immune cells may aid in the development of novel therapeutic 
approaches and offer a new chance to control pathogenic mechanisms in malaria.
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1.4 Aim of project
The present study aims at examining the effects that P, chabaudi AS infection have on 
DC function in vitro, with the view that a better understanding of how the malaria 
parasite affects DC function could have important implications for vaccine design and 
immunotherapy and might aid in the development of effective DC-based vaccines. 
Moreover, as the morbidity and mortality associated with malaria are derived exclusively 
from the asexual erythrocytic stages, Î examined whether intact, trophozoite-infected 
erythrocytes modulate key functions of DCs that may potentially lead to or contribute to 
more generalised immunosuppression in the host. In particular, the erythrocytic 
trophozoite stage was selected for this study first because the majority of the parasite 
induced changes in the infected erythrocytes have been shown to occur during this stage 
(Newbold, 1984); secondly because trophozoite-infected erythrocytes are less fragile 
compared to cells harbouring the schizont stage of the parasite (Newbold et a l, 1982), 
limiting the possibility that various metabolites released in the culture following schizont 
rupture might be responsible for any effects observed on DC function.
76
2. Materials and Methods
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2.1 Tissue culture
2.1.1 Animals
Female BALB/c mice were purchased from Harlan Olac (Bicester, U.K.). DO 11.10 
SCID mice, with CD4*** T cells specific for OVA323-339 peptide in the context of I-A'* 
recognised by the KJ1.26 clonotypic antibody (Haskins et al, 1983; Murphy et a l, 1990) 
were bred in-house at the Central Research Facility, University of Glasgow. All mice 
were kept under specific pathogen-free conditions and first used between 6 and 8 weeks 
of age in accordance with local and U.K. Home Office ethical regulations.
2.1.2 Parasites
Plasmodium chabaudi chabaudi AS strain was originally isolated from adult thicket rats 
(Jhamnomys rutilans) in 1967 by Professor David Walliker (University of Edinburgh) 
from La Maboke, Central African Republic. The strain was subsequently established in 
laboratory mice and cloned by limiting dilution (Walliker et a l, 1971). Stabilates of 
parasites, derived from the original AS parent clone, were maintained by 
cryopreservation in liquid nitrogen and subpassage through mice.
2.1.3 Cryopreservation of blood
Infected blood, at a parasitaemia of 20-25% containing ring stage parasites, were 
collected by cardiac puncture from mice sacrificed in a CO2 chamber into a syringe 
containing sodium heparin (1000 i.u./ml) in phosphate buffer saline (PBS, pH 7.2) as an 
anticoagulant at 10 i.u. heparin per ml of blood. The infected blood was diluted with an 
equal volume of a sorbitol-glycerol solution (38% glycerol, 2.9% sorbitol, 0.63% NaCl). 
200[xl aliquots were dispensed into 1.2 ml cryopreservation vials (Nunc, Hereford, UK). 
The vials were snap frozen by immersion into liquid nitrogen and stored until needed.
2.1.4 Maintenance of P. chabaudi chabaudi AS
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For long term preservation, cryopreservation vials of blood infected with P, chabaudi AS 
parent were kept in liquid nitrogen (-196°C). Infected blood was recovered for 
experimental use by allowing the vials to thaw at room temperature. Once defrosted, an 
equal volume of a 17.5% sorbitol solution was added slowly with frequent mixing (Gray 
and Phillips, 1981). The diluted blood was administered by i.p. injection into one or two 
recipients naïve BALB/c mice from which the experimental groups were infected once 
the parasitaemia reached 20-30%.
2.1.5 Determination of parasitaemia
The level of parasitaemia of infected mice was determined by daily examination of 
stained thin blood smears. Samples were taken between 8:00 and 9:00 each day by 
piercing the tip of the tail with a lancet (BD, Oxford, UK). A new lancet was used for 
each experimental group. A drop of blood was placed at one end of a glass microscope 
slide (BDH, Poole, Dorset, UK), smeared and allowed to dry at room temperature. The 
smear was fixed in 100% methanol (AnalaR, BDH Ltd) and then stained in Giemsa’s 
stain (Gurr, BDH Ltd) (1:10 of Giemsa’s stain in Giemsa’s phosphate buffer (3g 
Na2HPÜ4 , 0.6 KH2PO4, 11 distilled water, pH 7.2) for 15 minutes. The slide was then 
rinsed in tap water, air dried and examined under oil immersion using xlOO objective and 
xlO eyepiece lenses on a Leitz S.M. Lux (Nutley, New Jersey, USA) binocular 
microscope. Percentage parasitaemia was determined by counting total infected and non­
infected erythrocytes in a total of at least 10 fields containing around 300 RBC/field.
2.1.6 Challenge infections
Parasites from frozen stock were injected i.p. into BALB/c mice and the parasitaemia 
monitored daily by examination of Giemsa’s stained thin blood smears. Plasmodium 
chabaudi AS asexual erythrocytic stages grow synchronously. When a patent 
parasitaemia developed, infected blood was recovered in heparin ( 1 0  i.u./ml) by cardiac 
puncture and diluted in PBS (Invitrogen, Paisley, UK) to the required concentration of 
parasitised erythrocytes (pRBCs). Experimental mice were infected with pRBCs
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administered i.p. as a 0.25 ml inoculum. Infected mice were held in reverse light/dark 
cycle so that parasites harvested at 08:00 hours were at the late trophozoite stage. Blood 
was collected when parasitaemia was 30-40 %. In all experiments the ratio of pRBC to 
DC was 100:1 unless otherwise stated.
2.1.7 Generation of bone marrow-derived DCs
GM-CSF was made by growing the x63 GM-CSF myeloma cell line transfected with 
mouse GM-CSF cDNA (Lutz et ah, 1999) for 3-5 days in complete RPMI (cRPMI: 
RPMI 1640 supplemented with 2-mercaptoethanol (2-ME, 50 p,M), L-Glutamine (2 mM), 
penicillin (100 fxg/ml), streptomycin (100 p,g/ml) (all from Invitrogen) and 10% foetal 
calf serum (FCS, Labtech International, East Sussex, UK)) supplemented with 0.8 mg/ml 
G418 (Sigma-Aldrich, Poole, UK) and then harvesting the supernatant.
Bone marrow-derived DCs were generated as previously described (Lutz et a l, 1999). 
Briefly, femurs and tibiae of BALB/c mice were removed aseptically and separated from 
the surrounding muscle. The end of each bone was removed and the bone marrow flushed 
out using a 26 gauge needle (BDH Microlance) and a syringe filled with RPMI 1640 
(Invitrogen). Cell clusters were disaggregated by vigorous pipetting before passing the 
cell suspension through sterile Nitex mesh (Cadisch & Sons, London, UK). Cells were 
centrifuged at 450g for 10 minutes and resuspended in cRPMI supplemented with 10% 
GM-CSF. The cell concentration was adjusted to 5x10^ cells/ml. 1ml aliquots were 
distributed in six-well plates (Coming/Costar, Cambridge, MA) containing 1ml of cRPMI 
supplemented with 10% GM-CSF and cultured at 37°C, 5%C02 in air (37°C, 5%C02). 
Fresh medium (2ml) was added to the cell cultures every three days. On day 6, DCs were 
harvested and cultured at the required concentration with RBCs or pRBCs for each 
individual experimental procedure as described below.
For DC maturation, 1 (xg/ml of LPS (from Salmonella abortus equi; Sigma-Aldrich) or 
3|iM of CpG (Sweet et a l, 2002) (Sigma-Genosys, Cambridge, UK) were added to the 
culture and incubated for 18h at 37°C, 5%C02.
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In some experiments, \\iM  ONO-AE3-208 (PGE2-EP4 antagonist) (Kabashima et a i, 
2003b), 10p,M GW9662 (PPAR-y antagonist) (Calbiochem, San Diego, CA)(Hammad et 
al., 2004), ImM L-NIL (L-NIL) (Calbiochem)(Moore et a l, 1994), 5pg/ml of anti-TGF- 
P antibody (R&D Systems, Minneapolis, USA) and 2nM 1-MT (a pharmacological 
inhibitor of the enzyme indoleamine 2,3-dioxygenase) (Sigma-Aldrich)(Cady and Sono, 
1991) were cultured with DCs at the time of RBC or pRBC addition.
2.1.8 In vitro culture of CD40L-transfected fibroblasts with DCs
The cell lines 3T3-CD40L and 3T3-SAMEN (Schulz et al., 2000) were kind gifts from 
Dr P. Hwu (NCI, Bethesda, MD). Cells were grown in cRPMI in T75 tissue culture flasks 
(Helena Biosciences, Gateshead, UK) and, when confluent, harvested and distributed in 
six-well plates (Coming Costar) at 2.5 x 10^  cells/ml of cRPMI. Bone marrow-derived 
DCs were prepared as previously described and cultured with infected (pRBC) or non­
infected erythrocytes (RBC) at a ratio of 1:100. After 24 h, DCs were harvested, 
resuspended at 1x10  ^cells/ml and cultured in a 1:1 ratio with either 3T3-CD40L or 3T3- 
SAMEN for a further 24 h. The level of CD40 expression on DCs was analysed by flow 
cytometry and culture supernatants collected for IL-12 cytokine analysis.
2.1.9 In vitro culture of DCs with fixed infected or nom-infected erythrocytes
Blood from Plasmodium chabaudi AS-infected mice was washed twice in PBS before 
being resuspended in cRPMI for addition to DCs. For fixation, infected blood was 
washed three times in PBS and resuspended in 0.5 % paraformaldehyde for 30 minutes at 
4°C. Fixed erythrocytes were then washed in PBS, resuspended in 0.06% gly-gly (Sigma- 
Aldrich) for 5 minutes at 4°C and washed twice more in PBS before being resuspended in 
cRPMI for addition to DCs. After 24 h of culture, DCs were stimulated with 1 [xg/ml of 
LPS (Sigma-Aldrich) and the expression of cell surface molecules on DCs analysed 18 h 
later by flow cytometry. To confirm complete fixation, 2x10^ fixed, infected erythrocytes 
could not establish infection when injected i.p into a female BALB/c mouse.
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2.1.10 Lymph node single cell suspension
Peripheral and mesenteric lymph nodes were aseptically removed from DO 11.10 
transgenic mice (Murphy et a l, 1990) on the SCID background (Saparov et a l, 1999). 
They were made into a single cell suspension by rubbing through Nitex mesh (Cadisch & 
Sons, London, UK) in cRPMI medium using a 2.5ml syringe plunger. Cells were 
centrifuged for 5 minutes at 450g and resuspended in cRPMI. The proportion of 
transgenic T cells in a lymph node preparation from these mice is approximately 95% as 
measured by flow cytometry (Figure 2.1). Cells were counted on a Neubauer 
Haemocytometer (Hawksley & Sons, Sussex, UK) using a phase contrast microscope. 
Viable cells were determined by Trypan Blue exclusion (see section 2.2.2 for details).
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Figure 2.1 Percentage of transgenic CD4^T cells in aDOl 1.10 SCID donor
The plots are of a lymph node preparation from a naïve DO 11.10 SCID mouse. Gate R1 
is set around the population of viable lymphocytes. Gate R2 is set around transgenic T 
cells (CD4^KJ^, after gating the plot on R l, and represent 94.4% of total cells.
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2.1.11 Antigen presentation assay
Bone marrow-derived DCs were centrifuged at 450g, resuspended at 1x10^ cells/ml and 
500^1 aliquots were distributed into 24-well tissue culture plates (Coming Costar) with 
pRBCs or RBCs. After 24 h incubation at 37 °C in 5 % CO2, DCs were antigen pulsed 
for 6 h with 5 mg/ml of LPS-free OVA (Worthington Biochemical, Freehold, NJ). An 
OVA-specific T cell hybridoma (DOll-GFP; supplied by Dr D. Underhill, Institute for 
Systems Biology, Seattle, WA) expressing green fluorescent protein (GFP) under the 
control of NFAT (Underhill et aL, 1999), was added to the cultures to achieve 1:1 DC: T 
cell ratio. A set of cells was pulsed with an equimolar concentration of OVA peptide (aa. 
323-339) (40pg/ml)(Sigma-Genosys) prior to the addition of T cells. GFP expression by 
CD4’*' T cells identified with PE-rat anti-mouse CD4 (BD Pharmingen, Oxford, UK) was 
determined by flow cytometry.
2.1.12 Thymidine incorporation assay
2x10^ DCs were cultured with 2x10^ pRBCs or RBCs in a 96 well plate (Corning Costar) 
for 24h at 37°C, 5%C02. OVA-specific T cells were isolated from the mesenteric and 
peripheral lymph nodes of DO 11.10 transgenic mice (Murphy et ah, 1990) on the SCID 
background (Saparov et ah, 1999) and cultured at a 1:1 ratio with DCs. T cell 
proliferation was analysed after 48, 72, 96 and 120 h of culture and assessed by 
incorporation of [^H] thymidine (0.5 p,Ci/well) (Radionucleotide Dispensary, Western 
Infirmary, Glasgow) for the last 24 h of culture. In some experiments, 1 Ong/ml of rIL-2 
or 5jxg/ml of anti-TGF-p (both from R&D Systems) were added at the beginning of the 
proliferation assay. Cells were harvested onto filter mats (Wallac, Boston, USA) using a 
Betaplate 96 well harvester (Wallac) and [^H] thymidine incorporation measured on a 
Betaplate liquid scintillation counter (Wallac).
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2.2 Cell viability/Apoptosis assay
2.2.1 Quantitation of viable DCs
DCs were co-cultured with RBCs or pRBCs in 6-well plates (Coming Costar) for 24h at 
37°C, 5% CO2 . Cells were harvested following several washes with ice cold PBS 
(Invitrogen). RBCs were lysed using Boyles’ solution (Tris-NH4C1 buffer) (Fonseca et 
ah, 2001) and the number of viable DCs recovered from each well quantified by Trypan 
blue (Sigma-Aldrich) exclusion.
2.2.2 Trypan Blue Exclusion Assay
Cell viability was analysed by using the trypan blue exclusion assay since trypan blue is 
excluded from viable cells. 50p,l of cell suspensions were diluted with 50p,l of 0.4% 
trypan blue (Sigma-Aldrich). The number of cells excluding trypan blue was assessed 
using a Neubauer Haemocytometer (Hawksley & Sons).
2.2.3 Annexin V/PI Assay
The Annexin V/Propidium Iodide (PI) assay was used to detect cell apoptosis. In 
apoptotic cells, the inner membrane phospholipid phosphatidylserine (PS) is exposed to 
the external cellular environment. Annexin V, a phospholipid-binding protein conjugated 
to FITC, binds to cells with exposed PS. Viable cells exclude PI (Vermes et a t, 1995). 
An Annexin V-FITC apoptosis detection kit was purchased from BD Pharmingen. Cells 
to be tested for apoptosis were washed twice in cold PBS (Invitrogen) and resuspended in 
binding buffer provided at a concentration of 1x10^ cells/ml. 100p,l aliquots of the cell 
suspension were incubated with 5p,l o f Annexin V-FITC and 5(aI of PI at room 
temperature for 15 minutes prior to analysis by flow cytometry.
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2.3 Flow cytometry
Approximately 5x10^ cells were transferred into 12 x 75mm polystyrene tubes (Falcon 
BD, Oxford, UK), centrifuged at 450g and resuspended in lOOfxl FcR blocking buffer 
(anti-CD 16/32, clone 2.4G2, hybridoma supernatant, 10 % mouse serum (Alba 
Bioscience, Edinburgh, UK) and 0.1 % sodium azide (Sigma-Aldrich)), to reduce non­
specific binding by Fc receptors, and the appropriate fluorochrome-conjugated or 
biotinylated primary antibodies. Details of antibodies used are described in table 2.1. All 
samples were incubated at 4°C in the dark for 20-30 minutes, washed with 2ml FACS 
buffer (PBS, 2 % FCS, and 0.05 % sodium azide) and, where appropriate, biotinylated 
antibodies were detected by incubation with lOOfxl of a 1/200 dilution of fluorochrome- 
conjugated streptavidin (Pharmingen) at 4°C in the dark for 20-30 minutes. The cells 
were then washed in FACS buffer and resuspended in 300p,l FACSflow (BD) and data 
acquired using a FACSCalibur flow cytometer equipped with a 488 nm Argon laser and a 
635 nm red diode laser and analysed using CellQuest software (both from BD 
Biosciences).
Prior to analysing labelled cells, forward scatter (FSC) and side scatter (SSC) were 
adjusted so cells of interest could be gated on the screen. Unstained samples were used as 
auto-fluorescence controls allowing settings to be adjusted so that auto-fluorescence 
background was roughly within the first decade of the log scale of the fluorescence 
intensity histogram. Unstained samples were compared with isotype and positively 
stained controls to confirm the correct scale. Compensation settings were set such that on 
an FL-1 vs FL-2 dot plot, an FL-1 positive population was negatively aligned with 
negative population, and an FL-2 positive population was horizontally aligned with the 
FL-2 negative population.
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Antigen Conjugate Clone Isotype
C D 4 P E G K 1 . 5 R a t  I g G 2 a k
C D 4 F I T C L 3 T 4 R a t  I g G 2 a k
C D 4 0 P e r C P R M 4 - 5 R a t  I g G 2 a k
C D 6 9 F I T C H 1 . 2 F 3 H a m s t e r  I g G  I X ,
I - A / I - E F I T C 2 G 9 R a t  I g G 2 a k
C D 4 0 F I T C 3 / 2 3 R a t  I g G 2 a k
C D 8 0 F I T C B 7 . 1 H a m s t e r  I g G  I X ,
C D 8 6 F I T C B 7 . 2 R a t  I g G 2 a k
C D l l c P E H L 3 H a m s t e r  I g G l X ,
Table 2.1 Monoclonal antibodies used for flow cytometry
All antibodies were purchased from BD Pharmingen and used according to 
manufacturers’ guidelines.
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2.3.1 Flow cytometric analysis
a. CD11C+
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Figure 2.2 Flow cytometric analysis of CD40 expression on bone marrow-derived DCs. 
Gate Rl is set around GDI Ic^ cells (a), drawn using the isotype control (b). Dot plots (c- 
f) and histograms (g-h) are gated on Rl to obtain the percentage of CD llc^ cells
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expressing CD40 (c-f) or the Mean Fluorescence Intensity (MFI) values (g). The marker 
Ml is set using the isotype control (h). FL1=CD40 expression. Plots are representative of 
three independent cultures. The obtained MFI and percentage positive values are used to 
plot the bar graphs shown throughout this thesis.
2.4 Preparation of erythrocyte ghosts from infected and non-infected 
mice
Ghosts from infected and non-infected erythrocytes were generated as previously 
described (Wunderlich et al., 1985). Briefly, blood was collected by cardiac puncture and 
washed three times in PBS. Infected and non-infected erythrocytes were concentrated in 
PBS supplemented with 113 mM of Glucose (Sigma-Aldrich) and 3% FCS. Infected 
erythrocytes were incubated in an equal volume of glycerol buffer (i.e. 10 % glycerol 
(Sigma-Aldrich) supplemented with 5 % FCS in PBS) for Ih at 4°C. Parasites and ghosts 
were separated in a continuous Percoll (Amersham Biosciences, Buckinghamshire) 
gradient (p: 1.02-1.10 g/cm"^) in intracellular medium buffer (IM: 20 mM NaCl, 120 mM 
KCl, 1 mM MgCl2 , 10 mM Glucose, 5 mM Hepes, pH 6.7) and centrifuged at 5000 g for 
30 minutes. Ghosts were then washed in IM buffer and layered on a two-step Percoll 
gradient (p: 1.01+1.02 g/cm"^) to separate them from possible ghosts that still contained 
parasites. Ghosts from non-infected erythrocytes were obtained by adding a 40-fold 
volume of phosphate buffer (5 mM NaH2P0 4 /Na2HP0 4 , 1 mM PMSF, 0.01 % Azide, pH 
8.5). The suspension was centrifuged at 32000g for 30 minutes. Ghosts from infected and 
non-infected erythrocytes were then washed three times in PBS before being resuspended 
in cRPMI for addition to DCs at a ratio of 100:1.
2.5 Haemozoin preparation and quantitation
Haemozoin was purified from supernatants obtained from cultures of Plasmodium 
falciparum  gametocytes, which were kindly provided by Dr Lisa Ranford-Cartwright, 
(Division of Infection and Immunity, IBLS, University of Glasgow, U.K) and endotoxin-
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&ee buffers and solutions used throughout. Supernatants were centrifuged for 20 minutes 
at 45Og. The pellet was washed three times in 2% SLS and resuspended in 6M Guanadine 
HCl. Following five to seven washes in PBS, the pellet was resuspended in PBS and 
sonicated for 90 minutes using Soniprep 150, (Sanyo Scientific, Bensenville, IL) at an 
amplitude of 5-8 microns to minimize aggregation and maintain the haemozoin in 
suspension. Total haeme content was determined as previously described (Sullivan et al., 
1996) by depolymerising haeme polymer in 1 ml of 20 mM NaOH/2 % SDS, incubating 
the suspension at room temperature for 2h and then reading the OD at 400 nm using UV 
visible spectrophotometer (Thermo Spectronic, HeMos, Cambridge, UK).
2.6 Cytokine analysis
For the detection of IL-12 (p40) and IL-10 produced by DCs, OptEIA^^ ELISA kits 
(BD) were purchased and standards and antibody pairs specific for the corresponding 
cytokine were used according to manufacturer’s instructions. Briefly, 96 well plates 
(Immulon-4 HBX, Dynex (West Sussex, UK)) were coated overnight at 4°C with 
100p,l/well of Anti-mouse IL-12 or Anti-mouse IL-10 monoclonal antibody diluted in 
0.2M Sodium Phosphate (1:250 dilution for IL-12 and 1:125 for IL-10), pH 6.5. After 3 
washes with PBS/0.05% Tween 20, non-specific binding sites were blocked for 1 hour at 
room temperature by adding 200p,l/well of PBS/10% FCS. After 3 washes with 
PBS/0.05% Tween 20, 100p,l of samples or serial dilutions of recombinant cytokine 
standards (rIL-12 dilutions starting at 4000pg/ml, rIL-10 dilutions starting at 2000pg/ml) 
were added to each well and incubated for 2 hours at room temperature. After incubation, 
the plates were washed 6 times and incubated with lOOpl of the appropriate anti-cytokine 
detection monoclonal antibody + Avidin-horseradish peroxidase conjugate for 1 hour at 
room temperature. Plates were washed a further 6 times before the addition of 100p,l/well 
of substrate solution (TMB). 50pl/well of stop solution (Sulphuric acid, 0.4M) were 
added before measuring the optical density (OD) at 450/630nm (dual wavelength mode) 
using a Dynex microplate reader. The OD values were converted to pg/ml of cytokine in 
supernatants by using Revelation software to analyse the standard curves obtained from
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serial dilutions of the cytokine standards. Detection limits were 31.3 pg/ml for IL-12 and 
15.6 pg/ml for IL-10.
For the detection of T cell cytokines (IL-4, IL-5, IL-10, IL-2, IFN-y and IL-12), Mouse 
Thl/Th2 6-Plex Antibody Bead kit (Biosource) was used according to manufacturer’s 
instructions. Briefly, all washing steps were performed by placing a 96 well filter-bottom 
microplate provided on a filtration apparatus and applying a vacuum sufficient to gently 
empty the wells, which have been pre-filled with 200pl of a Working Wash Solution 
provided. All incubation steps were carried out in the dark at room temperature and by 
placing the microplate on an orbital shaker. 25 [il of the antibody-coated beads were 
added to each well. After washing the plate twice, serial dilutions of cytokine standards 
(dilutions starting at 5.78ng/ml for IL-5, 11.47ng/ml for IL-4, 3.39ng/ml for IL-10, 
4.75ng/ml for IL-12, 7.92ng/ml for IL-2 and 5.43ng/ml for IFN-y) and samples were 
added to the appropriate wells and incubated for 2h. Following the incubation time, the 
plate was washed twice and lOOpil of diluted biotinylated detection antibody added into 
each well and incubated for Ih. The wells were then washed twice before adding lOOpl 
Streptavidin-RPE (fluorescent), which was incubated for 30 minutes. Finally, the plate 
was washed three times before addition of lOOp.1 of Working Wash Solution and then 
loaded into the Luminex platform to read the analyte concentration.
2.7 Microscopic analysis
2.7.1 Bright field microscopy
5x10^ DCs were dispensed onto 13mm poly lysine (Sigma-Aldrich) coated coverslips 
(BDH) in 24 well plates (Coming Costar) and left to adhere overnight at 37°C, 5% CO2. 
5x10^ RBC or pRBC were added to DCs and incubated for a further 24h. Coverslips were 
mounted onto glass slides (BDH) and examined by bright field microscopy using an 
Axiovert S-100 Zeiss microscope (Carl Zeiss Ltd, Hertfordshire, UK) using a 63x oil 
immersion lens.
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2.7.2 Fluorescence microscopy
DCs and pRBC co-cultures were set up as described above. After 3h incubation at 37®C, 
5% CO2 DCs were stained with 0.5pg/ml of CTxB conjugated to Alexa Fluor 488 
(Molecular Probes, Oregon, USA) and incubated for 15 minutes at 37°C in 5% CO2 . 
Cells were then fixed with 0.5% paraformaldehyde for 20 minutes at 4°C. RBCs were 
stained with 5pg/ml of biotin-conjugated rat anti-mouse TER-119 monoclonal antibody 
(Pharmingen) for 10 minutes at 4°C. The biotinylated antibody was detected using 
streptavidin-FITC (Vector Laboratories, CA, USA). Vectashield containing DAPI 
(Vector Laboratories) was used to stain cell nuclei. Coverslips were mounted onto glass 
slides (BDH) and fluorescence microscopy performed using an Axiovert S-100 Zeiss 
microscope using a 63x oil immersion lens.
2.8 Total RNA extraction from bone marrow-derived DCs
RNeasy Midi kit was purchased from Qiagen (West Sussex, UK) and used according to 
the manufacturer’s instructions. Briefly, 2x10'^  bone marrow-derived DCs were cultured 
with 2x10* P. chabaudi AS-infected or non-infected RBCs for 6h at 37°C, 5%C02. Cells 
were then harvested and centrifuged for 5 minutes at 300g. Supernatants were carefully 
removed by aspiration and cells disrupted by adding 2ml of buffer RLT provided. Cells 
were homogenised by passing the lysate through a 20 gauge needle (BDH) fitted to an 
RNase-free syringe (BDH). 2ml of 70% ethanol (Sigma-Aldrich) was added to the 
homogenised lysate and mixed thoroughly. Samples were then applied to an RNeasy midi 
column and centrifuged for 5 minutes at 3000g. 2ml of buffer RWl supplied, was used to 
wash the column for 5 minutes at 3000g before carrying out on-column DNase digestion. 
160pl of DNase I incubation mixture provided was added directly onto the RNeasy silica- 
gel membrane and incubated for 15 minutes at room temperature. 2ml of buffer RWl was 
then added to the column and incubated for 5 minutes at room temperatuie, before 
centrifuging it for 5 minutes at 3000g. The column was washed twice for 5 minutes at 
3000g with 2.5ml of buffer RPE supplied. To elute, the RNeasy column was transferred 
to a new 15ml collection tube and 150pl of RNase-free water (Invitrogen) added directly
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onto the RNeasy silica-gel membrane and incubated for 5 minutes at room temperature. 
The column was then centrifuged for 3 minutes at 3000g and the elution step carried out 
one more time using the same amount of RNase-free water. The total RNA extracted was 
stored at -20°C for gene array analysis. Mouse Genome 430 2.0 Array was purchased 
from Affymetrix and experiments performed at the Sir Henry Wellcome Functional 
Genomics Facility at the University of Glasgow,
2.9 Statistical analysis
Results are expressed as mean ± standard error. Significance was determined by one-way 
ANOVA in conjunction with the Tukey test, using Minitab. A p-value of p<0.05 was 
considered significant.
2.9.1 Statistical methods for identifying dififerentially expressed genes in microarray 
data.
Microarray technology certainly has the potential to greatly enhance our knowledge 
about gene expression. Due to the ability of this technique to monitor the expression 
levels of thousands of genes simultaneously, microarray experiments generate massive 
amounts of data. Therefore methods are needed to determine whether changes in gene 
expression are experimentally significant. Data obtained from microarray analysis has to 
be interpreted cautiously. Fluorescence intensities from replicate microarrays cannot 
generally be compared directly, but only after appropriate calibration (or normalization) 
(Huber et al., 2002), due to variation in sample treatment, labelling, dye efficiency and 
detection. Furthermore, since different laboratories may use different array technologies 
to profile the same genes, it would be beneficial to be able to combine expression 
measurements within a single analysis, as utilization of data from different technologies 
has the potential to reduce the need to duplicate experiments. However, this will require 
the different measurements to be comparable. For instance, expression levels measured 
by cDNA microarrays are usually reported as a ratio of the signal from a target mRNA 
sample relative to one from a co-hybridized reference mRNA sample (Schena et al..
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1995). This method complicates a direct comparison with results from other technologies 
as the reported ratios depend on the chosen mRNA reference. It is therefore extremely 
desirable that a researcher has the best possible analytical tools available to make the 
most of the information that this powerful technology has to offer.
As microarray data is often noisy and not normally distributed (Hunter et al., 2001), it is 
challenging to construct a statistical data model applicable to all microarray data sets. In 
this context, non-parametric methods that do not assume a specific distribution of data are 
particularly attractive. Recently, a powerful new test statistics, based on calculating rank 
products (RP) from replicate experiments to define differentially expressed genes, has 
been successfully implemented and is now used as the standard method for microarray 
data analysis at the Sir Henry Wellcome Functional Genomics Facility at the University 
of Glasgow (Breitling et al., 2004b). A major advantage of this new technique is the ease 
with which results from different array technologies can be combined in one analysis. As 
long as the results can be expressed as rank lists, it does not matter whether they are 
produced by two-colour cDNA arrays or Affymetrix oligonucleotide chips.
The strength of the RP approach relies on making relatively weak assumptions about the 
data. In an experimental setup, only a minority of the genes are assumed to significantly 
change their expression levels (Breitling et al., 2004b). This may seem relatively 
restrictive, as it is easy to imagine experimental setups where the majority of the genes 
are differentially expressed. However, in these circumstances, one will usually want to 
know the most important genes. In this context, relevant changes are considered to be 
always large, while small changes may have statistically but rarely biological 
significance; thus significant gene regulation is almost a ‘switch-like’ process (Breitling 
et al., 2004b). Equal variance for all genes, changes being independent of each other and 
measurements being independent between replicate arrays are among the other weak 
assumptions that makes this method a powerful statistical test for identifying 
differentially expressed genes under two experimental conditions (Breitling et al., 
2004b). The principle behind the RP method is briefly described in Figure 2.3
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Rank Products
Replicate A Replicate B
e n e P o s i t i o n G e n e  P o s i t i o n G e n e R P p o s i t i o n
a 1 a 1 b 0 . 1 1
b 2 g 2 d 0 . 2 2
c 3 c 3 f 0 . 3 3
d 4 b 4 h 0 . 4 4
e 5 e 5 - - - - - - - - - - - - - i 0 . 5 5
f 6 f 6 a 0 . 6 6
g 7 d 7 c 0 . 7 7
h 8 i 8 e 0 . 8 8
i 9 h 9 g 0 . 9 9
C a l c u l a t e  R P  =  g e n e  p o s i t i o n  i n  A  x  g e n e  p o s i t i o n  i n  B
n n
Figure 2.3 Principle of Rank Product Analysis. Genes are sorted by 
increasing/decreasing Fold Change (FC). The probability (p) of a gene to be found at the 
top of the list if the lists were random is p  = l /n \  where n is the total number of genes 
and k the number of replicates. This probability can be calculated as a Rank Product 
(RP). The RP values can then be used to sort tlie genes in a new list where genes with the 
smallest RP values are the most interesting candidates. In the example shown above the 
RP for gene d  is RPd = 4/9 x 7/9. The significance level {p’)  is then calculated using a 
permutation-based procedure and determines the likelihood of observing each gene so 
high on the lists just by chance. For example, p  ’ for gene d is the probability that all the 
other genes in the list are not at position 2. Once p  ’ has been calculated, the False 
Discovery Rate (FDR) is determined, which identifies whether a gene has been randomly 
regulated. For gene d, the FDR will define whether its position in the list is just an 
artefact of the experimental procedure.
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Another major advantage of the RP method is that it provides data that are suitable to be 
used in the Iterative Group Analysis (iGA) approach (Breitling et al, 2004a) (Figure 2.4). 
This method is based on the idea that a concerted expression change of some members of 
the same functional class is physiologically relevant (Breitling et al., 2004a). Therefore, 
iGA identifies functional classes of genes that are significantly changed and also which 
of the class members are most likely to be differentially expressed (Breitling et a l, 
2004a), thus facilitating, improving and accelerating the biological interpretation of 
microarray experiments (Breitling et al., 2004a).
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Iterative Group Analysis
Position Gene
Step 1
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Gene p value
a 0.3
b 0.9
c 0.5
d 0.8
e C S )
f 0.6
£
h 0.4
i 0.7
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Figure 2.4 Principle of Iterative Group Analysis. Step 1. Genes are sorted by increasing 
Fold Change (FC) values (or any other choice of metrics of differential expression) and 
assigned to functional classes based on their GeneOntology assignments. Step 2. The p  
value (i.e. the probability of observing members of a given class at a particular position in 
the list by chance) for each gene belonging to a specific functional class is determined. 
The position in the list that yields the smallest p  value is used to determine the cut-off of 
the class. All class members above that position are considered as ‘potentially 
differentially expressed’. Step 3. The smallestp  value determined is assigned as the PC 
(Probability of Change) value of the class. Step 4. All classes are sorted by their PC 
values and the classes with the lowest value are the most significantly changed.
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3. Assessing the effects of P. chabaudi AS-infected erythrocytes
on DC function in vitro.
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3.1 Introduction
Host resistance against infectious organisms requires the development of an appropriate 
immune response. As previously mentioned in section 1.2.5, DCs play a key role in 
determining the type of induced response. These cells have evolved to monitor the 
environment, detect pathogens and trigger T cell activation providing a link between the 
innate and adaptive immune systems (Adams et a l, 2005). In turn, many pathogens have 
evolved mechanisms to subvert the function of these important cells thereby modulating 
the host’s immune response to their advantage (Rescigno, 2002; Rescigno and Borrow, 
2001).
It is now widely accepted that encounter with parasites can strongly modify DC function 
and lead to altered T cell responses (Sher et al., 2003). Some parasites may lead to DC 
activation. Nevertheless there is evidence indicating that although activated by pathogens, 
mature DCs may either fail to respond or are functionally suppressed. For instance 
Langerhans cells in the skin of mice infected with S. mansoni become activated but are 
unable to migrate from the epidermis. This inhibition appears to be mediated by 
prostaglandin D2 produced by the parasite and may help delay the subsequent adaptive 
response (Angeli et a l, 2001). Similarly, infection with T. gondii selectively activates 
human DCs by increasing MHC class II, CD86 and CD83 but not CD40, CD54 or CD80 
expression. However, these DCs induce apoptosis of T cells (Wei et a l, 2002).
Other parasites may instead avoid activating DCs in the first place. For instance, helminth 
antigens do not appear to be able to directly induce DC maturation, at least as far as 
increased expression of classical DC maturation markers such as MHC class II, CD80 
and CD86 is concerned (MacDonald et a l, 2001; Whelan et a l, 2000). Particularly 
interesting is the inhibition of DC maturation induced by the malaria parasite P. 
falciparum (Urban et a l, 1999). Malaria-infected erythrocytes were found to bind to the 
surface of myeloid DCs in vitro and to markedly suppress the normal upregulation of 
MHC class II molecules, adhesion molecules (e.g. ICAM-1) and costimulatory molecules 
(CD83 and CD86) on DCs following LPS stimulation. The resulting DCs were severely
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impaired in their capacity to induce antigen-specific primary and secondary T cell 
responses (Urban et aL, 1999). The receptors on the surface of DCs mediating this 
inhibitory effect were shown to be the integrins CD36 and CD51 (Urban et al., 2001b). 
The major parasite molecule interacting with these integrins appeared to be a functionally 
conserved domain of P. falciparum erythrocyte membrane protein 1 (pfEMPl) (Urban 
and Roberts, 2002), a molecule that undergoes antigenic variation (Biggs et a l, 1991).
DCs exposed to blood-stage malaria parasites were also shown to suppress CD8^ T cell 
responses against the liver stages of this parasite and inhibit CD8^ T cell priming 
following vaccination with irradiated sporozoites (Ocana-Morgner et a l, 2003). As 
effective liver-stage immunity is essential to protect against new infection, this method of 
immunosuppression may benefit the parasite by leaving individuals open to constant re­
infection (Ocana-Morgner et a l, 2003). The ability of malaria parasites to inhibit the 
maturation of DCs could be involved not only in parasite-specific immunosuppression 
(Ho et a l, 1986), but also in the suppression of responses to heterologous antigens such 
as vaccines as well as unrelated pathogens (Cook, 1985; Enwere et a l, 1999; Greenwood 
et a l, 1972; Mabey et a l, 1987; McGregor, 1962; Thursz et a l, 1995; Williamson and 
Greenwood, 1978),
In this study I examined whether P. chabaudi AS-infected erythrocytes modulated key 
functions of DCs that may potentially lead, or contribute to more generalised 
immunosuppression. A better understanding of how the malaria parasite interferes with 
DC biology may therefore contribute to the development of new therapeutic approaches 
and aid in the development of a much needed malaria vaccine.
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3.2 Results
3.2.1 Optimisation of culture conditions
In order to investigate the effects that infected erythrocytes have on DC function, 
preliminary experiments were carried out to determine the correct ratio of pRBC:DC in 
co-culture systems. For this purpose, pRBCs or control uninfected RBC, were incubated 
with bone marrow-derived DCs at a ratio of 1:1, 10:1 and 100:1. After a 24h incubation, 
one set of cells was analysed for the expression of the surface markers MHC class II and 
CD40. Another set of cells was challenged with LPS and the levels of costimulatory 
molecules analysed 18h later. DCs cultured in growth medium alone and those 
challenged with LPS served as negative and positive controls respectively.
The results show that pRBCs did not induce DC maturation at any of the ratios tested 
(Fig 3.1) as the levels of MHC class II and CD40 were the same as those of the untreated 
control DCs and DCs treated with RBCs. However pRBCs were able to induce a dose- 
dependent suppression of the ability of pRBC-treated DCs to respond to LPS stimulation 
in vitro as seen by the reduced levels of MHC class II and CD40 (Fig 3.2). To ensure that 
the viability of DCs was not affected by the presence of pRBCs in the culture system, the 
number of viable DCs was quantified by trypan blue exclusion after 24h incubation with 
pRBCs. DCs alone and DCs incubated with RBCs served as controls. The results show 
pRBC and RBC did not have an effect on the number of viable DCs recovered after each 
treatment (Fig 3.3).
The ability of pRBC-treated DCs to respond to LPS stimulation in vitro was consistently 
found to be affected when using 100 pRBC : 1 DC hence this ratio was used in all the 
experiments described in this thesis to further investigate the role of pRBCs in the 
modulation of DC function in vitro.
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Figure 3.1 Surface expression of MHC class II (a) and CD40 (b) on bone marrow- 
derived DCs after 24h of culture with non-infected (RBC) or P. chabaudi AS-infected 
erythrocytes (pRBC). 5x10^ DCs were incubated with 5x10^, 5 x 1 or 5x10^ pRBC to 
achieve a ratio of pRBC:DC of 1:1, 10:1 and 100:1 respectively. An equal number of 
RBCs were used as controls. DCs treated with Ipig/ml of LPS (DC+LPS) and those 
grown in medium only (DC) served as positive and negative controls respectively. 
Results are expressed as the mean fluorescence intensity of duplicate cultures as 
determined by flow cytometric analysis of gated CDl Ic^ cells.
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Figure 3.2 Surface expression of MHC class II (a) and CD40 (b) on bone marrow- 
derived DCs following LPS stimulation. DCs were cultured for 24h with non-infected 
(RBC) or P. chabaudi AS infected erythrocytes (pRBC) as described in figure 3.1, then 
treated withlpg/ml of LPS for a further 18h. Results were analysed as described in figure 
3.1.
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Figure 3,3 DC viability after incubation with P. chabaudi AS infected erythrocytes. 
2x10^ bone marrow- derived DCs were cultured either in growth medium alone (DC) or 
in the presence of non-infected (DC+RBC) or P. chabaudi AS infected erythrocytes 
(DC+AS) at a ratio of 1:100, After 24h incubation, DC viability was assessed by trypan 
blue exclusion. Results show the mean value of viable cells ± standard error of triplicate 
cultures per group.
105
3.2.2 Effect of P. chabaudi AS-infected erythrocytes on resting DCs
Having established that pRBCs did not induce DC maturation as observed by the levels 
of MHC class II and CD40, I wanted to extend this observation to other costimulatory 
molecules by examining the expression of CD80 and CD86 as well as MHC class II and 
CD40 in order to confirm previous results, DCs were pre-incubated with pRBCs and the 
expression of surface markers examined 24h later by flow cytometry. The results show 
that DCs expressed very low levels of surface MHC class II, CD40, CD80 and CD86 
when cultured in growth medium alone, confirming their immature state in culture (Fig. 
3.4). Stimulation with LPS promoted a significant increase in the expression level of all 
of the costimulatory molecules tested. However, DCs incubated for 24h with RBCs or 
pRBCs did not increase expression of MHC class II, CD40, CD80 and CD86, indicating 
that pRBCs did not induce DC activation directly.
Cytokine production by DCs was also examined and the results show that DCs exposed 
to RBCs or pRBCs produced small though detectable amounts of both IL-12 and IL-10 
that were considerably lower than observed after LPS stimulation but not significantly 
different than RBC-treated controls or untreated DCs (Fig. 3.5).
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Figure 3.4 Surface expression of MHC class II (a), CD40 (b), CD80 (c) and CD86 (d) on 
bone marrow-derived DCs following incubation with non-infected (RBC) or P. chabaudi 
AS infected erythrocytes (AS). 2x10® DCs were cultured with 2x10* infected erythrocytes 
(DC+AS) or with an equal number of non-infected erythrocytes (DC+RBC) for 24h. 
Control DCs remained unstimulated (DC) or were stimulated with 1 p-g/ml of LPS 
(DC+LPS). Results show the mean fluorescence intensity ± standard errors of triplicate 
cultures per group as determined by flow cytometric analysis of gated CDllc^ cells. * 
p<:0.05 significant difference between DC+LPS and DC.
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Figure 3.5 Cytokine production by DCs following incubation with infected and non- 
infected erythrocytes. Concentration of IL-12p40 (a) and ILIO (b) secreted by DCs alone 
(DC), DCs stimulated with lp,g/ml of LPS (DC+LPS), DCs incubated with non-infected 
erythrocytes (DC+RBC) or with P. chabaudi AS infected erythrocytes (DC+AS). 2x10® 
DCs were cultured with 2x10* infected erythrocytes or with an equal number of non- 
infected erythrocytes. DCs treated with LPS and those grown in medium only served as 
positive and negative controls respectively. After 24h of culture, supernatants were 
harvested for cytokine analysis. Error bars indicate standard errors of triplicate cultures 
per group. * psO.05 significant difference between DC+AS and DC+LPS.
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3.2.3 Effect of P. chabaudi AS-infected erythrocytes on DC responses to LPS in vitro
Having demonstrated that pRBCs did not directly induce DC maturation, I examined 
whether pRBC- treated DCs retained their ability to mature in response to LPS treatment 
in vitro by examining the levels of MHC class II, CD40, CD80 and CD86. DCs were 
exposed to RBCs or pRBCs for 24 h and subsequently challenged with LPS. After 18 h 
of LPS stimulation, the expression levels of all of the above molecules increased 
significantly (Fig. 3.6). However, DCs pre-incubated with pRBCs and subsequently 
challenged with LPS, showed significantly lower levels of expression of MHC class II, 
CD40, and CD86 compared to those observed when cells were not treated with pRBCs or 
were pre-incubated with RBCs prior to LPS challenge.
Cytokine production following treatment with LPS was also analysed and the results 
show that DCs treated with pRBCs were still able to produce appreciable levels of IL-12 
and IL-10 in response to LPS although the amount of IL-12 produced was significantly 
lower compared with the amount detected when DCs were pre-incubated with RBCs 
(Fig. 3.7), To exclude the possibility that the reduced levels of costimulatory molecules 
and cytokine production by pRBC-treated DCs was due to DC death following LPS 
treatment, an Annexin V/ Propidium Iodide assay was carried out for each experimental 
group. The results show that similar levels of necrotic and apoptotic DCs were detected 
in all the conditions tested (Fig. 3.8).
Having established that activation of DCs in response to LPS treatment in vitro is 
suppressed by infected erythrocytes, I examined whether the observed result was specific 
to the LPS response alone, I therefore decided to challenge pRBC-treated DCs with CpG, 
which induces DC maturation through the TLR9 signalling pathway as opposed to LPS, 
which has been shown to mediate signalling through TLR4 (Akira et al,, 2001). DCs 
were exposed to RBCs or pRBCs for 24 h and subsequently challenged with CpG. After 
18 h of CpG stimulation, the level of surface CD40 increased in all control groups (Fig. 
3.9). However, DCs pre-incubated with pRBCs and subsequently challenged with CpG,
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showed reduced CD40 expression compared to DCs, which were not treated with pRBCs 
or were pre-incubated with RBCs prior to CpG challenge.
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Figure 3.6 MHC class II, CD40, CD80 and CD86 on bone marrow-derived DCs 
expressed either as the mean fluorescence intensity (a,c,e and g) or as percentage positive 
cells (b,d,f and h) following LPS stimulation. DCs were cultured for 24h with non- 
infected (RBC) or P. chabaudi AS infected erythrocytes (AS) as described in figure 3.4, 
then treated withlp,g/ml of LPS for a further 18h. Control DCs remained unstimulated 
(DC) or treated with 1 [xg/ml of LPS (DC+LPS). Results are shown as the mean 
fluorescence intensity ± standard errors of triplicate cultures per group (a, c, e and g) or 
as the mean percentage positive cells ± standard errors of triplicate cultures per group (b, 
d, f  and h). * psO.05 significant difference between DC+AS+LPS and DC+RBC+LPS. 
p:s0.05, groups significantly different from DC.
I l l
iIt)I
a. IL-12p40
1600
1200
800
400
DC LPS RBC+LPS A S+L PS
1I1)
b. IL-10
1.6
1.2
0.8
0.4
DC LPS RBC+LPS A S+LPS
Treatments
Figure 3.7 Cytokine production by DCs following LPS stimulation after 24h pre­
incubation with infected and non-infected erythrocytes. Concentration of IL-12p40 (a) 
and ILIO (b) secreted by DCs alone (DC), DCs stimulated with Ip-g/ml of LPS (LPS), 
DCs pre-incubated with non-infected erythrocytes (RBC+LPS) or P. chabaudi AS 
infected erythrocytes (AS+LPS) and challenged with LPS. 2x10® DCs were cultured with 
2x10* infected erythrocytes or with an equal number of non-infected erythrocytes. After 
24h of co-culture, DCs were stimulated with Ipg/ml LPS for a further 18h and 
supernatants harvested for cytokine analysis. DCs treated with LPS alone and those 
grown in medium only served as positive and negative controls respectively. Error bars
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indicate standard errors of triplicate cultures per group. * p^0,05 significant difference 
between AS+LPS and RBC+LPS .
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Figure 3.8 DC viability following LPS treatment after pre-incubation with P. chabaudi 
AS infected or non-infected erythrocytes. 2x10^ DCs were cultured with 2x10® infected 
erythrocytes (DC+AS) or with an equal number of non-infected erythrocytes (DC+RBC) 
for 24h then treated with 1 p,g/ml of LPS. After 18h of culture, DCs were harvested and
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the percentage of apoptotic cells within each culture condition was measured using the 
Annexin V/ PI staining assay. DCs stimulated with 1 }ig/ml of LPS only (DC+LPS) were 
used as controls. Jurkat T cells treated with camptothecin served as positive controls. 
Flow cytometric data is shown. Results are representative of three separate cultures.
In all the groups tested, cells were primarily Annexin V-FITC and PI negative, indicative 
of viable cells not undergoing apoptosis. A small percentage of cells were Annexin V- 
FITC positive and PI negative, indicating cells undergoing apoptosis. A minor population 
of cells were observed to be Annexin V-FITC and PI positive, indicating that they were 
in end stage apoptosis or already dead (Vermes et aL, 1995).
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Figure 3.9 Surface expression o f CD40 on bone marrow-derived DCs after 18h 
stimulation with either LPS or CpG in vitro. 2x10^ DCs were incubated with medium 
alone (no RBC) or in the presence of non-infected (RBC) or P.chabaudi AS infected 
erythocytes (AS) at a ratio of 1:100. After 24h o f culture, DCs were treated with either 
Ipg/ml o f LPS or 3pM of CpG for a further 18h. Control DCs remained unstimulated. 
Results are shown as the mean fluorescence intensity of duplicate cultures per group.
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Since CD40-CD40L interaction between DCs and T cells in vivo is known to play a 
crucial role in the production of bioactive IL-12 and upregulation of adhesion and 
costimulatory molecules (Celia et ah, 1996; Schulz et aL, 2000), bone marrow-derived 
DCs were stimulated with CD40L transfected fibroblasts (Figure 3.10). The results show 
that DCs treated with RBCs significantly upregulated CD40 expression in response to 
CD40L and produced high levels of IL-12 p40. CD40 ligation however did not rescue the 
reduced maturation of DCs treated with pRBCs although, as previously observed with the 
LPS treatment, these cells were still able to produce IL-12 p40 but to a lesser extent than 
the control groups.
Antigen presentation by DCs plays a crucial role in initiating T cell priming (Banchereau 
et al., 2000). I therefore investigated the ability of DCs to present heterologous antigens 
to T cells after treatment with infected erythrocytes. Both OVA protein and OVA peptide 
(aa.323-339) were used as the antigen. In order to detect antigen presentation independent 
of costimulation, I took advantage of the OVA-specific T cell hybridoma (DOll-GFP) 
that expresses green fluorescent protein (GFP) upon TcR ligation (Underhill et ah, 1999). 
The results show that DCs pre-incubated with RBCs prior to OVA loading showed the 
same antigen presenting ability as cells that were grown in medium only. However, the 
ability of DCs to activate the OVA-specific T cell hybridoma was significantly reduced 
when they were pre-incubated with pRBCs before antigen loading (Fig. 3.11). 
Furthermore, the degree of suppression was significantly greater when OVA protein was 
used compared to OVA peptide, suggesting that the antigen processing machinery might 
be affected, although further experiments will be required to confirm this hypothesis.
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Figure 3.10 P. chabaudi AS infected erythrocytes inhibit the LPS-induced maturation of 
DCs independently of CD40 ligation. 1x10^ DCs were cultured with 1x10® infected 
erythrocytes (AS) before stimulation with CD40L-expressing fibroblasts (filled bars) or 
control fibroblasts (open bars) at a 1:1 ratio of fibroblasts:DCs. Untreated DCs (Con) and 
non-infected erythrocytes treated DCs (RBC) were used as controls. DCs were incubated 
with fibroblasts for a further 18 h before analysing CD40 expression (a) and cytokine 
production (b). CD40 expression on DCs is shown as the mean fluorescent intensity as 
determined by flow cytometric analysis of gated CDllc^ cells. IL-12 production is 
shown as the mean Optical Density (CD) read at 450 nm. Results show the mean value ± 
standard error of triplicate cultures per group. *, psO.05 (AS RBC).
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Figure 3.11 Antigen presentation by DCs treated with P. chabaudi AS infected 
erythrocytes. 5x10^ DCs were cultured with 5x10^ infected erythrocytes (AS). Untreated 
DCs (control) and non-infected erythrocyte-treated DCs (RBC) were used as controls. 
After 24 h of culture, the cells were antigen pulsed with (a) 5 mg/ml of OVA or (b) with 
an equimolar amount of OVA peptide (40 |xg/ml) for 6 h. The level of antigen 
presentation was determined by incubating DCs with the OVA-specific DOll.lO-GFP 
hybridoma at 1:1 DC : T cell ratio and T cell activation assessed 24 h later by flow 
cytometry. Results are expressed as the mean fluorescence intensity of GFP expression 
by CD4^ T cells ± standard error. * p^0.05 significant difference between AS and RBC.
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~ significant difference between P. chabaudi AS-treated DCs pulsed with OVA (a) and 
P. chabaudi AS-treated DCs pulsed with peptide (b).
3.2.4 Comparing the effects of P. chabaudi AS and P. chabaudi ER on DC function in 
vitro.
As previously described in section 1.1.4.1, P. chabaudi AS causes an acute primary 
parasitaemia from which most mice recover. Conversely, P. chabaudi ER is a much more 
virulent strain and it is fatal after the peak of parasitaemia (Beale et al., 1978). Having 
these two parasite strains available, I decided to compare their effects on DC function 
with the view of P. chabaudi ER having more profound effects on DCs due to its 
virulence.
I have previously shown that P. chabaudi AS did not affect DC viability (Fig. 3.3). I 
therefore examined whether the same could be demonstrated using P. chabaudi ER. For 
this purpose DCs were incubated with either P. chabaudi AS- or P. chabaudi ER-infected 
erythrocytes or with uninfected controls and their viability was determined 24h later by 
trypan blue exclusion. The results show that the same number of viable DCs was 
recovered after each treatment (Fig. 3.12).
Since P. chabaudi ER infected erythrocytes did not affect DC viability, I wanted to 
analyse whether this parasite strain suppressed the LPS-induced maturation and antigen 
presenting abilities of DCs to a greater extent compared to the effects observed when 
using P. chabaudi AS infected erythrocytes. The results show that the ability of (ER)- 
pRBC- treated DCs to respond to LPS stimulation in vitro was significantly affected as 
demonstrated by the reduced levels of MHC class II. However, the suppression of MHC 
class II expression was not significantly greater than the suppression induced by (AS)- 
pRBCs (Fig. 3.13). The same result was obtained when comparing the antigen presenting 
ability of DCs treated with (ER)- and (AS)-pRBCs (Fig. 3.14). Both parasite strains 
inhibited the ability of DCs to present OVA to the OVA-specific T cell hybridoma,
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however the effect observed following treatment of DCs with the different parasite strains 
did not differ significantly. Therefore parasite virulence did not seem to exert more 
profound effects on some of the key functions of DCs compared to the less virulent 
strain. Further experiments are necessary to elucidate the role of parasite virulence on DC 
function. For the purpose of the present study it was sufficient to know that the effects 
exerted by P. chabaudi ER infected erythrocytes were not dramatically different from 
those induced by P. chabaudi AS thus the former could be used in future experiments if 
required.
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Figure 3.12 DC viability after incubation with different P. chabaudi sXmirvs. 2x10^ bone 
marrow-derived DCs were cultured in the presence of non- infected (DC+RBC), P. 
chabaudi AS (DC+AS) or P. chabaudi ER (DC+ER) infected erythrocytes at a ratio of 
1:100. After 24h incubation, DC viability was assessed by trypan blue exclusion. Results 
show the mean value of viable cells ± standard error of triplicate cultures per group.
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Figure 3.13 Surface MHC class II expression on bone marrow-derived DCs following 
LPS stimulation after 24h pre-incubation with different P. chabaudi strains. 2x10^ DCs 
were treated with either 2x10® P.chabaudi AS (AS expt, empty bars) or P. chabaudi ER 
infected erythocytes (ER expt, filled bars). After 24h of incubation, DCs were stimulated 
with 1 [xg/ml of LPS and the expression of MHC class II examined 18h later by flow 
cytometric analysis of gated CDl Ic^ cells. DCs treated with LPS alone (DC+LPS) and 
those pre-incubated with non-infected erythocytes (RBC) prior to LPS challenge served 
as controls. Results are shown as the relative expression of MHC class II calculated as the 
mean fluorescence intensity of DCs after the different treatments divided by the mean 
fluorescence intensity of DCs, which did not receive any activating stimulus ± standard 
errors of triplicate cultures per group. * p<:0.05 significant difference between P. 
chabaudi ER-treated DCs and the corresponding control RBC. + p^0.05 significant 
difference between P. chabaudi AS-treated DCs and the corresponding RBC control.
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Figure 3.14 Antigen presentation by DCs treated with P. chabaudi AS or P. chabaudi 
ER infected erythrocytes. 5x10^ DCs were cultured with 5x10^ infected erythrocytes (AS 
or ER). Non-infected erythrocyte-treated DCs (RBC) were used as controls. After 24 h of 
culture, the cells were antigen loaded with 5 mg/ml of OVA (empty bars) and the level of 
antigen presentation was determined as described in figure 3.10. One set of cells was 
treated with lp,g/ml of LPS immediately after addition of T cells (filled bars). * p^O.05 
significant difference between P. chabaudi AS- and P. chabaudi ER-treated DCs in the 
LPS treated group compared to the corresponding RBC-treated DCs. ~ ps:G.05 
significant difference between P. chabaudi AS- and P. chabaudi ER-treated DCs 
compared to RBC-treated DCs in the LPS negative group.
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3.3 Discussion
DCs are central to the initiation and regulation of the adaptive immune response during 
infection (Adams et a l, 2005). They are specialised for the uptake, transport, processing 
and presentation of antigens to T cells (Adams et aL, 2005). DCs reside as immature cells 
with high phagocytic capacity in all peripheral tissues. Encounter with pathogens triggers 
DC maturation, characterised by phenotypic and functional changes that culminate in 
their complete transition from antigen-capturing cells to efficient antigen presenting cells. 
This maturation process is accompanied by cy to skeletal reorganization, reduced 
phagocytic activity, acquisition of cellular motility, migration to lymphoid tissues, 
enhanced T cell activation potential and the development of characteristic cytoplasmic 
extensions usually referred to as ‘dendrites’ (Quah and O'Neill, 2005). Furthermore, 
mature DCs secrete cytokines that determine the type of ensuing immune response and 
upregulate the expression of adhesion and costimulatory molecules, which are involved 
in bidirectional signalling between DCs and T cells, modulating both T cell activation 
and DC function (Quah and O'Neill, 2005).
The experiments described in this chapter were aimed at investigating how some of the 
above functions of DCs are affected during blood-stage malaria infections. I initially 
examined the ability of pRBCs to induce DC activation by analysing the expression of 
MHC class II and costimulatory molecules CD40, CD80 and CD86 on their surface. The 
results showed that pRBCs did not activate DC directly, which was also confirmed by the 
lack of production of IL-12 and IL-10 cytokines. This finding appeared to contrast 
previous reports where P.chabaudi AS schizonts were found to cause direct activation of 
DCs in vitro (Seixas et aL, 2001). Similarly, DCs isolated from P. yoelii infected mice 
during peak parasitaemia were also found to be activated and could efficiently process 
and present antigen to naïve T cells (Luyendyk et aL, 2002; Perry et aL, 2005; Perry et 
aL, 2004). Since in this study DCs were exposed to trophozoite-infected erythrocytes, 
collectively these reports indicate that not only different parasites {P.yoelii vs 
P. chabaudi) but also different stages of the same parasite (trophozoites vs schizonts) may 
exert different effects on DC function.
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The concept of chronologically different stages of the parasite life cycle interfering with 
one another in the context of an on going infection is not new to this field. Ocana- 
Morgner et al (Ocana-Morgner et aL, 2003) have shown that P. yoelii blood stage 
infection inhibited the establishment of a protective cytotoxic T cell response against the 
initial liver stage, leaving the host susceptible for the next infection. It is therefore 
possible that specific blood stages might suppress DC function to protect the more 
vulnerable stages (schizonts and merozoites) in order to allow progression of the disease. 
Supporting this hypothesis is the finding that human and rodent malaria parasites were 
found to release pro-inflammatory exoantigens following schizont rupture, which 
stimulated macrophages to secrete TNF-a in vitro (Bate et aL, 1988; Kwiatkowski et aL, 
1989; Taverne et aL, 1990b). In the same study, Ocana-Morgner and colleagues also 
showed that infected erythrocytes did not activate DCs directly in vitro (Ocana-Morgner 
et aL, 2003), confirming observations reported in the present study but contrasting 
previous reports by other authors (Luyendyk et aL, 2002; Ferry et aL, 2005; Perry et aL, 
2004). However, it is not clear what blood-stage of the parasite was used in the 
experiments carried out by Ocana-Morgner et aL On the other hand a possible reason for 
these discrepancies might rely on the degree of parasitaemia achieved during infection. In 
fact, although all of the studies above used the non-lethal parasite line 17X, experiments 
were carried out in different strains of mice. Ocana-Morgner et aL (Ocana-Morgner et aL,
2003) used BALB/c mice, which develop a high parasitaemia (49%) when infected with 
P. yoelii 17X whereas other authors used B10.D2 mice, which instead develop a 
relatively low parasitaemia (13%) (Luyendyk et aL, 2002; Perry et aL, 2005; Perry et aL,
2004), therefore genetic differences may account for the results obtained.
So far I have shown that pRBCs did not induce DC activation. The maturation process is 
associated with many coordinated events such as production of cytokines, up-regulation 
of co-stimulatory molecules, and increased ability to activate T cells (Banchereau et aL,
2000). I therefore examined the ability of DCs to mature in response to LPS treatment in 
vitro after incubation with pRBCs. The results demonstrate that DCs treated with pRBCs 
prior to LPS challenge were severely impaired in their ability to upregulate the 
expression of costimulatory molecules MHC class II, CD40 and CD86. In addition, the
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viability of these cells was maintained in both pRBC-treated and control cultures (as 
examined by Annexin/PI staining). These findings supported previous studies with P. 
falciparum infected erythrocytes and human monocyte-derived DCs (Urban et aL, 1999) 
as well as in vitro and in vivo studies of P.yoelii with murine DCs (Ocana-Morgner et aL, 
2003). Nevertheless, in the present study pRBC-treated DCs were still able to produce 
appreciable levels of IL-12p40 in response to LPS although the amount produced was 
significantly lower than the control cultures. Furthermore, pRBC-treated DCs did not 
produce significant levels of IL-10 cytokine. The latter result contrasts Ocana-Morgner et 
al. (Ocana-Morgner et aL, 2003) and Perry et al. (Perry et al., 2005) data where 
inhibition of IL-12 production was observed in favour of production of high levels of IL­
IO. Once again I reasoned that the differences observed may be attributed to the different 
parasites used and that, although in Ocana-Morgner’s studies (Ocana-Morgner et aL, 
2003) P. yoelii was found to suppress the LPS-induced maturation of DCs in vitro as 
observed with P. chabaudi AS in the present study, the causal effect of the parasites 
might be by different mechanisms.
As explained previously in section 1.2.3, DCs can sense microbes directly by recognizing 
molecular patters within microbial carbohydrates, lipids and nucleic acids using highly 
conserved pattern-recognition receptors (Janeway and Medzhitov, 2002; Reis e Sousa, 
2001). Such receptors include Toll-like receptors (Thoma-Uszynski et aL, 2001; 
Underhill and Ozinsky, 2002). TLR4 has been shown to mediate signalling through 
interaction with LPS from Gram-negative bacteria (Akira et aL, 2001). Unmethylated 
CpG DNA motifs, highly represented in bacterial DNA, are instead TLR9 ligands (Akira 
et aL, 2001). The distribution of TLRs on DC subsets favours specialisation of each cell 
type to respond to different pathogens. In particular, human myeloid DCs express all 
TLRs with the exception of TLR9, which is selectively expressed by plasmacytoid DCs 
(Colonna et aL, 2002). Accordingly, plasmacytoid DCs respond to CpG DNA but not to 
LPS whereas myeloid DCs respond to LPS but not to CpG DNA (Colonna et aL, 2002). 
By contrast, TLR9 is shared by both myeloid and plasmacytoid DCs in the mouse and 
they are both activated by CpG DNA (Sparwasser et aL, 1998). To analyse whether 
pRBCs affected TLR9 signalling specifically, pRBC-treated DCs were challenged with
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CpG aiid the levels of surface CD40 expression analysed 18h later by flow cytometiy. 
The results clearly show that even when stimulated with a TLR9 ligand, pRBC-treated 
DCs were not able to mature efficiently as observed by their reduced levels of CD40 
expression compared to control cells. This result demonstrates that pRBCs affects the 
maturation of DCs independently of the TLR ligand used, inducing a generalised 
suppression of DC activation. This observation may explain why malaria infected 
individuals have suppressed immune responses to a number of different pathogens 
(Greenwood et a l, 1972; McGregor, 1962; Williamson and Greenwood, 1978) and why 
they are more susceptible to secondary infections such as Salmonella septicemia (Mabey 
et al.y 1987), tuberculosis (Enwere et al., 1999), herpes zoster (Cook, 1985) and hepatitis 
B (Thursz et ah, 1995).
It has been suggested recently that during malaria infection in vivo, DCs are activated 
during early infection and then show TLR tolerance later in infection, becoming 
unresponsive to LPS stimulation (Perry et al., 2005). However, this does not seem to be 
the case with P. chahaudi AS since, as explained earlier, there is no evidence of direct 
maturation of DCs by pRBC in the present study. A possible explanation for the transient 
increased expression of activation markers observed on DCs ex vivo might be the high 
concentration of pro-inflammatory cytokines caused by the early stage of infection 
(Langhome et aL, 2004). In support of this, a recent report described that DCs activated 
through inflammatory cytokines without pathogenic stimulation upregulated markers of 
activation but were unable to drive CD4^ T cell differentiation (Sporri and Reis e Sousa,
2005).
The ability of DCs to interact with CD40L on T cells in vivo has also been proposed to 
explain the differences between in vivo and in vitro studies (Perry et al., 2004). 
Interestingly in the present study, DC maturation could not be rescued when pRBC- 
treated DCs were treated with CD40L transfected fibroblasts, suggesting that the 
suppressive effects exerted by P. chabaudi AS-infected erythrocytes may be more 
profound than those induced by P. yoelii infection. The signalling events involved in DC 
maturation following LPS and CD40L stimulation have been previously described in
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Figures 1.3 and 1.4 respectively and undoubtedly represent an oversimplification of the 
complex series of events that may occur realistically. Inhibition of DC maturation 
following both LPS and CD40L stimulation suggests that pRBCs might alter the 
interaction of specific signalling proteins shared by both pathways. For instance, TRAF6 
is one of the signalling molecules recruited following both LPS and CD40L stimulation. 
pRBCs may therefore block DC activation by interfering with the recruitment of TRAF6 
or with its interaction with other signalling molecules. Indeed, at the present time, this 
possibility remains purely speculative and further studies are required to elucidate the 
maturation signalling events that may be disrupted in DCs following pRBC treatment.
To investigate whether the observed effect on DC function could produce a defect in 
antigen presentation, I analysed the ability of pRBC-treated DCs to induce proliferation 
of a T cell hybridoma specific for OVA. These cells only require the presentation of 
antigen by MHC for activation and are thus insensitive to the ability of APC to provide 
costimulatory activity (Underhill et al., 1999). The results show that the antigen 
presenting ability of DCs treated with pRBCs prior to antigen loading was significantly 
reduced, a result, which concurred with the reduced expression of MHC class II 
previously found.
Collectively the results presented in this chapter demonstrate that pRBCs exert profound 
effects on the ability of DCs to carry out key functions that are necessary for the 
development of an appropriate immune response. It is now widely accepted that 
encounter with parasites can strongly modify DC function and lead to altered T cell 
responses both in vitro and in vivo (Sher et aL, 2003). This can be achieved by altering 
the maturation state of DCs leading to alternatively functional T cells (such as regulatory 
cells) or a failure of T cell activation leading to T cell anergy, as extensively described in 
section 1,2.5. Parasites may induce these altered T cell responses as a mechanism to 
avoid functional T cell responses directed against them, thus enhancing their chances of 
survival. Besides directly interacting with DCs, parasites may alter the development of 
protective immune responses by releasing parasite products, which may modulate DC 
function, or by inducing DCs to secrete immunoregulatory factors such as prostaglandins
127
(Harizi and Gualde, 2002) and TGF-p (Li et aL, 2005), which are known to suppress DC 
function and therefore the induction of appropriate T cell responses. Since DCs play a 
pivotal role in the induction of primary immune responses, it is reasonable to assume that 
altered or suppressed T cell responses may result as a consequence of impairment of DC 
function.
In subsequent chapters I directly analyse all of the above possibilities by investigating the 
phenotype of the T cell response induced by pRBC-treated DCs, the involvement of 
selected parasite components, soluble parasite factors and immunoregulatory molecules 
potentially secreted by DCs following interaction with pRBC, in the observed 
suppression of DC function. A better insight of the mechanisms employed by the malaria 
parasite to interfere with DC biology may help to open new avenues for the 
understanding of immunosuppression observed during malaria infection and develop new 
treatment strategies.
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4. P, chabaudi AS “treated DC fail to induce functional T cell
responses in vitro.
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4.1 Introduction
The ability to prime naïve T cells is a unique and critical function of DCs both in vitro 
and in vivo (Adams et aL, 2005). Effective priming of naïve T cells results in their clonal 
expansion and differentiation into cytokine secreting effector cells and memory cells 
(Adams et aL, 2005). As described in section 1.2.6, immune responses to different types 
of pathogens are associated with different types of effector responses directed by 
polarised Thl and Th2 cell subsets. Furthermore, DCs may induce the development of 
‘alternatively’ functional T cells, which are commonly referred to as ‘regulatory T cells’. 
These latter cells include Trl cells, which secrete high levels of IE-10, and Th3 cells, 
which secrete TGF-|3 (Jonuleit and Schmitt, 2003) (see section 1.2.5.2).
Besides inducing functional Thl/Th2 cell responses and T regulatory cells, interaction of 
DCs with T cells may result in failure of T cell activation leading either to T cell anergy 
or T cell apoptosis. T cell anergy is defined as a state in which the cell is viable but fails 
to display certain functional responses (proliferation and IL-2 production) upon exposure 
to its specific antigen and results from partial T cell activation due to a lack of adequate 
co-stimulation (Alegre et ah, 2001; Techier et aL, 2001) (refer to sections 1.2.5.1 and 
1,2.5.3 for more details). Deletion or apoptosis of antigen-specific T cells instead may be 
induced following engagement of death receptors, such as Fas (Hildeman et al., 2002) or 
may be controlled by members of the Bcl-2 family of proteins (Li et aL, 2004a) (refer to 
section 1.2.5.4 for more details). The induction of regulatory T cells, T cell anergy and T 
cell apoptosis represent important mechanisms for the maintenance of central and 
peripheral tolerance. Nevertheless, there is now evidence indicating that certain 
pathogens adopt these mechanisms to avoid the establishment of effector T cell responses 
directed against them (extensively discussed in sections 1.2.6-1.2.10),
In chapter 3 ,1 analysed the effects that P. chabaudi AS-infected erythrocytes have on 
DCs in terms of antigen presentation, expression of costimulatory molecules and cytokine 
production, important requirements for activation and differentiation of naïve T cells. I 
showed that all of the above functions were downregulated following exposure of DCs to
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infected erythrocytes, suggesting that the ability of these cells to prime naïve T cells into 
effector T cells might be affected. In this chapter I addressed this issue directly by 
analysing the phenotype of the T cell response induced by P. chabaudi AS-infected 
erythrocytes.
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4.2 Results
4.2.1 The ability of DCs to induce the proliferation of naïve TcR transgenic T cells in 
vitro is affected by P. chabaudi AS infected erythrocytes
As mentioned earlier, DCs play a pivotal role in the induction of primary immune 
responses by efficiently activating naïve T cells (Adams et aL, 2005). To evaluate 
whether pRBC-treated DCs retained this ability, I assessed the capacity of these cells to 
activate naïve, OVA-specific TcR transgenic T cells. DCs were treated with RBCs or 
pRBCs for 24 h and then pulsed with either OVA protein or OVA peptide for 6 h. 
Untreated DCs were used as controls. OVA-specific transgenic T cells were added to the 
culture and the proliferative response assessed after 72h of culture. DCs cultured in the 
absence of RBCs, and DCs pre-treated with RBCs before OVA loading, had the same 
ability to induce in vitro proliferation of naïve OVA-specific T cells (Figure 4.1a). 
However, this capacity was significantly reduced when DCs were pre-incubated with 
pRBCs before antigen loading. In addition, the defect observed was greater when the 
cells were pulsed with OVA protein than OVA peptide, suggesting that pRBCs may 
interfere with both the antigen processing and presentation pathways (Figure 4.1a). 
Furthermore, to exclude the possibility that treatment of DCs with pRBCs could alter the 
dynamics of the T cell proliferative response, I harvested the T cells at 48, 72,96 and 120 
h of culture (Figure 4.1b). The results clearly show that the ability of pRBC-treated DCs 
to induce T cell proliferation was significantly downregulated compared to the control 
group throughout the observation period.
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Figure 4.1 P. chabaudi AS infected erythrocytes inhibit the ability of DCs to induce 
naïve T cell proliferation. 2x10^ DCs were treated with 2x10^ P. chabaudi AS infected 
(AS) or non-infected erythrocytes (RBC) for 24 h. (a - b). DCs were then pulsed with 5 
mg/ml of OVA (a-b) or with 40p,g/ml of OVA peptide for 6 h (a). OVA-specific 
transgenic T cells were isolated from lymph nodes of DO 11.10 SCID mice and added to 
the culture to achieve 1:1 DC: T cell ratio. [^H] thymidine was added for the last 18h of a 
72h culture (a) or of a 48, 72, 96 and 120h cultures (b). Results show mean proliferation 
of triplicate cultures ± standard error. *, pa0.05 (AS Vj" RBC).
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4.2.2 Cytokine production by TcR transgenic T cells in vitro is affected by P. chabaudi 
AS infected erythrocytes
DCs treated with Plasmodium-mÎQQXQà erythrocytes or taken from infected mice have 
been shown to present peptide derived from parasite proteins to CD4^ T cells (Bruna- 
Romero and Rodriguez, 2001; Perry et aL, 2004). Studies with bone marrow-derived DCs 
(Seixas et aL, 2001) and with splenic DCs (Luyendyk et aL, 2002) also showed that P. 
chabaudi- or P. yoelii- infected erythrocytes can induce increased expression of MHC 
class II and costimulatory molecules by DCs as well as production of IL-12, which are 
necessary for activation of naïve T cells. Furthermore, splenic DCs isolated from P. 
yoelii- infected mice have been shown to activate naïve CD4^ T cells to produce IL-2 and 
can support production of IFN-y and TNF-a (Perry et aL, 2004). Collectively, these 
observations suggest that the initial interaction of DCs with infected erythrocytes would 
result in a Thl CD4^ T cell response, as observed during an early acute infection in vivo 
(Langhome et aL, 2002). For this reason, the major cytokines involved in Thl and Th2 
responses were investigated. DCs were treated with RBCs or pRBCs for 24 h and then 
loaded with OVA protein for 6 h. OVA-specific transgenic T cells were added to the 
culture and the concentration of IL-2, IL-12, IFN-y, IL-5, IL-10 and IL-4 were measured 
in supernatants harvested after 24, 48 and 72 h of culture (Figure 4.2a - f). The results 
revealed that both Thl and Th2 cytokine production was downregulated in the pRBC- 
treated groups compared to controls.
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Figure 4.2 Cytokine production by T cells is downregulated following incubation with P. 
chabaudi AS-treated DCs. The concentration of (a) IL-2, (b) IL-12, (c) IFN-y, (d) IL-5, 
(e) IL-10 and (f) IL-4 secreted by OVA-specific T cells after incubation with DCs treated 
with non-infected (filled diamonds) or P. chabaudi AS-infected erythrocytes (empty 
diamonds) were measured in supernatants harvested after 24, 48 and 72 h of culture. 
Experimental cultures were set up as described in figure 4.1. The data show preliminary 
results obtained from one experiment only. Results show tlie mean concentration of 
duplicate cultures.
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4.2.3 TcR transgenic T cell viability is not affected by P, chabaudi AS-treated DCs
As mentioned earlier, apoptosis of antigen-specific T cells may provide a potential 
mechanism used by pathogens to evade host protective immune responses directed 
against them. In fact, apoptotic deletion of T cells has been suggested to be one of the 
mechanisms responsible for the suppression of T cell responses observed during malaria 
infection (Wipasa et a l, 2001). To investigate the possibility that the lack of T cell 
proliferation and cytokine production previously observed was due to T cell death, an 
Annexin V/ Propidium Iodide assay was carried out. Experimental cultures were set up as 
described in 4.2.2. T cells were harvested after 24h and the percentage of apoptotic cells 
within each culture condition was determined by flow cytometry. The results showed that 
the previously observed reduction of T cell proliferation and cytokine production could 
not be explained by T cell death as similar levels of necrotic and apoptotic T cells were 
detected in each culture condition (figure 4.3).
4.2.4 The expression of CD69 on TcR transgenic T cells in vitro is not affected by P. 
chabaudi AS infected erythrocytes
Having established that pRBC-treated DCs were not able to induce OVA-specific T cell 
proliferation in vitro but did not induce antigen-specific T cell apoptosis, I examined 
whether these DCs were still capable of providing T cell activating signals. One of the 
earliest cell surface antigens expressed by T cells following activation is CD69, which is 
detectable within one hour of ligation of the T cell receptor/CD3 complex (Ziegler et al., 
1994). Experimental cultures were set up as described in 4.2.2. T cells were harvested 
after 24h of culture and the percentage of antigen-specific T cells expressing CD69 
determined by flow cytometry. Surprisingly, the results revealed that there was not a 
significant difference in the percentage of OVA-specific T cells expressing CD69 
between RBC and pRBC-treated groups (Figure 4.4), suggesting that although the T cells 
became equally activated, pRBC-treated DCs failed to induce efficient T cell 
proliferation.
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Figure 4.3 T cell viability is not affected following incubation with P. chabaudi AS- 
treated DCs. Experimental cultures were set up as described in figure 4.1. After 72h of 
culture, T cells were harvested and the percentage of apoptotic cells within each culture 
condition was measured using the Annexin V/ PI staining assay. Flow cytometric data is 
shown. Histograms are gated on CD4^ T cells. Results are representative of three separate 
cultures.
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Figure 4,4 P. chabaudi AS-treated DCs do not affect T cell activation. DC-T cell co- 
cultures were set up as described in figure 4.1. CD69 expression was assessed on 
DO 11.10 T cells harvest from SCID mice by flow cytometric analysis after 24h of DC-T 
cell co-culture. Results are expressed as the percentage of antigen-specific cells 
expressing CD69 in cultures stimulated OVA pulsed DC (OVA; filled bars) or DC only 
(Control; empty bars). Results show the mean of triplicate cultures ± standard error.
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4.2.5 P. chabaudi AS-treated DCs induce the development of anergic T cells in vitro.
To further characterise the phenotype of the T cell response induced by pRBC-treated 
DCs, I tested whether the observed suppression of the OVA-specific T cell proliferation 
could be rescued by addition of exogenous IL-2, a hallmark of anergic cells (DeSilva et 
at., 1991). Furthermore, as TGF-p is now known to be a potent regulatory cytokine 
exerting suppressive effects on both DCs and T cells (Li et a l, 2005), I also investigated 
whether it played a role in the observed downregulation of the OVA-specific T cell 
response. As explained in sections 1.2.6-1.2.10, pathogens may drive the development of 
inappropriate (Thl vs Th2) or ineffective (anergic T cells or regulatory T cells) T cell 
responses that cannot support the development of a protective immune response. They 
may achieved this by directly inducing DCs to produce TGF-p, which will in turn 
suppress the development of protective T cell responses; alternatively they may alter the 
activation state of DCs leading them to favour the development of Th3 cells, which 
secrete TGF-p (Jonuleit and Schmitt, 2003) (refer to section 1.2.7 for more details). 
Moreover, it was recently shown that soluble components of P. falciparum, P. berghei 
and P. yoelii infected erythrocytes activated both native (platelet-derived) and 
recombinant latent TGF-p directly, suggesting that malaria parasites may use this 
cytokine to avoid protective immune responses being directed against their elimination 
(Omer et a l, 2003),
Experimental cultures were set up as described in 4.2.2. Exogenous rIL-2 and anti-TGF- 
p neutralizing antibodies were added at the beginning of the proliferation assay and T 
cells harvested after 72h of culture. The results showed that DCs pre-treated with RBCs 
before OVA loading induced normal proliferation of naïve OVA-specific T cells. 
However, this capacity was significantly reduced when DCs were pre-incubated with 
pRBCs prior to antigen loading therefore confirming previous observations (Figure 4.5). 
Treatment with anti-TGF-P antibody did not rescue the T cell proliferative response, 
therefore excluding the possibility that this cytokine might be involved in the observed 
suppression of the OVA-specific T cell proliferation. The proliferation of T cells was 
instead increased to levels equal to those reached by control cultures when exogenous
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rIL-2 was added to the culture. This result suggested that pRBC-treated DCs induced the 
development of T cells with an anergic phenotype.
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Figure 4.5 P. chabaudi AS-treated DC induce anergic T cell responses. 2x10^ DCs were 
treated with 2x10^ P. chabaudi AS infected (AS) or non-infected erythrocytes (RBC) for 
24 h. lOng/ml of rIL-2 or 5[xg/ml of anti-TGF-p were added at the begirming of the 
proliferation assay. DCs were pulsed with 5 mg/ml of OVA. OVA-specific transgenic T 
cells were isolated from lymph nodes of DO 11.10 SCID mice and added to the culture to 
achieve 1:1 DC: T cell ratio. fH ] thymidine was added for the last 18h of a 72h culture. 
Results show mean proliferation of triplicate cultures ± standard error. *, p:s0,05 (AS 
RBC).
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4.3 Discussion
As extensively described in section 1.1.5, studies using murine models of malaria have 
shown that T cells play a pivotal role in protective immunity to malaria. This knowledge 
was substantiated by early experiments showing that parasitaemia could not be controlled 
in T cell-deficient animals (Jayawardena et a l, 1977; Weinbaum et a l, 1976). 
Nevertheless, T cell responses were shown to be suppressed during malaria infection in 
both humans and experimental animal models. Suppression of T cell responses to both 
parasite and heterologous antigens was observed in P. falciparum infected individuals. 
Patients with acute P. falciparum malaria were found to have a parasite-specific T cell 
proliferative defect that persisted for more than four weeks following treatment (Ho et 
a l, 1986). This observation suggested that blood-stage malaria infections might suppress 
responses important for immunity to malaria to allow parasite survival as well as raising 
the possibility that patients infected with P. falciparum might not respond as well to a 
malaria vaccine as would uninfected individuals. Depressed responsiveness to 
heterologous antigens was originally reported in 1962 by measuring the antibody 
responses of infected and uninfected children to vaccination with tetanus toxoid 
(McGregor, 1962). Later studies confirmed this observation as well as reporting reduced 
antibody responses to the O antigen of Salmonella typhimurium in children with acute 
malaria (Greenwood et a l, 1972) (see section 1.1.7 for more details on malaria-induced 
immunossuppression).
Many different mechanisms have been suggested to explain the suppression of T cell 
proliferative responses during malaria infection. Apoptosis of T cells (Wipasa et a l,
2001), parasite inhibition of macrophage activation and antigen processing (Arese and 
Schwarzer, 1997; Schwarzer et a l, 1998; Schwarzer et al, 2003; Schwarzer et a l, 1992; 
Scorza et a l, 1999), inhibition of DC maturation or alteration of DC function (Urban et 
a l,  1999; Urban and Roberts, 2002, 2003; Urban et a l, 2001b) and involvement of T 
regulatory cells (Hisaeda et a l, 2004) are among some possible explanations.
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In this chapter I investigated the phenotype of the T cell response induced by pRBC- 
treated DCs. I showed that the interaction of pRBC-treated DCs with T cells resulted in 
almost complete loss of T cell proliferation and cytokine production. More importantly, 
this defect was not due to the failure of T cells to recognise antigen as they increased the 
expression of the early activation marker CD69 to the same extent as control cultures. 
These observations suggested that pRBC-treated DCs were able to induce T cell 
activation, however the signalling events leading to T cell proliferation were somehow 
impaired, resulting in failure to induce effector Thl/Th2 cell responses. Moreover, the 
observed inhibition of T cell proliferation did not seem to be mediated by IL-10 as this 
cytokine was not present in the culture, excluding the potential induction of IL-10- 
secreting T regulatory cells by pRBC-treated DCs. Furthermore, the involvement of 
TGF-p, potentially produced either by the DCs themselves following interaction with 
pRBCs or following the development of Th3 regulatory T cells, was excluded by adding 
a neutralising antibody to the culture, as it did not rescue the suppressed T cell 
proliferative response. Instead, the proliferation of T cells returned to levels equal to 
those reached by control cultures when exogenous rIL-2 was added to the culture system, 
indicating that pRBC-treated DCs promoted the development of T cells with anergic 
properties. As mentioned earlier, anergic cells result from partial T cell activation due to 
a lack of adequate co-stimulation (Alegre et al., 2001; Lechler et al., 2001) In this regard, 
the data presented here are consistent with previous observations described in chapter 3, 
where pRBCs were shown to affect DC maturation by down-regulating the expression of 
costimulatory molecules CD40 and CD86.
In conclusion I have demonstrated that P. chabaudi AS-infected erythrocytes affected the 
ability of DCs to induce an efficient T cell response, leading to the development of an 
anergic rather than an effector T cell phenotype. This observation agrees with the 
suppression of immunity observed in malaria-infected patients. The inability to mount an 
appropriate T cell response may explain the reason why many infected individuals suffer 
increased secondary infections such as Salmonella and meningitis (Williamson and 
Greenwood, 1978) as well as not being able to control viral infections such as EBV 
(Whittle et a l, 1984). A better insight of the mechanisms employed by the malaria
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parasite to interfere with DC biology could therefore help to open new avenues for the 
understanding of immunosupression observed during malaria infection and develop new 
treatment strategies.
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5.1 Introduction
In the past few years there has been growing interest in studying DC function in the 
context of infections as these cells have a crucial role in the activation of naïve T cells 
and thereby, in the induction of adaptive immunity. It is becoming increasingly clear that 
many pathogens have evolved immune evasion strategies that may be targeted at the 
induction of the immune response by interfering with DC biology (Rescigno and Borrow, 
2001 ; Sher et al., 2003).
It has been reported that soluble molecules from the eggs of the helminth parasite S. 
mansoni (SEA) suppressed the LPS-induced activation of immature murine DCs, 
including MHC class II, costimulatory molecules CD80 and CD86 as well as IL-12 
production (Kane et al., 2004). T. gondii was also found to suppress the ability of 
immature DC to participate in innate immunity and to induce adaptive immune responses 
by rendering DCs resistant to subsequent activation by TLR ligands or CD40 ligation 
(McKee et al., 2004). The functional consequences of T. gOM^fn-mediated suppression of 
DC activation were in fact manifested in a relative inability of infected immature DC to 
activate naive CD4^ T cells, or to secrete cytokines, such IL-12 and TNF-a, that play 
important roles in innate and/or adaptive immunity (McKee et al., 2004). Furthermore, it 
has been demonstrated that infection of mature human monocyte-derived DCs by 
cytomegalovirus resulted in a reduced ability to stimulate T cells in an allogeneic mixed 
leukocyte reaction via a novel mechanism, the release of soluble CD83 (Senechal et al., 
2004). As mentioned in previous chapters, P. falciparum asexual erythrocytic stages were 
shown to impair the ability of human DCs to undergo maturation on exposure to LPS in 
vitro and it has been suggested that this effect was mediated through the binding of CD36 
to a parasite-derived molecule (PfEMPl) on tlie infected erythrocyte surface (Urban et 
a l, 1999; Urban et a l, 2001b).
Understanding the actual mechanisms used by parasites to suppress DC function may aid 
in the development of appropriate and effective vaccines. For instance, the effects of 
immunosuppressive agents potentially used by pathogens to downregulate DC function
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could be reversed following their identification and knowledge of their mechanism of 
action, leading to enhancement of DC function and improvement of DC-based 
therapeutic treatments. In fact, with their powerful antigen presenting ability, DCs have 
the potential to overcome parasite-induced suppression of immune responses and instead 
induce effective anti-parasite immunity. Thus, DC-based therapies may provide a useful 
approach to induce potent cell-mediated responses against parasite. In order to optimise 
this approach, a thorough understanding of how parasites interact with DCs and the 
mechanisms they adopt to induce DC suppression would be extremely beneficial for 
future vaccine design.
In this chapter I investigated the role of selected parasite components in the parasite- 
mediated inhibition of DC function. Both haemozoin, the end-product of the 
haemoglobin catabolism by intraerythrocytic malaria parasite, and soluble parasite factors 
secreted by pRBCs (which have not been identified yet) were found to contribute 
significantly to the immunosuppressive effects induced in DCs, demonstrating that 
products of the intra-erythrocytic stages of malaria parasites can directly alter murine DC 
function in vitro.
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5.2 Results
5.2.1 DCs incubated simultaneously with P. chabaudi AS and LPS retained their ability 
to mature in vitro.
Having established in previous chapters that pRBCs affected key DC functions, I focused 
on dissecting the possible mechanisms used by the parasites to exert their effects. To 
address this issue I initially examined whether pRBCs induced immediate suppression of 
DC function by simultaneously incubating pRBCs and LPS with bone marrow-derived 
DCs. The expression of MHC class II and the costimulatory molecules CD40, CD80 and 
CDS6 by DCs was examined 24h later by flow cytometry. The results showed that DCs 
expressed low levels of surface MHC class II, CD40, CD80 and CD86 when cultured in 
growth medium alone, thus confirming their immature state in culture (Fig. 5.1). 
Stimulation with LPS promoted a significant increase in the expression of all of the 
costimulatory molecules tested. Furthermore, DCs incubated simultaneously with pRBCs 
and LPS retained their ability to mature in vitro as they showed similar expression levels 
of MHC class II, CD40, CD80 and CD86 to DCs treated with RBCs and LPS or LPS 
alone. This finding suggested that pRBCs required a longer pre-incubation period with 
DCs to affect the LPS-induced maturation of DCs in vitro.
5.2.2 P. chabaudi AS-infected erythrocytes required 6h of incubation with DCs to exert 
their suppressive effects.
In order to investigate when DC-pRBC interactions led to suppression of DC function, 
DCs were incubated with RBCs or pRBCs for 6, 12 or 18h. Each experimental culture 
was then stimulated with LPS for a further 18h and the expression levels of MHC class II 
and costimulatory molecules CD40, CD80 and CD86 analysed 24h later by flow 
cytometry. The results showed that the ability of DCs to respond to LPS treatment in 
vitro was significantly affected when DCs were pre-incubated with pRBCs for 6h before 
LPS challenge as observed by the reduced levels of CD40 and CD86 expression (Fig.
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5.2). The upregulation of MHC class II and CD80 in response to LPS stimulation was 
instead inhibited after 12h of incubation with pRBCs suggesting that the expression of 
costimulatory molecules CD40 and CD86 might be more sensitive to the suppressive 
effects induced by pRBCs. Furthermore, although the expression of CD80 was 
dowregulated after 12h of incubation with pRBCs, it was not significantly affected when 
DCs were pre-incubated with pRBCs for 18h prior to LPS challenge. This finding 
suggested that the effects induced by pRBCs on the expression level of CD80 were 
transient.
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Figure 5.1 pRBCs did not immediately suppress the LPS-induce maturation of DCs in 
vitro, 2x10*^  DCs were cultured simultaneously with 2x10* P. chabaudi AS-infected 
erythrocytes and lp,g/ml of LPS (AS+LPS) or with non-infected erythrocytes and LPS
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(RBC+LPS) for 24h. Unstimulated DCs (DC) or DCs stimulated wltli 1 pig/ml of LPS 
(DC+LPS) served as negative and positive controls respectively. Surface expression of 
MHC class II (a), CD40 (b), CD80 (c) and CD86 (d) on DCs was determined by flow 
cytometric analysis of gated CD llc^ cells. Results show the mean fluorescence intensity 
± standard errors of triplicate cultures per group.
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Figure 5.2 pRBCs required 6h incubation with DCs to downregulate the expression of 
costimulatory molecules on DCs in response to LPS treament in vitro. 2x10^ DCs were 
cultured with 2x10® P. chabaudi AS-infected erythrocytes (AS) or with non-infected 
erythrocytes (RBC) for 6,12 and 18h. Each culture was then stimulated with Ifxg/ml of 
LPS for a further 18h. Surface expression of MHC class II (a), CD40 (b), CD80 (c) and
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CD86 (d) on DCs was determined by flow cytometric analysis of gated CDllc^ cells. 
Results show the mean fluorescence intensity ± standard errors of triplicate cultures per 
group. * p^0.05 significant difference between RBC and AS at the indicated time point.
5.2.3 Erythrocytes infected with P. chabaudi AS-ring stage suppressed the LPS-induced 
maturation of DCs in vitro.
As previously mentioned in section 1.4, trophozoite-infected RBCs were used in all the 
experiments described in this thesis. However, it has been reported that P. chabaudi AS 
schizonts activated DCs in vitro (Seixas et a l, 2001), suggesting that different blood 
stages might exert different effects on DC function. I therefore investigated the effects 
that the early ring stage of the parasite’s intra-erythrocytic cycle had on the LPS-induced 
maturation of DCs in vitro. DCs were incubated with RBCs or pRBCs. After 24h of co­
culture, DCs were stimulated with LPS and the expression of MHC class II, CD40, CD80 
and CD86 examined 18h later by flow cytometry (Fig. 5.3). DCs incubated with RBCs 
matured in response to LPS treatment as observed by the elevated levels of all of the 
costimulatory molecules analysed. However, when DCs were incubated with pRBCs 
prior to LPS challenge, the expression levels of MHC class II, CD40 and CD86 were 
significantly dowregulated. This finding suggested that the early stages of the parasite’s 
intra-erythrocytic life cycle (ring and trophozoites) led to suppression of DC maturation 
in response to LPS treatment in vitro whereas, according to previous reports (Seixas et 
al., 2001), more mature stages (shizonts) led to DC activation. It is therefore possible that 
specific blood stages might suppress DC function to protect the more vulnerable stages 
(schizont and merozoites) in order to allow progression of the disease, as previously 
discussed in chapter 3. The latter hypothesis can only be tested in vivo, as it is not clear 
whether trophozoite-infected erythrocytes have the ability to mature to the schizont stage 
in vitro under cell culture condition (refer to 5.2.9 for details).
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Figure 5.3 pRBCs harbouring early ring stages inhibited the LPS-induced maturation of 
DCs in vitro. 2x10^ DCs were cultured with 2x10® P. chabaudi AS-infected erythrocytes 
(AS) or with non-infected erythrocytes (RBC). After 24h of co-culture, DCs were 
challenged with lp,g/ml of LPS for a further 18h. Surface expression of MHC class II (a), 
CD40 (b), and CD86 (c) on DCs was determined by flow cytometric analysis of gated 
CDllc^ cells. Results show the mean fluorescence intensity ± standard errors of triplicate 
cultures per group. * p^O.OS significant difference between RBC and AS.
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5.2.4 Fixed P. chabaudi-ïrxfQoXQà erythrocytes suppressed the LPS-induced maturation of 
DCs.
To analyse whether parasite viability or development was necessary to modulate DC 
function, pRBCs (and RBC controls) were fixed with paraformaldehyde, which cross­
links proteins, normally through free amino groups and preserve cell structure. DCs were 
incubated with fixed RBCs or fixed pRBCs for 24h and then stimulated with LPS for 
18h. The expression of MHC class II and co-stimulatory molecules CD40, CD80 and 
CD86 were examined 18h later by flow cytometry. Non-fixed RBCs and pRBCs served 
as controls. DCs treated with RBCs or fixed RBCs prior to LPS challenged matured 
efficiently as observed by the high levels of all of the costimulatory molecules tested (Fig 
5.4). As previously observed in chapter 3, treatment of DCs with viable pRBCs 
significantly downregulated the expression levels of MHC class II, CD40 and CD86 
following LPS stimulation. The same result was observed when fixed-pRBCs were used 
indicating that parasite viability was not a necessary requirement to induce suppression of 
DC function in vitro. Furthermore, the data also indicate that the suppression of the LPS- 
induced maturation observed when using viable pRBCs was not due to a more mature 
erythrocytic stage of the parasite, which might have developed following adaptation to 
cell culture conditions; pRBC fixation would in fact arrest parasite growth ensuring that 
only trophozoite-stages are present in the culture. Therefore the above results indicate 
that the observed suppression of the LPS-induced maturation of DCs is specifically 
mediated by the trophozoite stage.
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Figure 5.4 Fixed pRBCs inhibited the LPS-induced maturation of DCs in vitro. 2x10^ 
DCs were treated for 24 h with non-infected (RBC; filled bars) or P. chabaudi AS- 
infected erythrocytes (AS; open bars) that were non-fixed (intact) or fixed (fixed) prior to 
stimulation with LPS (1 pg/ml) for 18 h. DC activation was characterised by examination 
of (a) MHC class II, (b) CD40, (c) CD80 and (d) CD86 expression on the DC surface by 
flow cytometric analysis of gated CD llc^ cells. Results show the mean fluorescence 
intensity ± standard errors of triplicate cultures per group, * pa0.05 significant difference 
between RBC and AS.
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5.2.5 Fixed-pRBCs required 6h of incubation with DCs to exert their suppressive effects.
To further confirm that trophozoite-infected erythocytes were responsible for the 
modulation of DC functions previously analysed in chapter 3, I initially investigated 
whether the dynamics of the LPS-induced suppression of DCs induced by fixed-pRBCs 
were similar to those observed when using viable parasites. DCs were incubated with 
fixed-RBCs or fixed-pRBCs for 6 or 12h. Each experimental culture was then stimulated 
witli LPS and the expression levels of MHC class 11 and costimulatory molecules CD40, 
CD80 and CD86 analysed 18h later by flow cytometry. The ability of DCs to respond to 
LPS treatment in vitro was significantly affected when DCs were pre-incubated with 
fixed-pRBCs. Particularly MHC class II and CD86 expression were affected after only 6h 
of incubation of DCs with fixed-pRBCs (Fig. 5.5). The upregulation of CD40 in response 
to LPS stimulation was instead inhibited after 12h of incubation with pRBCs. Contrary to 
observations made with viable pRBCs, the expression of CD80 was not significantly 
affected when DCs were incubated with fixed-pRBCs for 12h prior to LPS stimulation. 
Overall, these findings suggested that the dynamics of suppression induced by fixed- 
pRBCs were very similar to that induced by non-fixed pRBCs, confirming that viable 
pRBCs were not necessary to induce suppression of DC function in vitro and that 
trophozoite-stages are responsible for the observed effects.
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Figure 5.5 Fixed pRBCs required 6h incubation with DCs to downregulate the 
expression of costimulatory molecules on DCs in response to LPS treament in vitro. 
2x10* DCs were cultured with 2x10* fixed P. chabaudi AS-infected erythrocytes (AS fix) 
or with fixed non-infected erythrocytes (RBC fix) for 6 and 12h. Each culture was then 
stimulated with Ipg/ml of LPS for a further 18h. Surface expression of MHC class II (a), 
CD40 (b), CD80 (c) and CD86 (d) on DCs was determined by flow cytometry. Results 
show the mean fluorescence intensity ± standard errors of triplicate cultures per group. * 
p:s0.05 significant difference between RBC and AS at the indicated time point.
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5.2.6 Fixed-pRBCs inhibit the antigen presenting ability of DCs in vitro.
To further ensure that fixed-pRBCs suppressed DC functions in a manner similar to that 
observed when viable pRBCs were used, the antigen presenting ability of fixed-pRBC- 
treated DCs was analysed by using DO 11.10 OVA-specifîc T cell hybridoma cells that 
express green fluorescent protein (GFP) upon TcR ligation (Underhill et al., 1999) as 
previously described in section 3.2.3. DCs were incubated with fixed-RBCs or flxed- 
pRBCs for 24h and then pulsed with OVA protein for 6h. Non-fixed RBCs and pRBCs 
were used as controls. OVA-specifîc T cells were added to each culture and GFP 
expression, indicative of antigen presentation independent of co-stimulation, examined 
24h later by flow cytometry. DCs incubated with RBCs or fixed-RBCs prior to antigen 
loading efficiently presented OVA as observed by high levels of GFP expression by T 
cells. However, the ability of DCs to activate the OVA-specific T cell hybridoma was 
significantly reduced when they were incubated with pRBCs or fixed-pRBCs (Fig. 5.6), 
indicating that viable and fixed-pRBCs might use a common suppressive mechanism.
5.2.7 pRBC-ghosts did not suppress the LPS-induced maturation of DCs in vitro.
In order to understand the mechanisms involved in the parasite-mediated modulation of 
DC function, I initially analysed the effect that parasite proteins, expressed on the 
erythrocyte membrane, had on DC function. DCs were exposed to plasma membranes 
(ghosts) isolated from RBCs or pRBCs. After 24 h of culture, DCs were challenged with 
LPS and the expression of costimulatory molecules examined 18 h later by flow 
cytometry. Intact RBCs and pRBCs were used as controls (Fig. 5.7). DCs upregulated the 
expression of costimulatory molecules MHC class II and CD40 when they were 
incubated with RBCs or RBC-ghosts prior to LPS challenge. pRBC-treated DCs were not 
able to efficiently respond to LPS treatment as the levels of MHC class II and CD40 were 
significantly downregulated, confirming previous results. However, DCs exposed to 
pRBC-ghosts retained their ability to respond to LPS stimulation as the levels of MHC 
class II and CD40 were not significantly affected. This finding suggested that parasite 
molecule expressed on the erythrocyte membrane did not modulate DC activation.
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Figure 5.6 Fixed Plasmodium chabaudi AS-infected erythrocytes inhibited antigen 
presentation by DCs. 5x10^ DCs were treated with non-infected (RBC; filled bars), or P. 
chabaudi AS-infected erythrocytes (AS; open bars) that were non-fixed (intact) or fixed 
(fixed). After 24 h of culture, the cells were pulsed with 5 mg/ml of OVA for 6 h. The 
level of antigen presentation was determined by incubating DCs with the OVA-specifîc 
DOll.lO-GFP hybrydoma at 1:1 DC : T cell ratio and T cell activation assessed 24 h 
later by flow cytometry. Results are expressed as the mean fluorescence intensity of GFP 
expression by CD4^ T cells ± standard error. *, pi^ O.OS significant difference between 
RBC and AS.
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Figure 5.7 pRBC-ghosts did not affect the ability of DCs to mature in response to LPS 
treatment in vitro. 5x10^. DCs were incubated with intact erythrocytes (intact) or RBC 
ghosts (ghosts) from non-infected (RBC; filled bars) or P. chabaudi AS-infected 
erythrocytes (AS; open bars), for 24 h prior to stimulation with LPS (1 pg/ml) for 18 h. 
DC activation was characterised by analysis of (a) MHC class II and (b) CD40 expression 
on the DC surface by flow cytometry. Results show the mean fluorescence intensity ± 
standard errors of triplicate cultures per group. * p^O.05 significant difference between 
RBC and AS.
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5,2.8 Activation of DCs in response to LPS treatment in vitro was suppressed by 
haemozoin.
Having established that the LPS-induced maturation of DCs in vitro could be modulated 
by pRBCs, but was not due to the effects of parasite proteins expressed on the erythrocyte 
cell membrane, I focused my attention on haemozoin (HZ), a byproduct of haemoglobin 
digestion. One of the reasons that led me to investigate the role of HZ in the parasite- 
induced modulation of DC function was the altered morphology of DCs following a 24h 
incubation with pRBCs (Fig.5.8a-b). DCs were dispensed on polylysine-coated coverslips 
and left to adhere overnight before addition of RBCs or pRBCs. After 24h of co-culture, 
coverslips were transferred onto glass slides and examined by bright-field microscopy. 
DCs showed their characteristic cell morphology with many long processes when 
cultured with RBCs. In contrast, incubation with pRBCs caused a dramatic change in cell 
morphology with “black pigment” clearly visible inside DCs. This may be due to the 
uptake of pRBCs and HZ formation. To verify whether DCs could internalise intact 
pRBCs, DCs and pRBCs co-cultures were set up as described above and incubated for 
3h. DCs were stained with Choleratoxin, which stain lipid rafts and provide a clear cell 
membrane staining, facilitating DC visualisation by fluorescence microscopy (Nichols, 
2002; Ribi et al., 1988). pRBCs were instead stained with Biotin-conjugated rat anti­
mouse TER-119 monoclonal antibody, which reacts with a 52-kDa molecule associated 
with glycophorin A on cells of the erythroid lineage (Kina et al., 2000). Coverlips were 
transferred onto glass slides using mounting medium containing DAPI to reveal cell 
nuclei (Fig. 5.8c). Examination of prepared slides by fluorescence microscopy revealed 
the presence of pRBC inside DC as shown by visible blue stains inside the RBC, 
indicative of parasite nuclei. To investigate the effects of HZ on DC function, I initially 
analysed its ability to activate DCs directly in vitro. DCs were treated with 1, 5,10 or 20 
pM of HZ and the expression of MHC class II and costimulatory molecules CD40 and 
CD86 examined 24h later. DCs grown in medium only and those treated with LPS served 
as negative and positive control respectively. DCs expressed very low levels of surface 
MHC class II, CD40 and CD86 when cultured in growth medium alone, confirming their 
immature state in culture (Fig. 5.8d-f). Stimulation with LPS promoted a significant
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increase in the expression level o f all o f the costimulatory molecules tested. However, 
DCs incubated for 24h with HZ did not increase expression of MHC class II, CD40 and 
CD86, indicating that HZ did not induce DC activation at any o f the concentrations 
tested. To ensure that DCs internalised HZ efficiently, DC were observed by bright-field 
microscopy (Fig. 5.8g-j). Deposits o f HZ were clearly visible, as black “spots” inside 
DCs. Furthermore the magnitude o f HZ deposition inside DCs seemed to be proportional 
to the concentration of HZ added to the cultures. I then examined whether HZ-treated 
DCs were still able to respond to LPS treatment in vitro (Fig. 5.8k-m). Experimental 
cultures were set up as described above and stimulated with LPS for 18h. The results 
clearly showed that as the concentration of HZ increased, the LPS-induced maturation of 
DCs was downregulated, as observed by the reduced levels o f MHC class II, CD40 and 
CD86. Collectively these findings suggest that HZ is a key factor involved in the 
suppression o f murine DC function in vitro.
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Figure 5.8 Haemozoin (HZ) affected the ability of DCs to respond to LPS treatment in 
vitro. (a-b)lxlO^ DCs were incubated with P. chabaudi AS-infected or non-infected 
erythrocytes. After 24h of co-culture, cells were examined by bright-field microscopy 
using a 63x oil immersion lens, (c) Experimental cultures were prepared as described 
above. After 3h of co-culture, DCs were stained with 0.5pg/ml of CTxB-Alexa Fluor 488 
(green) and then fixed with 0.5% of paraformaldehyde. Infected erythrocytes were 
stained with Biotinylated-TER-119 antibody, which reacts with a 52-kDa molecule 
associated with glycophorin A on cells of the erythroid lineage, and detected using 
streptavidin-FITC (red). Cell nuclei were revealed using Vectashield with DAPI (blue). 
Images were obtained using an Axiovert S-100 Zeiss microscope fitted with a 63x oil 
immersion lens, (d-f) 2x10* DCs were cultured with IpM, 5pM, lOpM and 20pM of HZ. 
After 24 h, the level of expression of (d) MHC class II, (e) CD40 and (f) CD86 was 
determined by flow cytometry, (g-j) 2x10* DCs were cultured with (g) IpM, (h) 5pM, 
(i)lOpM and (j) 20pM of HZ. After 24h of culture, cells were examined by bright-field 
microscopy using a 63x oil immersion lens, (k-m) After 24h of culture with HZ, 1 pg/ml 
of LPS was added to DCs and the levels of (k) MHC class II, (1) CD40 and (m) CD86 
analysed 18 h later by flow cytometry. All results are shown as the mean fluorescence 
intensity of triplicate cultures ± standard error. p^0.05 (mM HZ vs LPS).
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5.2.9 A soluble factor(s) released by pRBCs modulated the LPS-induced maturation of 
DCs in vitro.
Having established that HZ played an important role in modulating DC function, I 
decided to investigate whether the parasite used additional mechanisms to efficiently 
exert its suppressive effects on DC function. I addressed this issue by using a transwell 
culture system where pRBCs and DCs were separated by a 0.4pm pore size membrane. 
This allowed me to investigate whether DCs had to interact directly with pRBCs to be 
modulated. DCs were cultured in the lower compartment of a transwell culture plate. 
pRBCs were added to the upper compartment and incubated for 24h. DCs were then 
challenged with LPS and the expression of MHC class II and CD40 examined 24h later 
by flow cytometry. Supernatants were also collected for cytokine analysis. RBCs and 
pRBCs cultured with DCs directly were used as controls.
DCs cultured directly with RBCs or separated by a membrane efficiently responded to 
LPS challenged as observed by the high levels of expression of both MHC class II and 
CD40 (Fig. 5.9a-b). Consistent with previous results, treatment of DCs with pRBCs 
significantly affected their ability to mature in response to LPS stimulation as the 
expression levels of MHC class II and CD40 were significantly downregulated. In 
addition, IL-12 production by DCs treated with pRBCs was significantly suppressed and 
small amounts of IL-10 were detected (Fig 5.9c-d). The same results were found when a 
membrane separated DCs and pRBCs, suggesting that a soluble factor(s) secreted by 
pRBCs might also be involved in the modulation of DC function in vitro. To ensure that 
this was the case, further experiments were designed to rule out the possibility that HZ 
was causing the observed effects. In fact, although the size of P. chabaudi AS HZ has not 
been reported, studies using different species of Plasmodium revealed that the average 
size of HZ crystals ranged between 50 and 600nm (Noland et al,, 2003). Fïaving used a
0.4pm pore size membrane to separate DCs from pRBCs, the possibility still remained 
that during the 24h incubation period some pRBCs could have ruptured as a result of the 
culture conditions, allowing HZ to pass through the membrane. Alternatively, the 
parasites could have undergone schizogony during the incubation time, releasing HZ into
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the culture. Conflicting ideas exist regarding the ability of the parasites to undergo the 
full erythrocytic cycle under cell culture conditions (i.e. 37°C, 5%C02). In fact 
Plasmodium species are generally cultured in plates placed in a candle jar that provides 
an atmosphere of 3% C02-17% O2 or in vials that allow for continuous flow of medium 
into culture vessels with an atmosphere of 7% C02-l% 02-92% N2 (Schuster, 2002). 
However, it is possible that some parasites might adapt to the new growth conditions and 
be able to undergo schizogony (fig.5.9e-f). For these reasons, a series of experiments 
involving high-speed centrifugations were designed to ensure that supernatants harvested 
from pRBCs after 24h incubation under cell culture conditions were HZ-ffee.
RBCs and pRBCs were cultured for 24h at 37°C and 5%C02. Cells were centrifuged for 
10 min at 450g (later referred to as Tow-speed centrifugation’). Supernatants were 
collected and either added to DCs or centrifuged further at 32000g (later referred to as 
‘high-speed centrifugation’) for 20 min before addition to DCs. To further ensure that 
uncontaminated supernatants were used in the experiments, an additional set of 
supernatants were prepared and subjected to high-speed centrifugation followed by filter 
sterilisation through a 0.2pm pore size membrane filter before addition to DCs. A pellet 
was recovered following the high-speed centrifugation and was also incubated with DCs 
to analyse whether it would suppress responses to LPS. After 24h incubation, DCs were 
challenged with LPS and the levels of CD40 expression examined 18h later by flow 
cytometry (Fig 5.9g).
DCs incubated with RBC supernatants derived from both the low- and the high-speed 
centrifugations matured efficiently in response to LPS stimulation as observed by the 
high levels of CD40 expression. However, DCs treated with pRBC supernatants obtained 
following both low- and high-speed centrifugations showed significantly lower levels of 
CD40 expression indicating that DCs were not able to respond to LPS treatment in vitro. 
Visualisation of DCs by bright field microscopy revealed that pRBC supernatants derived 
from the low-speed centrifugation contained parasite components as “black depositions” 
were clearly visible inside DCs and these deposits could therefore be responsible for the 
observed effect (Fig. 5.9h). However, pRBC supernatants derived from the high-speed
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centrifugation lacked parasite contamination as DCs cleai'ly retained their characteristic 
cell morphology and lacked black depositions in the cytoplasm (Fig. 5.9i). This finding 
reinforced the idea that a soluble factor(s) might be responsible for the observed 
suppression of DC maturation.
The pellet recovered from the high-speed centrifugation did not downregulate the 
expression of CD40 (Fig 5.9g), indicating that DCs were able to mature efficiently in 
response to LPS stimulation in vitro. This finding suggested either that the pellet did not 
contain HZ or the amount of HZ released by pRBCs was not significantly high to induce 
inhibition of DC function, the latter probably due to inappropriate culture conditions for 
parasite growth. The notion of having a pellet, which did not contain or had very low 
levels of HZ was further reinforced by the solubility of the pellet in the culture medium 
where HZ is instead insoluble.
To further characterise the nature of the soluble factor(s) released by pRBCs, I heat 
inactivated the supernatants obtained following the high-speed centrifugation before they 
were added to DCs. RBC and pRBC supernatants were prepared as described above and 
heated to 100°C for 20min then centrifuged for 10 min at 450g and passed through a 0.2 
pm pore size membrane filter before addition to DCs. After 24h incubation DCs were 
challenged with LPS and the expression of CD40 examined 18h later (Fig. 5.9j).
Confirming previous findings, DCs incubated with the pRBC supernatant preparations 
derived from both the low- and high-speed centrifugations were unable to mature 
efficiently following LPS stimulation as observed by the downregulation of CD40 
expression. However, when the supernatants were heat inactivated, DCs retained their 
ability to respond to LPS treatment, as the level of CD40 expression by DCs was not 
significantly different from the RBC control. This finding suggested that soluble parasite 
factors must be in their native form to cause suppression of DC function in vitro.
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Figure 5.9 pRBCs released a soluble factor that affected the ability of DCs to respond to 
LPS treatment in vitro, (a-b) DCs were treated for 24 h with non-infected (RBC; filled 
bars) or P. chabaudi AS-infected erythrocytes (AS; open bars), either directly (contact) or 
separated by a 0.4 pm pore size membrane (Transwell) prior to stimulation with LPS (1 
pg/ml) for 18 h. DC activation was characterised by examination of (a) MHC class II and 
(b) CD40 expression on the DC surface by flow cytometric analysis of gated CD llc^ 
cells. Results show the mean fluorescence intensity ± standard errors of triplicate cultures 
per group. * p^0.05 significant difference between RBC and AS. (c-d) Concentration of 
IL-12p40 (c) and ILIO (d) secreted by DCs that were treated for 24 h with non-infected 
(RBC; filled bars) or P. chabaudi AS-infected erythrocytes (AS; open bars) either 
directly (contact) or separated by a 0.4 pm pore size membrane (Transwell) prior to 
stimulation with LPS (1 pg/ml) for 18 h. After 24h of culture, supernatants were 
harvested for cytokine analysis. Error bars indicate standard errors of triplicate cultures 
per group. * p^O.05 significant difference between RBC and AS. (e-f) Giemsa’s stained 
thin blood smears taken either directly fi*om a P. chabaudi AS infected BALB/c mouse 
(e) or after 24h incubation of pRBCs under cell culture conditions (37°C, 5%C02). Cells
168
were photographed using an Axiovert S-100 Zeiss microscope using a 63x oil immersion 
lens, (g) DCs were treated for 24 h with supernatants derived from non-infected (RBC; 
filled bars) or P. chabaudi AS-infected erytlirocytes (AS; open bars) prior to stimulation 
with LPS (1 pg/ml) for 18h. Supernatants were obtained after incubating RBCs or pRBCs 
for 24h and subjecting them to either a 450g centrifugation (S/n-low) or a 32000g 
centrifugation (S/n-high). An additional set of cells was centrifuged at 32000g followed 
by filter sterilisation through a 0,2 pm pore size membrane (S/n (high+ FS)). DC 
activation was characterised by examination of CD40 expression on the DC surface by 
flow cytometric analysis of gated CD 11 o’*" cells. Results show the mean fluorescence 
intensity ± standard errors of triplicate cultures per group. * p:s0.05 significant difference 
between RBC and AS. (h-i) DCs were incubated with the supernatant of P. chabaudi AS 
infected erythrocytes derived either from a 45Og centrifugation (h) or a 32000g 
centrifugation (i). After 24h, cells were examined by bright-field microscopy using a 63x 
oil immersion lens, (j) DCs were incubated with P. chabaudi AS supernatants obtained 
following a 45Og or a 32000g centrifugation as described in (g). An additional set of 
supernatants obtained following a 32000g centrifugation, was heated to 100°C and filter 
sterilised through a 0.2 pm pore size membrane prior to addition to DCs (heated S/n 
(high+FS)). Results show the mean fluorescence intensity ± standard errors of triplicate 
cultures per group. * p^O.05 significant difference between RBC and AS.
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5.3 Discussion
In previous chapters I showed that malaria infected erythrocytes did not directly activate 
bone marrow-derived DCs in vitro; rather, they inhibited the LPS induced upregulation of 
Class II MHC and costimulatory molecules (CD40 and CD8 6 ) on DCs (chapter 3) and 
significantly reduced the ability of these cells to induce naïve T cell proliferation (chapter
4).
In search of a mechanistic explanation for these observations, I initially examined 
whether pRBCs induced immediate suppression of DC function. To address this issue 
DCs were incubated simultaneously with pRBCs and LPS and the expression of MHC 
class II and the the costimulatory molecules CD40, CD80 and CD8 6  examined 24h later 
by flow cytometry. The results showed that pRBC-treated DCs were able to mature in 
response to LPS treatment, as the levels of all of the costimulatory molecules tested were 
significantly upregulated. This finding suggested that pRBCs required a longer 
incubation period with DCs to exert their inhibitory effect. The above observation led me 
to investigate the time that pRBCs required to interact with DCs in order to modulate 
their function. DCs were incubated with pRBCs for 6 , 12 and 18h. Each experimental 
culture was then challenged with LPS and the expression of MHC class II and the 
costimulatory molecules CD40, CD80 and CD8 6  examined 24h later by flow cytometry. 
The results showed that pRBCs had to interact with DCs for at least 6 h before inhibiting 
their ability to respond to LPS stimulation in vitro, as observed by the reduced expression 
of CD40 and CD8 6 . The level of MPIC class II was instead suppressed following a 12h 
incubation period with pRBCs, perhaps indicating that CD40 and CD8 6  are more 
sensitive to the suppressive effects induced by pRBCs. Alternatively, they might be 
selectively downregulated by the parasites before significantly affecting MHC class II 
expression to ensure that appropriate co-stimulation is not provided to T cells, thus 
impeding the development of appropriate T cell responses directed against them. 
Interestingly, the level of CD80 expression was also significantly downregulated 
following a 12h incubation of DCs with pRBCs, Nevertheless, the latter appeared to be a 
transient suppression, as the expression of CD80 returned to normal levels when analysed
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after an 18h incubation period. Whether these differences in kinetics reflect a specific 
mechanism used by pRBCs to suppress DC function or merely represent differences in 
their overall sensitivity to the parasite remains unclear. Nevertheless, these data suggest 
that in order to induce their suppressive effects, pRBCs have to interact with DCs for at 
least 6 h. The erythrocytic cycle of P. chabaudi requires 24h to complete within its host, 
with the parasites developing into a more mature stage every 6 h. Therefore, the observed 
suppression of DC function might be the result of the interaction of a more mature 
parasite form with DCs. Alternatively, following phagocytosis, trophozoite-infected 
erythrocytes might remain viable within the DCs and actively suppress their function. I 
therefore decided to examine whether the suppression of DC function was specifically 
induced by the trophozoite stage and whether their viability was a necessary requirement.
To address the above questions, pRBCs were fixed and incubated with DCs prior to LPS 
challenge. Fixed pRBCs were found to significantly affect the ability of DCs to mature in 
response to LPS stimulation. Furthermore, they also required at least 6 h of incubation 
with DCs to exert their inhibitory effect and significantly reduced the antigen presenting 
ability of DCs. Therefore fixed-pRBCs showed a similar pattern of modulation of DC 
function observed when using non-fixed pRBCs. The lack of a requirement for viable 
parasites confirmed that trophozoite-infected erythrocytes rather than a more mature 
erythrocytic stage (schizont) were responsible for the observed suppression of DC 
maturation. It also suggested that an isolatable parasite product was mediating this effect. 
To address this issue, I initially focused on analysing the effect that parasite proteins 
expressed on the erythrocyte membrane have on DC function.
It is known that the erythrocytic development of the parasites is coupled with changes in 
the host cells, including the host cell plasma membranes (Wunderlich et a l, 1987). It is 
also well established that parasites express ‘neo-proteins’ on the host cell surface some of 
which are reported to induce protective immunity (Aikawa and Miller, 1983; Schmidt- 
Ullrich et aL, 1983; Sherman, 1985). Moreover, it has been suggested that the ability of 
P. falciparum  to inhibit DC maturation is mediated through the binding of CD36 to a 
parasite-derived molecule (PfEMPl) on the infected erythrocyte surface (Urban et aL,
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1999; Urban et a l, 2001b). Erythrocytes infected with P. chabaudi AS were also shown 
to be able to adhere to specific cell types and sequester by interacting with molecules 
such as CD36 (Mota et aL, 2000). To assess the involvement of parasite proteins present 
on the erythrocyte membrane in the observed suppression of DC activation, I exposed 
DCs to plasma membrane ghosts derived from infected or non-infected erythrocytes, 
prior to LPS challenge. Ghosts isolated fiom infected erythrocytes did not alter the ability 
of DCs to respond to LPS treatment in vitro, suggesting that parasite antigens expressed 
on the erythrocyte plasma membranes did not induce the suppression previously 
described following contact with DCs in vitro. In support of this finding is the 
observation that immunisation of mice with pRBC ghosts induced protection from 
parasite challenge (Wunderlich et aL, 1988), suggesting that ghosts, unlike intact 
parasites, are not inherently immunosuppressive.
As mentioned earlier, trophozoite-infected erythrocytes were used in all the experiments 
described in this thesis. In order to develop to this stage, parasites have to polymerise the 
haeme, a toxic byproduct of haemoglobin digestion, into the non-toxic form known as 
haemozoin (HZ), which accumulates into the parasite’s digestive vacuole (Francis et aL, 
1997; Olliaro and Goldberg, 1995; Slater et aL, 1991). Since fixed pRBCs had an effect 
on the LPS-induced maturation of DCs and pRBC-ghosts did not, HZ seemed to be a 
good candidate to investigate the mechanism involved in the parasite-induced modulation 
of DC function. I therefore incubated DCs with HZ, purified from supernatants obtained 
from cultures of P. falciparum gametocytes. The results showed that purified HZ did not 
activate DCs directly, however it significantly inhibited the LPS-induced maturation of 
DCs in a dose dependent manner. These observations are consistent with previous reports 
suggesting that HZ is able to impair the differentiation and functional capacity of human 
monocytes and murine macrophages through the production of IL-10 and/or induction of 
peroxisome proliferators-activated receptor-y (Deshpande et aL, 2004; Morakote and 
Justus, 1988; Schwarzer et aL, 1998; Scorza et aL, 1999; Skorokhod et aL, 2004). 
However, the precise mechanisms accounting for the suppressive effects of HZ remain to 
be elucidated, although in an early study, HZ was reported to increase degradation of 
protein kinase C, which plays a crucial role in signal transduction and expression of
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membrane antigens (Schwarzer et al., 1993). In addition, an other report by the same 
authors suggested that accumulation of HZ within phagolysosomes indirectly caused a 
defect in antigen processing through the generation of potent bioactive lipid derivatives 
(Schwarzer et aL, 2001). Both of the above studies were carried out using human 
monocytes. Furthermore, a more recent report showed that HZ inhibited the maturation of 
human monocyte-derived DCs (Skorokhod et aL, 2004). Nevertheless, the involvement 
of HZ in suppression of DC function remains controversial, as other investigators suggest 
a pro-inflammatory role of HZ, possibly via TLR-9 activation (Coban et aL, 2005; Coban 
et aL, 2002; Jaramillo et aL, 2005; Jaramillo et aL, 2003; Jaramillo et aL, 2004; 
Pichyangkul et aL, 1994; Pichyangkul et aL, 2004). One possible explanation for this 
disparity in results may simply relate to differences in the HZ preparations. For instance, 
Paolo Arese and colleagues prevented the complete removal of adherent membranes from 
the HZ preparation as no phagocytosis of the pigment was observed in this case 
(Schwarzer et aL, 1992), an approached also used in the present study. Conversely, other 
investigators had additional incubation steps with proteinases and lipases in their 
preparations (Coban et aL, 2002; Jaramillo et aL, 2003).
While carrying out the experiments described in this chapter, I realised that the observed 
suppression of DC function was consistently greater when live infected erythrocytes were 
used. This observation suggested that other parasite products could also be involved and 
might therefore have cumulative effects on the suppression of DC function. In order to 
address this issue, I initially examined whether interaction of DCs with pRBCs was 
necessary to modulate DC function. DCs and pRBCs were separated by a 0.4pm pore 
size membrane and cultured for 24h prior to LPS stimulation. The ability of DCs to 
mature in response to LPS treatment in vitro was significantly downregulated suggesting 
that soluble parasite products could be present in the cultures and might mediate the 
observed effect. However, It has been reported that the size of HZ crystals belonging to 
different species of Plasmodium ranged between 50 and 600nm (Noland et aL, 2003). 
Although the ability of the parasites to undergo the full erythrocytic cycle under cell 
culture conditions has not been reported yet, the possibility still remained that the 
observed effect was due to HZ passing through the 0.4pm pore size membrane used to
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separate the cells. For this reason, a series of experiments involving low- and high-speed 
centrifugations were designed to ensure that pRBC supernatants were free from HZ. The 
LPS-induced maturation of DCs was found to be significantly affected when DCs were 
incubated for 24h with the supernatants derived from both the low- and high-speed 
centrifugations. Particularly, it was clear that pRBC supernatants derived from the high­
speed centrifugation lacked HZ as visualisation of DCs by bright field microscopy 
showed absence of black pigment within DCs and the cells retained their characteristic 
morphology. This finding reinforced the idea that a soluble factor(s) might be responsible 
for the suppression observed. Furthermore, the fact that the early ring stages were found 
to suppress the LPS-induced maturation of DCs further supported the involvement of 
soluble parasite factors in the observed modulation of DC function. To further 
characterise the nature of this factor, pRBC supernatants obtained following the high­
speed centrifugation were heat-inactivated prior to addition to DCs. After 24h incubation 
DCs were challenged with LPS and the level of CD40 expression on DCs analysed 18h 
later by flow cytometry. The results obtained from this experiment showed that DCs 
retained their ability to mature in response to LPS treatment in vitro when treated with 
heat-inactivated supernatants, suggesting that a soluble factor(s) potentially secreted by 
the parasites has to be in its native form to induce suppression of DC activation. 
Treatment of the pRBC-derived supernatant with proteinases and lipases would aid in the 
identification of the nature of this potential immunosuppressive factor, an experiment, 
which due to time constrains could not be carried out for the present study. Interestingly, 
early reports have shown that blood-stage exoantigens from F. yoelii and P. falciparum 
were pro-inflammatory and induced the release of TNF-a from macrophages (Bate et al, 
1992b; Taverne et a l, 1990a; Taverne et a l,  1990b). The capacity of the exoantigens to 
stimulate macrophages to secrete TNF-a did not require the presence of a protein or a 
carbohydrate but was associated with a lipid, whose activity was shown to be abolished 
by treatment with phospholipase C (Bate et a l, 1992a; Bate et a l, 1992b),
More recent studies using P. yoelii infections showed that a soluble factor(s) specifically 
inhibited IL-2 production by responding CD4^ T cells (Luyendyk et a l, 2002). The 
authors used a transwell culture system where T cells purified from OVA TcR transgenic
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mice were cultured with spleen cells from uninfected mice in the inner well of the two- 
chamber system. Spleen cells from infected mice were instead placed in the outer well. 
The soluble factor was suggested to be produced by CDllb^ cells purified from spleen 
cells isolated from infected mice. The effect that pRBC alone had on the IL-2 production 
by T cells was not directly examined in the above study.
Another study by Ocana-Morgner et ah (Ocana-Morgner et a l, 2003) found that 
interaction of blood-stage parasites with DCs induced the secretion of soluble factors that 
inhibited the activation of CD8  ^T cells in vitro. The authors suggested that these factors 
were secreted by DCs as the inhibitory activity was not found in the incubation medium 
of pRBC alone thus confirming the results previously found by Luyendyk et a l 
(Luyendyk et a l, 2002). However, Ocana-Morgner et a l carried out their study by 
transferring incubation media onto fresh DCs, rather than using a transwell system and 
they did not take into account the fact that other parasite products (such as HZ) could be 
present in the culture media. Nevertheless it is still possible that the differences observed 
between the above and the present studies were due to the different parasite species used 
in the experiments {P. yoelii vs P. chabaudi).
In the present chapter I have demonstrated that haemozoin, rather that infected 
erythrocyte membranes, is responsible for the observed suppression of DC activation in 
vitro. Furthermore, soluble factors secreted by pRBCs also seem to contribute 
significantly to the immunosuppressive effects induced in DCs. Although parasites may 
affect DC function by actively secreting suppressive factors, they may also induce DCs to 
secrete or express factors that could in turn modulate their activation state, resulting in an 
overall inability of these cells to induce protective responses against the parasites. In the 
next chapter I analyse this possibility directly by investigating the involvement of some 
of the most common immunoregulatory agents, which could be potentially induced by 
DCs following interaction with pRBCs, in the observed suppression of DC activation. 
Identification, followed by a deep understanding of the mechanisms of action of these 
suppressive agents, may be beneficial for future therapeutic treatments and vaccine 
designs where replaeement of DC suppression in favour of DC activation would be
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particularly advantageous. Furthermore, the identification of specific immunosuppressive 
factors released by DCs may also help in settings where immunosuppression would be 
clinically beneficial, such as in the case of autoimmune diseases.
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6. Investigating the role of selected immunoregulatory 
molecules on the LPS-induced activation of DCs in vitro
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6.1 Introduction
As previously described in section 1.2.6, pathogens generally cause priming of immature 
DCs to become mature effector DCs that drive appropriate Thl or Th2 responses. 
However, there is now evidence describing the ability of certain pathogens to prime for 
an alternative subset of DCs, characterised by having altered activation states 
(Auffermann-Gretzinger et ah, 2001; Dolganiuc et a l, 2003; Geijtenbeek et a l, 2003; 
Karp et a l, 1996; McGuirk et a l, 2000; Nigou et a l, 2001; Urban et a l, 1999; van der 
Kleij et a l ,  2002). These ‘alternatively activated DCs’ may not be able to induce 
appropriate effector T cell responses directed against various pathogens. Instead they may 
drive the generation of anergic or regulatory T cells, or even induce T cell apoptosis, 
providing a mechanism used by certain pathogens to avoid host immune responses 
directed against their elimination. Examples of pathogens promoting the generation of 
this type of DCs were extensively discussed in sections 1.2.7.1 and 1.2.7.2. P. falciparum 
has been identified as being one of the pathogens belonging to this category as it has been 
shown to suppress the maturation of DCs and therefore their ability to stimulate naïve T 
cells (Urban et a l, 1999).
Besides directly modulating DC activation, pathogens may induce host cells to secrete or 
express factors that will in turn affect the activation state of DCs. Production of PGEz, 
NO and TGF-p, as well as PPAR-y activation and IDG expression by DCs, all represent 
possible immunoregulatory mechanisms that pathogens may potentially use to suppress 
DC function (Gosset et a l, 2001; Grohmann et a l, 2000; Harizi et a l, 2003; Holt et a l, 
1993; Li et a l,  2005). Ail of the above molecules and their potential involvement in 
modulating DC functions have been previously discussed in section 1.2.8. Although they 
could all have a direct effect on T cells, in this chapter I focus on their effects on the LPS- 
induced maturation of DCs as a preliminary study. However, as it was not possible to use 
positive controls in my experiments and as I have not replicated the above findings in the 
system used in the present study, some caution should be exercised when interpreting the 
results presented in this chapter. Furthermore, due to time constraints, all the inhibitors or 
antagonists were used at a single concentration previously shown to block respective
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activities by other investigators. To ensure the validity of the results presented herein, 
optimal dilutions for each of the molecules tested should be determined in the future.
Understanding the involvement of the above mediators in the regulation of immune 
responses in human diseases could have important consequences in the improvement of 
therapeutic treatments. Agonists of PPAR-y are already being used for the treatment of 
type II (non-insulin dependent) diabetes and are also considered as potential therapeutic 
agents for cancer treatment (Dubuquoy et aL, 2002; Murphy and Holder, 2000). 
Moreover it has been shown that administration of rosiglitazone (a PPAR-y ligand) 
reduces the severity of inflammation in patients with mild to moderate cases of ulcerative 
colitis (Kornbluth, 2001; Lewis et al,, 2001). Similarly, encouraging results from phase II 
clinical trials were obtained by inducing IDO expression in autoimmune rheumatoid 
arthritis (Kremer et a l, 2003), implying that it might be possible to induce IDO 
expression in settings where immunosuppression would be clinically beneficial. 
Therefore, the experiments presented in this chapter were designed with the view that a 
better understanding of the involvement of these mediators following pRBC-DC 
interaction could be useful for therapeutic approaches and help to improve the 
effectiveness of potential malaria vaccines.
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6.2 Results
6.2.1 PGE2-EP4 signalling is not involved in the suppression of the LPS-induced 
maturation of P. chabaudi AS-treated DCs in vitro.
The role of host eicosanoids in modulating immunity is well documented and it is now 
widely accepted that DCs produce lipid mediators, such as PGE2, which are well known 
to be involved in immune suppression (Harizi and Gualde, 2004). Furthermore, DCs 
themselves have been shown not to be refractory to the effects of PGE2 . In fact, 
exogenously added or endogenously released PGE2 was reported to act on DCs by 
inducing the production of endogenous IL-10, which suppresses IL-12 production and 
alters antigen presentation by inhibiting MHC class II protein expression (Harizi et aL, 
2002). Moreover, many parasites, including P. falciparum (Kilunga Kubata et aL, 1998), 
have been reported to produce prostaglandins and prostaglandin-like molecules (Noverr 
et aL, 2003), representing a possible mechanism used by parasites to alter DC function. 
This knowledge prompted me to investigate whether the observed suppressive effects 
induced by pRBCs on DC function were partly mediated by the action of PGE2 that could 
be potentially produced either by DCs following interaction with pRBCs or by the 
parasite itself.
PGE2 exerts its action by binding to four different types of G-protein-coupled receptors 
known as EPi, EP2, EP3 and EP4 (Narumiya et aL, 1999). Although mouse bone marrow- 
derived DCs express all four EP receptor subtypes, their production of cytokines and 
expression of MHC class II molecules were shown to be modulated through EP2- and 
EP4- dependent mechanisms (Harizi et aL, 2003). These data were proved by the use of 
EP2 and EP4 agonists, which significantly promoted the production of endogenous IL-10 
from bone marrow-derived DCs and decreased their expression of MHC class II 
molecules (Harizi et aL, 2003) As an EP4-selective antagonist was readily available, I 
decided to carry out a preliminary experiment to investigate whether PGE2-EP4 signalling 
was involved in the suppression of the LPS-induced maturation of pRBC-treated DCs.
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DCs were cultured with RBCs or pRBCs in the presence or absence of the EP4 antagonist 
for 24h and then stimulated with LPS in vitro. The expression of MHC class II and the 
co-stimulatory molecules CD40 and CD8 6  were examined 18h later by flow cytometry. 
The results showed that DCs cultured in growth medium in the presence or absence of the 
EP4 antagonist expressed low levels of surface MHC class II, CD40 and CD8 6 , 
confirming their immature state in culture (figure 6.1). When stimulated with LPS, DCs 
cultured alone or with RBCs upregulated the expression level of all of the costimulatory 
molecules tested regardless of the presence of the EP4 antagonist. As shown previously, 
DCs cultured with pRBCs had a significantly reduced ability to respond to LPS treatment 
in vitro. Furthermore, the presence of the EP4 antagonist in the culture did not rescue the 
ability of DCs to mature in response to LPS, suggesting that the PGE2-EP4 signalling 
pathway did not play a role in the modulation of DC function during incubation with 
pRBCs. Nevertheless, as mentioned above, PGE2 might exert its effects through other 
receptors thus the involvement of PGE2 in the observed inhibition of DC maturation 
cannot be ruled out yet and further experiments will be required to elucidate the role of 
PGE2 in the modulation of DC function during interaction with pRBCs.
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Figure 6.1 Effect of PGE2-EP4 signalling on the LPS-induced maturation of P. chabaudi 
AS- treated DCs in vitro. 2x10^ DCs were cultured with 2x10* P. chabaudi AS-infected 
erythrocytes (AS) or with non-infected erythrocytes (RBC) in the absence (vehicle) or 
presence of IfrM ONO-AE3-208 (EP4 antagonist) (Kabashima et al., 2003b). After 24h 
of co-culture, DCs were challenged with lp,g/ml of LPS for a further 18h. Control DCs 
remained unstimulated (DC) or treated with LPS alone (LPS). Surface expression of 
MHC class II (a), CD40 (b) and CD86 (c) on DCs was determined by flow cytometric 
analysis of gated CDllc^ cells. Results show the mean fluorescence intensity ± standard 
errors of triplicate cultures per group. * paO.05 significant difference between RBC and 
AS treated with the EP4 antagonist. p^0.05 significant difference between RBC and AS 
treated with vehicle only.
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6 .2 . 2  PPAR-y signalling is not necessary to induce suppression of LPS-induced activation 
of DCs in vitro.
Recent reports have shown that DCs express PPAR-y and that agonist-induced activation 
of PPARg can influence DC maturation (Gosset et aL, 2001). Furthermore Appel et aL 
(Appel et at., 2005) reported that TLR ligand-induced activation and migration of human 
monocyte-derived DCs, as well as their ability to initiate lymphocyte proliferation, was 
impaired upon PPAR-y activation. For these reasons I investigated the involvement of 
PPAR-y activation in the reduced ability of pRBC-treated DCs to mature in response to 
LPS challenge.
Experimental cultures were set up as described in 6.2.1 and a PPAR-y antagonist was 
used to block PPAR-y activation. DCs cultured in growth medium in the presence or 
absence of the PPAR-y antagonist expressed low levels of surface MHC class II, CD40 
and CD8 6  and when challenged with LPS, they upregulated the expression level of all of 
the costimulatory molecules tested. However DCs cultured with pRBCs were not able to 
respond to LPS treatment in vitro even when PPAR-y activation was blocked (figure 6.2). 
This result excludes the possibility that PPAR-y ligation is responsible for the observed 
suppression of DC function during incubation with pRBCs.
6.2.3 Nitric oxide is not necessary to induce suppression of LPS-induced activation of 
DCs in vitro.
Nitric oxide (NO) and other reactive nitrogen intermediates (RNI) have been reported to 
suppress T cell proliferative responses during many infections (Candolfl et aL, 1994; 
Gregory et al., 1993; O’Connor et aL, 2000; Sternberg and McGuigan, 1992) as well as 
being involved in the modulation of DC function. NO was shown to selectively 
downregulate the expression of the costimulatory molecule CD8 6  on monocyte-derived 
DCs in response to LPS or soluble CD40 ligand and led to a decreased eapacity of DCs to 
stimulate T cells in vitro (Corinti et aL, 2003). Furthermore, NO was reported to inhibit 
the release of IL-10 and IL-12p40 by mature DCs as well as the secretion of chemokines
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crucially involved in T cell reeruitment (IP-IO/CXCLIO and RANTES/CCL5) (Corinti et 
aL, 2003).
Here I examined the role of NO in the observed suppression of pRBC-treated DC 
function by blocking the action of NO synthase, the enzyme responsible for its generation 
(Korhonen et aL, 2005). Experimental cultures were set up as previously described in 
6.2.1. Cells were treated with L-NIL, a potent and selective inhibitor of NO synthase 
(figure 6.3). DCs cultured in growth medium alone or witli RBCs were able to upregulate 
the expression of MHC class II, CD40 and CD8 6  following LPS treatment regardless of 
the presence of L-NIL in culture. However, blocking NO synthase activity did not reverse 
the maturation defect observed in the pRBC-treated cultures as DCs did not upregulate 
the levels of the costimulatory molecules tested in response to LPS challenge. This 
finding suggests that NO does not play a significant role in the pRBC-induced 
suppression of DC maturation.
184
a. MHC II b. CD40
I 250200
40
30
O IL
r ii
□  Vehicle
■  PPAR-Y antagonist
J l
RBC AS DC LPS RBC AS
c. CD8 6
40 1
I 30 -
20
10
IP S RBC ASDC
Figure 6.2 Effect of PPAR-y on the LPS-induced maturation of P. chabaudi AS- treated 
DCs in vitro. 2x10^ DCs were cultured with 2x10* P. chabaudi AS-infected erythrocytes 
(AS) or with non-infected erythrocytes (RBC) in the absence (vehicle) or presence of 
lOfxM GW9662 (PPAR-y antagonist) (Hammad et ah, 2004). After 24h of co-culture, 
DCs were challenged with Ipg/ml of LPS for a further 18h. Control DCs remained 
unstimulated (DC) or treated with LPS alone (LPS). Surface expression of MHC class II 
(a), CD40 (b) and CD8 6  (c) on DCs was determined as described in figure 6.1. Results 
show the mean fluorescence intensity ± standard errors of triplicate cultures per group. * 
ps0.05 significant difference between RBC and AS treated with the PPAR-y antagonist. 
~ p^O.05 significant difference between RBC and AS treated with vehicle only.
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Figure 6.3 Effect of NO on the LPS-induced maturation of P. chabaudi AS- treated DCs 
in vitro. 2x10^ DCs were cultured with 2x10* P. chabaudi AS-infected erythrocytes (AS) 
or with non-infected erythrocytes (RBC) in the absence (vehicle) or presence of ImM L- 
NIL (L-NIL), a selective inhibitor of NO synthase (Moore et a l, 1994), After 24h of co­
culture, DCs were challenged with Ipg/ml of LPS for a further 18h. Control DCs 
remained unstimulated (DC) or treated with LPS alone (LPS). Surface expression of 
MHC class II (a), CD40 (b) and CD86 (c) on DCs was determined as described in Figure 
6.1. Results show the mean fluorescence intensity ± standard errors of triplicate cultures 
per group. * ps0.05 significant difference between RBC and AS treated with L-NIL. ~ 
p<:0.05 significant difference between RBC and AS treated with vehicle only.
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6.2.4 TGF"(3 is not necessary to induce suppression of LPS-induced activation of DCs in 
vitro.
TGF-p has been reported to regulate the maturation of differentiated DCs and DC- 
mediated T cell responses (Li et aL, 2005). The presence of TGF-P in LPS-stimulated DC 
cultures inhibited the expression of MHC class II and costimulatory molecules, which 
attenuated the antigen presenting function of DCs (Geissmann et al., 1999). In addition, 
DC maturation and IL-12 production induced by inflammatory cytokines such as IL-1 
and TNF-a were also shown to be inhibited by TGF-P (Geissmann et aL, 1999). It is 
therefore reasonable to assume that pathogens may induce host cells to secrete active 
TGF-P, which could potentially affect DC function and promote their survival. The 
significance of TGF-p activation for parasite survival has recently been demonstrated for 
malaria parasites (Omer et aL, 2003). Soluble components of P. falciparum, P. berghei 
and P. yoelii infected erythrocytes were shown to be directly able to activate both native 
(platelet-derived) and recombinant latent TGF-p (Omer et aL, 2003).
Due to the involvement of TGF-j3 in the modulation of DC function, I investigated its 
role in the observed suppression of the LPS-induced maturation of pRBC-treated DCs. 
Experimental cultures were set up as described in 6.2.1 and an anti-TGF-p antibody was 
used to block any suppressive effects that this cytokine may exert on DC function. The 
results clearly showed that the ability of pRBC-treated DCs to respond to LPS treatment 
in vitro was not rescued by blocking TGF-j3 production as the levels of MHC class II, 
CD40 and CD86 were significantly lower than control cultures (figure 6.4). This finding 
suggests that TGF-P does not play a significant role in the inability of pRBC-treated DCs 
to mature in response to LPS challenge in vitro.
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Figure 6.4 Effect of TGF-p on the LPS-induced maturation of P. chabaudi AS- treated 
DCs in vitro. 2x10^ DCs were cultured with 2x10* P. chabaudi AS-infected erythrocytes 
(AS) or with non-infected erythrocytes (RBC) in the presence of 5fxg/ml anti-TGF-p 
antibody (anti-TGF-p) or IgGl isotype control (Isotype). After 24h of co-culture, DCs 
were challenged with Ifxg/ml of LPS for a further 18h. Control DCs remained 
unstimulated (DC) or treated with LPS alone (LPS). Surface expression of MHC class II 
(a), CD40 (b) and CD86 (c) on DCs was determined as described in figure 6.1. Results 
show the mean fluorescence intensity ± standard errors of triplicate cultures per group. 
*p:s0.05 significant difference between RBC and AS treated with the anti-TGF-
P antibody. ~ p^O.05 significant difference between RBC and AS treated with the isotype 
control.
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6.2.5 Indoleamine 2,3-dioxygenase expression is not necessary to induce suppression of 
LPS-induced activation of DCs in vitro.
Recently there has been a growing interest in investigating an immunosuppressive 
mechanism, involving tryptophan catabolism by DCs that express the enzyme 
indoleamine 2,3-dioxygenase (IDO). It has been reported that one mechanism by which 
IDO exerts its immunosuppressive effects is by altering the biology of the IDO- 
expressing APCs (Hwu et aL, 2000; Munn et aL, 1999). This notion prompted me to 
investigate the role of IDO in the inhibition of DC function observed following treatment 
with pRBCs. A pharmacological inhibitor of IDO (1-MT) (Cady and Sono, 1991) was 
used to inhibit IDO activity in vitro. DCs were cultured with RBCs or pRBCs in the 
presence or absence of 1-MT for 24h and then stimulated with LPS in vitro. The 
expression of MHC class II and co-stimulatory molecules CD40 and CD86 were 
examined 18h later by flow cytometry (figure 6.5). As previously shown, DCs cultured 
with pRBCs were not able to respond to LPS treatment in vitro as the levels of MHC 
class II, CD40 and CD86 were significantly lower than control cultures. Furthermore, the 
presence of 1-MT in the culture did not reverse the maturation defect observed following 
LPS stimulation, suggesting that IDO expression in DCs did not play a significant role in 
the inhibition of DC activation following incubation with pRBCs.
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Figure 6.5 Effect of indoleamine 2,3-dioxygenase on the LPS-induced maturation of P. 
chabaudi AS- treated DCs in vitro. 2x10^ DCs were cultured with 2x10* P. chabaudi AS- 
infected erythrocytes (AS) or with non-infected erythrocytes (RBC) in the absence 
(vehicle) or presence of 2nM 1-MT (IMT) (Cady and Sono, 1991), After 24h of co- 
culture, DCs were challenged with 1 p,g/ml of LPS for a further 18h. Control DCs 
remained unstimulated (DC) or treated with LPS alone (LPS). Surface expression of 
MHC class II (a), CD40 (b) and CD86 (c) on DCs was determined as described in figure 
6.1, Results show the mean fluorescence intensity ± standard errors of triplicate cultures 
per group. *p^0.05 significant difference between RBC and AS treated with 1-MT. 
p:^0.05 significant difference between RBC and AS treated with vehicle only.
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6.3 Discussion
In previous chapters I have demonstrated that P, chabaudi AS-treated DCs had limited 
ability to mature in response to LPS treatment in vitro (chapter 3) and could not induce an 
appropriate T cell response, leading to the development of an anergic rather than an 
effector T cell phenotype (chapter 4). Subsequent studies revealed that haemozoin played 
an important role in the observed modulation of DC biology (chapter 5). However 
transwell experiments opened up the possibility that soluble factors, either secreted by the 
parasites or the DCs themselves, might be involved in altering DC function thus exerting 
cumulative effects on the observed suppression of DC function (chapter 5). In fact, due to 
the long co-existence of the malaria parasite with its host, it is very likely that the parasite 
has developed a number of mechanisms whereby it manipulates the host’s immune 
response to enhance its chances of survival.
In this chapter I investigated whether selected immunoregulatory molecules were 
involved in the observed suppression of the LPS-induced maturation of pRBC-treated 
DCs. I focused on the possible effects that PGE2 (Harizi and Gualde, 2004) NO (Bogdan, 
2001; Brunet, 2001) and TGF-P (Geissmann et ah, 1999) might have on DCs due to their 
well-known involvement in immune regulation in many different infections. I also 
investigated the role of PPAR-y (Appel et a/., 2005; Gosset et aL, 2001) and IDO 
expression (Hwu et aL, 2000; Munn et aL, 1999) on the observed suppression of DC 
function due to their reported roles in immune modulation.
As extensively discussed in section 1.2.8.1, prostaglandins are well known 
immunoregulatory molecules (Harizi and Gualde, 2004). DCs have been reported to 
produce prostaglandins, especially PGE2, which can act in an autocrine manner and 
suppress some key functions of the secreting cell itself or in a paracrine manner and 
modulate the biology of cells present in the local environment (Harris et al., 2002). P. 
falciparum  was shown to produce prostaglandins, both endogenously and exogenously 
(Kilunga Kubata et a l, 1998). Prostaglandin production was shown to be highest in the 
trophozoite and schizont stages in the parasite life cycle (Kilunga Kubata et aL, 1998).
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This observation raised the possibility that parasite-derived prostaglandins might play a 
role in the modulation of the host defence mechanism against malaria infection. For 
instance, an increased level of TNF-a during malaria infection was reported to suppress 
parasite growth in vivo (Clark et al., 1987; Taverne et al., 1994). Lowering the host TNF- 
a  production by parasite-produced PGE2 would therefore be beneficial to the parasite, 
since PGE2 regulates the levels of TNF-a (Kunkel et aL, 1988; Renz et aL, 1988). It is 
therefore reasonable to assume that parasites may suppress immune responses directed 
against them either by producing prostaglandins themselves or by inducing DCs to 
secrete these lipid mediators, which will in turn suppress their function. For these 
reasons, I investigated whether PGE2 was responsible for the reduced ability of pRBC- 
treated DCs to mature in response to LPS-treatment in vitro. Since PGE2 was shown to 
modulate DC function via the EP# receptor subtype (Harizi et aL, 2003) and having an 
EP# antagonist readily available in the laboratory, I decided to examine whether the 
observed suppression of DC function was partly mediated by the action of PGE2 through 
interaction with the EP# receptor. In this context, the results showed that PGE2-EP# 
signalling did not play a significant role in suppressing the LPS-induced activation of 
DCs following incubation with pRBCs. Nevertheless, the involvement of PGE2 in 
parasite-induced suppression of DC function cannot yet be ruled out. In fact, DCs can 
produce other prostanoids including thromboxanes A2 (TXA2) and PGD2, which have 
been reported to modulate the adaptive immune response through their action on DCs. 
For instance, PGD2 was reported to affect the migratory properties of Langerhans cells 
(Angeli et aL, 2001) and the maturation of human DCs (Gosset et aL, 2003), as well as 
suppressing the CD40- and LPS-induced IL-12 secretion by murine splenic DCs 
(Faveeuw et aL, 2003). Moreover, PGEa-induced inhibition of DC function was also 
reported to be mediated by interaction with the EP2 receptor (Harizi et aL, 2003).
A recent study reported the induction of IDO expression in DCs following interaction of 
PGE2 with the EP2 receptor subtype (Braun et aL, 2005). IDO-expressing DCs were 
shown to suppress T cell proliferative response in vitro (Terness et aL, 2002) and were 
tolerogenic when injected in vivo (Grohmann et aL, 2000). Using a pharmacological 
inhibitor of IDO (1-MT), I investigated whether IDO expression could mediate the
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suppression of LPS-induced activation observed in pRBC-treated DCs. The results 
demonstrated that the maturation defect could not be rescued following treatment of DCs 
with 1-MT, excluding the involvement of IDO in the parasite-induced modulation of DC 
function observed in the present study.
Like PGE2, NO can exert its effects in an autocrine or paracrine fashion on neighbouring 
cells (Korhonen et al., 2005). Both exogenous and endogenous NO have been reported to 
suppress the antigen presenting function of DCs by selectively downregulating the 
expression of costimulatory molecules in response to LPS or soluble CD40L in vitro as 
well as inhibiting the release of IL-10 and IL-12p40 by mature DCs (Corinti et al., 2003). 
Therefore parasites may potentially induce the production of NO by DCs to subvert 
immune responses directed against them. Using a selective inhibitor of NO synthase 
activity, I tested whether NO played a role in the inability of pRBC-treated DCs to 
mature in response to LPS challenge. Blocking NO synthase activity did not reverse the 
maturation defect thus excluding the possibility that NO might be directly involved in the 
modulation of DC function in the culture system used.
TGF-p is a potent regulatory cytokine produced by a wide variety of cells including DCs 
(Li et aL, 2005) and it has been reported to affect DC function. For instance, the presence 
of TGF”j3 in LPS-stimulated DC cultures was shown to inhibit the expression of MHC 
class II and costimulatory molecules, which attenuated the antigen presenting function of 
DCs (Geissmann et aL, 1999). In addition, TGF-P was also reported to be responsible for 
the suppression of DC maturation and IL-12 production induced by inflammatory 
cytokines such as IL-1 and TNF-a (Geissmann et aL, 1999). As previously discussed in 
section 1.2,8.5, there is evidence that many pathogens have evolved mechanisms to 
induce host cells to secrete active TGF-p, which in turn suppresses APC function, 
enhancing pathogen survival. In particular, soluble components of P. falciparum, P. 
berghei and P. yoelii infected erythrocytes were shown to be directly able to activate both 
native (platelet-derived) and recombinant latent TGF-P (Omer et aL, 2003). However, in 
the present study TGF-p did not seem to be an important factor involved in the 
suppression of DC maturation observed following pRBC treatment, as the addition of a
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TGF-p-neutralising antibody in the culture did not rescue the LPS-induced maturation of 
pRBC-treated DCs.
The involvement of PPAR-y in the modulation of DC function has been previously 
discussed in section 1.2.8.2. Activation of PPAR-y has been shown to inhibit the 
maturation of both murine (Faveeuw et at., 2000) and human monocyte-derived DCs 
(Gosset et al., 2001) A more recent report showed that TLR ligand-induced activation 
and migration of human monocyte-derived DCs, as well as their ability to initiate 
lymphocyte proliferation, was impaired upon PPAR-y activation (Appel et al., 2005). 
Activation of PPAR-y resulted in down-regulation of costimulatory and adhesion 
molecules by DCs and reduced secretion of cytokines and chemokines involved in T 
lymphocyte activation and recruitment (Appel et al., 2005).
The involvement of PPAR-y activation during malaria infection has also been reported. 
PPAR-y was found to enhance the phagocytosis of P. falciparum infected erythrocytes by 
macrophages by upregulating the expression of CD36 (Serghides and Kain, 2001). 
However, it was shown that P. falciparum infected erythrocytes inhibited DC maturation 
in vitro through the binding of CD36 to a parasite-derived molecule (PfEMPl) on the 
infected erythrocyte surface (Urban et aL, 1999; Urban et aL, 2001b). Therefore what 
seems to be initially a protective mechanism induced by PPAR-y activation could 
actually enhance parasite survival within the host by altering DC activation states. 
Another study carried out by Paolo Arese and colleagues showed that the parasite 
pigment haemozoin inhibited the maturation of human monocyte-derived DCs via PPAR- 
y activation (Skorokhod et aL, 2004). Haemozoin was also found to be responsible for the 
suppression of DC function in the present study, as discussed in chapter 5. However, 
PPAR-y did not seem to mediate this suppression as the use of a PPAR-y antagonist did 
not rescue the ability of pRBC-treated DCs to respond to LPS treatment in vitro.
The results presented in this chapter clearly rule out the participation of some of the most 
common immunoregulatory molecules studied in the suppression of pRBC-treated DC 
function, although the role of PGEi requires further investigation due to its reported
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ability to module DC function via interaction with the EP2 receptor subtype. Additional 
studies are therefore necessary to gain a better understanding of the mechanisms by 
which the malaria parasite exerts its immunosuppressive effects on DC function. The 
events leading to DC hyporesponsiveness following interaction of DCs with infected 
erythrocytes are undoubtedly complicated given the antigenic and developmental 
complexity of the malaria parasite and the long co-evolution with its host. Improving the 
knowledge of these events could have important implications for vaccine design and 
immunotherapy and might aid in the development of effective DC-based vaccines. Since 
none of the molecules tested in this chapter had an effect on DC function, gene 
expression analysis seemed to be an alternative way to gain an overall idea of the 
molecular events involved during DC-pRBC interaction.
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7, Gene expression analysis of P. chabaudi AS-treated DCs
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7.1 Introduction
Gene array technology is a powerful method that provides researchers with the 
opportunity to analyse the expression patterns of thousands of genes simultaneously in a 
short period of time (Schena et ah, 1995). In a clinical context, identification of 
differentially expressed genes may lead to improved diagnosis and treatment guidance, 
early disease detection and clinical outcomes prediction. Moreover, relating specific 
groups of genes with specific biological states is a critical step toward understanding the 
underlying molecular mechanisms characterising a specific disease and will therefore aid 
in the identification of novel therapeutic targets (Troyanskaya et aL, 2002).
Spotted long cDNA microarray and in situ synthesis oligonucleotide arrays (Affymetrix) 
are currently the most widely used array systems (Li et aL, 2002). The basic concept 
behind the use of DNA arrays for gene expression is quite simple: labeled cDNA ‘targets’ 
(derived firom the mRNA of an experimental sample) are hybridized to nucleic acid 
probes attached to the solid support. Multiple samples of interest are labeled either with 
different dyes and hybridized simultaneously against a single array (spotted cDNA array) 
or with the same dye and hybridized separately against multiple arrays {in situ 
oligonucleotide arrays) (Huber et aL, 2002). In each case, the relative abundance of a 
gene transcript in these samples is determined by comparing the corresponding 
fluorescence intensities (Brown and Botstein, 1999) (Diagram 7.1).
The existence of different types of arrays for measuring gene expression makes 
consistency and reproducibility across technology important issues. Being able to use 
data interchangeably across techniques would be very beneficial, as this would 
potentially reduce the need to duplicate experiments. Unfortunately, at the present time, 
there are issues in both technologies that should be resolved before it is possible to 
transform measurements from either technology to a general index of gene expression 
(Kuo et aL, 2002; Li et aL, 2002).
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Diagram 7.1 Principle of microarray technology. mRNA is isolated from samples of 
interest and converted into labelled cDNA, which is then hybridized to the array. The 
DNA sequences spotted on the array are referred to as ‘probes’, whereas the nucleic acid 
samples hybridized onto the array (whose identity/abundance is being detected) are 
generally referred to as ‘targets. When using a spotted-DNA array, labeled targets are 
mixed and hybridized simultaneously on a single array. If oligonucleotide arrays are 
used, targets are hybridized onto separate arrays. The Affymetrix oligonucleotide array 
uses ‘probe-pair sets’ consisting of a collection of ‘probe pairs’ (16-20) related to a 
common gene or fraction of a gene. Probe pairs are short fixed-length probes consisting 
of a Perfect Match (PM, a 25 base-pairs oligonucleotide complementary to a sequence of 
interest) and a Mismatch probes (MM, same as PM but with a single base change at 
position 13, in order to achieve more homogeneous hybridization conditions. Regardless
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of the type of array used, the relative abundance of a gene transcript is determined by 
comparing the corresponding fluorescence intensities. In the spotted two-colour DNA 
array, the ratio of the red and green fluorescence intensities for each spot is indicative of 
the relative abundance of the corresponding DNA probe in the two nucleic acid target 
samples (green, gene is over-expressed in green-labeled sample compared to red-labeled 
sample; red, gene is over-expressed in red-labeled sample compared to green-labeled 
sample; yellow, gene is equally expressed in both samples). In the case of oligonucleotide 
arrays, the expression measures are generally based on differences of PM-MM, with the 
intention to correct for background and non-specific binding.
7.1.1 Spotted cDNA versus Oligonucleotide (Affymetrix) arrays
Sensitivity and specificity are the two major features that researchers are concerned with 
in performing microarray analysis. The length of the DNA employed as the probe 
sequence on the arrays is a key factor in determining the specificity and sensitivity of the 
two commercial arrays mentioned above (Li et al., 2002). In spotted cDNA arrays, the 
sequence of probes can vary from 500 to 5000 base pairs. One of the problems associated 
with having such large sequences is that it becomes difficult to control the hybridization 
efficiency of various cDNA probes. Hybridization conditions are based on the length and 
composition of nucleic acid fragments (Southern et al., 1999), As A-T pairs are known to 
be less stable than G-C pairs (Southern et al., 1999), probes with higher G-C content tend 
to have increased hybridization stability due to the higher proportion of stable base pairs 
(Herwig et ah, 2000).
The issue of non-specific hybridization is also an important limitation of the cDNA-based 
arrays (Kuo et a l,  2002; Li et a l ,  2002). In addition to probe length affecting 
hybridization efficiency, probe sequences with sequence homology to other probes may 
further impinge on this issue (Schadt et a l, 2000). Different genes may in fact encode 
common domains and may have some degree of sequence identity with proteins from 
other genes (Evertsz et a l, 2001; Kane et a l, 2000). As a result, gene families pose a 
potential problem because in many cases these genes have a great degree of sequence
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identity and can only be distinguished from each other by the design and use of gene- 
specific hybridization probes (Li et a l, 2002). Spotting more specific cDNA probes of 
the unique regions from a set of genes and reducing the length of the probe sequences 
could reduce some of the limitations, which might be encountered when using cDNA 
arrays (Kuo et a l, 2002).
In order to accomplish high sensitivity and specificity, Affymetrix introduced a system 
that involves the use of a series of specific and non-specific gene probe sets that are 
intended to result in a more accurate discrimination between true signal and random 
hybridization. Each gene or portion of a gene in the Affymetrix system is represented by 
16-20 oligonucleotides of 25 base-pairs (KothapalU et al, 2002). The fixed-length probes 
are designed to be perfectly complementary to a target sequence, minimizing cross- 
hybridization with highly homologous genes (Kuo et a l, 2002; Li et a l, 2002). A partner 
probe that is identical except for a single base mismatch in its center, which theoretically 
provides maximal disruption of hybridization (KothapalU et a l, 2002), is generated for 
each probe (see 4a in Figure 1). The difference in hybridization signals between the 
partners, as well as their intensity ratios, serves as indicators of specific target abundance. 
These probe pairs, called the Perfect Match probe (PM) and the Mismatch probe (MM), 
are intended to give more homogeneous hybridization conditions in order to increase the 
specificity and sensitivity of the assay (Li et a l, 2002). Unfortunately, the use of the 
mismatch probe information can sometimes interfere with fold change calculations of 
gene expression. For instance, the strong signal associated with some of the MM probes 
can interfere with the detection of some genes present in the samples (KothapalU et a l,
2002), (Table 7.1 summarises the main differences between the two microarrays 
described).
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Spotted arrays Affymetrix arrays
One probe per gene 16-20 probe-pairs per gene
Probes of varying lengths Probes are 25 base-pair long
Large probe sequences reduce 
hybridization efficiency and 
maximize cross-hybridization 
with homologous genes
Fixed-length probes improve 
hybridization efficiency and 
minimize cross-hybridization 
with homologous genes
Problem: Sometimes strong 
signals associated with MM 
probe can interfere with 
detection of some genes
Two target samples per array One target sample per array
Table 7.1 Spotted cDNA versus Affymetrix oligonucleotide arrays: Summary of 
differences and limitations.
Despite potential disadvantages associated with the MM probes, the Affymetrix 
oligonucleotide arrays seem to give a more accurate and comprehensive scenario of gene- 
expression profiles, which in turn ensures with a high probability that further research 
work will proceed down the correct path (Kuo et aL, 2002; Li et al., 2002). For these 
reasons, the Affymetrix arrays were used in the present study to analyse the gene 
expression profile of DCs following treatment with P. chabaudi AS infected erythrocytes 
or uninfected controls, to gain an overall idea of the molecular events involved during 
DC-pRBC interaction. Although gene array technologies allow the simultaneous 
measurement of the expression level of thousands of genes in a cell population, these 
experiments may lead to a high level of ‘noise’ in the resulting data. This latter problem 
may be worsened if a number of variables are introduced in the experimental design, 
therefore particular care must be taken when planning array experiments. To keep the 
level of noise in the resulting data to a minimum, bone marrow-derived DCs were used in 
the experiments described in this chapter, rather than DCs purified from infected animals. 
This approach allowed the investigation of changes in DC gene expression, which are
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solely due to parasite interaction with the DCs, without being influenced by various other 
factors, such as the presence of cytokines and other cells in the environment. The present 
work was therefore designed with the view of gaining a deeper insight of the parasite- 
induced changes in DCs and provides a way to select specific gene products, which may 
potentially play an important role in the observed suppression of DC function, thus 
providing the basis for future investigation.
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7.2 Results
Previous experiments have shown inhibition of the LPS-induced maturation of DCs 
beginning to occur by 6 h of incubation with pRBCs (chapter 5). Therefore gene 
expression in these DCs must be either up- or down regulated by this time. Although 
suppression of DC function was most marked after 24h, I was concerned that changes in 
gene expression may have come and gone by this point. I therefore extracted RNA for 
microarray analysis from DCs, which have been incubated with pRBCs for 6 h. To ensure 
that these DCs were functionally impaired, a set of cells was stimulated with LPS for a 
further 18h and the expression of MHC class II and costimulatory molecules CD40 and 
CDS6  analysed by flow cytometry (Figure 7.1). The results show that CD40 and CD8 6  
expression was significantly reduced in pRBC-treated DCs compared to RBC controls. 
Instead, MHC class II expression was not affected at this time point. This finding is 
consistent with previous results shown in chapter 5, indicating that after 6 h incubation 
with pRBCs, DCs begin to show signs of a functional defect.
Details on cell preparations and RNA extraction were described in chapter 2. The Sir 
Henry Wellcome Functional Genomics Facility at the University of Glasgow performed 
the microarray experiment and data analysis. Results shown in Table 7.2 and 7.3 were 
selected based on their potential involvement in the modulation of DC function and were 
obtained by using the Rank Product (RP) method, where data are expressed as rank lists 
(Breitling et al,, 2004b). Results shown in Table 7.4 and 7.5 were instead obtained by 
using the iterative Group Analysis (iGA) approach, which identifies functional classes of 
gene that are significantly changed (Breitling et al., 2004a). The basic principles of the 
above methods were described in chapter 2 .
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Figure 7.1 Surface expression of MHC class II (a), CD40 (b) and CD8 6  (c) on bone 
marrow-derived DCs following LPS stimulation in vitro. DCs were cultured for 6 h with 
non-infected (RBC) or P. chabaudi AS infected erythrocytes (AS) and then treated 
withlfxg/ml of LPS for a further 18h. Results were obtained by flow cytometric analysis 
of gated CDl Ic^ cells and are shown as the mean fluorescence intensity ± standard errors 
of triplicate cultures per group. * p^O.05 significant difference between AS and RBC.
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Table 7.2 Upregulated genes expressed by DCs treated with P. chabaudi AS-infected 
erythrocytes for 6 h. Results shown were obtained using the Rank Products approach (RP) 
(Breitling et al., 2004b).
R P T i t l e R a n k
4 . 5 8 COX-2 4
2 3 . 0 5 Thrombospondin-1 1 7
2 5 7 . 9 9 12-Lipoxygenase 1 5 3
2 6 6 . 7 9 Haeme Oxygenase-1 1 5 7
3 2 1 . 6 6 Clusterin 1 8 2
Table 7.3 Downregulated genes expressed by DCs treated with P. chabaudi AS-infected 
erythrocytes for 6 h. Results shown were obtained using the Rank Products approach (RP) 
(Breitling et al., 2004b).
R P T i t l e R a n k
6 7 . 9 0 CD47 3 9
2 8 0 . 8 1 BNIP3 1 4 3
3 3 0 . 2 4 COX-1 1 7 3
5 0 0 . 6 6 Bcl-2-like protein 1 1 2 6 1
5 5 7 . 6 1 Tyrosine-3 Mono-oxygenase 2 8 0
5 6 3 . 9 2 Cytochrome c 2 8 6
7 1 0 . 1 7 Fis 1 3 5 2
8 1 6 . 9 0 Hipk2 4 0 4
1 0 6 5 . 9 5 Caspase 3 5 0 0
1 3 9 5 . 5 7 Tripartite motif protein 27 6 6 5
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7. 3 Discussion
The use of a whole mouse genome expression array allowed the investigation of over 
39,000 genes, 587 of which were found to be upregulated and 723 downregulated in bone 
marrow-derived DCs following treatment with pRBCs. Due to time constraints, a detailed 
analysis of this data was not possible. I therefore selected to discuss some genes, which 
encode molecules that may potentially affect DC function and are therefore worth further 
investigation.
7.3.1 Molecules involved in the modulation of DC functions
7.3.1.1 Eicosanoids
The cyclooxygenases, COX-1 and COX-2, are enzymes involved in thromboxane and 
prostaglandin synthesis (Harizi and Gualde, 2004). Particularly, COX-2 is an inducible 
gene that generates high levels of prostaglandins during inflammation, whereas COX-1 is 
constitutively expressed in most tissues and generates prostaglandins for physiological 
homeostasis (Seibert and Masferrer, 1994). In the present study, COX-2 gene expression 
was found to be the 4^*^ most upregulated gene in pRBC-treated DCs (Table 7:2), whereas 
COX-1 was downregulated (Table 7.3). This observation is particularly interesting in the 
current study, as PGE2 is known to affect the maturation, cytokine production, Th cell 
polarising ability and migration of DCs (Harizi et a l, 2003; Harizi et a l, 2001; Harizi et 
a l, 2002). Although PGE2 has been shown to exert its action by binding to four different 
types of G-protein-coupled receptors, EPi, EP2, EP3 and EP4 (Narumiya et a l, 1999), EP2 
and EP4 have been reported to play a central role in the modulation of DC functions by 
PGE2 (Harizi et a l, 2003; Meja et aî., 1997). The involvement of PGE2 in the observed 
suppression of DC function has been previously investigated by carrying out a 
preliminary experiment using an EP4-selective antagonist (chapter 6 ). The results shown 
in chapter 6  suggested that the PGE2-EP4  signalling pathway did not play a role in the 
modulation of DC function, as treatment of DCs with the EP4 antagonist did not rescue 
the ability of DCs to mature in response to LPS stimulation in vitro. However, since
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PGEz also exerts its effects through the EP2 receptor, the involvement of this molecule, as 
well as other prostaglandins, in the observed suppression of pRBC-treated DCs cannot be 
excluded yet. Furthermore, prostaglandins might act directly on T cells to inhibit their 
proliferation. In fact it has been reported that PGE2-EP4 signalling in T cells potently 
suppresses their activation and proliferation (Narumiya, 2003), providing a possible 
mechanism used by the parasite to induce inappropriate T cell responses, as previously 
described in chapter 4. Thus, the observation that COX-2 gene expression is upregulated 
in pRBC-treated DCs further reinforces the possibility that prostaglandins might play a 
significant role in the observed suppression of DC function.
Formation of prostaglandins is determined by the relative expression of pro-inflammatory 
cytokines, which increase COX-2 gene expression and anti-inflammatory cytokines, 
which instead decrease COX-2 expression (Harris et al., 2002). There is also evidence 
that prostaglandins regulate chemokine receptor expression and migration of DCs. In the 
presence of IL -la  and TNF-a, PGE2 has been reported to upregulate the expression of 
CCR7 and enhance DC migration in response to CCL19 or CCL21 (Harizi et ah, 2002). 
Therefore, the observed upregulation of the genes encoding the pro-inflammatory 
cytokines IL-la/p  and TNF-a (Table 7.4) is consistent with the upregulation of COX-2, 
which in turn concurs with the increased expression of many chemokine ligands found in 
pRBC-treated DCs (Table 7.4).
Gene expression of 12-lipoxygenase, an enzyme that catalyses the production of pro- 
inflammatory leukotrienes from arachidonic acid (Harizi and Gualde, 2004), was also 
found to be increased in pRBC-treated DCs (Table 7.2). The relevance of this enzyme in 
the progression of many human diseases such as cancer, atherosclerosis and rheumatoid 
arthritis, has been demonstrated in the past (Yoshimoto and Takahashi, 2002). In a 
murine model of helminth infection, 12/15-lipoxygenase was found to be responsible for 
the suppressive activity of myeloid cells by generating lipid mediators, which triggered 
PPAR-y activation (Brys et ah, 2005). Although the involvement of PPAR-y activation in 
the suppression of pRBC-treated DC function has been previously excluded in the current 
study (chapter 6), 12-lipoxygenase might exert its suppressive effects on DCs by using a
212
mechanism other than PPAR-y activation. In this regard, it has been shown that lipoxin 
production, which is catalysed by lipoxygenase, selectively affected chemokine receptor 
signalling in murine DCs during T. gondii infection, resulting in defective DC migration 
and decreased IL-12 responses (Aliberti et ah, 2002).
Therefore, the observed upregulation of COX-2 and lipoxygenase gene expression in 
pRBC-treated DCs suggest a possible role of these gene products in the modulation of 
DC function, providing the basis for further investigation.
7.3.1.2 Thrombospondin-1
Thrombospondin-1 (TSF-1) was found to be the 17‘^  most upregulated gene in pRBC- 
treated DCs (Table 7.2). TSP-1 is an extracellular matrix glycoprotein, which was first 
discovered as a stored protein of «-granules that was released upon platelet activation. 
The first studies of its function therefore focused on its roles in platelet aggregation and 
fibrin clot formation and also its effects on the endothelial and smooth muscle cells of 
blood vessel walls (Tucker, 2004). These studies identified a multiplicity of functions 
including effects on cell attachment, motility, proliferation, cell-cell contact and cell 
aggregation (Tucker, 2004).
DCs have been shown to be an abundant source of TSP-1, both in the steady state and 
during activation by danger signals (Doyen et al., 2003). More importantly, endogenous 
TSP-1 has been reported to actively render DCs refractory to subsequent stimulation thus 
contributing to the arrest of the inflammatory response (Doyen et al., 2003). This notion 
is particularly interesting in the present study, as it was previously shown that pRBCs 
inhibit the ability of DCs to mature in response to LPS treatment in vitro as observed by 
the reduced levels of MHC Class II expression on DCs as well as costimulatory 
molecules CD40 and CD86 (chapter 3).
In view of the results obtained following gene array analysis, it seems reasonable that 
pRBCs might stimulate DCs to release TSP-1, which will in turn act on the secreting DC
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itself as well as bystander cells. Indeed further experiments will be required to confirm 
this hypothesis and understand the mechanism by which TSP-1 exerts its 
immunosuppressive effects on DCs. In this regard, it has been reported that ligation of 
TSP-1 with CD47 and CD36 inhibited cytokine production and maturation of DCs in 
response to bacterial stimulation (Armant et a l, 1999; Demeure et a l, 2000; Doyen et a l,
2003). TSP/CD47 and TSP/CD36 ligation was found to prevent the upregulation of 
costimulatory molecules, the loss of endocytic activity and the acquisition of an increased 
capacity to stimulate T cell proliferation and IFN-y production (Demeure et a l, 2000). 
These findings were also consistent with a report indicating that anti-CD36 monoclonal 
antibody delivered a negative signal to DCs, resulting in decrease of IL-12 production 
and phenotypic maturation (Urban et a l,  2001b). Moreover, TSP-1 has been shown to 
inhibit the expression of the early T cell activation marker CD69 through ligation of 
CD47, which is also a costimulatory receptor on T cells (Li et a l, 2001).
The ability of pRBC-treated DCs to prime naïve T cells in vitro has been analysed in 
chapter 4 where it was found that the expression of CD69 on T cells was not significantly 
affected by pRBCs. This finding therefore suggests that TSP-1 might not be involved in 
the modulation of T cell responses in the context of blood stage malaria infections. 
However, despite the observed upregulation of CD69, pRBCs were found to significantly 
affect the ability of DCs to induce efficient T cell responses, leading to the development 
of an anergic rather than an effector T cell phenotype. Interestingly, in a different report 
TSP-1 was shown to promote the induction of anergy in naïve T cell (Avice et a l, 2001), 
leaving open the possibility that this molecule might play an important role in the 
suppression of DC function and subsequent induction of inappropriate T cell responses 
during blood stage malaria infection.
7.3.1.3 Haeme Oxygenase-1
Haeme oxygenase-1 (HO-1) is an intracellular enzyme that degrades haeme and inhibits 
immune responses and inflammation in vivo (Kikuchi et a l, 2005). In the present study, 
HO-1 was found to be upregulated in DCs treated with pRBCs (Table 7.2). The
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upregulation of HO-1 gene expression seemed particularly interesting, as this molecule 
has recently been reported to block DC maturation and to inhibit pro-inflammatory 
immune responses (Chauveau et a l, 2005). Chauveau et a l presented evidence that 
induction of HO-1 expression in DCs interfered with the LPS-induced maturation process 
in vitro, resulting in the downregulation of the phenotypic maturation markers, as well as 
modulation of cytokine production critical for DC maturation and for efficient effector T 
cell responses (Chauveau et a l,  2005). In the present study these changes were 
consistently found in DCs following interaction with pRBCs, suggesting a possible role 
of HO-1 in the modulation of DC function during blood stage malaria. Furthermore, since 
HO-1 has been shown to degrade haeme to free divalent iron and carbon monoxide (CO) 
(Otterbein and Choi, 2000), it is possible that the inhibition of T cell proliferation and 
cytokine production previously observed in chapter 4 might be due to CO formation, as 
CO has recently been reported to inhibit lymphocyte proliferation (Song et al., 2004). 
Therefore HO-1 is not only a marker for immature DCs; instead it appears to have the 
potential to affect DC functions by inhibiting T cell responses and inducing T cell anergy.
The induction of HO-1 in DCs following pRBC interaction may result as a mechanism to 
degrade the haeme present in native haemozoin (HZ), which was shown to consist of a 
core of polymerised haeme derived from host haemoglobin (Arese and Schwarzer, 1997). 
Several studies, conducted both in vivo and in vitro have shown that phagocytes are 
unable to digest HZ and alteration of certain important functions of the phagocytes may 
be related to persistence of undigested HZ in these cells (Schwarzer et ah, 1998; 
Schwarzer and Arese, 1996; Schwarzer et al., 1993; Schwarzer et a l, 1992). Consistent 
with the above reports, this study also showed that HZ suppressed the LPS-induced 
maturation of DCs in vitro (chapter 5). Therefore, it is reasonable to assume that HZ 
might activate HO-1 due to the presence of haeme in its structure, leading to DC 
suppression. However, Schwarzer and colleagues demonstrated in an early study that HZ 
blocked the induction of HO-1 in human monocytes. However HZ did not result in a 
generalised impairment of the mechanism of HO-1 activity as, HZ-laden cells were still 
able to induce HO-1 activity when challenged with free haeme (Schwarzer et a l, 1999) 
Furthermore, alkali-solubilised HZ was shown to be an efficient inducer of HO-1 when
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added to monocytes or monocyte-fed HZ, strongly suggesting that the haeme component 
of HZ is potentially capable of acting as an inducer of HO-1, but needs to be converted to 
soluble free haeme in order to show these properties (Schwarzer et a l, 1999). Therefore, 
the lack of HO-1 induction seems to be mainly due to the structural characteristic of HZ.
The above observations appear to contrast with the observed upregulation of HO-1 gene 
expression in the present study. However, besides being induced by haeme itself, in most 
cell types, HO-1 is inducible by inflammatory stimuli and oxidative stress (Kikuchi et aL, 
2005). In fact IL-1, IL-6 and TNF-a were all shown to cause a marked induction of HO-1 
mRNA in mouse liver (Rizzardini et aL, 1993). In this regard genes associated with the 
inflammatory response pathway were found to be upregulated in the present study, a 
result consistent with the upregulation of HO-1. Therefore HO-1 may play an important 
role in the suppression of DC function in the context of blood-stage malaria infection. 
Indeed, induction of HO-1 in tissue macrophages and monocytes has been reported in 
fatal P. falciparum malaria (Clark et aL, 2003). Nevertheless, whether pRBCs actually 
modulate DC function by inducing HO-1 activity remains to be determined and should 
therefore be the focus of future studies.
7.3.2 Molecules Involved in the control of DC apoptosis
7.3.2.1 CD47
CD47 is a cell-surface molecule expressed on nearly all haematopoietic cells (Brown and 
Frazier, 2001) and has been shown to be involved in DC apoptosis (Johansson et aL, 
2004) as well as inducing cell death in many other different cell types including B cells 
(Mateo et ah, 1999), activated T cells (Pettersen et al., 1999) and endothelial cells 
(Freyberg et al., 2000). In the present study, CD47 gene expression was found to be 
downregulated in pRBC-treated DCs (Table 7.3). This observation is consistent with 
previous finding shown in chapter 3 where pRBCs were found not to induce apoptosis 
DCs in vitro.
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As mentioned earlier, it has been reported that CD47 also played a significant role in 
modulating DC function through interaction with TSP-1 (Armant et al., 1999; Demeure 
et a l, 2000; Doyen et al., 2003). The downregulation of CD47 gene expression would 
therefore suggest that, if TSP-1 truly mediated the observed suppression of DC function, 
it might use a mechanism other than CD47 ligation. Alternatively, it is possible that 
upregulation of CD47 gene expression might occur at an earlier/later time, as gene 
expression analysis was only carried out after a 6h incubation period of DCs with pRBCs. 
However, at the present time, the importance of TSP-1 and CD47 in the modulation of 
DC function in the context of blood-stage malaria infections can only be speculated upon 
and should be the focus for future studies.
7.3.2.2 Bel-2 proteins
The Bcl-2 family of proteins includes the best-characterised regulators of apoptosis (Li et 
al., 2004a). Proteins of this family directly regulate the release of mitochondrial 
apoptogenic factors (Li et a l, 2004a). Many of the pro-apoptotic family members, such 
as Bax, Bid, Bim and Bmf, are localised in the cytoplasm. Apoptotic stimulation results 
in their translocation to the mitochondria and induction of the release of apoptogenic 
factors, such as cytochrome c (Li et a l, 2004a). This will in turn activate the cysteine 
protease family (known as caspases), probably by inhibiting anti-apoptotic members of 
the family and activating multi-domain members like Bax (Antonsson et a l,  2000; 
Antonsson et a l, 2001; Li et a l, 2004a).
In the present study, the expression level of pro-apoptotic genes was downregulated, 
whereas anti-apoptotic genes were upregulated, further supporting the viability of DCs 
following interaction with pRBCs (Hou and Van Parijs, 2004). For instance, the pro- 
apoptotic genes, Bcl-2-like protein 11 and BNIP3 were downregulated (Table 7.3). The 
latter finding is particularly interesting not only because it supports the viability of DCs 
in the culture system used but also because BNIP3 has been reported to induce T cell 
apoptosis by binding to CD47 on T cells (Lamy et a l, 2003). The ability of pRBC-treated 
DCs to induce T cell responses in vitro has been previously investigated in chapter 4
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where T cell viability was not found to be affected. Thus, the downregulation of BNÏP3 
gene expression in pRBC-treated DCs further reinforces the idea that pRBCs do not 
induce DCs to deliver apoptotic signals to T cells following their interaction.
Tyrosine-3 Mono-oxygenase (also known as 14-3-3 theta) is a cytoplasmic protein, which 
has been reported to bind directly to Bax and to inhibit its translocation and integration 
into the mitochondrial membrane, therefore blocking the release of apoptogenic factors 
(Nomura et aL, 2003). Thus, over-expression of Tyrosine-3 Mono-oxygenase could be 
expected to inhibit Bax-induced apoptosis. In the present study however Tyrosine-3 
Mono-oxygenase gene expression was found to be dowregulated (Table 7.3), possibly 
indicating induction of Bax-induced apoptosis in pRBC-treated DCs. Nevertheless, 
cytochome c and caspase 3, which are expected to be activated following Bax 
translocation into the mitochondria (Antonsson et aL, 2000), were both found to be 
downregulated (Table 7.3). Nevertheless, DC viability was further substantiated by the 
downregulation of many other pro-apoptotic genes such as Tetratricopeptide repeat 
domain 11 (Fis 1) (Table 7.3) (Lee et aL, 2004), Homeodomain interacting protein kinase 
2 (Hipk2) (Table 7.3) (D'Orazi et aL, 2002; Zhang et a l, 2003), and Tripartite motif 
protein 27 (Table 7.3) (Dho and Kwon, 2003). Furthermore Clusterin, which has been 
associated with cell survival (Pearse et aL, 1992) was found to be upregulated in pRBC- 
treated DCs (Table 7.2), consistent with the observed viability of DCs in the experimental 
culture tested. Indeed these ideas remain entirely speculative at the present time and they 
might be over simplified. In fact the involvement of so many different genes encoding the 
various apoptotic signals emphasises the complexity of the interactions that might take 
place during this phenomenon.
Collectively, DNA microarray analysis of pRBC-treated DCs emphasised the induction 
of a strong pro-inflammatory response occurring during the initial interaction of DCs 
with pRBCs, a finding typically reported during malaria infection (Stevenson and Riley,
2004). Nevertheless, as explained above, some mediators of inflammation might in turn 
inhibit DC function, perhaps at a later time point during infection, thus providing a
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possible mechanism used by the parasites to modulate the immune response to their 
advantage.
The possible involvement of TSP-1, HO-1 and prostaglandins in the observed 
suppression of DC function represent only a few interesting molecules, which have been 
highlighted herein as a result of gene array technology. Undoubtedly, the microarray data 
might contain information on many other genes encoding molecules, which could 
potentially induce DC suppression following pRBC interaction. However due to the 
limited amount of time available, detailed analysis of these results could not be 
extensively carried out. Nevertheless, the data presented in this chapter shed light on 
potential molecules that might be involved in the modulation of DC function, providing 
the basis for future functional studies. Experiments using inhibitors of the molecules 
described above and analysis of protein production will be required to gain a better 
understanding of the involvement of these molecules during blood-stage malaria 
infection.
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8. Conclusions
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8.1 Conclusions
During malaria infection there is significant depression of the host’s immune response to 
concurrent infections (Bomford and Wedderbum, 1973; Cook, 1985; Mabey et aL, 1987; 
Whittle et aL, 1984) as well as the response to the parasite itself (Brasseur et aL, 1983; 
Ho et aL, 1986; Troye-Blomberg et aL, 1984), Furthermore, infection with Plasmodium 
species impinges on the success of vaccination against unrelated organisms (Greenwood 
et aL, 1972; McGregor, 1962; Williamson and Greenwood, 1978), a significant obstacle 
to initiatives aimed at expanding childhood immunisation in malaria endemic regions. 
Using the murine P. chabaudi AS model, I examined whether pRBCs can suppress the 
function of DCs, which are central to the initiation and regulation of the adaptive immune 
response (Adams et aL, 2005). Impairment of DC function may therefore inhibit the 
induction of adaptive immunity to heterologous antigens, providing a potential 
explanation for epidemiological studies linking endemic malaria with secondary 
infections and reduced vaccine efficacy.
The present study revealed that pRBCs do not directly activate bone marrow-derived DCs 
in vitro', rather, they inhibit the LPS induced upregulation of Class II MHC and 
costimulatory molecules (CD40 and CD86) on DCs, as well as the production of IL-12 
and IL-10 cytokines (chapter 3). pRBCs also inhibit DC activation in response to CpG 
and CD40 ligation indicating that multiple signalling pathways are affected, causing a 
generalised suppression of DC function. Furthermore, interaction with pRBCs 
significantly reduces the ability of DCs to induce OVA-specific T cell proliferation and 
cytokine production (chapter 4). However, although pRBC-treated DCs have a reduced 
ability to activate an GVA-speciflc T cell hybridoma, indicative of defective antigen 
presenting function, these cells are still capable of inducing the expression of the early 
activation marker CD69 on OVA-specific T cells (chapter 4). This finding suggests that 
the observed proliferation defect is not due to the failure of T cells to recognise antigen 
and that the amount of antigen presented, although significantly reduced, is sufficient to 
activate naïve T cells. Nevertheless, pRBC-treated DCs induce an anergic rather than an 
effector T cell phenotype (chapter 4), a result which is consistent with the suppression of
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immunity observed in malaria-infected patients (Bomford and Wedderburn, 1973; Cook, 
1985; Lam et aL, 1991; Mabey et aL, 1987; Moormann et aL, 2005; Thursz et aL, 1995; 
Whittle et aL, 1984).
Since pRBCs were present in DC cultures during the assessment of the OVA-specific T 
cell proliferation, I was aware of the possibility that the parasites might directly induce 
inhibitory effects on the T cells rather than inhibiting their proliferation by affecting DC 
function. I initially addressed this issue by lysing the pRBCs following a 24h incubation 
period with DCs. However, this procedure induced DC activation, thus affecting the 
outcome of the proliferation assay. I therefore carried out an APC-independent T cell 
proliferation assay by coating tissue culture plates with anti-CD3/anti-CD28 antibodies 
(which mimic the signals that T cells would receive from functional DCs) prior to 
addition of pRBCs and T cells (100:1, PRBC:T cell). Nevertheless, the results obtained 
by using this system varied significantly among experiments, with some assays showing 
control RBCs being as inhibitory as pRBCs when compared to cultures that did not 
receive any erythrocytes. These different outcomes might be due to the large number of 
RBCs non-specifically blocking the interaction of T cells with the antibodies. Although 
the issue of whether pRBCs induce suppression of T cell proliferation by affecting DC 
function or by having a direct effect on the T cells could not be resolved in vitro, ongoing 
studies in our laboratory provide strong evidence supporting the former scenario. In fact, 
results from in vivo experiments have shown that DCs purified from spleens of infected 
animals and pulsed with OVA, could not induce effector OVA-specific T cell responses 
when transferred into healthy recipients, which received CFSE-labelled OVA-specific 
DO 11,10 T cells (in press).
It is known that presentation of antigen to T cells is an essential step in the induction of 
primary immune responses (Obst et aL, 2005). Low levels of antigen presentation may 
fail to induce a response, or stimulate only moderate levels of clonal expansion (Gett et 
aL, 2003). If the magnitude of the peptide:MHC signal received by T cells (signal 1) is 
sufficiently strong, it may overcome the requirement for costimulation (signal 2) in T cell 
priming (Bachmann et aL, 1998) and it can also influence the Thl/Th2 polarisation of the
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resulting T cell response (Constant and Bottomly, 1997). Thus high doses of 
peptide:MHC can polarise towards Thl, with lower doses more likely to induce Th2 
responses (Guery et ah, 1996; Obst et aL, 2005). Therefore, the dose and duration of 
antigen presentation, can significantly affect the type of adaptive immune response 
induced. In this regard, it is still not knovm how much antigen (heterologous and 
homologous) is taken up by APCs during malaria infection and, more importantly, how 
much is subsequently presented to T cells and for how long this presentation persists. 
Clearly, these are important questions, which should be the focus of future investigations 
in order to gain a deeper understanding of how the malaria parasite suppresses the 
development of protective immune responses.
A new method for studying antigen processing and presentation has been recently 
described (Itano et aL, 2003) in which a protein antigen and a peptide:MHC II complex 
derived from this antigen could be monitored simultaneously in vivo. This system uses 
the YAe antibody, which specifically recognises the peptide (derived from the
MHC I-E molecule) in the context of I-A^ (Murphy et aL, 1992; Rudensky et aL, 1991). 
Linking the E a peptide with an appropriate fluorescent protein (e.g. Green Fluorescent 
Protein-GFP) will allow the visualisation of both uptake and presentation of antigen. 
Furthermore, TcR transgenic TEa mice, whose CD4^ T cells recognise the Ea/I-A^ 
complex, are also available (Grubin et aL, 1997). Thus, by using fluorescently labelled 
antigen, the YAe antibody and these antigen-specific CD4^ T cells, it is possible to 
monitor the uptake and presentation of antigen as well as visualising the interaction 
between APCs and T cells both in vitro and in vivo.
The above system has been recently established in our laboratory and has been used to 
exaniine how pRBCs affect the ability of DCs to process and present heterologous 
antigen in vitro. When the proportion of DCs expressing E a peptide was measured, no 
significant difference between RBC and pRBC-treated DCs could be observed (O. 
Millington, personal communication). This does not necessarily contradict my findings in 
which pRBC-treated DCs were less able to activate hybridoma T cells since the two 
systems use different readouts of presentation; one is phenotypic, the other functional. As
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yet, no functional analysis on T cell activation has been carried out using the E a  system 
and this would clearly be the focus of future studies. However, it is intriguing to think 
that two experimental systems may respond differently to parasite inhibition since human 
studies have revealed that certain vaccines appear to induce protective responses 
irrespective of malaria status and hence the immunosuppressive effect of malaria 
infection may not extend to all antigens (Greenwood et al,, 1972). In fact, while 
diminished antibody response to tetanus toxoid and to the O antigen of S. typhimurium 
were reported in children with acute malaria, their antibody response to the H antigen of 
S. typhimurium and their cellular immune responses were normal (Greenwood et al., 
1972). The E a system could therefore help us to gain a better insight in the uptake and 
presentation of heterologous antigens during malaria infection in vivo and depending on 
the outcome of the Ea-specific T cell response induced by pRBC-treated DCs, it could 
perhaps aid in understanding why T cell responses to certain antigens are not affected 
during malaria. Furthermore, besides examining presentation of heterologous antigens, 
this system can be used to investigate presentation of parasite antigens in vivo. This can 
be achieved by developing transgenic parasites expressing Ea-GFP (currently underway 
in our laboratory). The fluorescent moiety will allow tracking of parasites and antigen in 
vivo, while the expression of Ea will help to investigate how this antigen is presented to 
the immune system and how T and B cells respond. Moreover, the anatomical location of 
uptake of Ea-GFP-expressing parasites and presentation of Ea by APCs can be identified 
by using laser-scanning cytometry (ESC) (Grierson et a l, 2005; Smith et a l, 2004) and, 
by using APC-specific markers, it is possible to characterise the phenotype of the APC 
engaged in antigen presentation as well as determining the magnitude and duration of 
antigen presentation during infection in vivo.
As mentioned earlier, the initial interactions between APCs and T cells determines the 
nature of the developing immune response and studies in our laboratory have shown that 
differences in the duration and/or frequency of these interactions underlie the outcome of 
priming versus tolerance (Zinselmeyer et a l, 2005). The movement of CD4^ T cells in 
lymph nodes was imaged and compared during the induction of oral priming and 
tolerance. Primed T cells were shown to form larger and longer-lived clusters compared
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to tolerised cells (Zinselmeyer et al., 2005). This study was possible due to the use of 
multi-photon microscopy, which allows to image fluorescently labelled cells in intact 
tissue in real-time. The application of this technique during malaria infection is a logical 
extension of the present study and will enable us to investigate whether pRBC-treated 
DCs are capable of inducing the activation and clustering of T cells around the DCs and 
examine the subtle differences underling the development of immune responses in 
malaria infected animals compared to controls. Gaining further knowledge of the 
mechanisms and requirements for the induction of immunological priming is critical to 
improve therapeutic strategies for the prevention and treatment of malaria and for the 
development of an effective malaria vaccine.
My initial experiments, which established that pRBCs do indeed inhibit DC function, 
were followed by studies aimed at investigating the mechanisms of suppression. Fixation 
of pRBCs immediately after harvesting enabled me to examine whether parasite viability 
and development was a necessary requirement for the observed inhibition of DC 
function. Isolation of pRBC-ghosts enabled me to analyse whether parasite-derived 
antigens expressed in the erythrocyte membrane played an important role in modulating 
DC function. Finally purification of haemozoin, a byproduct of haemoglobin digestion 
and the use of a transwell system enabled me to analyse the involvement of haemozoin 
and soluble factors potentially secreted by pRBCs in the suppression of the LPS-induced 
activation of DCs in vitro. While neither parasite growth or parasite-derived antigens 
expressed in the erythrocyte membrane are responsible for the observed modulation of 
DC maturation, haemozoin, and soluble factors secreted by pRBCs, contribute 
significantly to the immunosuppressive effects induced in DCs in vitro. A deeper 
understanding of the mechanisms employed by haemozoin to induce its effects is a 
necessary step for finding ways to induce haemozoin degradation, in an attempt to rectify 
the functional impairment of DCs and should therefore be the focus of future studies. 
Similarly, identification of parasite-derived soluble factors and investigation of their 
mechanism of action would be worthwhile. In this regard, treatment of pRBC-derived 
supernatants with proteases and lipases would provide a first step in their identification. 
This could be followed by purification and identification of potential proteins and/or
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lipids. For instance, proteins may be purified by 2-D gel electrophoresis and either 
enzymatically or chemically cleaved (Gevaert and Vandekerckhove, 2000). The obtained 
peptide mixtures can then be analysed by mass spectrometric techniques, which will 
retrieve possible candidate proteins (Gevaert and Vandekerckhove, 2000). Similarly, 
analytical technologies have been developed for the detection and quantification of lipid 
species. Lipid extracts can be separated on a chromatographic column and eluted species 
identified and quantified by on-line mass spectroscopy (Hermansson et al., 2005).
Although haemozoin and parasite-secreted factors were found to suppress DC function, I 
analysed potential mechanisms used by the parasite to exert these effects on DCs. I 
therefore investigated whether interaction with pRBCs would induce DCs to secrete 
immunosuppressive factors, which could potentially act in an autocrine manner and affect 
the function of the secreting cell itself or in a paracrine fashion and suppress the function 
of bystander cells (chapter 6). Since none of the most common immunoregulatory 
molecules selected for this study (NO, TGF-p, PGEz acting through the EP4 receptor, 
PPAR-y and IDG) seemed to be involved in the suppression of DC activation, gene 
expression analysis seemed the most appropriate approach to gain an overall view of the 
molecular events involved during DC-pRBC interaction. In this regard, microarray 
analysis of pRBC-treated DCs shed light on some possible molecules that might play a 
role in the observed suppression of DC function, such as TSP-1 and HO-1 (chapter 7). 
Future work using enzyme inhibitors/blocking antibodies/receptor blockers should be 
carried out to validate this information. Furthermore, although genomics studies may 
provide important information on the expression of genes encoding proteins that might be 
involved in the modulation of DC function, protein production cannot be fully 
characterised by gene expression analysis alone. Alternative splicing and post- 
translational modification of proteins give rise to a large increase in protein diversity 
resulting in fewer protein-coding genes than there are proteins. For these reasons, 
proteomics (i.e. the large scale study of proteins) is a useful tool and would therefore be 
the ‘next step’ following genomic analysis. The 2-D Fluorescence Difference Gel 
Electrophoresis (DIGE) system allows the separation of up to three protein samples on a 
single 2-D gel. Protein samples are labeled with different fluorescent dyes, mixed and run
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on the same gel, which is then viewed by fluorescence at different wavelengths, much 
like a microarray (Westermeier and Marouga, 2005). This method leads to highly 
accurate qualitative and quantitative results as gel-to-gel variations are eliminated 
(Westermeier and Marouga, 2005).
The identification of suppressive agents secreted either by the parasites or the DCs 
themselves and understanding their mechanism of action could have important 
implications for vaccine design and immunotherapy and might aid in the development of 
effective DC-based vaccines against malaria. Furthermore, these suppressive agents may 
have broader applications as potential therapeutic molecules in settings where 
immunosuppression would be clinically beneficial, such as in the case of autoimmune 
diseases. For instance, it would be interesting to analyse the effects of haemozoin 
administration on diseases like rheumatoid arthritis. In this regard, experiments similar to 
those carried out using ES-62 on the collagen induced arthritis model (Mclnnes et al.,
2003) would be ideal for examining its therapeutic potential.
Similar to haemozoin, ES-62, a glycoprotein secreted by the rodent filarial nematode 
Acanthocheilonema viteae, was shown to exhibit broad immunomodulatory activities in 
vitro that were in general anti-inflammatory (Harnett et al., 2003). In fact, ES-62 reduced 
antigen-driven B and T lymphocyte proliferation, inhibited the ability of macrophages to 
produce Thl/proinflammatory cytokines such as IL-12, TNF-a, and IL-6, modulated DC 
maturation to preferentially elicit Th2-polarised responses, and induced spleen cells to 
produce IL-10 (Harnett and Harnett, 2001). Filarial nematode infection was also shown in 
some cases to modulate the human immune response to heterologous antigens, including 
vaccines (Stewart et al., 1999). In vitro and in vivo studies using the collagen-induced 
arthritis model clearly demonstrated that ES-62 could potently suppress inflammation 
(Mclnnes et al., 2003), providing powerful proof of the concept that molecular 
characterization of the host-parasite relationship offers therapeutic potential in the context 
of autoimmune diseases.
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A bstract
Background: Dendritic cells (DCs) are central to  the Initiation and regulation of the 
adaptive immune response during infection. Modulation of DC function may therefore allow 
evasion of the immune system by pathogens. Significant depression of the host’s systemic 
immune response to both concurrent infections and heterologous vaccines has been 
observed during malaria infection, but the mechanisms underlying this immune 
hyporesponsiveness are controversial.
Results: Here, we demonstrate that the blood stages of malaria infection induce a failure of 
DC function in vitro and in vivo, causing suboptimal activation of T cells involved in 
heterologous immune responses. This effect on T-cell activation can be transferred to 
uninfected recipients by DCs isolated from infected mice. Significantly, T cells activated by 
these DCs subsequently lack effector function, as demonstrated by a failure to  migrate to 
lymphoid-organ follicles, resulting in an absence of B-cell responses to heterologous antigens. 
Fractionation studies show that hemozoin, rather than infected erythrocyte (red blood cell) 
membranes, reproduces the effect of intact infected red blood cells on DCs. Furthermore, 
hemozoin-containing DCs could be identified in T-cell areas of the spleen in vivo.
Conclusions: Plasmodium infection inhibits the induction of adaptive immunity to 
heterologous antigens by modulating DC function, providing a potential explanation for 
epidemiological studies linking endemic malaria with secondary infections and reduced vaccine 
efficacy.
Journal o f  Biology 2006. 5:5
5.2 Journal o f  Biology 2006, Volume 5, Article 5 Millington et of. http://jbiol.eom/content/5/2/S
Background
Malaiia is the major parasitic disease of humans throughout 
the üopics and subtropics, mainly affecting children under 
5 years of age and causing 500 million clinical cases and up 
to 2.7 m illion deaths each year [1]. In addition to infection- 
induced mortality, malaria is also associated witlr public- 
health problems resulting from impairment of immune 
responses. Although this immunosuppression may have 
evolved as a meclianism by whicli the parasite can prevent 
immune-mediated clearance [2-8], it leaves malaria-infected 
individuals or experimental animals more susceptible to 
secondary infections, sucli as non-typhoidal Salmonella [9], 
herpes zoster virus [10], hepatitis B virus [11], Moloney 
leukemia virus [12] and nematode infection [13], as well as 
Epstein-Barr virus reactivation [14-17]. Because tire efficacy 
of heterologous vaccines can also be suppressed in malaria- 
infected patients [18-21], children showing clinical signs of 
malaria are rarely immunized until after anti-malarial 
chemoprophylaxis, wliich can improve the response to vac­
cination [22]. In a recent study o f a new conjugate vaccine 
against pneumococci, efficacy was reduced during the 
malaria transmission season [23], demonstrating the possi­
ble impact o f malaria infection on large-scale vaccine 
regimes. Certain vaccines, however, seem to induce protec­
tive responses irrespective of malaria status and the 
immunosuppressive effect o f malaria infection might tlius 
not extend to all antigens [20]; studies in vivo are required to 
investigate this controversy further. Several animal studies 
have described suppression of immune function by Plas­
modium parasites in vitro and in vivo [24-34], but tire mecha­
nisms involved remain unclear.
detected by inaeased expression of the antigen CD86 and 
the cytoldne interferon-a (IFN-a) in vitro [41]. In contrast, 
the asexual erythrocytic stages of P. falciparum were shown to 
impair the ability of human DCs to undergo maturation in 
vitro [42]. Indeed, peripheral blood DCs of P. falciparum- 
infected children showed reduced levels of tire major Iristo- 
compatibility complex (MHC) molecule HIA-DR compared 
with uninfected controls [43], suggesting a reduced activ­
ation stale. Thus, the ability of malaria parasites to inhibit 
maturation of DCs could be involved not only in parasite- 
specific immunosuppression but also in the suppression of 
responses to heterologous antigens such as vaccines and 
umelated pathogens [2,19,20]. As human malaria parasites 
are host-specific, however, observations on the effect of 
human malaria on DCs are largely limited to studies in vitro.
Here, we describe the meclranisrn underlying tlris suppres­
sion of immunity in vitro and in vivo. DC activation is 
dynamically altered by parasitized erytlirocytes (pRBCs), 
partly because of deposition of the malarial pigment hemo­
zoin (HZ) within these cells. Following presentation of het­
erologous antigen by pRBC-exposed DCs, there is less 
expansion of CD4+ 'helper" T cells that are essential for die 
induction of adaptive immunity. Subsequendy, migradon 
of T cells to lymphoid follicles is abrogated, leading to 
defective B-cell expansion and differentiation and a failure 
of the antibody response. These studies explain why immu­
nity to malaria is slow to develop and why protection 
against secondary infections is reduced in Plasmodium- 
infected individuals.
Dendritic cells (DCs) have a aucial role in the activation of 
T cells and consequently in tire induction of adaptive 
immune responses and immunity [35,36]. There is evidence 
that many pathogens have evolved medianisrns that subvert 
DC function, thereby modulating the host's immune 
response to tlieir advantage [37,38]. Recent studies have 
revealed that DCs are important in malaria infection, partic­
ularly during the early events of induction of the protective 
immune response to infection [39,40]. It has been reported 
that red blood cells (RBCs) infected with sclrizont-stage 
Plasmodium falciparum activate plasmacytoid DCs as
Results
Suppression of heterologous immune responses 
during maiaria infection
We first examined the response to a heterologous antigen 
during Plasmodium chabaudi (AS strain) infection (Figure la) 
to determine whetlrer this murine model reflected the clini­
cal immunosuppression obseived witlr P. falciparum infec­
tion [18-21]. Mice were immtmized with the model antigen 
ovalbumin (OVA) and lipopolysaccliaride (LPS) to act as 
adjuvant at various times after infection, and OVA-specific 
serum immunoglobulin G (IgG) was measured 21 days later.
Figure I (see figure on the following page)
Suppression of immunity by P. chabaudi infection, (a) BAL8/c mice were infected with 10^  P. chabaudi (AS strain) parasites by intra-peritoneal 
injection and the proportion of peripheral blood cells parasitized (parasitemia) was monitored by Giemsa’s stain of peripheral blood smears.(b) Uninfected (squares) or P. chabaudi-infected (circles) BALB/c mice w ere immunized with OVA/LPS at the indicated times after infection. Three 
weeks after immunization, sera were analyzed for OVA-specific IgG, Data represent the mean of three mice per group ±1 standard deviation (s.d.) 
and are representative of two similar experiments (*p ^  0.05, ^  ^  0.005 uninfected versus P. chabaudi-infected). (c) Spleen cells from uninfected 
(open bars) or P. chabaudi-infected (filled bars) BALB/c mice immunized with OVA/LPS 10 days post-infection w ere re-stimulated in vitro as indicated 
and supernatants assayed for levels of IFN-y (left) and IL-5 (right) after 48 h.
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Uninfected, immunized animals generated OVA-specific IgG 
responses, but OVA and LPS administered 6 hours and 12 
days after infection witlr P. chabaudi produced significantly 
reduced levels of IgG (Figure lb ). Interestingly, suppression 
was lower in mice immunized during increasing levels of 
parasite infection (parasitemia; Figure lb , 4 days). By 21 
days post-infectioir, infected animals had regained immune 
responsiveness and mounted antibody responses of a similar 
magnitude to those seen in uninfected controls (Figure lb, 
21 and 28 days). Production of OVA-stimulated and con- 
canavalin A (ConA) mitogen-stimulated T-cell cytokines was 
reduced in cultures of splenocytes taken from mice infected 
witlr R  chabaudi 10 days before immmrization (Figme Ic). 
Thus, as described for P. falciparum in humans, P. chabaudi 
infection in mice induces suppression of immirne responses, 
although tliese studies reveal that. In the animal model at 
least, tlris is a Irighly dynamic phenomenon.
Modulation of DCs in vitro by infected erythrocytes
DC activation is central to induction of adaptive immunity 
[35], and previous studies have suggested that several pro- 
tozoarr pathogens have evolved meclranisrns to suppress this 
resporrse aird consequendy to reduce immrme-rnediated pro­
tection [44]. Human DCs cultured witlr P. falciparum- 
infected erythrocytes are hyporesponsive to stimulation witlr 
LPS and less capable of stimulatiirg CD4+ T-cell responses 
[42]. This observation remains controversial, however, as 
studies using rnurirre models have suggested that DCs may 
be activated during increasing parasitemia in vivo [45] and 
following culture in vitro witlr parasite schizont-rnfected 
erythrocytes [40].
As the results above indicated that immune resporrsiveness 
in vivo is dyrramically regrrlated durmg infectioir, we studied 
the ability of P. chabaudi-infected erythrocytes to modulate 
DCs directly, by examining tire expression of MHC dass II 
and co-stimulatoiy molecules on DCs. Bone-marrow- 
derived DCs were incubated with infected erythrocytes and 
the expression of surface markers examined at various times 
over the following 24 hours. Our results show that DCs 
expressed very low levels of surface MHC dass II and tire co­
stimulatory molecules CD40, CD80 and CD 86 when cul­
tured in growth medium alone, thus confirming the 
immature state of these DCs in culture (Figure 2a-d). Stimu­
lation with LPS promoted a significarrt increase in the 
expressioir level of all co-stirnulatory molecules within 6 
hours. DCs incubated witlr RBCs or pRBCs did irot, 
however, increase expression of MHC dass II, CD40, CD80 
and CD86, indicating that malaria parasites do not induce 
DC activation directly. Analysis of cytokine production 
showed that DCs exposed to RBC or pRBCs produce small, 
though detectable, amounts of both interleuldns IL-12 arrd 
IL-10 tlrat are a thousarrd-fold lower tharr those observed
after LPS stimulation (Figme 2e,f), suggesting tlrat the pres­
ence of parasites does not result in DC activation. The via­
bility of treated DCs and control cells was quantified after 
24 hours of culture by trypan blue exdusion (Figure 2g) and 
propidium iodide (PI) and aimexin V staining (data not 
shown) and was irot sigirificantly affected by pRBCs.
Having established tlrat pRBCs at a ratio of 100:1 do not 
directly induce DC maturation, we examined whether 
pRBC-treated DCs retained their ability to mature in 
response to LPS treatmeirt in vitro. DCs were exposed to 
RBCs or pRBCs for 24 hours and subsequently challenged 
with LPS. After 18 hours of LPS stimulation, the expression 
levels of MHC class II, CD 40, CD80 and CD86 increased 
significairtly (Figure 3a-d). DCs pre-incubated with pRBCs 
and subsequently challenged witlr LPS, however, showed 
significantly lower levels of expression of MHC class II, 
CD40, and CD86 compared witlr tlrose observed when cells 
were irot treated witlr pRBCs or were pre-incubated with 
RBCs before tire LPS challenge (Figure 3a-d). Kinetic studies 
demonstrated that the ability of pRBCs to induce this 
hyporesponsive state in DCs required at least 6 hours pre­
incubation before the addition of LPS (data not shown). 
Cytokine production following treatment with LPS showed 
tlrat, although DCs treated with pRBCs could still produce 
appreciable levels of IL-12 and ID 10 in response to LPS, 
the amount produced was significantly lower than that pro­
duced by DCs pre-incubated witlr RBCs (Figure 3e,f). As 
the interaction between CD40 on DCs and its ligand 
CD40L on T cells in vivo is Imown to be aucial in the pro­
duction of bioactive IL-12 and upregulation of adhesion 
and co-stimulatoiy molecules [46,47], we stimulated bone- 
marrow-derived DCs with CD40L-transfected fibroblasts 
(Figure 3g,h). DCs treated with RBCs significantly upregu- 
lated CD40 expression in response to CD40L and produced 
high levels of the iirducible IL-12p40 subunit. CD40 liga­
tion, however, did not rescue the reduced maturation of 
DCs treated witlr pRBCs, although, as previously observed 
with the LPS treatment, these cells still produced ID12 p40 
but to a lesser extent than the control groups.
Modulation of DCs in vivo during malaria infection
As om results suggested that malaiia-infected eiythrocytes 
might modulate the responsiveness of DCs in vitro, we next 
investigated the activation status of splenic DCs in vivo 
during a time-course of infection with P. chabaudi. DCs iso­
lated from spleens of mice 4 days after infection showed a 
moderately activated phenotype, as demonstrated by 
inaeased expression of CD40 and CD80 (Figure 4a), con­
firming previous reports [45]. DCs isolated from infected 
animals 12 and 20 days after infection, however, showed a 
reduced level of activation, with lower levels of CD 40, 
CD80, CD86 and MHC class II molecules on their surface
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Figure 2
p. chabaudi-infected erythrocytes do not activate DCs directly in vitro. DCs (2 x  10 )^ were cultured with 2x10® infected erythrocytes (DC+pRBC; 
filled circles) or with an equal number of uninfected erythrocytes (DC+RBC; empty circles). Control DCs remained unstimulated (DC; empty 
squares) or were stimulated with I p.g/ml of LPS (DC+LPS; filled squares). Results show the mean fluorescence intensity of (a) MHC class H,
(b) CD40, (c ) CD80, and (d) CD86, as determined by FACS analysis of gated CD I Ic'' cells at various times of co-culture. Supernatants were 
analyzed for concentrations of (e )  IL-12 (p40 subunit) and (f) IL-10 secreted by DCs after 24 h of incubation, (g) The number of viable DCs was 
determined by trypan blue exclusion. Results show the mean value ± standard error (s.e.) of triplicate samples per group.
compared witli DCs from uninfected animals (Figure 4b,c). 
Whereas DCs from uninfected mice upregulated CD40, 
CD80 and CD86 following LPS stimulation (Figure 4d-g), 
DCs isolated from the spleens of P. chabaudi-infected mice
remained refr actory to in vitro LPS-induced maturation, with 
reduced levels of these molecules following stimulation. 
Tlius it seems tlrat, in vivo, DCs are activated soon after 
infection, and the level of activation on DCs is reduced
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Figure 3
P. chabaudi-infected erythrocytes inhibit the LPS and CD40L-induced maturation of DCs, DCs were cultured with infected (pRBC) or uninfected 
(RBC) erythrocytes for 24 h, as described in Figure 2, then treated with I |xg/ml of LPS for a further 18 h. (a-f) Results were analyzed as described 
in Figure 2 (*p S  0.05 pRBC versus RBC). (g,h) DCs (I x  10*) were cultured with 1x10® infected erythrocytes (pRBC) before stimulation with 
CD40L-expressing fibroblasts (filled bars) or control fibroblasts (open bars) at a 1:1 ratio of fibroblasts;DCs. Untreated DCs (Con) and uninfected 
erythrocyte-treated DCs (RBC) were used as controls. DCs w ere incubated with fibroblasts for a further 18 h before analyzing CD40 expression 
and cytokine production. CD40 expression on DCs is shown as tiie mean fluorescent intensity on CD 11 c+ cells. IL-12 production is shown as the 
mean optical density (OD) read at 450 nm. Results show the mean value ± s.e. of triplicate samples pei- group (*p s  0.05 pRBC versus RBC).
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Modulation of DC activation in vivo during P. chabaudi infection, (a-c) Splenic CD I lc+ DCs were isolated from P. chabaudi infected mice at various 
times (filled bars) or from uninfected controis (open bars) and analyzed by flow cytometry for the indicated markers. Data are expressed as mean 
fluorescence intensity relative to uninfected samples ± I s.d. (*p ^  0.05 uninfected versus P. chabaudi-infected). (d-g) Splenic DCs from uninfected 
(open bars) or P. chabaudi-infected (filled bars; 12 days post-infection) BALB/c mice were restimulated in vitro with LPS (I (tg/ml) for 18 h before 
analysis by flow cytometry for (d) MHC class II, (e) CD40, (f) CD80 and (g) CD86. Data are expressed as mean fluorescence intensity relative to  
uninfected, unstimulated samples ±1 s.d. (*p £  0.05, s  0.005 uninfected versus P. chabaudi-infected for the same treatment).
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Figure 5
Identification of P. chabaudi components that inhibit LPS-induced DC maturation, (a-c) DCs (2 x  10^ ) were treated for 24 h with uninfected RBC 
(open bars) or infected RBC (pRBC; filled bars) that were untreated or fixed before stimulation with LPS (I p.g/ml) for 18 h. DC activation was 
characterized by analysis of (a) MHC class II, (b) CD40, and (c) CD86 expression on CD I Ic  ^DC surfaces by FACS (*p <  0.05 pRBC versus RBC, 
+p  <  0.05 fixed pRBC versus fixed RBC). (d ,e ) DCs (5 x  10^ ) w ere incubated with intact erythrocytes or RBC ghosts from uninfected (open bars) 
or infected erythrocytes (filled bars), for 24 h before stimulation with LPS for 18 h. DC activation was characterized by analysis of (d) MHC class II 
and (e) CD40 expression on the DC surface by FACS (*p s  0.05 pRBC versus RBC).
following the peak of infection (days 12-20), and this 
cannot be abrogated by m iaobial stimulation ex vivo.
Identification of P. chabaudi com ponents that induce 
DC hyporesponsiveness
As we had demonstrated that malaria infection modulates 
key aspects of DC function, we wanted to examine the pos­
sible mechanisms involved. Initially, to determine whether 
maturation of tire parasite from tlie trophozoite stage to tire 
sclrizont stage in vitro or some metabolic process within the 
pRBCs was required for induction of DC hyporesponsive­
ness, pRBCs were fixed with paraformaldehyde and incu­
bated witlr DCs for 24 hours before the addition of LPS 
(Figure 5a-c). The expression levels of MHC class II, CD40 
and CDS 6 were significantly reduced when DCs were co­
cultured with fixed pRBCs before LPS challenge, confirming 
that trophozoite-infected erythrocytes downregulate DC 
activation in response to LPS treatment and suggestiirg that
growth and maturation of the parasite into schizonts is not 
required for suppression. In an attempt to understand the 
meclranisrns involved in tire parasite-mediated modulatioir 
of DC furrction, we investigated tire role of selected parasite 
components on tire LPS-induced maturation of DC .^ We 
addressed tlris question iiritially by analyzing the effect that 
parasite proteins expressed on the erythrocyte surface mem- 
braire have oir DC furrction. DCs were exposed to RBC 
membranes (ghosts) isolated from infected or urrirrfected 
erytlrrocytes. After 24 hours of culture, DCs were challenged 
with LPS and the expression of co-stirnulatory molecules 
analyzed 18 hours later (Figure 5d,e). Our results clearly 
show tlrat ghosts isolated from pRBCs did not alter tire 
ability of DCs to resporrd to LPS treatment in vitro, as 
observed by the levels of MHC class II and CD40, demon­
strating that proteins expressed on tire surface membranes 
of pRBCs are apparerrtly rrot essential for the modulation of 
DC function.
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Deposition of HZ in DCs suppresses maturation, (a) HZ content in bone-marrow-derived DCs {In vitro), purified DCs {Ex vivo) and spleen sections 
{In vivo) was visualized by light microscopy (top images) or by false-coloring malaria pigment viewed in bright-field image (red) and superimposing 
over the fluorescent CD 11c image (green), (b) CD I Ic* DCs were analyzed for size and granularity by flow cytometry 12 days post-infection with 
P. chabaudi or in uninfected controls. Data are expressed as the mean forward scatter or side scatter of triplicate samples ± I s.d. (*p s  0.05,
*p s  0.005 uninfected versus P. chabaudi-infected). (c-e) 2x10* DCs were cultured with I p,M. 5 p,M, 10 p,M and 20 p-M of HZ. After 24 h, the 
level of expression of (c) MHC class II, (d) CD40 and (e) CD86 on CD I Ic* cells was determined by FACS analysis, (f-h) After 24 h culture with HZ. 
I p.g/ml LPS was added to DCs and the levels of (f) MHC class II, (g) CD40, and (h) CD86 were analyzed 18 h later by FACS. All results are shown 
as tfie mean fluorescence intensity on CD I Ic* DCs in triplicate samples ± s.e. (*p ^  0.05 HZ versus LPS).
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Having established that parasite proteins expressed on the 
erytlirocyte cell membrane are not responsible for the mod­
ulation of LPS-induced maturation of DCs in vitro, we 
focused our attention on HZ, a by-product of hemoglobin 
digestion. We observed that bone-manow-derived DCs cul­
tured in vitro witli infected erytlirocytes accumulated intra­
cellular malarial pigment (Figure 6a). Flow cytometric 
analysis of splenic DCs, identified by C D llc  expression, 
also demonstrated an increase in the size and granularity of 
DCs during infection (Figure 6b), and DCs isolated ex vivo 
as well as DCs in spleen sections showed conspicuous HZ 
deposition (Figure 6a).
In order to assess the role of HZ in the parasite-induced 
modulation of DC function, we initially analyzed its ability 
to activate DCs directly in vitro (Figure 6c-e). Even at the 
highest dose (20 (jlM), HZ did not induce DC maturation, 
as the levels of MHC class II, CD40 and CDS 6 were the 
same as tlie levels expressed by untreated controls. We then 
examined whether HZ-treated DCs still responded to LPS 
treatment in vitro (Figure 6f-h). Our data clearly demon­
strate a dose-dependent inhibition of the LPS-induced mat­
uration of DCs by HZ, as seen by tlie reduced levels of MHC 
class II, CD40 and CD86. Taken together, these results indi­
cate tliat HZ, ratlier than pRBC membranes, is a key factor 
involved in the suppression of murine DC function in vitro 
and in vivo.
Failure of pRBC-treated DCs to  induce T-cell 
effector function
The above experiments clearly implicated HZ-mediated sup­
pression of DC function in the failure of antibody production 
and in the delayed acquisition of protective immunity seen 
during malaria infection in vivo. To examine the functional 
consequences of malaiia on DC function directly, we exam­
ined the ability o f affected DC  ^to activate naive, OVA-specific 
T-cell receptor-ti ansgenicT cells. These cells allow monitoring 
of the antigen-spedfic CD4* T-cell response as their antigen 
spedfidty is known and they can be tracked using a dono- 
typic antibody directed against their T-cell receptor. One of 
the earliest cell-surface antigens expressed by T cells following 
activation is CD 69, whidi is detectable witliin an hour of 
ligation of the T-cell receptor complex [48]. Interestingly, 
there was no significant difference in tlie percentage of OVA- 
specific T cells expressing CD 69 between RBC-treated and 
pRBC-treated groups (Fi^rre 7a), showing that T cells inter­
acting with modulated DCs are equally activated.
To investigate whether treatment o f DCs witli pRBCs could 
alter the dynamics of the T-cell proliferative response, we 
harvested theT cells at 48, 72, 96 and 120 hours o f culture 
(Figure 7b). The ability o f pRBC-treated DCs to induce 
T-cell proliferation was dramatically reduced compared to
tlie control group throughout tlie observation period (see 
Figure 7b). Analysis of T-cell production of IL-2, IL-5, IL-10 
and IFN-y (Figure 7c-f) revealed that eadi cytokine was 
downregulated in tlie pRBC-treated groups compaied with 
RBC-treated controls. The observed reduction in T-cell pro­
liferation and cytoldne production could not be explained 
by T-cell deatli, as similar levels of necrotic and apoptotic T 
cells were detected in both conditions by FACS analysis of 
propidium iodide and annexin staining (data not shown). 
Thus, altliough DCs pre-treated witli pRBCs in vitro can 
induce initial activation of naive CD4+ T cells, causing upreg­
ulation of CD69, these T cells fail to proliferate effectively 
and have a reduced ability to secrete effector cytokines.
Suppression of T- and B-cell proliferation during 
malaria infection
To characterize fully the downstream effects of HZ-induced 
DC hyporesponsiveness on heterologous immime respon­
siveness, we directly investigated antigen-spedfic T-cell 
responses in vivo by transferring traceable OVA-spedfic CD4+ 
T cells into redpient mice [49]. This allows us to follow the 
response of a small, but detectable, number of antigen- 
spedfic CD4* T cells during the induction of an adaptive 
immune response. Cells were transferred into redpients fol­
lowing the initial peak o f parasitemia (day 12 of infection) 
and immunized 1 day later. In P. chabaudi-infected immu­
nized mice, OVA-specific CD4+ T cells underwent a similar 
initial activation to that of antigen-spedfic T cells in unin­
fected mice, as estimated by upregulation of CD69 (Figure 
8a) and increased size/blastogenesis (also an indicator of 
activation; data not shown), confirming the in vitro observa­
tion (see Figure 7a). Antigen-spedfic CD4* T cells in lymph 
nodes and in spleen failed to expand to the same extent in 
infected mice as in uninfected controls (Figure 8b), however, 
partly because tlie antigen-spedfic CD4+ T cells made a 
reduced number of divisions (Figure 8c). Interestingly, we 
did not detect increased apoptosis (determined by annexin 
staining) of OVA-specific T cells transferred into malaria- 
infected individuals (data not shown).
One of the most significant components of CD4* T-cell effec­
tor function is migration into primary lymphoid follides to 
interact with, and provide help for, antigen-spedfic B cells 
[50]. To track the effect o f malaria infection on these popula­
tions, we transferred B-cell-receptor transgenic B cells spedfic 
for hen egg-white lysozym e  (HEL) taken from tlie MD4 trans­
genic mouse, together witli tlie OVA-spedfic DO l 1.10 T cells 
and immunized witli OVA coupled to HEL [51]. B-cell expan­
sion in uninfected animals peaked 5 days after immunization 
(Figure 9a). Expansion of HEL-spedfic B cells was almost 
completely ablated in P. chabaudi-infected animals immu­
nized witli OVA-HEL/LPS (Figure 9a), however, suggesting a 
defect in B-ceU activation and/or T-cell help in infected mi ce.
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F igure 7
P. chabaudHnfected erythrocytes inhibit the ability of DCs to  efficiently activate naive T cells in vitro. DCs (2 x  10^ ) w ere treated with infected 
(pRBC) or uninfected (RBC) erythrocytes for 24 h. DCs were then loaded with 5 mg/ml of OVA for 6 h, 5 x 10^  untreated (Control), RBC or 
pRBC-treated DCs and 5x 1 0^  DOl  1.10 lymph node cells w ere then co-cultured. (a) CD69 expression assessed on DO l 1.10 Tcells 24 h later by 
FACS analysis. Results are expressed as the percentage of antigen-specific cells expressing CD69 In cultures stimulated by OVA-pulsed DCs (filled 
bars) or by DCs only (open bars). Results show the mean of triplicate samples ± s.e. (b) pH]thymidine was added for the last 18 h of culture; c.p.m., 
counts per min. Results show mean proliferation of OVA-specific T cells after incubation with DCs treated with uninfected RBCs (open circles) or 
pRBCs (filled circles) in triplicate samples ± s.e. The concentrations of (c) lL-2, (d) IL-S (e ) IL-10, and (f) IFN-y secreted by OVA-specific T cells 
after incubation with DCs treated with uninfected RBCs (open circles) or pRBC^ (filled circles) were measured in supernatants harvested after 24, 
48, and 72 h of culture.
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Figure 8
Suppression of CD4+ T-cell expansion by P. cbabaudi infection in vivo, (a) Uninfected (open bars) or P. chabaudi-infected (filled bars) BALB/c mice 
received DO 11. 10 T cells and remained unimmunized or were immunized with OVA/LPS 12 days post-infection. Expression of CD69 on splenic 
OVA-speciflc T cells was assessed 18 h post-immunlzation. Results shown are the proportion of OVA-spedfjc CD4+KJ1.26^ T cells expressing CD69 
and represent the mean of three mice per group ± I s.d. (b) Uninfected (squares) or P. cbobaudi-infected (circles) BALB/c mice were transferred and 
immunized (filled symbols) or remained unimmunized (open symbols) and the akolu te number of OVA-specific T cells in spleen (left) and lymph 
nodes (right) calculated at various times. Results show the mean number of CD4+KJ1.26+ T cells and represent the mean of three mice per group 
± I s.d. (*p ^  0.05, #p g  0.005 uninfected and immunized versus P. cfiafaaudi-infected and immunized), (c) Representative CFSE profiles of OVA- 
speciflc T cells are shown (left) and data shown as the mean proportion of CD4+KJ l.26+ cells under each CFSE peak in uninfected (open bars) and 
P. chabaudi-infected (filled bars) following immunization (bottom histogram) or in unlmmunized controls (upper histogram). Data represent the mean 
of 3 mice per group ±i s.d. (*p ^  0.05, <  0,005 uninfected and immunized versus P. chabaudi-infected and immunized).
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Failure of heterologous antigen-specific T-cell 
migration during malaria Infection
Optimal expansion of antigen-specific B cells requires their 
cognate interaction witli CD4+ T cells [52,53]; we tlierefore 
examined the localization of OVA-specific CD4+ T cells fol­
lowing immunization. Five days after immunization of 
uninfected mice, clonal expansion of antigen-specific T cells 
was evident by immimohistochemistiy, and these cells had 
begun to migrate into B-cell follicles (Figure 9b). In 
P. chabaudi-infected mice, however, not only were tlrere 
reduced numbers of OVA-specific T cells, but these cells were 
almost completely excluded from B-cell follicles (see Figure 
9b). Migration was quantified using laser-scamring cytome­
try [54,55]. As shown in Figure 9c, tire average proportion of 
OVA-specific CD4+ T cells in B-cell follicles was significantly 
reduced in P. chabaudi-infected mice following immuniza­
tion compared witlr uninfected, immunized animals. This 
demonstrates that in infected animals, CD4+ T cells fail to 
migrate into follides and tirerefore fail to interact with 
antigen-spedfic B cells, botir essential steps in the induction 
of protective, adaptive immunity. Importantly, these failures 
in T- and B-cell function are similar to situations in wliich 
immune tolerance is induced [56-58], altirough few studies 
have directly examined the interaction of T and B cells in vivo 
during the course of infections. It should be noted tiiat, in 
contrast to the early inflammatory stage of the infection, 
normal lymphoid architecture was apparent when these 
defects in migration were observed, with clearly distinguish­
able, intact B- and T-cell areas (see Figure 9b).
To investigate whether the failure of T-cell migration into 
follides was simply due to a potential alteration in lym­
phoid architecture or chemoldne gradients caused by 
malaria infection, OVA-speciflc CD4+ T cells were initially 
activated in vitro with bone-marrow-derived DCs and pRBCs 
and then transferred into uninfected redpient mice. Expan­
sion of T cells stimulated in vitro with DCs cultured with 
infected RBCs was reduced following transfer compared 
with expansion of OVA-spedfic T cells activated in tire pres­
ence of uninfected erytiirocytes (Figure 9d), and these cells 
also failed to migrate into B-cell follides (data not shown).
To address whether the defect in T-cell migration was due to 
their activation in the context of parasite infection or to 
modulation of DC function, highly purified DCs from the 
spleens o f malaria-infected animals or uninfected controls 
were pulsed with OVA and transferred into naive BALB/c 
recipient mice along with DO 11.10 T cells labeled with tire 
fluorescent dye 5,6-carboxy-sucdnimidyl-fluorescein ester 
(CFSE). Following transfer of OVA-pulsed DCs from uirin- 
fected mice, T cells divided effrdently, as seen by CFSE dilu­
tion (Figure 9e). In mice transfened with OVA-pulsed DCs 
purified from the spleens of malaria-infected mice.
however, OVA-specific CD4+ T cells failed to divide to the 
same extent (see Figure 9e), suggesting tirat DCs exposed to 
malaria parasites are less capable of inducing effective T-cell 
responses. Fmtirermore, DCs purified from in vitro culture 
witlr pRBCs and pulsed with antigen were less able to 
iirduce air optimal T-cell response upon transfer to uirin- 
fected recipients (data not shown). Thus the defect iir T-cell 
function and migration is primarily due to the modulation 
of DC function by the malaria parasite, and not simply the 
result of activation of T cells in the context o f infection.
Discussion
Several previous reports have suggested a generalized sup­
pression of irirmtme responses during infection with Plas­
modium [2-10,12-21,24-34,59]. One possible mechanism 
could be impairment o f the functiorr of DCs, a cell type that 
is essential in the generatiorr of the primary immune 
responses [42]. But tire significance of this observation for in 
vivo studies, the implications for downstream immunologi­
cal function, and what (if any) parasite componeirt mediated 
this effect remained urrclear. Here, we have shown tirat DCs 
are modulated by tire malaria parasite and are suppressed by 
infectiorr with P. chabaudi through the malarial pigment HZ. 
Importantly, Plasmodium infection also causes a sigrrificant 
defect in tire induction of irnrnuire respoirses in vivo: expan­
sion and migration of CD4+ T cells is greatly reduced, result­
ing irr a consequent reduction irr the interaction between 
these T cells and B cells arrd in the help they can provide to 
the B cells. Despite severely impaired T-cell migration arrd 
effector function, early stimulatiorr o f arrtigen-spedfic CD4+ 
T cells is not affected by malaria infectiorr, as T cells stimu­
lated in vitro and in vivo upregulate CD69, suggesting that, 
despite suppression of DC frmctiorr, there is sufficient 
arrtigeir preserriatron to induce irritial T-cell activation.
Although the observed defect in CD4+ T-cell function seems 
to be directly related to inhibition o f DCs, it has also beerr 
suggested that optimal T-cell expansion and differentiation 
requires the interactiorr o f T and B cells [60]. Thus it may be 
tirat the failure of DCs to activate properly and subsequently 
irrduce T-cell migration into B-cell follides also results in 
the reduced expansion of CD4+ T cells observed here. 
Nevertheless, the failure of optimal CD4+ T-cell exparrsron 
arrd migration durirrg infection dearly results in the abroga­
tion of B-cell expansion arrd a subsequent abserrce o f arrtr- 
body production at spedfic time-points during infection. 
Thus, protective, systemic immunity agairrst non-parasite 
antigens, and presumably against parasite antigens, fails to 
develop effectively.
Although alterations in the ardritecture of the spleen during 
infectiorr witlr P. chabaudi have been described [61], these
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clianges were less evident in our model, with intact B220+ 
B-cell follicles still clearly discernible by day 17 of infection 
(see Figure 9b). Interestingly, infected mice immimized on 
day 4 of infection (when lymphoid structure is already dis­
rupted [61]) were able to generate antibody responses, sug­
gesting that despite tire breakdown in architecture, immune 
priming is still nonnal in tliese mice.
Our important finding drat activated T cells fail to migrate 
into follicles may in part be due to splenic alterations not 
visualized in our immunohistochemical staining for B220, 
or to alteration of chemoldne giadients important for T-cell 
migration in infected mice. To address drese issues, we 
transferred T cells that had been primed in vitro in the pres­
ence of malaria parasites into uninfected recipient mice 
with normal lymphoid ardritecture. In addition, we immu- 
irized naive, uninfected mice with OVA-loaded DCs whidr 
had been cultured in vitro with infected erydnocytes. hr all 
of these situations we could separate the effect o f parasites 
upon DCs or T cells from the described disruption of lym­
phoid ardritecture (see Figure 9). In each case, T cells 
primed hr the presence of malaria parasites orT cells primed 
by DCs exposed to infection failed to differentiate fully fol­
lowing transfer iirto uirrnfected recipients. Thus, alteration 
of splenic ardritecture alone cannot account for our obser­
vations, suggesting that the failure in T-cell differentiation is 
due to DC modulation.
Another possible explanatioir for the observed defect in the 
iirduction of immunity could be drrough competitioir for 
access to airtigerr between adoptively transferred OVA- 
spedfic T cells and endogenous malarial antigen-specific T 
cells, llrus, a large dose of blood-bome parasite antigens
could impede tire induction of otlrer (frystander') immune 
responses. But studies examining bystander responses in 
other parasitic diseases (for example, [62-65]), as well as the 
potent stimulatory capadty of mycobacteria-containing 
complete Freurrds' adjuvairt [66], suggest tirat sudr inhibi­
tion of immunity does not occur, despite poteirtially large 
amounts of competiirg airtigens. In our experimeirts, iraive 
OVA-spedfic CD4+ T cells activated in vitro arrd in vivo in tire 
preseirce of infected erythrocytes upregulated CD 6 9 to the 
same extent as T cells stimulated in rminfected controls, sug­
gesting tirat suffrdent access to antigen was available to ini­
tiate T-cell sigiraliirg cascades (see Figures 7 arrd 8). 
Furtlrermore, trairsfer o f T cells activated in tire presence of 
infected erythrocytes, or transfer of purified DCs from 
infected mice into urrinfected redpients, transferred the 
immunosuppressive phenotype, suggesting that the effect 
cannot be ascribed to out-cornpetition of the OVA-specific T 
cells by malaria-spedfic cells (see Figures 8 and 9).
In search of a mechanistic explarration for these observa­
tions, we irritially focused on analyzirrg the effect that para­
site proteins expressed on the erytiirocyte membrane might 
have on DC functiorr. It is knowir that tire developmerrt of 
tire parasites within erythrocytes is coupled with changes in 
the host cells, indudiirg the host-cell plasma membranes 
[67], arrd it is well established that parasites express 'neo- 
pro teirrs' on tire host-cell surface, some of which are 
reported to induce protective immunity [68-70]. Erythro­
cytes infected with the rodent-spedfrc strain P. chabaudi 
adlrere to spedfic cell types by interacting witlr molecules 
such as CD36 [71]; this is known as cytoadlrerence. Impor­
tantly, tire interaction of P. falciparum-mfected RBCs with 
CD36 has been shown to mediate suppression of DC
Figure 9
P. chabaudi Infection causes reduced expansion of B cells and failure of CD4+ T-cell migration through modulation of DCs. (a) Uninfected (squares) 
or P. cbabaudMnfected (circles) BALB/c mice received OVA-specific CD4+ T cells and HEL-spedfIc B cells 12 days after Infection and w ere 
immunized with OVA-HEL/LPS (filled symbols) 24 h later. Controls remained unimmunized (open symbols). Results shown are the absolute number 
of HEL-speclfic B cells in the spleen (left) and lymph nodes (LN, right) and represent the mean of 3 mice per group ± I s.d. and are representative of 
3 similar experiments (*p 0.05, <  0,005 uninfected and immunized versus P. c/iobauc/f-infected immunized), (b) Five days after immunization,
spleens from the mice described in (a) were snap frozen and prepared for immunohistochemistry. Sections were stained using biotinylated-KJ 1.26 
followed by Streptavidln-AlexaFluor 647 to detect OVA-specific T cells (red) and B220-F1TC to  identify B-cell areas (green). Images shown are 
representative of 3 mice per group from 2 similar experiments, ( c )  Sections stained as in (b) were analyzed by laser-scanning cytometry. Results are 
expressed as mean proportion of OVA-specific T cells per unit area In the regions indicated. The number of OVA-specific T cells contained in 
identically sized regions of follicle and periarterlolar lymphoid sheath (PALS) was calculated and expressed as a proportion of total Kj 1.26+ cells in 
the section to avoid bias due to  the difference in expansion between uninfected and infected spleens. Results represent triplicate readings of 3 mice 
per group ± 1 s.d. (*p £  0.05 uninfected and immunized versus P. chabaudi-infected and immunized), (d) Bone-marrow-derived DCs w ere cultured 
with P. chabaudi pRBCs (circles) or RBCs (squares) for IS h before pulsing with 5 mg/m! OVA (filled symbols). Controls remained unpulsed (open 
symbols). OVA-specific CD4+ T cells were then added at a ratio of 1:1 and cultured for 72 h in vitro. T cells were isolated, washed and transferred 
into uninfected recipients immunized 48 h before transfer to  synchronize the immune response. Clonal expansion was then assessed as described 
above. Results show the mean proportion of CD4+KJ1.26+ T cells and represent the mean of 3 mice per group ± I s.d. (*p ^ 0.05, RBC-cuItured, 
OVA-pulsed DCs versus pRBC-cultured, OVA-pulsed DC), ( e )  DCs were purified from spleens of uninfected or P. cbaboudi-infected mice and 
pulsed with 5 mg/ml OVA for 2 h. Cells were then harvested, washed and 5 x1 0 ^  DCs transferred into uninfected BALB/c mice along with 
CFSE-labeled OVA-specific T cells. The level of CFSE in OVA-specific CD4+ cells was analyzed 5 days later, as described in Figure 8.
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function [72]. Examination of the P. chabaudi genome has 
not, however, revealed any homologs of the P. falciparum 
protein PfEMPl [73], which is important in sequestration 
[72]. Rather, a separate multigene family expressing surface 
antigens was identified in P. chabaudi [73], which may have 
a role in cytoadlrerence [74].
Another important difference between P. chabaudi (tire 
rodent-specific strain used here) and the human-specific 
strain P. falciparum is the presence of surface complexes, 
known as Imobs, in P. falciparumdnfecteà erytlrrocytes, 
whidr strengthen interactions between pRBCs and receptors 
expressed on otlrer cells [75]. P. chabaudi-infected pRBCs 
have no evident knobs [76]. Thus, although P. falciparum 
and P. chabaudi show spedfic differences in their medra- 
nisms of cytoadherence, pRBC-mediated DC suppression 
might occur' tlrrough interactions with membrane mol­
ecules, sudr as CD36. We therefore exposed DCs to erythro­
cyte ghosts from infected or uninfected erytlrrocytes, before 
the EPS drallenge. Ghosts isolated from pRBCs did not alter 
the ability of DCs to respond to EPS treatment in vitro, sug- 
gestirrg tirat parasite antigens expressed on tire erythrocyte 
plasma membranes do not induce the suppression previ­
ously described following corrtact with DCs in vitro. In 
support of tlris fitrding is tire observation tirat irnmunisa- 
tioir o f mice with pRBC ghosts can induce protectiorr from 
parasite challenge [77], suggesting that protein structure is 
mairrtained on erytlrrocyte ghosts and tirat ghosts, unlike 
intact parasites, are not inherently immurrosuppressive.
As fixed pRBCs suppressed the EPS-induced maturatlorr of 
DCs whereas pRBC membranes did not, HZ seemed to be a 
good candidate to investigate wherr looldng at the mecha­
nism of parasite-induced modulatiorr o f DC functiorr. Pre’vi- 
ous reports have suggested that HZ impairs the 
differentiation and functional capacity of human m ono­
cytes arrd rrrurine macrophages through the production of  
ID 10 and/or the induction of peroxisome proliferator- 
activated receptor-y (PPAR-y) [78-82]. Tire exUapolatioir of 
these results to DCs remains somewhat controversial, 
however, with other workers suggesting a proinflammatory 
role for HZ, possibly via the Toll-like receptor-9 [83-86]. 
Our results suggest that intracellular parasite components, 
includirrg HZ, do indeed suppress DC maturation and furrc- 
tion in vitro. The exact mechanism involved in this suppres­
sion remains undefined, although it is interesting tirat 
phagocytosis of HZ has been found to increase degradation 
of protein kinase C [87]. Tlrus, degradation of key irrüacel- 
lular signaling molecules may be one medranism by which 
Plasmodium parasites suppress DC function. Togetlrer, these 
results suggest that in contrast to P. falciparum, intracellular 
HZ rather than P. chahaudi-dervved membrane-expressed 
proteirrs is responsible for the suppression of APC furrction.
The results presented here dearly demonstrate that DC func­
tion is dynamically modulated in vitro arrd in vivo by asexual 
blood-stage malaria parasites. These findirrgs support previ­
ous studies with P. falciparum-infected erythrocytes and 
humarr rnonocyte-derived DCs [42] as well as studies in 
vitro and in vivo of Plasmodium yoelii witlr murine DCs [88]. 
Otlrer studies suggest, however, that P. chabaudi sdrizonts 
activate DCs in vitro [40]. Sirrrilarly, in previous studies 
[45,89], DCs isolated from P. yodu-irrfected rrrice durirrg 
peak parasitemia were found to be activated arrd to effi- 
cieirtly process arrd preserrt arrtigen to naive T cells. In tire 
preserrt study, DCs exposed to trophozoite-infected erytlrro­
cytes show impaired maturatioir in response to stimulation, 
indicating that it is not only different parasites (P. yoelii 
versus P. chabaudi) but also different stages (Uophozoites 
versus schizorrts) that have different effects on DC function. 
Inter es tirrgly, the observed differerrces irr the ability of 
pRBCs to stimulate DC maturation may arise through con­
tamination of par asite material witlr mycoplasmas, which 
are lorown to contain potent Toll-like receptor (TER) ligands 
that efficiently activate DCs [90-92].
It has recently been suggested tirat, during malaria irrfection 
in vivo, DCs are activated during early infection and then 
show TER tolerance later in infection, becoming unrespon­
sive to EPS stimulation [93]. We believe this not to be the 
case with P. chabaudi, however, because we see no evidence 
of direct maturatlorr of the DCs by tire parasite (see Figure 
2). In addition, activated DCs show arr increased ability to 
sthnulate T-cell proliferation and cytoldrre productiorr [36], 
neither of wlrich were observed in the T-cell assays in tire 
current study. Rather, we suggest that the transieirt irrcreased 
expression of activation markers on DCs ex vivo reflects the 
high corrcentrations of pro-irrflamrnatory cytokiires caused 
by the early stage of infectiorr [94]. In support of tlris, a 
recerrt report described that DCs activated through inflam­
matory cytokines without patlrogeiric stimulation upregu­
lated markers of activation but were unable to drive CD 4+ 
T-cell differentiatiorr [95].
The ability of DCs to interact with CD40L on T cells in vivo 
has also been used to explain tire differerrces between in vivo 
and in vitro studies [45]. hrterestirrgly, in our study we could 
not rescue DC maturation wherr pRBC-treated DCs were 
stimulated with CD40L-trarrsfected fibroblasts, also suggest­
ing that TER tolerance (the refractory state of DCs to a 
second stimulation with a TER ligarrd) is rrot involved in the 
failure of DCs to respond to stimulatiorr. Tlris suggests that 
the effects that P. chabaudi-infected erytlrrocytes exert on DC 
function in vitro might be more profound than those 
induced by P. yoelii infection. Whetlrer these dr anges to tire 
C D llc7 population as a whole reflect drarrges in individual 
subsets of DCs awaits further investigatiorr. Importantly, we
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have shown that the immunosuppression seen is due to this 
inhibition of DC function rather than to suppression of T 
cells or breakdown of splenic architecture, as transfer of T 
cells activated in tire context of parasites in vitro or of DCs 
from infected mice was sufficieirt to prevent subsequent 
T-cell differentiation in uninfected recipients (see Figure 9).
The results presented here demonstrate, for the first time, 
that suppression of immuirity associated with P. chabaudi 
affects multiple populations of cells essential for develop­
ment of immunity. DC function is impaired during parasite 
infection, as a result of ingestion of FIZ, arrd although CD4+ 
T cells specific for a non-parasite antigen become activated 
following immunization, th ^  fail to expand clonally as effi- 
cieirtly as in uninfected controls. Crucially, these T cells sub­
sequently show a defect in tlreir ability to migrate into B-cell 
areas and, consequently, fail to provide effective help for 
B-cell expansion and antibody production. These results 
demonstrate an overall defect in priming of heterologous 
immune responses during Plasmodium infection and 
provide an explanation for increased secondary infections 
and the reduced efficacy o f vaccines in areas where malaria 
is endemic.
Materials and methods 
Animals and challenge infections
Female BALB/c mice were purchased fiom Harlan Olac 
(Bicester, UK). DO 11.10 mice, witli CD4+ T cells specific for 
tlie 0VA323,339 peptide in the context o f tire MHO class II 
molecule I-A^  recognized by the KJ1.26 clonotypic antibody 
[96] were obtained originally from N. Lycke, University of 
Goteborg, Sweden. MD4 mice containing HEL-specific B 
cells [51] were baclccrossed onto the BALB/c backgrocmd. 
All mice were maintained at Biological Services, University 
of Glasgow, under specific patliogen-fiee conditions and 
first used between 6 and 8 weeks of age in accordance with 
local and UK Home Office regulations.
To initiate a malaria infection, mice were inoculated with 
1 X 10  ^P. chabaudi AS-infected erytlrrocytes intm-peiitoneally. 
Parasitemia was monitored by thin blood smears stained 
with Giemsa's stain. Peak parasitemia occurred at 5-6 days 
post-iirfection, after wlrich time parasite levels declined and 
remained at low but usually detectable levels for tire 
remainder of the experiments (see Figure la), as previously 
described [97]. Infected mice were held in  a reverse 
light/dark cycle so that parasites harvested at 08:00 h were 
at the late trophozoite stage. For studies in vitro, blood was 
collected when parasitemia was 30-40%. Infected blood was 
recovered into hepariir (10 lU/ml) by cardiac prmcture and 
diluted in phosphate-buffered saliire (PBS; Invitrogen, 
Paisley, UK) to the required concentration o f pRBCs.
At various tirrres following malaria infection, mice were 
immunized intravenously with 500 pg OVA (Sigma- 
Aldrich, Poole, UK), or a conjugate o f OVA and HEL 
(Biozyme, Gwent, UK) [50], along with 50 ng LPS (from 
Salmonella equi-abortus; Sigma-Aldrich).
Preparation of bone-marrow DCs
DCs were prepared from bone marrow as previously 
described [98]. Cell suspensions were obtained from femurs 
and tibias of female BALB/c mice. The bone-marrow cell 
concentration was adjusted to 5 x 10  ^cells/ml and cultured 
in six-well plates (Corning Costar, New York, USA) in 
complete RPMI (cRPMI; RPMI 1640 supplemented with 
L-glutamine (2m M ), penicillin (lOOU/ml), streptomycin 
(100 pg/ml) (all from Invitrogen) and 10% fetal calf serum 
(FCS; Lab tech International, Ringmer, UK) containing 10% 
of culture supernatant from X63 myeloma cells transfected 
with mouse granulocyte-macrophage colony stimulating 
factor (GM-CSF) cDNA. Fresh medium was added to the 
cell cultures every 3 days. On day 6, DCs were harvested and 
cultured at the required concentration for each individual 
experimental procedure, as described below. This teclmique 
generated a large number of CD llc+ DCs largely free from 
granulocyte and monocyte contamination, as previously 
desaibed [98].
In vitro culture of DCs with fixed infected or 
uninfected erythrocytes
Blood from P. chabaudi AS-infected mice was washed twice 
in PBS before being resuspended in cRPMI for addition to 
DCs. For fixation, infected blood was washed tliree times in 
PBS and resuspended in 0.5% paraformaldehyde for 30 min 
at 4°C. Fixed erytlrrocytes were then washed in PBS, resus­
pended in 0.06% Gly-Gly (Sigma-Aldridr) for 5 min at 4'‘C 
and washed twice more in PBS before being resuspended in 
cRPMI for addition to DC. After 24 h culture, DCs were stim­
ulated witlr 1 pg/ml LPS and the expression of cell-surface 
molecules was arralyzed 18 h later by flow cytometry. To 
confirm complete fixation, we showed that 2 x 10  ^ fixed, 
iirfected erytlrrocytes could not establish infection when 
irrjected irrtra-peritoneally into a female BALB/c mouse.
In vitro culture of CD40L-transfected fibroblasts 
with DCs
The cell lines 3T3-CD40L and 3T3-SAMEN [46] were Idnd 
gifts from P. Hwu (NCI, Bethesda, USA). Cells were grown 
in cRPMI in 175 tissue culture flasks (Heleira Biosciences, 
Gateshead, UK) and, when confluerrt, harvested and distrib­
uted in six-well plates at 2.5 x 10^ cells/ml of cRPMI. Bone 
marrow-derived DCs were cultured with infected or unin­
fected erythrocytes at a ratio o f 1:100. After 24 h, DCs were 
harvested, resuspended at 1 x 10*’ cells/ml and cultured irr a 
1:1 ratio with either 3T3-CD40L or 3T3-SAMEN cells for a
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furtlier 24 h. The level of CD40 expression on DCs was ana­
lyzed by flow cytometry and culture supernatants collected 
for IL-12 cytokine analysis.
T-cell stimulation in vitro
Bone-marrow DCs were centrifuged at 450 xg, resuspended 
at 1 x 10® cells/rnl and 500 pi aliquots were disUibuted into 
24-well tissue cultirre plates (Coming Costar) with pRBCs 
or RBCs. After 24 h incubation at 37 °C  in 5% CO^, DCs 
were antigen-loaded for 5 h with 5 rng/rnl OVA (Worthing­
ton Biochemical, Freehold, USA). OVA-specific T cells were 
isolated from the mesenteric and peripheral lymph nodes of 
D O ll.lO  transgenic mice [96] on the SCID background and 
cultured at a 1:1 ratio with DCs. T-cell proliferation was 
assessed after 48, 72, 96 and 120 h of culture and assessed 
by incorporation of [% ]thymidine (0.5 pCi/well) for the 
last 24 h of culture. Cells were harvested using a Betaplate 
96-well harvester (Wallac Oy, Turku, Finland) and 
[^H] thymidine incorporation measured on a Betaplate 
liquid scintillation counter (Wallac).
Cytokine assay
For tire detection of IL-12 (p40 and p70) and IL-10, 
OptEIA™ enzyme-linked immunosorbent assay (ELISA) 
kits (Becton Dickinson, Oxford, UK) were used according to 
the manufacturer's instructions. For T-cell cytokines. Mouse 
Thl/Th2 6-Plex Idt (Biosource, Nivelles, Belgium) was used 
according to tire manufacturer's instructions. For analysis of 
cytokine production ex vivo, single-cell suspensions of 
spleen cells were prepared by rubbing tlrrough Nitex mesh 
(Cadisch & Sons, London, UK) in RPMI 1640 medium. 
After washing, cells were resuspended at 4 x 10® cells/ml in 
cRPMI, either alone or with 1 mg/ml OVA or 5 pg/ml con- 
canavalin A (ConA; Sigma-Aldridr) and superrratants 
sampled after 48 h. These were stored at -20 °C until analy­
sis by standard sarrdwldr ELISA protocol (arrtibodies used: 
for IFN-y capture, R4-6A2; for IFN-y detection, XMG1.2; for 
IL-5 capture, TRKF5; for IU5 detectiorr, TRKF4; Phaimingen, 
Oxford, UK) arrd the levels of cytokine in superrratants cal­
culated by comparison with recombiirant cytoldne starr- 
dards (R& D Systems, Abmgdon, UK).
Flow cytom etry
Aliquots of 1 X 10® cells in 12 x 75 rrrrn polystyrene tubes 
(Falcon BD, Oxford, UK) were resuspended in  100 pi FACS 
buffer (PBS, 2% PCS and 0.05% NaNg) contairring Pc Block 
(2.4G2 hybridoma supernatant) as well as the appropriate 
combinations of the following antibodies: anti-CD4-PerCP 
(clone RM4-5), anti-GDIIc-PE (doire HL3), anti-CD40- 
FrrC (done 3/23), anti-CD69-PE (clone H1.2F3), anti- 
CD80-FITC (clone 16-lOAl), arrti-CD86-FITC (done GLl), 
anti-MHC-II (clone 2G9), anti-B220-PE (done RA3-6B2), 
PE-harnster IgG isotype control, FlTC-rat IgG2a, k  isotype
control and FlTC-hamster IgGl, X isotype control (anti-TNP) 
(all Pharmingen), biotinylated KJ1.26 antibody or biotiny- 
lated HEL. Biotinylated antibodies were detected by incuba­
tion witlr fluorochrorne-conjugated strqrtavidin (Pharmingen). 
After washing, samples were analyzed using a FACSCalibur 
flow cytometer equipped witlr a 488 irm argoir laser and a 
635 rrm red diode laser and analyzed using CellQuest soft­
ware (both BD BioSdences, Oxford, UK).
Preparation of erythrocyte ghosts from infected and 
uninfected m ouse blood
Ghosts from infected and uninfected eiytlrrocytes were gen­
erated as previously described [67]. Briefly, blood was col­
lected into heparin by cardiac puncture and washed three 
times in PBS. Infected and uninfected erythrocytes were 
concentrated hr PBS supplemented witlr 113 mM glucose 
(Sigma-Aldrich) and 3% FCS. Infected erythrocytes were 
incubated in an equal volume of glycerol buffer (10% glyc­
erol (Sigma-Aldridr) supplemented with 5% FCS in PBS) 
for 1 h at 4°C. Parasites and ghosts were separated in a con­
tinuous Percoll (Amersham Biosdences, Little Chalfont, 
UK) gradient (p: 1.02-1.10 g/cm^) in intracellular medium  
buffer (IM: 20 mM NaCl, 120 mM KCl, 1 mM MgClg, 
10 mM glucose, 5 mM Hepes pH 6.7) by centrifugation at 
5,000 x g  for 30 min. Ghosts were then washed in IM buffer 
and layered on a two-step Percoll gradient (p: 1.01+1.02 
g/cm^) to separate them from ghosts that might still contain 
parasites. Ghosts from uninfected erytlrrocytes were 
obtained by adding a 40-fold volume of phosphate buffer 
(5 mM NaHgPO,^/Na2HPO^, 1 mM PMSP, 0.01% azide, pH 
8.5). The suspension was centrifuged at 32,000 x g for 
30 min. Ghosts from infected and uninfected erythrocytes 
were then washed tlrree times in PBS before being resus­
pended in cRPMI for addition to DCs at a ratio o f 100:1.
Hemozoin preparation
HZ was isolated from supernatants obtained from cultures 
of P. falciparum gametocytes, kindly provided by Lisa 
Rairford-Caitwright, (Division of Infection arrd Immunity, 
University of Glasgow, UK). Endotoxiir-free buffers arrd 
solutioirs were used throughout. Superrratants were cen­
trifuged for 20 rrrirr at 450 x g. The pellet was washed three 
times in 2% SLS and resuspended in 6 M guanidine HCl. 
Following 5-7 washes irr PBS, tire pellet was resuspended in 
PBS and sonicated for 90 min using Soniprep 150 (Sanyo 
Scientific, Benseirville, USA) at an amplitude o f 5-8 pm to 
minimize a^egatioir and maiirtain the HZ in suspension. 
Total heme conteirt was determirred as previously described 
[99] by depolymerizing heme polymer in 1 ml of 20 mM 
NaOH and 2% SDS, incubatirrg the suspension at room  
temperature for 2 h and then readirrg the optical derrsity at 
400 rrm using a UV-visible Plelios spectrophotometer 
(Thermo Spectrorric, Cambridge, UK). DCs were pulsed
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with 1-20 pM HZ - a concentration range similar to tirat 
seen when DCs were cultured at a 1:100 ratio witlr pRBCs.
A ssessm en t of antigen-specific antibody responses
Peripheral blood was collected and the plasma was sepa­
rated by centrifugation at 450 x ^ for 10 min and stored at 
-20'’C until analysis. OVA-specific IgG was measured by 
standard sandwich ELISA using a peroxidase-conjugated 
anti-mouse total IgG (Sigma-Aldrich).
Adoptive transfer of antigen-specific lymphocytes
Lymph irodes and spleens were homogenized and the result­
ing cell suspeirsions washed twice by centrifugation at 400 x 
g for 5 min and resuspended in RPMI. The proportions of 
antigen-specific T cells were evaluated by flow cytometry, 
arrd syngeneic recipients received 3x10® antigen-spedfic 
cells. In some experiments, cells were labeled with the fluo­
rescent dye CFSE (Molecular Probes, Oregon, USA) immedi­
ately before use [100]. The level of CFSE in cells was 
analyzed by flow cytometry and expressed as the mean pro­
portion of antigen-specific T cells under eaclr CFSE peak.
Immunohistochemistry
Spleens were frozen in liquid nitrogen in OCT embedding 
medium (Miles, Elkart, USA) in cryomoulds (Miles) and 
stored at -70°C. Tissue sections (8 pm) were cut on a cryo­
stat (ThermoShandon, Cheshire, UK) and stored at -20 °C. 
Sections were blocked and stained as previously described 
[55], using B220-FITC to stain B-cell areas and biotinylated- 
KJ1.26 to detect OVA-spedfic D O ll.lO  cells, and visualized 
using Streptavidin-Alexa Fluor 547 (Molecular Probes). All 
photographs were taken at 2Ox magnification.
To visualize HZ deposition in DCs, cells were photographed 
using an Axiovert S-lOO Zeiss microscope using a 63x oil- 
immersion lens by normal bright-field imaging. To image 
HZ in splenic DC, 8 pm sections were cut as described 
above and stained with biotinylated-CDllc followed by 
Streptavidin-HRP and finally tyramide-488 (PerkinElmer, 
Boston, LISA). Images were then taken of bright-field and 
green fluorescence and the images merged by inverting and 
then false coloring the bright-field image sudr tirat 
deposited HZ appeared red arrd CDl Ic appeared green.
Laser-scanning cytom etry
Sections were stained as described above. Sections were 
then scairned on a laser-scanning cytometer equipped with 
argon, helium, ireoir, and ultraviolet lasers (Compucyte, 
Cambridge, USA) and visualized with the Opeirlab imaging 
system (Improvision, Coventry, UK). Tire localization of  
transgenic T cells and B-cell follides were plotted. Using 
tlrese tissue maps the number of transgenic T cells in 
defined gates was calculated for three gates irr p err arteriolar
lymphoid sheath (PALS) and tlnee B-cell follicle gates per 
section. Data are plotted as the mean proportion of trans- 
gerric T cells in each gate relative to tire irumber of trans­
genic T cells irr tire eirtire section and are the meair of 
triplicate readings from three mice per group.
Isolation of DCs from spleen
Spleeirs were exdsed and single-cell suspensions obtained 
as desaibed above. In some experiments, cells were stimu­
lated with 1 pg/ml LPS for 18 h before analysis by flow  
cytometry. To obtain purified DCs from spleens of rrrice, 
single-cell suspensions were labeled using a CD 11c isola­
tion Idt (Milterryi Biotec, Bisley, UK) according to the marru- 
facturer's instmctioirs, DCs were then purified using two MS 
magnetic columirs (Milterryi Biotec) arrd found to be 85- 
95% pure by flow cytometric analysis.
Statistical analysis
Results are expressed as mean ± starrdard enor or standard 
deviation as indicated. Significance was determined by one­
way AN OVA in conjunction with the Tukey test usiirg Mini tab. 
A p-value of less tlran 0.05 was considered sigrrificant.
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